<SEC-DOCUMENT>0001683168-26-003819.txt : 20260513
<SEC-HEADER>0001683168-26-003819.hdr.sgml : 20260513
<ACCEPTANCE-DATETIME>20260513161843
ACCESSION NUMBER:		0001683168-26-003819
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		61
CONFORMED PERIOD OF REPORT:	20260331
FILED AS OF DATE:		20260513
DATE AS OF CHANGE:		20260513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sunshine Biopharma Inc.
		CENTRAL INDEX KEY:			0001402328
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				205566275
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41282
		FILM NUMBER:		26973589

	BUSINESS ADDRESS:	
		STREET 1:		333 LAS OLAS WAY
		STREET 2:		CU4 SUITE 433
		CITY:			FORT LAUDERDALE
		STATE:			FL
		ZIP:			33301
		BUSINESS PHONE:		954-330-0684

	MAIL ADDRESS:	
		STREET 1:		333 LAS OLAS WAY
		STREET 2:		CU4 SUITE 433
		CITY:			FORT LAUDERDALE
		STATE:			FL
		ZIP:			33301

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Sunshine Biopharma, Inc
		DATE OF NAME CHANGE:	20091102

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Mountain West Business Solutions, Inc
		DATE OF NAME CHANGE:	20071030

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	mountain west business solutions,inc
		DATE OF NAME CHANGE:	20070607
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>sunshine_i10q-033126.htm
<DESCRIPTION>FORM 10-Q FOR MAR 2026
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:SBFM="http://sunshinebiopharma.com/20260331">
<head>
     <title>SUNSHINE BIOPHARMA INC. 10-Q</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_020_US%2DGAAP%2D2025%2D(with%2DECD) -->
<!-- Field: Set; Name: xdx; ID: xdx_036_SBFM_sunshinebiopharma.com_20260331 -->
<!-- Field: Set; Name: xdx; ID: xdx_041_20260101_20260331 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DDocumentFiscalYearFocus_2026 -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DEntityCentralIndexKey_0001402328 -->
<!-- Field: Set; Name: xdx; ID: xdx_079_SO_sunshine__i10q%2D033126.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06E_CAD_0_iso4217%2D%2DCAD -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_Segment_0_Segment -->
<body style="font: 10pt Arial, Helvetica, Sans-Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2026-01-01to2026-03-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2026-01-01to2026-03-31" id="Fact000004" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2026-01-01to2026-03-31" id="Fact000005" name="dei:DocumentFiscalYearFocus">2026</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2026-01-01to2026-03-31" id="Fact000006" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2026-01-01to2026-03-31" id="Fact000007" name="dei:EntityCentralIndexKey">0001402328</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0350" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0351" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2026-01-012026-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0381" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-01-012025-03-31_us-gaap_ComprehensiveIncomeMember" id="xdx2ixbrl0382" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0383" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0388" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0390" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="From2026-01-01to2026-03-31" id="xdx2ixbrl0408" decimals="INF" unitRef="Segment">1</ix:nonFraction>
  <ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="From2026-01-01to2026-03-31" id="xdx2ixbrl0410" decimals="INF" unitRef="Segment">1</ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="sbfm-20260331.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2026-01-01to2026-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-05-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-05-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_ComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_ComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_us-gaap_ComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_ComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_ComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_ComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-162024-04-17">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-16</xbrli:startDate>
        <xbrli:endDate>2024-04-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-072024-08-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-07</xbrli:startDate>
        <xbrli:endDate>2024-08-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-192022-10-20_custom_NoraPharmaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">SBFM:NoraPharmaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-19</xbrli:startDate>
        <xbrli:endDate>2022-10-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-10-20_custom_NoraPharmaMember_custom_MalekChamounMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">SBFM:NoraPharmaMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">SBFM:MalekChamounMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-10-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_NoraPharmaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">SBFM:NoraPharmaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-212024-04-22_custom_NoraPharmaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">SBFM:NoraPharmaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-21</xbrli:startDate>
        <xbrli:endDate>2024-04-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_NoraPharmaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">SBFM:NoraPharmaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_VehiclesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_VehiclesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_AllDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">SBFM:AllDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_AllDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">SBFM:AllDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_Director1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">SBFM:Director1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_Director2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">SBFM:Director2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_Director3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">SBFM:Director3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_Director4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">SBFM:Director4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_Director5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">SBFM:Director5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_Director1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">SBFM:Director1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_Director2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">SBFM:Director2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_Director3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">SBFM:Director3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_Director4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">SBFM:Director4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_Director5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">SBFM:Director5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_SeriesBPreferredStockMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_SeriesBPreferredStockMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-022025-01-03_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-02</xbrli:startDate>
        <xbrli:endDate>2025-01-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-022025-01-03_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-02</xbrli:startDate>
        <xbrli:endDate>2025-01-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-04-02_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-04-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-04-02_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-04-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-04-03_us-gaap_CommonStockMember_custom_RegisteredDirectOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">SBFM:RegisteredDirectOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-04-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-152025-10-16_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-15</xbrli:startDate>
        <xbrli:endDate>2025-10-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-152025-10-16_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-15</xbrli:startDate>
        <xbrli:endDate>2025-10-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_TradeableWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:TradeableWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_TradeableWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:TradeableWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_PreFunded2022WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:PreFunded2022WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_PreFunded2022WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:PreFunded2022WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_InvestorWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:InvestorWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_InvestorWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:InvestorWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_AprilWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:AprilWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_AprilWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:AprilWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_MayPreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:MayPreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_MayPreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:MayPreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_MayInvestorWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:MayInvestorWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_MayInvestorWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:MayInvestorWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_PreFunded2024WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:PreFunded2024WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_PreFunded2024WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:PreFunded2024WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_SeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:SeriesAWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_SeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:SeriesAWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_PreFunded2025WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:PreFunded2025WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_PreFunded2025WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:PreFunded2025WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-102024-02-11_custom_AprilWarrantsAndMayInvestorWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:AprilWarrantsAndMayInvestorWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-10</xbrli:startDate>
        <xbrli:endDate>2024-02-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_TradeableWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:TradeableWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_TradeableWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:TradeableWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_InvestorWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:InvestorWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_InvestorWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:InvestorWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_custom_SeriesBWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:SeriesBWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_custom_SeriesBWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:SeriesBWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="CAD">
      <xbrli:measure>iso4217:CAD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Segment">
      <xbrli:measure>SBFM:Segment</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><a href="#q1_001"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">Table of Contents</span></a></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>WASHINGTON,
D.C. 20549</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-variant: small-caps"><b>FORM
<span id="xdx_901_edei--DocumentType_c20260101__20260331_z84D5z3oh16d"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" id="Fact000016" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><span id="xdx_90C_edei--DocumentQuarterlyReport_c20260101__20260331_zftnEI2JEfSl"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" format="ixt:booleantrue" id="Fact000017" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span>
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">For
the quarterly period ended: <b><span style="text-decoration: underline"><span id="xdx_90D_edei--DocumentPeriodEndDate_c20260101__20260331_z7FD40pEtjP5"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" format="ixt:datemonthdayyearen" id="Fact000018" name="dei:DocumentPeriodEndDate">March 31, 2026</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><span id="xdx_905_edei--DocumentTransitionReport_c20260101__20260331_zPLkKdpC89he"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" format="ixt:booleanfalse" id="Fact000019" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">For
the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">Commission
File Number: <span id="xdx_903_edei--EntityFileNumber_c20260101__20260331_zRVKwhoeJDGk"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" id="Fact000020" name="dei:EntityFileNumber">001-41282</ix:nonNumeric></span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;<img src="logo.jpg" alt="" style="height: 97px; width: 225px"/></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 12pt"><b><span style="text-decoration: underline"><span id="xdx_902_edei--EntityRegistrantName_c20260101__20260331_zOs3TBmVzEB5"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" id="Fact000021" name="dei:EntityRegistrantName">SUNSHINE BIOPHARMA INC.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b><span id="xdx_90D_edei--EntityIncorporationStateCountryCode_c20260101__20260331_zeK0tFmcbXJf"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" format="ixt-sec:stateprovnameen" id="Fact000022" name="dei:EntityIncorporationStateCountryCode">Colorado</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityTaxIdentificationNumber_c20260101__20260331_zRp2v95qQQwc"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" id="Fact000023" name="dei:EntityTaxIdentificationNumber">20-5566275</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(State of other jurisdiction
    of incorporation)</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(IRS Employer ID No.)</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b><span id="xdx_908_edei--EntityAddressAddressLine1_c20260101__20260331_zURqaMjqIba2"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" id="Fact000024" name="dei:EntityAddressAddressLine1">333 Las Olas Way</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b><span id="xdx_908_edei--EntityAddressAddressLine2_c20260101__20260331_zM6XQ5DOTaDi"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" id="Fact000025" name="dei:EntityAddressAddressLine2">CU4 Suite 433</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b><span style="text-decoration: underline"><span id="xdx_90D_edei--EntityAddressCityOrTown_c20260101__20260331_zueV9c1dp7F6"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" id="Fact000026" name="dei:EntityAddressCityOrTown">Fort Lauderdale</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressStateOrProvince_c20260101__20260331_zC4EFhhFkFmb"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" id="Fact000027" name="dei:EntityAddressStateOrProvince">FL</ix:nonNumeric></span> <span id="xdx_902_edei--EntityAddressPostalZipCode_c20260101__20260331_z5K1TEVLPLB1"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" id="Fact000028" name="dei:EntityAddressPostalZipCode">33301</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">(Address
of principal executive offices)</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b><span style="text-decoration: underline">(<span id="xdx_90A_edei--CityAreaCode_c20260101__20260331_zncvRc49uN22"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" id="Fact000029" name="dei:CityAreaCode">954</ix:nonNumeric></span>)
<span id="xdx_90B_edei--LocalPhoneNumber_c20260101__20260331_ztDqLCPONzbh"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" id="Fact000030" name="dei:LocalPhoneNumber">330-0684</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">(Issuer&#8217;s
Telephone Number)</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">Securities registered
pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 40%; font-size: 10pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span style="text-decoration: underline">Title
    of Each Class</span></span></td>
    <td style="width: 20%; font-size: 10pt; text-indent: 0.35pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span style="text-decoration: underline">Trading
    Symbol</span></span></td>
    <td style="width: 40%; font-size: 10pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span style="text-decoration: underline">Name
    of Each Exchange on Which Registered</span></span></td></tr>
  <tr style="vertical-align: top">
    <td><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><span id="xdx_908_edei--Security12bTitle_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHNByVBWZYQ2"><ix:nonNumeric contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember" id="Fact000031" name="dei:Security12bTitle">Common
    Stock</ix:nonNumeric></span></span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><span id="xdx_908_edei--Security12bTitle_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCkNzDeiiHmh"><ix:nonNumeric contextRef="From2026-01-012026-03-31_us-gaap_WarrantMember" id="Fact000032" name="dei:Security12bTitle">Common
    Stock Purchase Warrants</ix:nonNumeric></span></span></p></td>
    <td><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center; text-indent: 0.35pt"><span style="font-family: Arial, Helvetica, Sans-Serif"><span id="xdx_90A_edei--TradingSymbol_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSSeOvK3TkYa"><ix:nonNumeric contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember" id="Fact000033" name="dei:TradingSymbol">SBFM</ix:nonNumeric></span></span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center; text-indent: 0.35pt"><span style="font-family: Arial, Helvetica, Sans-Serif"><span id="xdx_906_edei--TradingSymbol_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zj7Lzvhiqveg"><ix:nonNumeric contextRef="From2026-01-012026-03-31_us-gaap_WarrantMember" id="Fact000034" name="dei:TradingSymbol">SBFMW</ix:nonNumeric></span></span></p></td>
    <td><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">The
    <span id="xdx_900_edei--SecurityExchangeName_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSlfw2kkRb68"><ix:nonNumeric contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember" format="ixt-sec:exchnameen" id="Fact000035" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Stock Market LLC</span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">The
    <span id="xdx_90C_edei--SecurityExchangeName_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwvonK6f6p2h"><ix:nonNumeric contextRef="From2026-01-012026-03-31_us-gaap_WarrantMember" format="ixt-sec:exchnameen" id="Fact000036" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Stock Market LLC</span></p></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days: <span id="xdx_904_edei--EntityCurrentReportingStatus_c20260101__20260331_zWYpFdFyZsR4" title="Entity Current Reporting Status"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" id="Fact000038" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746;&#160; &#8239;No &#9744;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). <span id="xdx_90F_edei--EntityInteractiveDataCurrent_c20260101__20260331_z336t5dTROn5"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" id="Fact000039" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No&#160;&#9744;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;,
&#8220;smaller reporting company&#8221;, and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. (Check one)</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="width: 49%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Large accelerated
    filer&#160; &#9744;</span></td>
    <td style="width: 41%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Accelerated
    filer&#160; &#9744;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_901_edei--EntityFilerCategory_c20260101__20260331_zIWsbTCX9sXc"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" format="ixt-sec:entityfilercategoryen" id="Fact000040" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span>&#160;
    &#9746;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Smaller reporting company&#160;
    <span id="xdx_903_edei--EntitySmallBusiness_c20260101__20260331_zB07INwmahFg"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" format="ixt:booleantrue" id="Fact000041" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Emerging growth company <span id="xdx_901_edei--EntityEmergingGrowthCompany_c20260101__20260331_zZ1pumGj2PAj"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" format="ixt:booleanfalse" id="Fact000042" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). &#9744; Yes &#160;<span id="xdx_901_edei--EntityShellCompany_dbF_c20260101__20260331_zlSaJtJU3uGa"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" format="ixt:booleanfalse" id="Fact000043" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span> No</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
number of shares of the registrant&#8217;s common stock, par value $0.001, issued and outstanding as of May 13, 2026, was <span id="xdx_907_edei--EntityCommonStockSharesOutstanding_iI_c20260513_zM07jKsGZUNl"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2026-05-13" id="Fact000044" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,005,945</ix:nonFraction></span> shares.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b><span id="q1_001"></span>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 8%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="width: 84%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 8%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b><a href="#q1_002">PART I. FINANCIAL INFORMATION</a></b></span></td>
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Item 1.</span></td>
    <td><a href="#q1_003"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Financial Statements</span></a></td>
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">3</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td><a href="#q1_004"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Consolidated Balance Sheets as of March 31, 2026 (Unaudited) and December 31, 2025</span></a></td>
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">3</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td><a href="#q1_005"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Consolidated Statements of Operations
    and Comprehensive Loss for the Three Months Ended March 31, 2026 and 2025 (Unaudited)</span></a></td>
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">4</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td><a href="#q1_007"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and 2025 (Unaudited)</span></a></td>
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">5</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td><a href="#q1_006"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Consolidated Statement of Shareholders' Equity for the Three Months Ended March 31, 2026 and 2025 (Unaudited)</span></a></td>
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">6</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td><a href="#q1_008"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Notes to Unaudited Consolidated Financial Statements</span></a></td>
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">7</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Item 2.</span></td>
    <td><a href="#q1_009"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">15</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Item 3.</span></td>
    <td><a href="#q1_010"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Quantitative and Qualitative Disclosures About Market Risk</span></a></td>
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">22</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Item 4.</span></td>
    <td><a href="#q1_011"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Controls and Procedures</span></a></td>
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">22</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 8%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="width: 84%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b><a href="#q1_012">PART II. OTHER INFORMATION</a></b></span></td>
    <td style="width: 8%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Item 1.</span></td>
    <td><a href="#q1_013"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Legal Proceedings</span></a></td>
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">23</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Item 1A.</span></td>
    <td><a href="#q1_014"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Risk Factors</span></a></td>
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">23</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Item 2.</span></td>
    <td><a href="#q1_015"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></td>
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">23</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Item 3.</span></td>
    <td><a href="#q1_016"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Defaults Upon Senior Securities</span></a></td>
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">23</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Item 4.</span></td>
    <td><a href="#q1_017"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Mine Safety Disclosures</span></a></td>
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">23</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Item 5.</span></td>
    <td><a href="#q1_018"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Other Information</span></a></td>
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">23</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Item 6.</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="#q1_019">Exhibits</a></span></td>
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">23</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="#q1_020">Signatures</a></span></td>
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">24</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b>PART
I.&#160;</b>&#160;<b><span id="q1_002"></span>FINANCIAL INFORMATION</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"><b><span id="q1_003"></span>ITEM
1. FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Sunshine
Biopharma Inc.</span></p>

<p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif"><span id="q1_004"></span>Consolidated
Balance Sheets</span></p>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_309_111_zuzOM7KZwvLh" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20260331_zg6JsuG81sP5" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49A_20251231_zDgkB5qYnPyj" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">March 31,</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">December 31,</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">2026</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsAbstract_iB_zDAF1qfLKqwi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">ASSETS</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AssetsCurrentAbstract_iB_ziFHHCXc4AT8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Current Assets:</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_i01I_maCzT4x_zsPWLbr2dlp5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 66%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Cash and cash
    equivalents</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="width: 13%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2026-03-31" id="Fact000052" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,913,013</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="width: 13%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-12-31" id="Fact000053" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,123,308</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--AccountsReceivableNetCurrent_i01I_maCzT4x_zMSQCV37zlEg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Accounts receivable</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2026-03-31" id="Fact000055" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,011,632</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2025-12-31" id="Fact000056" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,459,864</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--InventoryNet_i01I_maCzT4x_zvfEK0DkHikg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Inventory</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2026-03-31" id="Fact000058" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,168,430</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2025-12-31" id="Fact000059" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,472,025</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--DepositAssets_i01I_d0_maCzT4x_zANum7R4tWG4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Deposits</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:DepositAssets" contextRef="AsOf2026-03-31" id="Fact000061" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,740</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:DepositAssets" contextRef="AsOf2025-12-31" id="Fact000062" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--PrepaidExpenseCurrent_i01I_maCzT4x_zhANgzSvRHN5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Prepaid
    expenses</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2026-03-31" id="Fact000064" format="ixt:numdotdecimal" decimals="0" unitRef="USD">618,361</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2025-12-31" id="Fact000065" format="ixt:numdotdecimal" decimals="0" unitRef="USD">798,384</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AssetsCurrent_iTI_mtCzT4x_maCz8iX_zfdAlkRJIuOf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Total Current Assets</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2026-03-31" id="Fact000067" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,783,176</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2025-12-31" id="Fact000068" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,853,581</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AssetsNoncurrentAbstract_iB_zbMnLw11LBd6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Long-Term Assets:</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iI_maCzu4a_zi0TYoKI5p4i" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Property &amp; equipment</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2026-03-31" id="Fact000073" format="ixt:numdotdecimal" decimals="0" unitRef="USD">516,349</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2025-12-31" id="Fact000074" format="ixt:numdotdecimal" decimals="0" unitRef="USD">557,370</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_maCzu4a_zIkCSZJ5xJ6h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Intangible assets</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2026-03-31" id="Fact000076" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,917,812</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2025-12-31" id="Fact000077" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,889,370</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseRightOfUseAsset_iI_maCzu4a_zqX6h8dgEB" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Right-of-use-asset</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2026-03-31" id="Fact000079" format="ixt:numdotdecimal" decimals="0" unitRef="USD">713,038</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2025-12-31" id="Fact000080" format="ixt:numdotdecimal" decimals="0" unitRef="USD">778,846</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--AssetsNoncurrent_iTI_mtCzu4a_maCz8iX_zC4q030ysNyf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Total Long-Term Assets</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2026-03-31" id="Fact000082" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,147,199</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2025-12-31" id="Fact000083" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,225,586</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--Assets_iTI_mtCz8iX_zT2iOr8Zjdt4" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">TOTAL
    ASSETS</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2026-03-31" id="Fact000085" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,930,375</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-12-31" id="Fact000086" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,079,167</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAbstract_iB_zuAAO5ABHs5c" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">LIABILITIES</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrentAbstract_iB_zLGOZk5gvl65" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Current Liabilities:</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AccountsPayableCurrent_i01I_maCzVRE_zUDyJSfmC6Zc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Accounts payable &amp; accrued
    expenses</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2026-03-31" id="Fact000094" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,104,868</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2025-12-31" id="Fact000095" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,664,212</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_ecustom--EarnoutPayable_i01I_d0_maCzVRE_zpYrnMWs8wy2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Earnout payable</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="SBFM:EarnoutPayable" contextRef="AsOf2026-03-31" id="Fact000097" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,797</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="SBFM:EarnoutPayable" contextRef="AsOf2025-12-31" id="Fact000098" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,797</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedIncomeTaxesCurrent_i01I_d0_maCzVRE_z3Fu1BkU1zj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Income tax payable</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="AsOf2026-03-31" id="Fact000100" format="ixt:numdotdecimal" decimals="0" unitRef="USD">268,276</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="AsOf2025-12-31" id="Fact000101" format="ixt:numdotdecimal" decimals="0" unitRef="USD">268,276</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_maCzVRE_zEINCHjp0S38" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Right-of-use-liability</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2026-03-31" id="Fact000103" format="ixt:numdotdecimal" decimals="0" unitRef="USD">209,226</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2025-12-31" id="Fact000104" format="ixt:numdotdecimal" decimals="0" unitRef="USD">215,637</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesCurrent_iTI_mtCzVRE_maCzDSO_zj9tahtGYfS4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Total Current Liabilities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2026-03-31" id="Fact000106" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,878,167</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2025-12-31" id="Fact000107" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,443,922</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesNoncurrentAbstract_iB_zus1hEgR37B7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Long-Term Liabilities:</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_maCzBsN_zqBUD2stLbC9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Right-of-use-liability</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2026-03-31" id="Fact000112" format="ixt:numdotdecimal" decimals="0" unitRef="USD">535,614</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2025-12-31" id="Fact000113" format="ixt:numdotdecimal" decimals="0" unitRef="USD">596,785</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesNoncurrent_iTI_mtCzBsN_maCzDSO_zU08UBIE4Y98" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Total Long-Term Liabilities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2026-03-31" id="Fact000115" format="ixt:numdotdecimal" decimals="0" unitRef="USD">535,614</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2025-12-31" id="Fact000116" format="ixt:numdotdecimal" decimals="0" unitRef="USD">596,785</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--Liabilities_iTI_mtCzDSO_maCzWNb_zoDqAberpG8h" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">TOTAL
    LIABILITIES</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2026-03-31" id="Fact000118" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,413,781</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2025-12-31" id="Fact000119" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,040,707</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--StockholdersEquityAbstract_iB_zwz63TKI8u5c" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">SHAREHOLDERS' EQUITY</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--PreferredStockValue_i01I_maCzhI7_zMJ1yr6oz8K7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Preferred
    Stock Series B $<span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zeyYgz5CCcu2" title="Preferred stock, par value"><span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zIQzozESOhD4" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2026-03-31_us-gaap_SeriesBPreferredStockMember" id="Fact000127" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000129" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.10</ix:nonFraction></ix:nonFraction></span></span> par value per share; <span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zes68A5tVBlf" title="Preferred stock, shares authorized"><span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zexyzwLcQTA7" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2026-03-31_us-gaap_SeriesBPreferredStockMember" id="Fact000131" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000133" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized <span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zWatuuFOYAnd" title="Preferred stock, shares issued"><span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zyKStcu1mOek" title="Preferred stock, shares outstanding"><span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z3qNrpiSYWMk" title="Preferred stock, shares issued"><span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zrEpZKkLyLj3" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2026-03-31_us-gaap_SeriesBPreferredStockMember" id="Fact000135" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2026-03-31_us-gaap_SeriesBPreferredStockMember" id="Fact000137" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000139" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000141" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">130,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2026-03-31" id="Fact000124" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2025-12-31" id="Fact000125" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--CommonStockValue_i01I_maCzhI7_zs7xwZofjzrf" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Common
    Stock $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_c20260331_ziItxfRVcsig" title="Common stock, par value"><span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_c20251231_zaSPIyBrzXpg" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2026-03-31" id="Fact000146" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31" id="Fact000148" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value per share; <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_c20260331_zEfrsjfWApQ7" title="Common stock, shares authorized"><span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_c20251231_z2apqlPVUb0h" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2026-03-31" id="Fact000150" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-12-31" id="Fact000152" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,000,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized <span id="xdx_90A_eus-gaap--CommonStockSharesIssued_c20260331_zjQgQqeSYQU8" title="Common stock, shares issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_c20260331_z1jXnQpTIQQ9" title="Common stock, shares outstanding"><span id="xdx_903_eus-gaap--CommonStockSharesIssued_c20251231_zGjtpl6gkDY6" title="Common stock, shares issued"><span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_c20251231_zKKEGMlNa0R6" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2026-03-31" id="Fact000154" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2026-03-31" id="Fact000156" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-12-31" id="Fact000158" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-12-31" id="Fact000160" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,905,945</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding at March 31, 2026 and December
    31, 2025</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2026-03-31" id="Fact000143" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,905</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-12-31" id="Fact000144" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,905</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--AdditionalPaidInCapital_i01I_maCzhI7_zK1a4fLPocKb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Capital
    paid in excess of par value</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2026-03-31" id="Fact000162" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,100,990</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2025-12-31" id="Fact000163" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,100,990</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i01I_pp0p0_maCzhI7_zS9wbTyN7di8" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Accumulated
    comprehensive income</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2026-03-31" id="Fact000165" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">343,306</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2025-12-31" id="Fact000166" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">65,309</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td></tr>
  <tr id="xdx_401_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_maCzhI7_zj0C0ZknCizb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Accumulated
    (Deficit)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2026-03-31" id="Fact000168" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">76,258,995</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-12-31" id="Fact000169" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">75,015,126</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquity_i01TI_mtCzhI7_maCzWNb_zP0GJ8WTTUq1" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">TOTAL
    SHAREHOLDERS' EQUITY</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-03-31" id="Fact000171" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,516,594</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31" id="Fact000172" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,038,460</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtCzWNb_zbGQL2L4rydi" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">TOTAL
    LIABILITIES AND SHAREHOLDERS' EQUITY</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2026-03-31" id="Fact000174" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,930,375</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2025-12-31" id="Fact000175" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,079,167</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif">See
Accompanying Notes To These Financial Statements.</span></p>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Sunshine
Biopharma Inc.</span></p>

<p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif"><span id="q1_005"></span>Consolidated
Statements of Operations and Comprehensive Loss (Unaudited)</span></p>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_113_zrG0l48vFT6i" summary="xdx: Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited)" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20260101__20260331_zNIx8SKYYSWj" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20250101__20250331_zKg6BP5mE0j8" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">March 31,</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">March 31,</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">2026</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--Revenues_maCznPY_zp5OZnYrpdKd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%"><span style="font-family: Arial, Helvetica, Sans-Serif">Sales</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="width: 13%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2026-01-01to2026-03-31" id="Fact000177" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,088,765</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="width: 13%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-03-31" id="Fact000178" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,901,341</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--CostOfRevenue_msCznPY_zIxlj1lxjysg" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Cost of sales</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2026-01-01to2026-03-31" id="Fact000180" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,907,775</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2025-01-012025-03-31" id="Fact000181" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,170,915</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--GrossProfit_iT_mtCznPY_maCzDUx_zvdxWNIYK0vl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Gross profit</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2026-01-01to2026-03-31" id="Fact000183" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,180,990</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2025-01-012025-03-31" id="Fact000184" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,730,426</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpenseAbstract_iB_zsf77wjR2IIa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">General &amp; Administrative Expenses:</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--ProfessionalFees_i01_maCzWTQ_zJc1QANsaRa1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Accounting</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2026-01-01to2026-03-31" id="Fact000189" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,809</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2025-01-012025-03-31" id="Fact000190" format="ixt:numdotdecimal" decimals="0" unitRef="USD">293,759</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--ProfessionalAndContractServicesExpense_i01_maCzWTQ_zd8bCGjk9vn2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Consulting</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:ProfessionalAndContractServicesExpense" contextRef="From2026-01-01to2026-03-31" id="Fact000192" format="ixt:numdotdecimal" decimals="0" unitRef="USD">143,148</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:ProfessionalAndContractServicesExpense" contextRef="From2025-01-012025-03-31" id="Fact000193" format="ixt:numdotdecimal" decimals="0" unitRef="USD">365,287</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--NoninterestExpenseDirectorsFees_i01_maCzWTQ_zBZ50clHFwq5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Director fees</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:NoninterestExpenseDirectorsFees" contextRef="From2026-01-01to2026-03-31" id="Fact000195" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:NoninterestExpenseDirectorsFees" contextRef="From2025-01-012025-03-31" id="Fact000196" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--LegalFees_i01_maCzWTQ_zqgcaCqaOP3e" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Legal</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2026-01-01to2026-03-31" id="Fact000198" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,076</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2025-01-012025-03-31" id="Fact000199" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,199</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--MarketingExpense_i01_maCzWTQ_zjjj8WR7FUk9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Marketing</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:MarketingExpense" contextRef="From2026-01-01to2026-03-31" id="Fact000201" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,223</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:MarketingExpense" contextRef="From2025-01-012025-03-31" id="Fact000202" format="ixt:numdotdecimal" decimals="0" unitRef="USD">398,361</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--OtherGeneralAndAdministrativeExpense_i01_maCzWTQ_zZ7JpuxNzuLa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Office</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2026-01-01to2026-03-31" id="Fact000204" format="ixt:numdotdecimal" decimals="0" unitRef="USD">871,608</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2025-01-012025-03-31" id="Fact000205" format="ixt:numdotdecimal" decimals="0" unitRef="USD">925,878</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzWTQ_z5thmFCeSWU8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif">R&amp;D</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2026-01-01to2026-03-31" id="Fact000207" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,724</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-03-31" id="Fact000208" format="ixt:numdotdecimal" decimals="0" unitRef="USD">215,277</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--SalariesAndWages_i01_maCzWTQ_zf4OO0mGdPI3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Salaries</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2026-01-01to2026-03-31" id="Fact000210" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,708,484</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2025-01-012025-03-31" id="Fact000211" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,525,446</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--Taxes_i01_maCzWTQ_zMHiw9NHFwSd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Taxes</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="SBFM:Taxes" contextRef="From2026-01-01to2026-03-31" id="Fact000213" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129,656</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="SBFM:Taxes" contextRef="From2025-01-012025-03-31" id="Fact000214" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,176</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--DepreciationDepletionAndAmortization_i01_maCzWTQ_zSaFCoC743n1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Depreciation
    &amp; amortization</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2026-01-01to2026-03-31" id="Fact000216" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,859</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2025-01-012025-03-31" id="Fact000217" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,793</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--GeneralAndAdministrativeExpense_i01T_mtCzWTQ_msCzDUx_zRIr9VebGtRg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Total General &amp; Administrative
    Expenses</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2026-01-01to2026-03-31" id="Fact000219" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,576,587</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-01-012025-03-31" id="Fact000220" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,026,176</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingIncomeLoss_i01T_mtCzDUx_maCzuwt_zKOCdGUsIsr6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">(Loss) From Operations</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2026-01-01to2026-03-31" id="Fact000222" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,395,597</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-01-012025-03-31" id="Fact000223" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,295,750</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_i01_maCz7tn_zKNG3mZYRNb2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Foreign exchange</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2026-01-01to2026-03-31" id="Fact000225" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2025-01-012025-03-31" id="Fact000226" format="ixt:numdotdecimal" decimals="0" unitRef="USD">451</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--InterestIncomeDebtSecuritiesOperating_i01_maCz7tn_zPEt49UGVLEd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Interest income</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:InterestIncomeDebtSecuritiesOperating" contextRef="From2026-01-01to2026-03-31" id="Fact000228" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,426</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:InterestIncomeDebtSecuritiesOperating" contextRef="From2025-01-012025-03-31" id="Fact000229" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,367</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--OtherIncome_i01_d0_maCz7tn_zLuIwpmtOczj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Other
    income</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:OtherIncome" contextRef="From2026-01-01to2026-03-31" id="Fact000231" format="ixt:numdotdecimal" decimals="0" unitRef="USD">103,320</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:OtherIncome" contextRef="From2025-01-012025-03-31" id="Fact000232" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--NonoperatingIncomeExpense_iT_mtCz7tn_maCzuwt_zzYf1Vf8OoE3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Total Other Income</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2026-01-01to2026-03-31" id="Fact000234" format="ixt:numdotdecimal" decimals="0" unitRef="USD">151,728</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2025-01-012025-03-31" id="Fact000235" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,818</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtCzuwt_maCzLyV_zZ6c4FSsMeOl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Net (loss) before income taxes</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2026-01-01to2026-03-31" id="Fact000237" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,243,869</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2025-01-012025-03-31" id="Fact000238" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,219,932</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_d0_msCzLyV_zcGFagKeULg1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Provision
    for income taxes</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2026-01-01to2026-03-31" id="Fact000240" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2025-01-012025-03-31" id="Fact000241" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">40,161</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_iT_mtCzLyV_maCz3pO_zBBlpTScqugi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Net (Loss)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2026-01-01to2026-03-31" id="Fact000243" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,243,869</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-03-31" id="Fact000244" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,179,771</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_maCz3pO_zy6SuAr3Vibj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Foreign exchange translation</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" contextRef="From2026-01-01to2026-03-31" id="Fact000246" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">277,997</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" contextRef="From2025-01-012025-03-31" id="Fact000247" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,189</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--ComprehensiveIncomeNetOfTax_iT_mtCz3pO_z9xBgHFNm0r9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Comprehensive (Loss)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2026-01-01to2026-03-31" id="Fact000249" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,521,866</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2025-01-012025-03-31" id="Fact000250" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,153,582</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--EarningsPerShareBasic_zeuSWWkN8o29" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">(Loss) per common share (Basic)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2026-01-01to2026-03-31" id="Fact000252" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.25</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-01-012025-03-31" id="Fact000253" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.44</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zKCZ5N1jqT4d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Weighted average common shares outstanding
    (Basic)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2026-01-01to2026-03-31" id="Fact000255" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,905,945</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-01-012025-03-31" id="Fact000256" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,703,293</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">See
Accompanying Notes To These Financial Statements.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Sunshine
Biopharma Inc.</span></p>

<p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif"><span id="q1_007"></span>Consolidated
Statements of Cash Flows (Unaudited)</span></p>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_302_112_zv3aqwZb5gll" summary="xdx: Statement - Consolidated Statements of Cash Flows (Unaudited)" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20260101__20260331_zbX5gpmtA9X6" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20250101__20250331_zDWSfUfs6Jf" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">March
    31,</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">March
    31,</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2026</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zbm49EnItUb7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Cash Flows
    From Operating Activities:</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--NetIncomeLoss_i01_pp0p0_maNCPBUzYoK_zaK8EoSnlr7a" style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Net (Loss)</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2026-01-01to2026-03-31" id="Fact000261" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,243,869</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-03-31" id="Fact000262" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,179,771</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zXeNBFTUXqol" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Adjustments to reconcile net
    loss to net cash used in operating activities:</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--DepreciationDepletionAndAmortization_i02_pp0p0_maNCPBUzYoK_zAvcfD5tkVr" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Depreciation
    and amortization</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2026-01-01to2026-03-31" id="Fact000267" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">76,859</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2025-01-012025-03-31" id="Fact000268" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">64,793</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInAccountsReceivable_i02N_pp0p0_di_msNCPBUzYoK_z6LGhbmn4Wx2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Accounts
    receivable</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2026-01-01to2026-03-31" id="Fact000270" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">609,601</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2025-01-012025-03-31" id="Fact000271" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">426,673</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInInventories_i02N_pp0p0_di_msNCPBUzYoK_zucyjGbDnL2g" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Inventory</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2026-01-01to2026-03-31" id="Fact000273" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">78,399</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2025-01-012025-03-31" id="Fact000274" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">568,834</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInDepositOtherAssets_i02N_pp0p0_di_msNCPBUzYoK_z6UW8PaqHWyl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Deposits</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDepositOtherAssets" contextRef="From2026-01-01to2026-03-31" id="Fact000276" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">71,740</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDepositOtherAssets" contextRef="From2025-01-012025-03-31" id="Fact000277" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">70,457</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInPrepaidExpense_i02N_pp0p0_di0_msNCPBUzYoK_zAOwE8961e3l" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Prepaid
    expenses</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2026-01-01to2026-03-31" id="Fact000279" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">154,726</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2025-01-012025-03-31" id="Fact000280" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">139,931</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_ecustom--IncreaseDecreaseInReductionInRightofuseAsset_i02_pp0p0_maNCPBUzYoK_z5pv68En0012" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Reduction
    in right-of-use asset</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><ix:nonFraction name="SBFM:IncreaseDecreaseInReductionInRightofuseAsset" contextRef="From2026-01-01to2026-03-31" id="Fact000282" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">52,788</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><ix:nonFraction name="SBFM:IncreaseDecreaseInReductionInRightofuseAsset" contextRef="From2025-01-012025-03-31" id="Fact000283" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">35,993</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i02_pp0p0_maNCPBUzYoK_z5gtxtFHN1Ee" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Accounts
    Payable &amp; accrued expenses</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2026-01-01to2026-03-31" id="Fact000285" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">455,836</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2025-01-012025-03-31" id="Fact000286" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">486,009</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i02_pp0p0_maNCPBUzYoK_zlgsPdixAgu9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Lease liability</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2026-01-01to2026-03-31" id="Fact000288" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">54,001</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2025-01-012025-03-31" id="Fact000289" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">17,160</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInAccruedIncomeTaxesPayable_i02_pp0p0_d0_maNCPBUzYoK_ztpEKv1ZoCi6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Income
    tax payable</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="From2026-01-01to2026-03-31" id="Fact000291" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">175</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="From2025-01-012025-03-31" id="Fact000292" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">40,161</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i02T_pp0p0_mtNCPBUzYoK_maCCERCzJTg_z2HNyN5M1Pm2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Net
    Cash Flows (Used In) Operating Activities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2026-01-01to2026-03-31" id="Fact000294" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,072,100</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-01-012025-03-31" id="Fact000295" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,695,002</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zlE5x3lHGSlb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Cash Flows
    From Investing Activities:</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--PaymentsToAcquireIntangibleAssets_i01N_pp0p0_di_msNCPBUzh1S_z1M0KG8WFb4d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Purchase
    of intangible assets</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2026-01-01to2026-03-31" id="Fact000300" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">99,389</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2025-01-012025-03-31" id="Fact000301" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">204,527</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_pp0p0_di_msNCPBUzh1S_z33r2g1dTN8k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Purchase
    of equipment</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2026-01-01to2026-03-31" id="Fact000303" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,129</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2025-01-012025-03-31" id="Fact000304" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,490</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInInvestingActivities_iT_pp0p0_mtNCPBUzh1S_maCCERCzJTg_zGxn72zM0Ca4" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Net
    Cash Flows (Used In) Investing Activities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2026-01-01to2026-03-31" id="Fact000306" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">104,518</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2025-01-012025-03-31" id="Fact000307" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">212,017</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zHDEUh4jXiVf" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Cash Flows
    From Financing Activities:</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--ProceedsFromWarrantExercises_i01_pp0p0_d0_maNCPBUz9PU_zIiq3ztb6BHg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Exercise
    of warrants</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2026-01-01to2026-03-31" id="Fact000312" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2025-01-012025-03-31" id="Fact000313" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">355,297</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_pp0p0_d0_mtNCPBUz9PU_maCCERCzJTg_ze8Wv3YluBy9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Net Cash Flows Provided by Financing Activities</b></span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2026-01-01to2026-03-31" id="Fact000315" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2025-01-012025-03-31" id="Fact000316" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">355,297</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_pp0p0_zL8rMbgYeCe8" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Cash and
    Cash Equivalents at Beginning of Period</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-12-31" id="Fact000318" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,123,308</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-12-31" id="Fact000319" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,686,529</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_pp0p0_mtCCERCzJTg_zZquoAStxFo9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Net increase
    (decrease) in cash and cash equivalents</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2026-01-01to2026-03-31" id="Fact000321" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,176,618</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2025-01-012025-03-31" id="Fact000322" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,551,722</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_402_eus-gaap--EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_pp0p0_z53LyQsOyQCi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Effect
    of exchange rate changes on cash</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="From2026-01-01to2026-03-31" id="Fact000324" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">33,677</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="From2025-01-012025-03-31" id="Fact000325" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">10,197</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_pp0p0_zoJmgzbUnNVi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Cash
    and Cash Equivalents at End of Period</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2026-03-31" id="Fact000327" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,913,013</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-03-31" id="Fact000328" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,124,610</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zPRHuSIVSUZh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Supplementary
    Disclosure of Cash Flow Information:</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--InterestPaidNet_i01_pp0p0_d0_zVmIlN7qdoof" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Cash
    paid for interest</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2026-01-01to2026-03-31" id="Fact000333" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2025-01-012025-03-31" id="Fact000334" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxesPaidNet_i01_pp0p0_d0_zGFwF9u29E3f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Cash
    paid for income taxes</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2026-01-01to2026-03-31" id="Fact000336" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2025-01-012025-03-31" id="Fact000337" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">See
Accompanying Notes To These Financial Statements.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"><b></b></span></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left; margin-top: 0; margin-bottom: 0"></p>

<p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Sunshine
Biopharma Inc.</span></p>

<p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif"><span id="q1_006"></span>Consolidated
Statements of Shareholders' Equity (Unaudited)</span></p>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left; margin-top: 0; margin-bottom: 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_300_114_z6SLhtqcM2Q2" summary="xdx: Statement - Consolidated Statements of Shareholders' Equity (Unaudited)" style="font: 9pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zQ5Jl416VVti" style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zVB7ZAiPAO13" style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zVnjmmcu6fgc" style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td id="xdx_4B1_us-gaap--StatementEquityComponentsAxis_us-gaap--ComprehensiveIncomeMember_zaWq8bIAE3w6" style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td id="xdx_4B1_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zngrtIi091Kj" style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td id="xdx_4BE_z2NzSquCznh5" style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">Number Of</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">Capital Paid</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">Number Of</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">Common Shares</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">Common</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">in Excess of
    Par</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">Preferred Shares</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">Preferred</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">Comprehensive</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">Accumulated</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">Three
    Months Period</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">Issued</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">Stock</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">Value</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">Issued</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">Stock</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">Income</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">Deficit</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">Total</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_430_c20260101__20260331_eus-gaap--StockholdersEquity_iS_zCxepx9bIOsa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">Balance December 31, 2025</span></td><td style="width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zx6VgGY6UO4" title="Beginning balance, shares" style="width: 6%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-12-31_us-gaap_CommonStockMember" id="Fact000346" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,905,945</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_CommonStockMember" id="Fact000339" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,905</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000340" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,100,990</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zwwUZuIZRBeg" title="Beginning balance, shares" style="width: 6%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-12-31_us-gaap_PreferredStockMember" id="Fact000348" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">130,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_PreferredStockMember" id="Fact000341" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_ComprehensiveIncomeMember" id="Fact000342" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">65,309</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td><td style="width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember" id="Fact000343" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">75,015,126</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td><td style="width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31" id="Fact000344" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,038,460</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--ComprehensiveIncomeNetOfTax_zB9CVee43dPg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Net (loss)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#8211;</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><span style="-sec-ix-hidden: xdx2ixbrl0350">&#8211;</span></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><span style="-sec-ix-hidden: xdx2ixbrl0351">&#8211;</span></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#8211;</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><span style="-sec-ix-hidden: xdx2ixbrl0352">&#8211;</span></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2026-01-012026-03-31_us-gaap_ComprehensiveIncomeMember" id="Fact000353" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">277,997</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember" id="Fact000354" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,243,869</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2026-01-01to2026-03-31" id="Fact000355" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,521,866</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td></tr>
  <tr id="xdx_43F_c20260101__20260331_eus-gaap--StockholdersEquity_iE_zTtCHmYq1rd1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Balance at March 31,
    2026</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--SharesOutstanding_iE_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcklNcZIrly4" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2026-03-31_us-gaap_CommonStockMember" id="Fact000364" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,905,945</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-03-31_us-gaap_CommonStockMember" id="Fact000357" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,905</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000358" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,100,990</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zQi4534wYQu9" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2026-03-31_us-gaap_PreferredStockMember" id="Fact000366" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">130,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-03-31_us-gaap_PreferredStockMember" id="Fact000359" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-03-31_us-gaap_ComprehensiveIncomeMember" id="Fact000360" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">343,306</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-03-31_us-gaap_RetainedEarningsMember" id="Fact000361" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">76,258,995</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-03-31" id="Fact000362" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,516,594</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_430_c20250101__20250331_eus-gaap--StockholdersEquity_iS_z77IJOrlgwg3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">Balance December 31, 2024</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLoxh7WNMBGk" title="Beginning balance, shares" style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000375" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,580,098</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000368" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,580</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000369" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93,354,907</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zjVo30yI1n0h" title="Beginning balance, shares" style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember" id="Fact000377" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">130,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember" id="Fact000370" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_ComprehensiveIncomeMember" id="Fact000371" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">829,959</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000372" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">69,039,774</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000373" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,500,754</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_iP3us-gaap--SharesOutstanding_zwwBDqHXiDza" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">Exercise of warrants</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_iP3us-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQ50hCkmJIJc" title="Exercise of warrants, shares" style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact000386" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">127,443</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact000379" format="ixt:numdotdecimal" decimals="0" unitRef="USD">127</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000380" format="ixt:numdotdecimal" decimals="0" unitRef="USD">355,171</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#8211;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><span style="-sec-ix-hidden: xdx2ixbrl0381">&#8211;</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><span style="-sec-ix-hidden: xdx2ixbrl0382">&#8211;</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><span style="-sec-ix-hidden: xdx2ixbrl0383">&#8211;</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-01-012025-03-31" id="Fact000384" format="ixt:numdotdecimal" decimals="0" unitRef="USD">355,298</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--ComprehensiveIncomeNetOfTax_zrLpctiuMzkj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Net (loss)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#8211;</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><span style="-sec-ix-hidden: xdx2ixbrl0388">&#8211;</span></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><span style="-sec-ix-hidden: xdx2ixbrl0389">&#8211;</span></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#8211;</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><span style="-sec-ix-hidden: xdx2ixbrl0390">&#8211;</span></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2025-01-012025-03-31_us-gaap_ComprehensiveIncomeMember" id="Fact000391" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,189</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="Fact000392" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,179,771</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2025-01-012025-03-31" id="Fact000393" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,153,582</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td></tr>
  <tr id="xdx_433_c20250101__20250331_eus-gaap--StockholdersEquity_iE_zWFRPs0iKXe5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Balance at March 31,
    2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmuif10LN2gj" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember" id="Fact000402" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,707,541</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember" id="Fact000395" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,707</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000396" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93,710,078</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td id="xdx_980_eus-gaap--SharesOutstanding_iE_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zZZvIEybZmeg" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-03-31_us-gaap_PreferredStockMember" id="Fact000404" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">130,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_PreferredStockMember" id="Fact000397" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_ComprehensiveIncomeMember" id="Fact000398" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">803,770</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember" id="Fact000399" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">70,219,545</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31" id="Fact000400" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,702,470</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">See
Accompanying Notes To These Financial Statements.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></p>

<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>Sunshine Biopharma
Inc.</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"><b><span id="q1_008"></span>Notes to Unaudited
Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>For the Three
Months Ended March 31, 2026 and 2025</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000406" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_802_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z2DeaOnl6Xod" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b><span style="text-decoration: underline">Note
1 &#8211;&#160;<span id="xdx_823_z8EtEQjhjm5g">Description of Business</span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
Company was incorporated under the name Mountain West Business Solutions, Inc. on August 31, 2006, in the State of Colorado. Effective
October 15, 2009, the Company acquired Sunshine Biopharma Inc. in a transaction classified as a reverse acquisition. Upon completion
of the reverse acquisition, the Company changed its name to Sunshine Biopharma Inc. and began operating as a pharmaceutical
company.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Sunshine
Biopharma has two wholly owned subsidiaries: (i) Nora Pharma Inc. (&#8220;Nora Pharma&#8221;), a Canadian corporation with a portfolio
of pharmaceutical products consisting of 60 generic prescription drugs on the market in Canada, and (ii) Sunshine Biopharma Canada Inc.
(&#8220;Sunshine Canada&#8221;), a Canadian corporation which develops and sells nonprescription, over-the-counter (&#8220;OTC&#8221;)
supplements. The Company operates the two subsidiaries as a <span id="xdx_901_eus-gaap--NumberOfOperatingSegments_dxL_uSegment_c20260101__20260331_zNOp7mPIYGI" title="Number of operating segments::XDX::1"><span id="xdx_90A_eus-gaap--NumberOfReportableSegments_dxL_uSegment_c20260101__20260331_zb7KR8S8GwB8" title="Number of reportable segments::XDX::1"><span style="-sec-ix-hidden: xdx2ixbrl0408"><span style="-sec-ix-hidden: xdx2ixbrl0410">single</span></span></span></span> business segment. Sales of the OTC supplements represent less than
3% of the Company&#8217;s total annual sales.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
Company is not subject to material customer concentration risks as it sells its products directly to pharmacies in several Canadian Provinces.
However, Provincial governments in Canada reimburse patients for their prescription drug expenditures to various degrees under drug reimbursement
programs, making generic drugs prices highly dependent on government policies which may change over time. The most recent negotiations
between the pan-Canadian Pharmaceutical Alliance (&#8220;pCPA&#8221;), the entity that negotiates drug prices on behalf of the government,
and the Canadian Generic Pharmaceutical Association (&#8220;CGPA&#8221;) resulted in updated generic pricing for certain products which
took effect on October 1, 2023. The updated prices are valid for three years and the agreement contains an option to extend for an additional
two years. On February 10, 2024, the Canadian federal government joined the generic drug reimbursement program as a payor under the Pharmacare
Act. This development further strengthened the Canadian generic drug market, which is the Company&#8217;s current focus.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">In
addition, the Company is engaged in the development of the following proprietary drugs:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">K1.1 mRNA, a lipid nano-particle
    (LNP) targeted for liver cancer</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">SBFM-PL4, a protease inhibitor
    for treatment of SARS Coronavirus infections</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000412" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock"><p id="xdx_80A_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zzs47lfM0e63" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b><span style="text-decoration: underline">Note
2 &#8211;&#160;<span id="xdx_82A_zp5BfBoUACYi">Basis of Presentation</span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
unaudited financial statements of the Company for the three month periods ended March 31, 2026 and 2025 have been prepared in accordance
with accounting principles generally accepted in the United States of America for interim financial information and pursuant to the requirements
for reporting on Form 10-Q and Regulation S-X. Accordingly, they do not include all the information and footnotes required by accounting
principles generally accepted in the United States of America for complete financial statements. However, such information reflects all
adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation
of the financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results
to be obtained for a full fiscal year. The balance sheet information as of December 31, 2025, was derived from the audited financial
statements included in the Company's financial statements as of and for the year ended December 31, 2025, included in the Company&#8217;s
Annual Report on Form 10-K filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on April 3, 2026. These financial
statements should be read in conjunction with that report.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<ix:exclude><p id="xdx_23C_znOhXfzLUpNg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zjcn0Xa3Y58j" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_239_zLC21IWcaG3f" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 7 -->
    <div id="xdx_231_zxgsixvzl1g4" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_231_zOH0xZAV98gc" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_znlCK3zRIQZ2" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000418" name="SBFM:ReverseStockSplitTextBlock"><p id="xdx_80C_ecustom--ReverseStockSplitTextBlock_zMBrGX1JIYm7" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b><span style="text-decoration: underline">Note
3 &#8211;&#160;<span id="xdx_82C_zqhTk9skmFO9">Reverse Stock Splits</span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Effective
April 17, 2024 and August 8, 2024, the Company completed <span id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20240416__20240417_zZEm5MJxDUae" title="Reverse stock split"><ix:nonNumeric contextRef="From2024-04-162024-04-17" id="Fact000420" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-100</ix:nonNumeric></span> and <span id="xdx_907_eus-gaap--StockholdersEquityReverseStockSplit_c20240807__20240808_zEdhenjeYUZf" title="Reverse stock split"><ix:nonNumeric contextRef="From2024-08-072024-08-08" id="Fact000422" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-20</ix:nonNumeric></span> reverse splits of its common stock, respectively. The
Company had previously completed three (3) reverse stock splits including a 1-for-200 reverse split on February 9, 2022, and two 1-for-20
reverse splits, one in 2019 and the other in 2020. The Company&#8217;s financial statements included in this report reflect all five
(5) reverse stock splits on a retroactive basis for all periods presented and for all references to common stock, unless specifically
stated otherwise.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; background-color: white">On
February 18, 2026, Dr. Steve N. Slilaty, the Company&#8217;s chief executive officer and holder of the majority of the voting power of
the stockholders of the Company, approved by written consent an authorization of the Company&#8217;s board of directors to effect a reverse
split of the Company&#8217;s issued and outstanding common stock in a ratio of up to 1-for-10, with the board of directors having the
discretion as to whether or not to effect the reverse split and at what ratio. The shareholder consent became effective March 23, 2026
(20 days after the definitive information statement relating to such consent was mailed to stockholders).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000424" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock"><p id="xdx_80E_eus-gaap--MergersAcquisitionsAndDispositionsDisclosuresTextBlock_zkAWd58ZUlv3" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b><span style="text-decoration: underline">Note
4 &#8211;&#160;<span id="xdx_827_zq1M8UeYyyqf">Acquisition of Nora Pharma Inc.</span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">On
October 20, 2022, the Company acquired all of the issued and outstanding shares of Nora Pharma Inc. (&#8220;Nora Pharma&#8221;), a Canadian
privately held pharmaceutical company. The purchase price for the shares was $<span id="xdx_906_eus-gaap--BusinessCombinationConsiderationTransferred1_pp0p0_c20221019__20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zkeRq1qaKeY5" title="Purchase price of shares"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2022-10-192022-10-20_custom_NoraPharmaMember" id="Fact000426" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,860,637</ix:nonFraction></span> which was paid in cash ($<span id="xdx_90D_eus-gaap--PaymentsToAcquireBusinessesGross_pp0p0_c20221019__20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zBLZdlIByqbl" title="Payments to acquire shares"><ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="From2022-10-192022-10-20_custom_NoraPharmaMember" id="Fact000428" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,346,637</ix:nonFraction></span>) and by
the issuance of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20221019__20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zhy3BozGrXO4" title="Stock issued for acquisition"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2022-10-192022-10-20_custom_NoraPharmaMember" id="Fact000430" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,850</ix:nonFraction></span> shares of the Company&#8217;s common stock valued at $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pp0p0_c20221019__20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zQYFB46JHll9" title="Stock issued for acquisition, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2022-10-192022-10-20_custom_NoraPharmaMember" id="Fact000432" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,514,000</ix:nonFraction></span> or $2,440.00 per share. Nora Pharma sells generic
pharmaceutical products in Canada. Nora Pharma&#8217;s operations are authorized by a Drug Establishment License issued by Health Canada.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">As
part of the consideration for Nora Pharma, the Company agreed to a $<span id="xdx_905_ecustom--EarnoutPayable_iI_uCAD_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember__srt--CounterpartyNameAxis__custom--MalekChamounMember_zb2Li8AFI7L6" title="Earnout payable"><ix:nonFraction name="SBFM:EarnoutPayable" contextRef="AsOf2022-10-20_custom_NoraPharmaMember_custom_MalekChamounMember" id="Fact000434" format="ixt:numdotdecimal" decimals="0" unitRef="CAD">5,000,000</ix:nonFraction></span> CAD ($<span id="xdx_90A_ecustom--EarnoutPayable_iI_uUSD_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember__srt--CounterpartyNameAxis__custom--MalekChamounMember_zOnq5VD5kxf6" title="Earnout payable"><ix:nonFraction name="SBFM:EarnoutPayable" contextRef="AsOf2022-10-20_custom_NoraPharmaMember_custom_MalekChamounMember" id="Fact000436" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,632,000</ix:nonFraction></span> USD) earnout amount payable to Mr. Malek
Chamoun, the seller of Nora Pharma. The earnout is payable in the form of twenty (20) payments of $250,000 CAD for every $1,000,000 CAD
increase in gross sales (as defined in the Purchase Agreement) above Nora Pharma&#8217;s June 30, 2022 gross sales, provided that his
employment with the Company is not terminated pursuant to the Company&#8217;s employment agreement with him. The total earnout amount
of $3,632,000 has been recorded as a salary payable. During the fiscal year ended December 31, 2023, the Company paid an earnout amount
of $<span id="xdx_905_ecustom--EarnoutLiabilityExpenseFirstInstallment_uCAD_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zY3tWokHGfld" title="Earnout liability expense, first installment"><ix:nonFraction name="SBFM:EarnoutLiabilityExpenseFirstInstallment" contextRef="From2023-01-012023-12-31_custom_NoraPharmaMember" id="Fact000438" format="ixt:numdotdecimal" decimals="0" unitRef="CAD">1,426,914</ix:nonFraction></span> CAD (approximately $<span id="xdx_903_ecustom--EarnoutLiabilityExpenseFirstInstallment_uUSD_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zs0NxXrA9d3"><ix:nonFraction name="SBFM:EarnoutLiabilityExpenseFirstInstallment" contextRef="From2023-01-012023-12-31_custom_NoraPharmaMember" id="Fact000439" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,036,500</ix:nonFraction></span> USD) for the fiscal year ended December 31, 2022. On April 22, 2024, the Company paid another
earnout amount of $<span id="xdx_90E_ecustom--EarnoutLiabilityExpenseSecondInstallment_uCAD_c20240421__20240422__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zfZrJ5g5oqC1" title="Earnout liability expense, second installment"><ix:nonFraction name="SBFM:EarnoutLiabilityExpenseSecondInstallment" contextRef="From2024-04-212024-04-22_custom_NoraPharmaMember" id="Fact000441" format="ixt:numdotdecimal" decimals="0" unitRef="CAD">3,093,878</ix:nonFraction></span> CAD (approximately $<span id="xdx_902_ecustom--EarnoutLiabilityExpenseSecondInstallment_uUSD_c20240421__20240422__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zGaPIbLfbqY2"><ix:nonFraction name="SBFM:EarnoutLiabilityExpenseSecondInstallment" contextRef="From2024-04-212024-04-22_custom_NoraPharmaMember" id="Fact000442" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,247,400</ix:nonFraction></span> USD) for the fiscal year ended December 31, 2023. As of December 31, 2025,
the remaining earnout balance was $<span id="xdx_906_ecustom--EarnoutLiabilityBalance_uCAD_c20250101__20251231__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zuOeX3DLC4ni" title="Remaining earnout balance"><ix:nonFraction name="SBFM:EarnoutLiabilityBalance" contextRef="From2025-01-012025-12-31_custom_NoraPharmaMember" id="Fact000444" format="ixt:numdotdecimal" decimals="0" unitRef="CAD">479,208</ix:nonFraction></span> CAD ($<span id="xdx_901_ecustom--EarnoutLiabilityBalance_uUSD_c20250101__20251231__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_z2Y22ItIazQc"><ix:nonFraction name="SBFM:EarnoutLiabilityBalance" contextRef="From2025-01-012025-12-31_custom_NoraPharmaMember" id="Fact000445" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,797</ix:nonFraction></span> USD). This remaining earnout amount is currently in dispute following dismissal
of Mr. Chamoun by the Company on April 14, 2025 (See Note 15).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000447" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p id="xdx_801_eus-gaap--IntangibleAssetsDisclosureTextBlock_zRMSdqXcZ4Z2" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b><span style="text-decoration: underline">Note
5 &#8211;&#160;<span id="xdx_823_zwxlD5TNgw8b">Intangible Assets</span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">Intangible assets
consisted of the following:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000449" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zrHEKQakZ3Sc" summary="xdx: Disclosure - Intangible Assets (Details - Intangible assets)" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="border-bottom: Black 1pt solid; vertical-align: bottom">
    <td><span id="xdx_8BC_zjUH5gaAFaSf" style="display: none">Schedule of intangible assets</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Period Ended</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left">Intangible assets at beginning of period, net</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_c20260101__20260331_zD5wRK6fN5Z5" title="Intangible assets at beginning of period" style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2025-12-31" id="Fact000451" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,889,370</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_c20250101__20251231_zdMKpexTbQc5" title="Intangible assets at beginning of period" style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-12-31" id="Fact000453" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,019,717</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left">Purchase of additional intangible assets (drug licenses &amp; dossiers)</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_c20260101__20260331_zDAq4Jptygvk" title="Purchase of additional intangible assets" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="From2026-01-01to2026-03-31" id="Fact000455" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,147</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_c20250101__20251231_zn7s50IPzU4d" title="Purchase of additional intangible assets" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="From2025-01-012025-12-31" id="Fact000457" format="ixt:numdotdecimal" decimals="0" unitRef="USD">774,355</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_c20260101__20260331_zBoFOLvWnGf7" title="Intangible assets at ending of period" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2026-03-31" id="Fact000459" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,957,517</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_c20250101__20251231_zRrJJxlOcb3b" title="Intangible assets at ending of period" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2025-12-31" id="Fact000461" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,794,072</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less impairment*</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_d0_c20260101__20260331_zucHPxh3hrYc" title="Less impairment" style="text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2026-01-01to2026-03-31" id="Fact000463" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_d0_c20250101__20251231_z8WFuNRTXsY8" title="Less impairment" style="text-align: right">(<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2025-01-012025-12-31" id="Fact000465" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,748,247</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">Less accumulated amortization</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20260331_zBjftBibnAV4" title="Less accumulated amortization" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2026-03-31" id="Fact000467" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,705</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20251231_z0qHyqKRU3h7" title="Less accumulated amortization" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2025-12-31" id="Fact000469" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156,455</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left">Intangible assets, net</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20260331_zv2kVbMPjWMg" title="Intangible assets, net" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2026-03-31" id="Fact000471" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,917,812</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20251231_zzC3glplQt55" title="Intangible assets, net" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2025-12-31" id="Fact000473" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,889,370</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">*
The impairment was a result of the determination by the Company that certain product licenses could not be commercialized</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

</ix:nonNumeric><p id="xdx_8A5_zLMyeyqstI9l" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<ix:exclude><p id="xdx_233_zq21jMzzxhhg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_23F_z5NLl4k58CN7" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_235_zG1H0h4yNtcc" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 8 -->
    <div id="xdx_232_zV2iFuqWa9ca" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_237_zrvr10L5Ds47" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zfAgCjhrSga9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000479" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_80E_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zMIx7KkCNkCd" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b><span style="text-decoration: underline">Note
6 &#8211;&#160;<span id="xdx_823_zbYbj6wcgaPi">Plant, Property and Equipment</span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Property,
plant and equipment are stated at cost. Depreciation of property, plant and equipment begins in the month when the asset is placed into
service and is provided using the straight-line method for financial reporting purposes at rates based on the estimated useful lives
of the assets. Estimated useful lives range from three to twenty years. Property, plant and equipment consist of the following:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000481" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--PropertyPlantAndEquipmentTextBlock_z6mp9R2mdPu1" summary="xdx: Disclosure - Plant, Property and Equipment (Details)" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="border-bottom: Black 1pt solid; vertical-align: bottom">
    <td><span id="xdx_8B6_z40TVLdXvfu8" style="display: none">Schedule
    of plant property and equipment</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49C_20260331_z72JAJAYhzSe" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_492_20251231_zAyr9df3LW6j" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Period Ended</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zjMYTRzIS1O3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%">Equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2026-03-31_us-gaap_EquipmentMember" id="Fact000483" format="ixt:numdotdecimal" decimals="0" unitRef="USD">352,278</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-12-31_us-gaap_EquipmentMember" id="Fact000484" format="ixt:numdotdecimal" decimals="0" unitRef="USD">335,464</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zJ0IJRA1hAe7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Computer equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2026-03-31_us-gaap_ComputerEquipmentMember" id="Fact000486" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,029</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-12-31_us-gaap_ComputerEquipmentMember" id="Fact000487" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69,139</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zq5fmfY3cMEf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2026-03-31_us-gaap_FurnitureAndFixturesMember" id="Fact000489" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,702</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-12-31_us-gaap_FurnitureAndFixturesMember" id="Fact000490" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,462</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_d0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z22PQyDrIIFa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2026-03-31_us-gaap_LeaseholdImprovementsMember" id="Fact000492" format="ixt:numdotdecimal" decimals="0" unitRef="USD">91,157</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-12-31_us-gaap_LeaseholdImprovementsMember" id="Fact000493" format="ixt:numdotdecimal" decimals="0" unitRef="USD">92,706</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zZwQlgZRqdcl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid">Vehicles</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2026-03-31_us-gaap_VehiclesMember" id="Fact000495" format="ixt:numdotdecimal" decimals="0" unitRef="USD">498,995</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-12-31_us-gaap_VehiclesMember" id="Fact000496" format="ixt:numdotdecimal" decimals="0" unitRef="USD">507,478</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzbhx_zBlydmVUX0ye" style="vertical-align: bottom; background-color: White">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2026-03-31" id="Fact000498" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,066,161</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-12-31" id="Fact000499" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,070,249</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzbhx_zeiRvQSraykh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">Less accumulated depreciation</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2026-03-31" id="Fact000501" format="ixt:numdotdecimal" decimals="0" unitRef="USD">549,812</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2025-12-31" id="Fact000502" format="ixt:numdotdecimal" decimals="0" unitRef="USD">512,879</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzbhx_zBsJlbwC3TO3" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left">Plant, property and equipment, net</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2026-03-31" id="Fact000504" format="ixt:numdotdecimal" decimals="0" unitRef="USD">516,349</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2025-12-31" id="Fact000505" format="ixt:numdotdecimal" decimals="0" unitRef="USD">557,370</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000507" name="us-gaap:InventoryDisclosureTextBlock"><p id="xdx_80B_eus-gaap--InventoryDisclosureTextBlock_z8d6pnAaH0r9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b><span style="text-decoration: underline">Note
7 &#8211;&#160;<span id="xdx_82E_zx5ntqyfPwBi">Inventory</span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Inventory
consists solely of finished goods purchased for resale. Inventory is stated at cost which represents the amount paid to acquire the finished
goods. The Company evaluates inventory for potential obsolescence based on a combination of factors, including (i) aging, (ii) historical
sell-through patterns, and (iii) product-specific considerations. When estimated net realizable value is lower than cost, the Company
records an allowance for obsolescence for the difference. Write-downs are recorded within cost of goods sold and are not subsequently
reversed.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">Inventory is comprised
of the following:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000509" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zU4MbZn7yvg4" summary="xdx: Disclosure - Inventory (Details)" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="border-bottom: Black 1pt solid; vertical-align: bottom">
    <td><span id="xdx_8B5_zETUbe8XGd6i" style="display: none">Schedule of inventory</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_490_20260331_zHkpY92a1YUi" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_495_20251231_zPXaqC6zP3Lc" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Period Ended</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--InventoryFinishedGoods_iI_zn2V82HAaZ93" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left">Finished goods</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2026-03-31" id="Fact000511" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,035,748</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2025-12-31" id="Fact000512" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,947,178</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--AllowanceForObsoleteInventory_iI_d0_msARNCzj7C_zCBCR87CSehl" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left">Allowance for obsolete inventory</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="SBFM:AllowanceForObsoleteInventory" contextRef="AsOf2026-03-31" id="Fact000514" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">867,318</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="SBFM:AllowanceForObsoleteInventory" contextRef="AsOf2025-12-31" id="Fact000515" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">475,797</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--InventoryNet_iI_zdZJYi514ez" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left">Total Inventory, net of allowance</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2026-03-31" id="Fact000517" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,168,430</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2025-12-31" id="Fact000518" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,472,025</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<ix:exclude><p id="xdx_235_zZpRwQOFimql" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_237_zPAY2iMo7lP9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zciqidIDdoWa" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zkpa0eM6xYD2" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 9 -->
    <div id="xdx_23C_z6W2Id57zkwh" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_231_zN5mGlgBEu14" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23C_z0ZoQ4EIptC5" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000525" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_807_eus-gaap--LesseeOperatingLeasesTextBlock_zWCY5Y0Zbhkh" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b><span style="text-decoration: underline">Note
8 &#8211;&#160;<span id="xdx_821_zuZsUxx7hggb">Leases</span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
Company has obligations as a lessee for warehouse and office space with initial non-cancellable terms in excess of one year. The Company
classified the lease as an operating lease. The lease contains a renewal option for a period of five years. Because the Company is certain
to exercise the renewal option, the optional period is included in determining the lease term, and associated payments under the renewal
option are included in the lease payments. The Company&#8217;s lease does not include termination options for either party to the lease
or restrictive financial or other covenants. Payments due under the lease contract include fixed payments plus a variable payment. The
Company&#8217;s office space lease requires it to make variable payments for the Company&#8217;s proportionate share of building&#8217;s
property taxes, insurance, and common area maintenance. These variable lease payments are not included in lease payments used to determine
lease liability and are recognized as variable costs when incurred.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Amounts
reported on the balance sheet as of March 31, 2026 were as follows:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000527" name="us-gaap:LeaseCostTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--LeaseCostTableTextBlock_zYThboU7nwxk" summary="xdx: Disclosure - Leases (Details - Lease information)" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;<span id="xdx_8BE_zIKgWA6AvVpa" style="display: none">Schedule of lease information</span></span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 83%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Operating lease ROU asset</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><span id="xdx_905_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20260331_zafwhQI5qDgk" title="Operating lease ROU asset"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2026-03-31" id="Fact000529" format="ixt:numdotdecimal" decimals="0" unitRef="USD">713,038</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Operating Lease liability - Short-term</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><span id="xdx_902_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20260331_zaa4VAJ76ZH5" title="Operating Lease liability - Short-term"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2026-03-31" id="Fact000531" format="ixt:numdotdecimal" decimals="0" unitRef="USD">209,226</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Operating lease liability - Long-term</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><span id="xdx_90D_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20260331_zAo3Rz0ElP16" title="Operating lease liability - Long-term"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2026-03-31" id="Fact000533" format="ixt:numdotdecimal" decimals="0" unitRef="USD">535,614</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Remaining lease term</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_90F_ecustom--LesseeOperatingLeasesRemainingLeaseTerm_c20260101__20260331_zDtTkwGTbcG4" title="Remaining lease term"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" id="Fact000535" name="SBFM:LesseeOperatingLeasesRemainingLeaseTerm">4
                                            Years 6 Months</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Discount rate</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20260331_zHglqOXb5u6k" title="Discount rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2026-03-31" id="Fact000537" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>%</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Amounts
disclosed for ROU assets obtained in exchange for lease obligations and reductions of ROU assets resulting from reductions of lease obligations
include amounts reduced from the carrying amount of ROU assets resulting from deferred rent.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Maturities
of lease liabilities under non-cancellable operating leases at March 31, 2026 are as follows:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000539" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zWPaPM7ACZnd" summary="xdx: Disclosure - Leases (Details - Maturities of lease payments)" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;<span id="xdx_8B5_zeE9O9ujvNoc" style="display: none">Schedule of maturities of lease liabilities</span></span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20260331_z7gTOmIqKAi2" style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_zIzx0IxDJXNf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 83%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2026</span></td>
    <td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="AsOf2026-03-31" id="Fact000541" format="ixt:numdotdecimal" decimals="0" unitRef="USD">158,031</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_z6p3oWnArCyk" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2027</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2026-03-31" id="Fact000543" format="ixt:numdotdecimal" decimals="0" unitRef="USD">201,011</ix:nonFraction></span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_zeo1i9pHWJ52" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2028</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2026-03-31" id="Fact000545" format="ixt:numdotdecimal" decimals="0" unitRef="USD">190,554</ix:nonFraction></span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_zlYLJ4n2U9Yb" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2029</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2026-03-31" id="Fact000547" format="ixt:numdotdecimal" decimals="0" unitRef="USD">180,634</ix:nonFraction></span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_iI_zIjglAIRDXOe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Thereafter</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><ix:nonFraction name="SBFM:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" contextRef="AsOf2026-03-31" id="Fact000549" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,610</ix:nonFraction></span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<ix:exclude><p id="xdx_23A_zuodFHcvfYa" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zoE9c9LwfuPc" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p></ix:exclude>


<ix:exclude><p id="xdx_23C_zIWgJ2IUlCt1" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zzXQ4iiePQ5l" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 10 -->
    <div id="xdx_235_zLv14U6O9VIa" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23D_z86Roi2DtNbi" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23E_zqdrg34wu4Ed" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p></ix:exclude>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000556" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_806_eus-gaap--IncomeTaxDisclosureTextBlock_zMc8Je7sKiSh" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b><span style="text-decoration: underline">Note
9 &#8211; <span id="xdx_825_zF0exUUgRsdc">Income Taxes</span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
Company&#8217;s income tax (expense) / benefit of $<span id="xdx_900_eus-gaap--IncomeTaxExpenseBenefit_c20260101__20260331__us-gaap--IncomeTaxAuthorityAxis__country--US_z5Gq1oSxMVc5" title="Income tax (expense) / benefit"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2026-01-012026-03-31_country_US" id="Fact000558" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--IncomeTaxExpenseBenefit_c20250101__20250331__us-gaap--IncomeTaxAuthorityAxis__country--US_ztyyHlDXBy2i" title="Income tax (expense) / benefit"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2025-01-012025-03-31_country_US" id="Fact000560" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,161</ix:nonFraction></span> for the three months ended March 31, 2026 and March 31, 2025, respectively,
is primarily due to operations outside of the United States and changes in valuation allowance related to certain deferred tax assets
generated or utilized in the applicable period.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Deferred
tax assets are regularly reviewed for recoverability by jurisdiction and valuation allowances are established based on historical and
projected future taxable losses and the expected timing of the reversal of existing temporary differences. The Company has recorded valuation
allowances against the majority of its deferred tax assets of March 31, 2026, and the Company expects to maintain these valuation allowances
until there is sufficient evidence that future earnings can be achieved, which is uncertain at this time.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
Company's consolidated financial statements contain various tax related entries as a result of operations of the two Canadian subsidiaries
and are in compliance with Canadian tax laws.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
Company only recognizes tax benefits from an uncertain tax position if it is more likely than not that the tax position will be sustained
on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial
statement from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized
upon ultimate resolution. To date, the Company has not recognized such tax benefits in its financial statements.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">On
July 4, 2025, the One Big Beautiful Bill Act ("OBBBA") was enacted in the U.S. The OBBBA makes permanent key elements of the
Tax Cuts and Jobs Act, including 100% bonus depreciation, domestic research cost expensing, and the business interest expense limitation.
<i>ASC Topic 740, Income Taxes</i>, requires the tax effects of changes in tax rates and laws to be recognized in the period in which
the legislation is enacted. Those effects, both current tax and deferred tax, are reported as part of continuing operations. The Company
is currently assessing the impact of OBBBA on its Consolidated Financial Statements but does not believe that the OBBBA will
have a material impact on the Company's income tax expense.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In July 2025, OBBBA amended section 951A for
taxable years beginning after December 31, 2025, replacing the prior Global Intangible Low-Taxed Income (&#8220;GILTI&#8221;) regime
with a net Controlled Foreign Corporation (&#8220;CFC&#8221;) tested income inclusion framework. The legislation also modified related
provisions, including the deduction under section 250 for amounts included under section 951A. The Company has evaluated the impact of
these changes on its income tax accounting and related disclosures under <i>ASC 740</i>, including the effect on its estimated annual
effective tax rate and taxes on foreign earnings. The Company does not expect the impact of these changes to be material to its financial
statements.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23D_zETox4qEjmx7" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zFbVrKpQEUPe" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><p id="xdx_235_zM69ery1aqS1" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zzG9j9wNGAFi" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_236_zFzNICVova8h" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 11 -->
    <div id="xdx_235_z8dAciA4YAPg" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_231_zf06a7Pvoj53" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_z081WOQ19HTd" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000568" name="SBFM:CompensationRelatedCostsDisclosureTextBlock"><p id="xdx_803_ecustom--CompensationRelatedCostsDisclosureTextBlock_z9wSjC2uBp6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b><span style="text-decoration: underline">Note
10 &#8211;&#160;<span id="xdx_826_zMBjyqxfVry">Management and Director Compensation</span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
Company paid its officers aggregate cash compensation of $<span id="xdx_905_eus-gaap--SalariesWagesAndOfficersCompensation_c20260101__20260331_zGCm2NvkgRMl" title="Officers compensation"><ix:nonFraction name="us-gaap:SalariesWagesAndOfficersCompensation" contextRef="From2026-01-01to2026-03-31" id="Fact000570" format="ixt:numdotdecimal" decimals="0" unitRef="USD">251,160</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--SalariesWagesAndOfficersCompensation_c20250101__20250331_zuoDamZJ3KJj" title="Officers compensation"><ix:nonFraction name="us-gaap:SalariesWagesAndOfficersCompensation" contextRef="From2025-01-012025-03-31" id="Fact000572" format="ixt:numdotdecimal" decimals="0" unitRef="USD">269,496</ix:nonFraction></span> for the three-month periods ended March 31, 2026 and 2025,
respectively.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
Company paid its directors aggregate cash compensation of $<span id="xdx_901_eus-gaap--NoninterestExpenseDirectorsFees_c20260101__20260331__srt--CounterpartyNameAxis__custom--AllDirectorsMember_zlSSZTZ77nnk" title="Directors cash compensation"><span id="xdx_90E_eus-gaap--NoninterestExpenseDirectorsFees_c20250101__20250331__srt--CounterpartyNameAxis__custom--AllDirectorsMember_zdjOyJoq1LAl"><ix:nonFraction name="us-gaap:NoninterestExpenseDirectorsFees" contextRef="From2026-01-012026-03-31_custom_AllDirectorsMember" id="Fact000574" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:NoninterestExpenseDirectorsFees" contextRef="From2025-01-012025-03-31_custom_AllDirectorsMember" id="Fact000575" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></ix:nonFraction></span></span> for each of the three-month periods ended March 31, 2026 and 2025
($<span id="xdx_90A_eus-gaap--NoninterestExpenseDirectorsFees_c20260101__20260331__srt--CounterpartyNameAxis__custom--Director1Member_z3Qm1mGxeSNk" title="Directors cash compensation"><span id="xdx_908_eus-gaap--NoninterestExpenseDirectorsFees_c20260101__20260331__srt--CounterpartyNameAxis__custom--Director2Member_zuqpt13lVj0c"><span id="xdx_90B_eus-gaap--NoninterestExpenseDirectorsFees_c20260101__20260331__srt--CounterpartyNameAxis__custom--Director3Member_zyo0TTG5Sj88"><span id="xdx_90F_eus-gaap--NoninterestExpenseDirectorsFees_c20260101__20260331__srt--CounterpartyNameAxis__custom--Director4Member_zP4Nmu8XVkik"><span id="xdx_901_eus-gaap--NoninterestExpenseDirectorsFees_c20260101__20260331__srt--CounterpartyNameAxis__custom--Director5Member_zpK3tJmPkAG2"><span id="xdx_905_eus-gaap--NoninterestExpenseDirectorsFees_c20250101__20250331__srt--CounterpartyNameAxis__custom--Director1Member_zj22bX0PRrge"><span id="xdx_905_eus-gaap--NoninterestExpenseDirectorsFees_c20250101__20250331__srt--CounterpartyNameAxis__custom--Director2Member_z3oiYXci0MBa"><span id="xdx_901_eus-gaap--NoninterestExpenseDirectorsFees_c20250101__20250331__srt--CounterpartyNameAxis__custom--Director3Member_z6NziEE1ATjd"><span id="xdx_90A_eus-gaap--NoninterestExpenseDirectorsFees_c20250101__20250331__srt--CounterpartyNameAxis__custom--Director4Member_z8kxXIQCgCra"><span id="xdx_903_eus-gaap--NoninterestExpenseDirectorsFees_c20250101__20250331__srt--CounterpartyNameAxis__custom--Director5Member_z43cJtQsHaTk"><ix:nonFraction name="us-gaap:NoninterestExpenseDirectorsFees" contextRef="From2026-01-012026-03-31_custom_Director1Member" id="Fact000577" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:NoninterestExpenseDirectorsFees" contextRef="From2026-01-012026-03-31_custom_Director2Member" id="Fact000578" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:NoninterestExpenseDirectorsFees" contextRef="From2026-01-012026-03-31_custom_Director3Member" id="Fact000579" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:NoninterestExpenseDirectorsFees" contextRef="From2026-01-012026-03-31_custom_Director4Member" id="Fact000580" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:NoninterestExpenseDirectorsFees" contextRef="From2026-01-012026-03-31_custom_Director5Member" id="Fact000581" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:NoninterestExpenseDirectorsFees" contextRef="From2025-01-012025-03-31_custom_Director1Member" id="Fact000582" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:NoninterestExpenseDirectorsFees" contextRef="From2025-01-012025-03-31_custom_Director2Member" id="Fact000583" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:NoninterestExpenseDirectorsFees" contextRef="From2025-01-012025-03-31_custom_Director3Member" id="Fact000584" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:NoninterestExpenseDirectorsFees" contextRef="From2025-01-012025-03-31_custom_Director4Member" id="Fact000585" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:NoninterestExpenseDirectorsFees" contextRef="From2025-01-012025-03-31_custom_Director5Member" id="Fact000586" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span></span></span></span></span></span></span> per director).&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000588" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z0cSDmzvLXij" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b><span style="text-decoration: underline">Note
11 &#8211;&#160;<span id="xdx_827_zqlYsOhx7Gna">Capital Stock</span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
Company&#8217;s authorized capital is comprised of <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_c20260331_zfHywfOGgZH1" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2026-03-31" id="Fact000590" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,000,000,000</ix:nonFraction></span> shares of common stock, par value $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20260331_zW4mXuAL7lF8" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2026-03-31" id="Fact000592" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span>, and <span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_c20260331__srt--TitleOfIndividualAxis__srt--DirectorMember_zBZOto6NZHY9" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2026-03-31_srt_DirectorMember" id="Fact000594" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,000,000</ix:nonFraction></span> shares of preferred
stock, $<span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20260331__srt--TitleOfIndividualAxis__srt--DirectorMember_zTpXD9DWYBAl" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2026-03-31_srt_DirectorMember" id="Fact000596" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.10</ix:nonFraction></span> par value. As of March 31, 2026, the Company had authorized <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zzIBLwDJDn9k" title="Preferred stock, shares authorized"><span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zmVXkKzxpwT8" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2026-03-31_us-gaap_SeriesBPreferredStockMember" id="Fact000598" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000600" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></ix:nonFraction></span></span> shares of Series B Preferred Stock. The Series B Preferred
Stock is non-convertible and non-redeemable. It has a liquidation preference equal to the stated value of $0.10 per share, relative to
the common stock and gives the holder the right to 1,000 votes per share. As of March 31, 2026, <span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zrqXSQEvdD5a" title="Preferred stock, shares outstanding"><span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zVGPa0S5ZXY9" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2026-03-31_us-gaap_SeriesBPreferredStockMember_srt_ChiefExecutiveOfficerMember" id="Fact000602" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-12-31_us-gaap_SeriesBPreferredStockMember_srt_ChiefExecutiveOfficerMember" id="Fact000604" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">130,000</ix:nonFraction></ix:nonFraction></span></span> shares of Series B Preferred
Stock were outstanding and held by the Company&#8217;s Chief Executive Officer.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">On
January 3, 2025, the Company issued <span id="xdx_907_eus-gaap--ConversionOfStockSharesIssued1_c20250102__20250103__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zP5cXv0nejl" title="Stock converted, shares issued"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2025-01-022025-01-03_us-gaap_CommonStockMember" id="Fact000606" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">127,443</ix:nonFraction></span> shares of common stock upon the exercise of <span id="xdx_900_eus-gaap--ConversionOfStockSharesConverted1_c20250102__20250103__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zwkYoJyH51B3" title="Stock converted, shares converted"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2025-01-022025-01-03_custom_SeriesBWarrantsMember" id="Fact000608" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">127,443</ix:nonFraction></span> Series B Warrants and received $<span id="xdx_90A_eus-gaap--ProceedsFromWarrantExercises_c20250102__20250103__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zsZN3W3qXy4j" title="Proceeds from warrant exercise"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2025-01-022025-01-03_custom_SeriesBWarrantsMember" id="Fact000610" format="ixt:numdotdecimal" decimals="0" unitRef="USD">355,298</ix:nonFraction></span>
in net proceeds.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">On
April 2, 2025, the Company issued <span id="xdx_905_eus-gaap--ConversionOfStockSharesIssued1_c20250401__20250402__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zc3jPVyy4ktd" title="Stock converted, shares issued"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2025-04-012025-04-02_us-gaap_CommonStockMember" id="Fact000612" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">660,000</ix:nonFraction></span> shares of common stock upon the exercise of <span id="xdx_90F_eus-gaap--ConversionOfStockSharesConverted1_c20250401__20250402__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zfKECF2GVxvh" title="Stock converted, shares converted"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2025-04-012025-04-02_custom_SeriesBWarrantsMember" id="Fact000614" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">660,000</ix:nonFraction></span> Series B Warrants and received $<span id="xdx_905_eus-gaap--ProceedsFromWarrantExercises_c20250401__20250402__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zU8k8UuhPru4" title="Proceeds from warrant exercise"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2025-04-012025-04-02_custom_SeriesBWarrantsMember" id="Fact000616" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,840,014</ix:nonFraction></span>
in net proceeds.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">On
April 3, 2025, the Company issued an aggregate of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250401__20250403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember_zbpIFmjAnzuc" title="Aggregate shares Issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-04-012025-04-03_us-gaap_CommonStockMember_custom_RegisteredDirectOfferingMember" id="Fact000618" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,188,404</ix:nonFraction></span> shares of common stock in connection with a registered direct offering and
received $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250401__20250403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember_zqNlYkY17PZf" title="Net proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-04-012025-04-03_us-gaap_CommonStockMember_custom_RegisteredDirectOfferingMember" id="Fact000620" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,828,596</ix:nonFraction></span> in net proceeds.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">On
October 16, 2025, the Company issued <span id="xdx_90F_eus-gaap--ConversionOfStockSharesIssued1_c20251015__20251016__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zc3yksZ0fY8" title="Stock converted, shares issued"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2025-10-152025-10-16_us-gaap_CommonStockMember" id="Fact000622" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span> shares of common stock upon the exercise of <span id="xdx_901_eus-gaap--ConversionOfStockSharesConverted1_c20251015__20251016__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zEQoAFSHTUmf" title="Stock converted, shares converted"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2025-10-152025-10-16_custom_SeriesBWarrantsMember" id="Fact000624" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span> Series B Warrants and received net proceeds
of $<span id="xdx_90F_eus-gaap--ProceedsFromWarrantExercises_c20251015__20251016__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zbOxhfV3BFd3" title="Net proceeds"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2025-10-152025-10-16_custom_SeriesBWarrantsMember" id="Fact000626" format="ixt:numdotdecimal" decimals="0" unitRef="USD">724,500</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">As
of March 31, 2026 and December 31, 2025, the Company had <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_c20260331_zufR67krgkK5"><span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_c20260331_zF266wFxJ4X4"><span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_c20251231_z42oS2fULTXd" title="Common stock, shares issued"><span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_c20251231_zyRqUKWfpyL9" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2026-03-31" id="Fact000627" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2026-03-31" id="Fact000628" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-12-31" id="Fact000630" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-12-31" id="Fact000632" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,905,945</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares of common stock issued and outstanding.</span></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
Company has declared no dividends since inception.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000634" name="SBFM:WarrantsDisclosureTextBlock"><p id="xdx_804_ecustom--WarrantsDisclosureTextBlock_zgefdF98JNlb" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b><span style="text-decoration: underline">Note
12 &#8211;&#160;<span id="xdx_82D_z41R79xKmNGg">Warrants</span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
Company accounts for issued warrants either as a liability or equity in accordance with <i>ASC 480-10</i> or <i>ASC 815-40</i>. Under
<i>ASC 480-10</i>, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other
assets, or a variable number of shares. If warrants do not meet liability classification under <i>ASC 480-10</i>, the Company considers
the requirements of <i>ASC 815-40</i> to determine whether the warrants should be classified as a liability or as equity. Under <i>ASC
815-40</i>, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering
event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change
in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss.
If warrants do not require liability classification under <i>ASC 815-40</i>, in order to conclude warrants should be classified as equity,
the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under <i>ASC
815-40</i> or other applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no
changes in fair value recognized after the issuance date.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<ix:exclude><p id="xdx_23B_zJfLvhNEeEVc" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_234_zoxsRfeT1kJk" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_239_zMKWhGaRtZj4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 12 -->
    <div id="xdx_23D_zmZkV5BS9N8e" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_231_zUHdBgPUpN58" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zrdHMwyvk3T6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">In
2022, 2023, 2024, and 2025, the Company completed six (6) financing events, and in connection therewith, it issued warrants as follows:</span></p>

<ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000640" name="SBFM:ScheduleOfWarrantsIssuedWithFinancingTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--ScheduleOfWarrantsIssuedWithFinancingTableTextBlock_z3kLv63CZYD2" summary="xdx: Disclosure - Warrants (Details - Warrants issued with financing)" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 9pt">&#160;<span id="xdx_8B7_zQgPJrzqilac" style="display: none">Schedule of warrants issued with financing</span></span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"><span style="font-size: 9pt">Issuance Date/Type</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Number</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Exercise
    Price</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"><span style="font-size: 9pt">Expiry Date</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 47%; text-align: justify"><span style="font-size: 9pt">Feb 17, 2022 (&#8220;Tradeable Warrants&#8221;)*</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_fKg_____zFNlPbkCNnu4" title="Warrants outstanding" style="width: 13%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2026-03-31_custom_TradeableWarrantsMember" id="Fact000642" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,051</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_z3XURb75j5Hd" title="Warrant expiration date"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-03-31_custom_TradeableWarrantsMember" id="Fact000644" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4,440.00</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 17%; text-align: justify"><span style="font-size: 9pt"><span id="xdx_90B_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_zwd5RSFiipmf" title="Warrant expiration date"><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_TradeableWarrantsMember" id="Fact000646" name="SBFM:WarrantExpirationDate">February 2027</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-size: 9pt">Mar 14, 2022 (&#8220;2022 Pre-Funded Warrants&#8221;)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--PreFunded2022WarrantsMember_zSDVm8DZs7Z9" title="Warrants outstanding" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2026-03-31_custom_PreFunded2022WarrantsMember" id="Fact000648" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,846</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--PreFunded2022WarrantsMember_zsWwnKfq3Aek" title="Warrant expiration date"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-03-31_custom_PreFunded2022WarrantsMember" id="Fact000650" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.00</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt"><span id="xdx_909_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--PreFunded2022WarrantsMember_zbHvGRYNtgc2" title="Warrant expiration date"><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_PreFunded2022WarrantsMember" id="Fact000652" name="SBFM:WarrantExpirationDate">Unlimited</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 9pt">Mar 14, 2022 (&#8220;Investor Warrants&#8221;)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_zlpEKgtvk7fa"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2026-03-31_custom_InvestorWarrantsMember" id="Fact000653" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,801</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_zXXBuzTZihpa"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-03-31_custom_InvestorWarrantsMember" id="Fact000654" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4,440.00</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt"><span id="xdx_909_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_zhehrWq1HAKl"><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_InvestorWarrantsMember" id="Fact000655" name="SBFM:WarrantExpirationDate">March 2027</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-size: 9pt">Apr 28, 2022 (&#8220;April Warrants&#8221;)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_z9UtQ5ylKBDb" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2026-03-31_custom_AprilWarrantsMember" id="Fact000656" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,862</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_z3tX4rpVkpkf"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-03-31_custom_AprilWarrantsMember" id="Fact000657" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7,520.00</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt"><span id="xdx_908_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_zDrzvMaDeGwk"><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_AprilWarrantsMember" id="Fact000658" name="SBFM:WarrantExpirationDate">April 2027</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 9pt">May 16, 2023 (&#8220;May Pre-Funded Warrants&#8221;)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_zzCltop3CFh3" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2026-03-31_custom_MayPreFundedWarrantsMember" id="Fact000659" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,751</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_zPq6QUFjLh2"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-03-31_custom_MayPreFundedWarrantsMember" id="Fact000660" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.00</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt"><span id="xdx_90C_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_z6WLCW2CXcei"><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_MayPreFundedWarrantsMember" id="Fact000661" name="SBFM:WarrantExpirationDate">Unlimited</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-size: 9pt">May 16, 2023 (&#8220;May Investor Warrants&#8221;)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_zfITJ50GfMAl" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2026-03-31_custom_MayInvestorWarrantsMember" id="Fact000662" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,952</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_zCZUCd9cxTtk"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-03-31_custom_MayInvestorWarrantsMember" id="Fact000663" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,180.00</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt"><span id="xdx_903_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_znIgoCy4VMBd"><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_MayInvestorWarrantsMember" id="Fact000664" name="SBFM:WarrantExpirationDate">November 2028</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 9pt">Feb 15, 2024 (&#8220;2024 Pre-Funded Warrants&#8221;)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--PreFunded2024WarrantsMember_zy1UPEFRHGt5" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2026-03-31_custom_PreFunded2024WarrantsMember" id="Fact000665" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--PreFunded2024WarrantsMember_zajtJ1lI2685"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-03-31_custom_PreFunded2024WarrantsMember" id="Fact000666" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.00</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt"><span id="xdx_905_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--PreFunded2024WarrantsMember_znK4aYMNJJQ3"><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_PreFunded2024WarrantsMember" id="Fact000667" name="SBFM:WarrantExpirationDate">Unlimited</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-size: 9pt">Feb 15, 2024 (&#8220;Series A Warrants&#8221;)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsMember_fKio___zn90kykWzd14"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2026-03-31_custom_SeriesAWarrantsMember" id="Fact000668" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,986</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-size: 9pt">**</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsMember_zPt1hEIIFu19"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-03-31_custom_SeriesAWarrantsMember" id="Fact000669" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4,200.00</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-size: 9pt">**</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt"><span id="xdx_90A_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsMember_zpfrT5HPcF73"><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_SeriesAWarrantsMember" id="Fact000670" name="SBFM:WarrantExpirationDate">August 2026</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 9pt">Feb 15, 2024 (&#8220;Series B Warrants&#8221;)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_fKio___zvirEpFfnwld"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2026-03-31_custom_SeriesBWarrantsMember" id="Fact000671" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,973</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-size: 9pt">**</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_zzQ60PND3ey1"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-03-31_custom_SeriesBWarrantsMember" id="Fact000672" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4,760.00</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-size: 9pt">**</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt"><span id="xdx_909_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_zsdf2Nigsi07"><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_SeriesBWarrantsMember" id="Fact000673" name="SBFM:WarrantExpirationDate">February 2029</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 9pt">Apr 3, 2025 (&#8220;2025 Pre-Funded
    Warrants&#8221;)</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--PreFunded2025WarrantsMember_zT99q5RoPUIb" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2026-03-31_custom_PreFunded2025WarrantsMember" id="Fact000674" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">260,000</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--PreFunded2025WarrantsMember_zyrbsgWJ1hO4" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-03-31_custom_PreFunded2025WarrantsMember" id="Fact000676" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 9pt"><span id="xdx_906_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--PreFunded2025WarrantsMember_z6t3H9lj4OE9"><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_PreFunded2025WarrantsMember" id="Fact000677" name="SBFM:WarrantExpirationDate">Unlimited</ix:nonNumeric></span></span></td></tr>
  </table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13px; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">These warrants trade on Nasdaq
    under the symbol SBFMW.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">**</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Subject to adjustment.</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AD_z5HcTIeerYsd" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">On
February 11, 2024, the Company redeemed all of the April Warrants and all of the May Investor Warrants for an aggregate purchase price
of $<span id="xdx_906_eus-gaap--PaymentsForRepurchaseOfWarrants_pp0p0_c20240210__20240211__us-gaap--AwardTypeAxis__custom--AprilWarrantsAndMayInvestorWarrantsMember_zivYVWX2iQEh" title="Payments for repurchase of warrants"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfWarrants" contextRef="From2024-02-102024-02-11_custom_AprilWarrantsAndMayInvestorWarrantsMember" id="Fact000679" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,139,651</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">As
of March 31, 2026, all of the 2022 Pre-Funded Warrants, all of the May Pre-Funded Warrants, all of the 2024 Pre-Funded Warrants, all
of the 2025 Pre-Funded Warrants, a total of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20260101__20260331__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_zQbLPOgNWyLi" title="Warrants exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2026-01-012026-03-31_custom_TradeableWarrantsMember" id="Fact000681" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,569</ix:nonFraction></span> Tradeable Warrants, <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20260101__20260331__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_zX9mPRLxsq5i" title="Warrants exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2026-01-012026-03-31_custom_InvestorWarrantsMember" id="Fact000683" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,401</ix:nonFraction></span> Investor Warrants, all of the Series A Warrants, and <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20260101__20260331__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_zjnNEqsQfuy4" title="Warrants exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2026-01-012026-03-31_custom_SeriesBWarrantsMember" id="Fact000685" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,269,303</ix:nonFraction></span>
Series B Warrants (as adjusted) were exercised resulting in aggregate net proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromWarrantExercises_c20260101__20260331__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_zex3fqzh3ESj" title="Proceeds from warrant exercises"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2026-01-012026-03-31_custom_SeriesBWarrantsMember" id="Fact000687" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,136,992</ix:nonFraction></span> received by the Company.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
Company&#8217;s outstanding warrants as of March 31, 2026 consisted of the following:</span></p>

<ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000689" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zwjN9QTuTio2" summary="xdx: Disclosure - Warrants (Details - Warrants outstanding)" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 9pt">&#160;<span id="xdx_8BA_z3oHWhyX2Sh1" style="display: none">Schedule of warrants outstanding</span></span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"><span style="font-size: 9pt">Type</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Number</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Exercise
    Price</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"><span style="font-size: 9pt">Expiry Date</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 47%; text-align: justify"><span style="font-size: 9pt">Tradeable Warrants</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--TradeableWarrants1Member_zCi5SgCW8vCl" title="Number of warrants outstanding" style="width: 13%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2026-03-31_custom_TradeableWarrants1Member" id="Fact000691" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">482</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--TradeableWarrants1Member_zFGms0kom2ek" title="Warrant exercise price" style="width: 13%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-03-31_custom_TradeableWarrants1Member" id="Fact000693" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">220.00</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 17%; text-align: justify"><span style="font-size: 9pt"><span id="xdx_90D_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--TradeableWarrants1Member_zhugGfv1zUD1" title="Expiry date"><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_TradeableWarrants1Member" id="Fact000695" name="SBFM:WarrantExpirationDate">February 2027</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-size: 9pt">Investor Warrants</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--InvestorWarrants1Member_zTfNuEF7Cyg1"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2026-03-31_custom_InvestorWarrants1Member" id="Fact000696" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">400</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--InvestorWarrants1Member_zroxUTMCZRul"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-03-31_custom_InvestorWarrants1Member" id="Fact000697" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4,000.00</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt"><span id="xdx_901_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--InvestorWarrants1Member_zWW4t5pyMry"><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_InvestorWarrants1Member" id="Fact000698" name="SBFM:WarrantExpirationDate">March 2027</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 9pt">Series B Warrants</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesBWarrants1Member_fKg_____zOtM0PWEXcO6"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2026-03-31_custom_SeriesBWarrants1Member" id="Fact000699" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,227,962</ix:nonFraction></span></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">*</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesBWarrants1Member_fKg_____zbY4R4eA4br9"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-03-31_custom_SeriesBWarrants1Member" id="Fact000700" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.07</ix:nonFraction></span></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">*</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 9pt"><span id="xdx_903_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--SeriesBWarrants1Member_zXvA6KIeZgL7" title="Expiry date"><ix:nonNumeric contextRef="From2026-01-012026-03-31_custom_SeriesBWarrants1Member" id="Fact000702" name="SBFM:WarrantExpirationDate">February 2029</ix:nonNumeric></span></span></td></tr>
  </table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 12px"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">As adjusted following the
    financing event of April 3, 2025 and subject to further adjustment of the number of warrants and exercise price upon certain corporate
    actions such that the aggregate exercise price of the warrants remains unchanged</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A6_zR3R2HostCad" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;&#160;</span></p>

<ix:exclude><p id="xdx_23A_zESQIFMCwDN7" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zocD2SlOhkac" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zcYhEYCYWg08" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zKw4anRdhnHd" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 13 -->
    <div id="xdx_230_z4rwE62mRo6j" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_236_z5gxvRbg9SMg" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zCI1MWE8iYZi" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000709" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_802_eus-gaap--EarningsPerShareTextBlock_zO7Ldk3ifIx9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b><span style="text-decoration: underline">Note
13 &#8211;&#160;<span id="xdx_829_zKfKVMw6O033">Earnings Per Share</span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
following table sets forth the computation of basic* net income (loss) per share:</span></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000711" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zpQEZ9JHPha3" summary="xdx: Disclosure - Earnings Per Share (Details)" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: justify"><span id="xdx_8B1_zECYMIfCWOZb" style="display: none">Schedule of computation of basic and diluted net income per share</span></td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td colspan="2" id="xdx_490_20260101__20260331_zlIAU8PI8XT6" style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td colspan="2" id="xdx_491_20250101__20250331_zQ3KM1lhh95" style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Quarter Ended March 31,</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zorBPa59UqDf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: justify">Net gain (loss) attributable to common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2026-01-01to2026-03-31" id="Fact000713" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,243,869</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2025-01-012025-03-31" id="Fact000714" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,179,771</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Weighted average outstanding shares of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331_zF5Bz74xNNWl" title="Weighted average outstanding shares of common stock"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2026-01-01to2026-03-31" id="Fact000716" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,905,945</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250331_zVHfdv2NhM6c" title="Weighted average outstanding shares of common stock"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-01-012025-03-31" id="Fact000718" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,703,293</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: justify">Net gain (loss) per share attributable to common stock</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20260101__20260331_zGmiQVdh5BBg" title="Net gain (loss) per share attributable to common stock">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2026-01-01to2026-03-31" id="Fact000720" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.25</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20250101__20250331_zSQMIZwOmeuh" title="Net gain (loss) per share attributable to common stock">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-01-012025-03-31" id="Fact000722" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.44</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">*
Diluted net income (loss) per share is not included in this table as the Company incurred net losses for the years ended December
31, 2026 and 2025 and inclusion of dilutive instruments would have an anti-dilutive effect.</span></p>

</ix:nonNumeric><p id="xdx_8A7_zbApCWCEJAw" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000724" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_801_eus-gaap--SegmentReportingDisclosureTextBlock_zLl9MK93R4X5" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b><span style="text-decoration: underline">Note 14 &#8211; <span id="xdx_827_z9UtBIoYlVqj">Segment Reporting</span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company operates as one operating segment,
which is also its one reportable segment, as the Chief Executive Officer, acting as the Chief Operating Decision Maker (&#8220;CODM&#8221;),
evaluates financial performance and allocates resources on a consolidated, enterprise-wide basis. The Company&#8217;s operations are managed
as an integrated pharmaceutical business focused on the research, development, and commercialization of prescription drugs and supplements.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Although the Company conducts activities through
multiple legal entities &#8212; including Sunshine Biopharma Inc. (U.S.), Sunshine Biopharma Canada Inc. (Canada), and Nora Pharma Inc.
(Canada) &#8212; these entities operate under a unified management structure with shared economic characteristics, common product development
objectives, and centralized decision making. As such, they do not meet the criteria for separate operating segments under <i>ASC 280 &#8211;
Segment Reporting</i>.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In accordance with <i>ASU 2023-07</i>, the Company
provides the following information regarding its single reportable segment:</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Measure of Segment Profit (Loss): The CODM evaluates performance using consolidated operating income (loss), which is consistent with the amounts presented in the accompanying consolidated financial statements.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Significant Segment Expenses: Research and development expenses, and supply chain costs, selling and marketing expenses, and general and administrative expenses are all incurred and reviewed on a consolidated basis.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Other Segment Items: Interest income, interest expense, foreign exchange gains and losses, and other non-operating items are also managed and reviewed on a consolidated basis.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Reconciliation: As the Company has only one reportable segment, no additional reconciliation to consolidated totals is required beyond what is presented in the consolidated statements of operations.</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s operations are conducted in
Canada and substantially all long-lived assets are located in this jurisdiction. Revenues are generated from customers located in Canada.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000726" name="us-gaap:LegalMattersAndContingenciesTextBlock"><p id="xdx_80D_eus-gaap--LegalMattersAndContingenciesTextBlock_zqyHjRQr0Yyd" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b><span style="text-decoration: underline">Note
15 &#8211; <span id="xdx_828_zSMDigiWGpV8">Legal Matters</span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On April 14, 2025, the Company terminated the
employment of Mr. Malek Chamoun, president of the Company&#8217;s wholly owned Canadian subsidiary, Nora Pharma. On April 17, 2025, the
Company received a demand letter from the attorneys of Mr. Chamoun requesting that the Company pay to Mr. Chamoun $7,307,025 CAD (approximately
$5,300,000 USD) within five (5) days. In response to the demand letter, the Company sent a letter on May 1, 2025 stating that the demands
contained in the demand letter, including the sum of $7,307,025 CAD (approximately $5,300,000 USD), are completely unfounded and that
it intends to defend itself vigorously. Following a series of communications between the parties&#8217; legal counsels, there has been
no response to the Company&#8217;s letter dated October 14, 2025, nor any action taken by Mr. Chamoun&#8217;s attorneys since that date.
No provision or accrual was made in the financial statements for any litigation liability or legal expense which the Company may incur
in connection with this alleged claim.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" escape="true" id="Fact000728" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zFW9S4GQ5LG9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b><span style="text-decoration: underline">Note
16 &#8211;&#160;<span id="xdx_82F_zDERCYJHIBVg">Subsequent Events</span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">On
April 14, 2026, the Company issued 100,000 restricted shares of common stock under the Company&#8217;s 2023 Equity Incentive Plan to
one of its directors for services.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

</ix:nonNumeric><p id="xdx_811_zPZ0Vhks20h6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<!-- Field: Page; Sequence: 14 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"><b><span id="q1_009"></span>ITEM
2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"><i>The
following discussion should be read in conjunction with our consolidated financial statements and notes thereto included herein. This
discussion includes&#160;forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the
Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. The statements regarding Sunshine
Biopharma Inc. contained in this Report that are not historical in nature, particularly those that utilize terminology such as &#8220;may,&#8221;
&#8220;will,&#8221; &#8220;should,&#8221; &#8220;likely,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;estimates,&#8221;
&#8220;believes&#8221; or &#8220;plans,&#8221; or comparable terminology, are forward-looking statements based on current expectations
and assumptions, and entail various risks and uncertainties that could cause actual results to differ materially from those expressed
in such forward-looking statements. Important factors known to us that could cause such material differences are identified in this report
and in our annual report on Form 10-K for the year ended December 31, 2025. We undertake no obligation to correct or update any forward-looking
statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law. You are
advised, however, to consult any future disclosures we make on related subjects in future reports we file with the SEC</i>.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b>About
Sunshine Biopharma</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">We
are a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology
and antivirals. We have two wholly owned subsidiaries: (i) Nora Pharma Inc. (&#8220;Nora Pharma&#8221;), a Canadian corporation, through
which we currently have 60 generic prescription drugs on the market in Canada, and (ii) Sunshine Biopharma Canada Inc. (&#8220;Sunshine
Canada&#8221;), a Canadian corporation through which we develop and sell OTC supplements.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">In
addition, we are conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an LNP encapsulated mRNA targeted
for liver cancer, and (ii) SBFM-PL4, a protease inhibitor for treatment of SARS Coronavirus infections.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b>Commercial
Operations</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Our
commercial operations are focused on the procurement of rights to generic pharmaceutical products for sale, currently in Canada and ultimately
around the world. We seek to secure such rights through various types of strategic arrangements, including:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>In-licensing and Supply
    Agreements:</b> Nora Pharma acquires the rights to import, market, sell and distribute the products in Canada by purchasing the drug
    dossiers from strategic partners. Nora Pharma then files the dossiers with Health Canada to obtain regulatory approval prior to marketing.
    The approval process at Health Canada takes on average of 12 months. The products are sold under Nora Pharma label. </span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Cross-licensing:</b>
    Nora Pharma acquires the rights to import, market, sell and distribute the products in Canada by receiving an authorization letter
    from pharmaceutical partners. The partners&#8217; products are already approved in Canada but we are still required to obtain our
    own approval from Health Canada, which takes on average 45-60 days. The products are sold under Nora Pharma label.</span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Distribution
    Agreements:</b> Nora Pharma acquires the rights to market, sell and distribute the products in Canada by signing distribution
    agreements with various pharmaceutical partners. The partners&#8217; products are already approved by Health Canada. The products
    are sold under the partners&#8217; label.</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<!-- Field: Page; Sequence: 15 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Generic
drugs are pharmaceutically equivalent to the brand name drugs. They contain identical medicinal ingredients in the same amounts as the
brands. Generic medications, however, may have different non-medicinal ingredients than the brand name drugs, but the generic developer
must show that these do not affect the safety, efficacy, or quality of the drug compared to the brand. When a generic drugs company wants
to sell a generic drug in Canada, it must file a generic drug submission with Health Canada. The submission is called an Abbreviated
New Drug Submission (ANDS). The submission is reviewed by scientists and health care experts at Health Products and Food Branch (HPFB)
of Health Canada. All generic drug submissions go through the same process as the brand name drug submissions. If the evaluation shows
that the generic drug meets all regulatory requirements (including patent and data protection considerations), Health Canada will issue
a Notice of Compliance (NOC) and a Drug Identification Number (DIN) to the applicant. The NOC and DIN signal the drug's official approval
in Canada and permit the applicant to market the drug in Canada. Once a company obtains the NOC and DIN for a drug, then it begins the
process with Pan-Canadian Pharmaceutical Alliance (pCPA)   to have the drug listed on the provincial and territorial formularies
and federal government drug benefit plans.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">We
currently have the following generic prescription drugs on the market in Canada:</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 30%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>Drug*</b></span></td>
    <td style="border-bottom: black 1pt solid; width: 37%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>Therapeutic
    Area</b></span></td>
    <td style="border-bottom: black 1pt solid; width: 33%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>Brand</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Alendronate</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Osteoporosis</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Fosamax&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Amlodipine</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cardiovascular</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Norvasc&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Apixaban</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cardiovascular</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Eliquis&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Aripiprazole</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Antipsychotic</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Abilify&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Atorvastatin</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cardiovascular</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Lipitor&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Azithromycin</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Antibacterial</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Zithromax&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Betahistine</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Vertigo</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Serc&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Bilastine</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Allergy</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Blexten&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Candesartan</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Hypertension</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Atacand&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Candesartan HCTZ</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Hypertension</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Atacand Plus&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Celecoxib</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Anti-inflammatory</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Celebrex&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cetirizine</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Allergy</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Reactine&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Ciprofloxacin</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Antibiotic</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cipro&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Citalopram</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Central nervous system</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Celexa&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Clindamycin</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Antibiotic</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Dalacin&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Clopidogrel</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cardiovascular</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Plavix&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Dapagliflozin</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Diabetes</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Forxiga&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Docusate</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Gastrointestinal</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Colace&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Donepezil</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Central nervous system</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Aricept&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Doxycycline</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Antibacterial</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Vibramycin&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Duloxetine</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Central nervous system</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cymbalta&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Dutasteride</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Urology</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Avodart&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Escitalopram</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Central nervous system</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cipralex&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Ezetimibe</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cardiovascular</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Ezetrol&#174;</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<!-- Field: Page; Sequence: 16 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 30%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Finasteride</span></td>
    <td style="width: 37%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Urology</span></td>
    <td style="width: 33%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Proscar&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Fluconazole</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Antifungal</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Diflucan&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Fluoxetine</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Central nervous system</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Prozac&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Gabapentin</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Central nervous system</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Neurontin&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Hydroxychloroquine</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Antimalarial</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Plaquenil&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Letrozole</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Oncology</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Femara&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Levetiracetam</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Central nervous system</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Keppra&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Lurasidone</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Antipsychotic</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Latuda&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Metformin</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Diabetes</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Glucophage&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Mirtazapine</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Central nervous system</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Remeron&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Montelukast</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Allergy</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Singulair&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Olanzapine</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Central nervous system</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Zyprexa&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Olanzapine ODT</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Central nervous system</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Zyprexa&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Olmesartan</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cardiovascular</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Olmetec&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Olmesartan HCTZ</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cardiovascular</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Olmetec Plus&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Pantoprazole</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Gastroenterology</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Pantoloc&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Paroxetine</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Central nervous system</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Paxil&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Perindopril</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cardiovascular</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Coversyl&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Pravastatin</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cardiovascular</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Pravachol&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Pregabalin</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Central nervous system</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Lyrica&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Prucalopride</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Women's Health</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Resotran&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Quetiapine</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Central nervous system</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Seroquel&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Quetiapine XR</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Central nervous system</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Seroquel XR&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Ramipril</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cardiovascular</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Altace&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Rizatriptan ODT</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Central nervous system</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Maxalt&#174; ODT</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Rosuvastatin</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cardiovascular</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Crestor&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Sertraline</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Central nervous system</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Zoloft&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Sildenafil</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Urology</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Viagra&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Tadalafil</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Urology</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cialis&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Telmisartan</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cardiovascular</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Micardis&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Telmisartan HCTZ</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cardiovascular</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Micardis Plus&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Topiramate</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Anticonvulsant</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Topamax&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Ursodiol</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cholelithiasis</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Urso&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Varenicline</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Smoking cessation</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Champix&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Zolmitriptan</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Central nervous system</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Zomig&#174;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Zopiclone</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Central nervous
    system</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Imovane&#174;</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">*
Our distribution agreements were terminated effective December 31, 2025, reducing the drugs we have on the market from 71 to
60.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<!-- Field: Page; Sequence: 17 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">In
addition to the 60 drugs currently on the market, we have 22 additional drugs in our pipeline including 12 we anticipate launching during
the remainder of 2026. These additional drugs will address various human health areas including cardiovascular, oncology, gastroenterology,
central nervous system, diabetes, urology, endocrinology, anti-infective, and anti-inflammatory.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span>We believe the addition of these
products to our existing portfolio will strengthen our presence in the Canadian $11.2 billion a year generic drug market (<i>IMARC Group</i>)
and provide us with greater access to pharmacies as we become more of a go-to supplier for every-day and specialty medicines.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b>Research
and Development</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
following table summarizes our proprietary drugs in development:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 30%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>Drug
    Candidate</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 44%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>Therapeutic
    Area/Indication</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 24%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>Development
    Stage</b></span></td>
    </tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">K1.1 (mRNA LNP)</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Oncology (Liver Cancer)</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Animal Testing</span></td>
    </tr>
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">SBFM-PL4
    (Small Molecule)</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Antiviral
    (SARS Coronavirus Infections)</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Animal
    Testing</span></td>
    </tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b><i>K1.1
Anticancer mRNA</i></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">In
June 2021, we initiated a new research project in which we set out to determine if certain mRNA molecules can be used as anti-cancer
agents. The data collected to date have shown that a selected group of mRNA molecules are capable of destroying cancer cells in vitro
including multidrug resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2).
Studies using non-transformed (normal) human cells (HMEC cells) showed that these mRNA molecules had little cytotoxic side effects. These
new mRNA molecules, bearing the laboratory name K1.1, were adapted for delivery into patients using a lipid nanoparticle (LNP) technology
similar to the one employed in the COVID-19 mRNA vaccines. On April 20, 2022, we filed a provisional patent application in the United
States covering our K1.1 mRNA molecules. The patent application was converted into a PCT Application on October 18, 2024 and published
by the United States Patent and Trademark Office (&#8220;USPTO&#8221;) on September 4, 2025.</span></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">In
November 2022, we concluded an agreement with a specialized commercial partner for the purposes of formulating our K1.1 mRNA molecules
into specific lipid nanoparticles for use in test animals including xenograft mice. The initial results of our animal testing indicated
that our K1.1 mRNA-LNP constructs were effective at reducing the size of liver cancer tumors in xenograft mice. We are currently seeking
to confirm these results by conducting additional xenograft experiments on a broader scale and in more detailed dose-response studies.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b><i>SBFM-PL4
SARS Coronavirus Treatment</i></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
initial genome expression products following infection by Betacoronavirus, the causative agent of COVID-19, are two large polyproteins,
referred to as pp1a and pp1ab. These two polyproteins are cleaved at 15 specific sites by two virus encoded proteases, called Mpro and
PLpro, to generate 16 different non-structural proteins essential for viral replication. Mpro and PLpro represent attractive anti-viral
drug development targets as they play a central role in the early stages of viral replication. PLpro is of particular interest as a therapeutic
target in that, in addition to processing essential viral proteins, it is also responsible for suppression of the human immune system
making the virus more life-threatening. PLpro is present only in Betacoronaviruses, the subgroup of Coronaviruses represented by the
highly pathogenic SARS-CoV, MERS-CoV, and SARS-CoV-2.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Our
Anti-Coronavirus research effort has been focused on developing an inhibitor of PLpro and, on May 22, 2020, we filed a provisional patent
application in the United States covering composition subject matter pertaining to small molecules for inhibition of the Coronavirus
PLpro as well as Mpro. Our provisional patent application, entitled <i>Inhibitors of Coronavirus Protease</i>, was converted into a PCT
patent application on April 30, 2021. On December 23, 2025, we received a Notice of Allowance from the USPTO for our PCT patent application. On May 7, 2026, we received an Issue Notification from the USPTO indicating
that the patent will be issued on May 12, 2026. In addition, the Issue Notification confirms that the patent is eligible for an extension
of 706 days and will therefore expire on April 6, 2043.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">In
February 2022, we expanded our PLpro inhibitors research effort by entering into a research agreement with the University of Arizona
for the purposes of conducting research focused on determining the in vivo safety, pharmacokinetics, and dose selection properties of
three University of Arizona owned PLpro inhibitors, to be followed by efficacy testing in mice infected with SARS-CoV-2 (the &#8220;Research
Project&#8221;). Under the agreement, the University of Arizona granted us a first option to negotiate a commercial, royalty-bearing
license for all intellectual property developed by University of Arizona under the Research Project. In addition, we and the University
of Arizona have entered into an option agreement (the &#8220;Option Agreement&#8221;) whereby we were granted a first option to negotiate
a royalty-bearing commercial license for the underlying technology of the Research Project. On September 13, 2022, we exercised our options,
and on February 24, 2023, we entered into an exclusive worldwide license agreement with the University of Arizona for all of the technology
related to the Research Project.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">We
have since broadened our objective to include the development of a first-in-class PLpro inhibitor to treat SARS-CoV2 and potentially
SARS-CoV and MERS-CoV infection in patients who could not use Paxlovid, Molnupiravir, or Remdesivir, due to concerns about drug interactions
and possible rebound infections and other side effects.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Our
current lead compound has been found to be active at sub micromolar concentrations against PLpro and exhibited antiviral activity in
SRAS-CoV-2 infected cells as well as in cells infected with several different variants of concern. In addition, our compound had favorable
pharmacokinetics properties in rodent species and exhibited preferred drug accumulation in the lungs over plasma. The compound was found
to be orally active in a K18-human-ACE2 transgenic mouse model and to significantly reduce virus load in the lungs of infected animals
in a dose-dependent manner without gross toxicities. In August 2024, we published these and other research results related to this project
in the Journal of Medicinal Chemistry (<i>J. Med. Chem. 2024, 67, 13681&#8722;13702</i>). A copy of this article is available on our
website at: www.sunshinebiopharma.com/scientific-publications. Additional research results on our lead compound have recently been submitted
for publication in the Journal of Medicinal Chemistry and the research article has been peer-reviewed and is currently in press.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">On
May 22, 2020, we filed a provisional patent application in the United States for a new treatment for Coronavirus infections. Our patent
application, entitled <i>Inhibitors of Coronavirus Protease</i>, covers composition subject matter pertaining to small molecules for
inhibition of the main Coronavirus protease, Mpro, an enzyme that is essential for viral replication. The patent application has a priority
date of May 22, 2020. On April 30, 2021, we filed a PCT application containing new research results and extending coverage to include
the Coronavirus Papain-Like protease, PLpro. The priority date of May 22, 2020 has been maintained in the newly filed PCT application.
On December 23, 2025, we received a Notice of Allowance from the USPTO for our PCT patent application. On May 7, 2026, we received an Issue Notification from the USPTO indicating
that the patent will be issued on May 12, 2026. In addition, the Issue Notification confirms that the patent is eligible for an extension
of 706 days and will therefore expire on April 6, 2043.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">On
April 20, 2022, we filed a provisional patent application in the United States covering mRNA molecules capable of destroying cancer cells
in vitro. The patent application contains composition and utility subject matter pertaining to the structure and sequence of the relevant
mRNA molecules. The patent application was converted into a PCT Application on October 18, 2024 and published by the USPTO on
September 4, 2025.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<!-- Field: Page; Sequence: 19 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Effective
February 24, 2023, we became the exclusive, worldwide licensee of the University of Arizona for three (3) patents related to small molecules
which inhibit the Coronavirus protease, PLpro.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Our
wholly owned subsidiary, Nora Pharma, owns 200 DIN&#8217;s issued by Health Canada for prescription drugs currently on the market in
Canada. These DIN&#8217;s were secured through in-licenses or cross-licenses from international manufacturers of generic pharmaceutical
products. Nora Pharma also owns the rights to sell 10 generic prescription drugs in Canada through distribution agreements with various
international partners under which Nora Pharma acts as distributor and receives a percentage of sales.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">In
addition, we own four (4) NPN&#8217;s issued by Health Canada including (i) NPN 80089663 which authorizes us to manufacture and sell
our in-house developed OTC product, Essential&#8226;9&#8482;, (ii) NPN 80093432 which authorizes us to manufacture and sell the OTC product,
Calcium-Vitamin D, (iii) NPN 80125047 which authorizes us to manufacture and sell the OTC product, L-Citrulline, and (iv) NPN 80127436
which authorizes us to manufacture and sell the OTC product, Taurine.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">On
September 30, 2025, we received official trademark registration from the United States Patent and Trademark Office (Registration No.
7,963,385) for &#8220;Sunshine Biopharma Inc.&#8221; and Design.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">On
April 15, 2026, we received official trademark registration from the Canadian Intellectual Property Office of Canadian trademark registration
(Registration No. LMC/TMA 1,402,862) for &#8220;Sunshine Biopharma Inc.&#8221; and Design.</span></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b>&#160;</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b><i>Comparison
of results of operations for the three months ended March 31, 2026 and 2025</i></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">During
the three months ended March 31, 2026, we generated $8,088,765 in sales, compared to $8,901,341 for the three months ended March 31,
2025, a decrease of $812,576 (9.1%). The decrease is largely a result of termination of our distribution agreements effective December
31, 2025. The direct cost for generating these sales was $5,907,775 (73.0%) for the three months ended March 31, 2026, compared to $6,170,915
(69.3%) for the three months ended March 31, 2025. Our gross profit for the three months ended March 31, 2026 was $2,180,990 (27.0%),
compared to $2,730,426 (30.7%) for the three months ended March 31, 2025, a decrease of $549,436.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">General
and administrative expenses during the three-month period ended March 31, 2026 were $3,576,587, compared to $4,026,176 during the
three-month period ended March 31, 2025, a decrease of $449,589. The decrease was the net result of decreases in certain expense
categories against modest increases in others. For example, while there was an increase in legal fees by $61,877 and salaries by
$183,038, there was a decrease in accounting fees by $117,950, consulting fees by $222,139, marketing expenses by $148,138, office
expenses by $54,270, and R&amp;D by $183,038. Overall, we incurred a loss of $1,395,597 from our operations for the three months
ended March 31, 2026, compared to a loss of $1,295,750 from our operations in the three-month period ended March 31,
2025.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">We had interest income of $48,426 during the three months ended March 31, 2026, compared to interest income of $75,367 during
the three months ended March 31, 2025, as a result of having less cash on hand.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">In
addition, we had a one-time payment of $103,320 in the three months ended March 31, 2026 which we did not have in the three months ended
March 31, 2025. This amount was allocated to us as part of a settlement of a class-action lawsuit against BF Borgers CPA PC, our previous
auditor whom we terminated in May 2024.</span></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">As
a result, we incurred a net loss of $1,243,869 ($0.25 per share) for the three months ended March 31, 2026, compared to a net loss of
$1,179,771 ($0.44 per share) for the three-month period ended March 31, 2025.</span></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<!-- Field: Page; Sequence: 20 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif">As of March
31, 2026, we had cash and cash equivalents of $6,913,013.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Net cash used in operating activities was $2,072,100
during the three months ended March 31, 2026, compared to $1,695,002 during the three-month period ended March 31, 2025. The increase
was largely a result of an increase in Nora Pharma&#8217;s accounts receivable.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Cash flows used in investing activities were $104,518
for the three months ended March 31, 2026, compared to $212,017 for the three months ended March 31, 2025. The decrease was the result
of fewer purchases of equipment and intangible assets (drug licenses) by Nora Pharma.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Cash flows provided by financing activities were
$0 during the three months ended March 31, 2026, compared to $355,297 during the three months ended March 31, 2025. The decrease was a
result of no warrant exercises taking place during the three months ended March 31, 2026, compared to $355,297 in warrant exercises during
the three months ended March 31, 2025.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We are currently generating revenue of approximately
$8 million per quarter and incurring a quarterly deficit of approximately $1.2 million. Our attention is currently focused on increasing
sales and streamlining operations to reduce expenses. We believe these measures could bring us to breakeven and make us less dependent
on the capital markets for financing. Our existing cash on hand together with cash we generate from sales will be sufficient to fund
our operations for the next 17 months. There is no assurance our estimates will be accurate. We have no committed sources of capital
and we anticipate that we will need to raise additional capital in the future for expansion of our generic pharmaceuticals sales operations
and further research and development. Additional capital may not be available on terms acceptable to us, or at all.</p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b>Critical
Accounting Estimates</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been
prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements
requires us to make estimates and judgments that affect the amounts of assets, liabilities, revenues and expenses, and related disclosure
of contingent assets and liabilities. On an on-going basis, we evaluate our estimates based on historical experience and on various other
assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about
the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these
estimates under different assumptions or conditions.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">For
a detailed list of significant accounting policies, please see our annual report on Form 10-K for the fiscal year ended December 31,
2025, including our financial statements and notes thereto included therein as filed with the SEC on April 3, 2026.</span></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b>Recently
Adopted Accounting Standards</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">We
have adopted all new accounting standards impacting operations.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b>Off
Balance-Sheet Arrangements</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">We
have not entered into any off-balance sheet arrangements.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<!-- Field: Page; Sequence: 21 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"><b><span id="q1_010"></span>ITEM
3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">We
are a smaller reporting company and are not required to provide the information under this item.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"><b><span id="q1_011"></span>ITEM
4. CONTROLS AND PROCEDURES</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b>Evaluation
of Disclosure Controls and Procedures</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Our
management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our
disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of
the period covered by this report.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">These
controls are designed to ensure that information required to be disclosed in the reports we file or submit pursuant to the Exchange Act
is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange
Commission, and that such information is accumulated and communicated to our management, including our CEO and CFO, to allow timely decisions
regarding required disclosure.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Based
on this evaluation, our management, including our CEO and CFO concluded that our disclosure controls and procedures were effective as
of March 31, 2026, at reasonable assurance levels.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b>Changes
in Internal Control Over Financial Reporting</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">There
were no changes in our internal control over financial reporting during the quarter ended March 31, 2026, that have materially affected,
or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<!-- Field: Page; Sequence: 22 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b><span id="q1_012"></span>PART
II. OTHER INFORMATION</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"><b><span id="q1_013"></span>ITEM
1. LEGAL PROCEEDINGS</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">We
are not party to, and our property is not the subject of, any material legal proceedings.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"><b><span id="q1_014"></span>ITEM
1A. RISK FACTORS</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">We
are a smaller reporting company and are not required to provide the information under this item.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"><b><span id="q1_015"></span>ITEM
2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">None.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"><b><span id="q1_016"></span>ITEM
3. DEFAULTS UPON SENIOR SECURITIES</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">None.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"><b><span id="q1_017"></span>ITEM
4. MINE SAFETY DISCLOSURES</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Not
Applicable.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"><b><span id="q1_018"></span>ITEM
5. OTHER INFORMATION</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; background-color: white">During
the quarter ended March 31, 2026, no Director or Officer of the Company <span id="xdx_902_eecd--Rule10b51ArrAdoptedFlag_dbF_c20260101__20260331_z7vgqFIPyuod" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_902_eecd--NonRule10b51ArrAdoptedFlag_dbF_c20260101__20260331_zpzj5M2dRG1i" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" format="ixt:booleanfalse" id="Fact000729" name="ecd:Rule10b51ArrAdoptedFlag"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" format="ixt:booleanfalse" id="Fact000730" name="ecd:NonRule10b51ArrAdoptedFlag">adopted</ix:nonNumeric></ix:nonNumeric></span></span> or <span id="xdx_905_eecd--Rule10b51ArrTrmntdFlag_dbF_c20260101__20260331_zXH8wSH5Adb9" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_90E_eecd--NonRule10b51ArrTrmntdFlag_dbF_c20260101__20260331_zESFUfM5kFK6" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" format="ixt:booleanfalse" id="Fact000731" name="ecd:Rule10b51ArrTrmntdFlag"><ix:nonNumeric contextRef="From2026-01-01to2026-03-31" format="ixt:booleanfalse" id="Fact000732" name="ecd:NonRule10b51ArrTrmntdFlag">terminated</ix:nonNumeric></ix:nonNumeric></span></span> a &#8220;Rule 10b5-1 trading arrangement&#8221;
or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined in Item 408(a) of Regulation S-K.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"><b><span id="q1_019"></span>ITEM
6. EXHIBITS</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 10%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="width: 1%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 89%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">31.1</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="sunshine_ex3101.htm">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a>*</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">31.2</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="sunshine_ex3102.htm">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2022</a>*</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">32.1</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="sunshine_ex3201.htm">Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a>**</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">101</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Inline XBRL Document Set
    for the financial statements and accompanying notes in Part I, Item 1, of this Quarterly Report on Form 10-Q.*</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">104</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Inline XBRL for the cover
    page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set.*</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 4.5pt; text-indent: 0.5in"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0px"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">*</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Filed herewith.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">**</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Furnished herewith.</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 23 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b><span id="q1_020"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized, on May 13, 2026.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>SUNSHINE BIOPHARMA INC.</b></span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="width: 47%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">/s/ Dr. Steve
    N. Slilaty</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Dr. Steve N. Slilaty</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Chief Executive Officer (principal executive officer)</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">/s/
    Camille Sebaaly</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">Camille Sebaaly</span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">Chief Financial
    Officer (principal financial and accounting officer)</span></p></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<!-- Field: Page; Sequence: 24; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>sunshine_ex3101.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>Exhibit 31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>18
USC, SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>SECTION
302 OF THE SARBANES OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">I,
Dr. Steve N. Slilaty, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">I have reviewed this quarterly
    report on Form 10-Q of Sunshine Biopharma Inc.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Based on my knowledge, this
    report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements
    made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
    report.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Based on my knowledge, the
    financial statements, and other financial information included in this report, fairly present in all material respects the financial
    condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The registrant&rsquo;s other
    certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange
    Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and
    15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Designed such disclosure
    controls and procedures, or caused such disclosure controls and procedure to be designed under our supervision, to ensure that material
    information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
    particularly during the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Designed such internal control
    over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
    reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes
    in accordance with generally accepted accounting principles;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Evaluated the effectiveness
    of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
    disclosure controls and procedures, as of the end of the period covered by this report based upon such evaluation; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Disclosed in this report
    any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent
    fiscal quarter (the registrant&rsquo;s fourth quarter in the case of an annual report) that has materially affected, or is reasonably
    likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The registrant&rsquo;s other
    certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to
    the registrant's auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent
    functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">All significant deficiencies
    and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
    affect the registrant's ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Any fraud, whether or not
    material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over
    financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Dated: May 13,
    2026</FONT></TD>
    <TD STYLE="width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><U>/s/
    Dr. Steve N. Slilaty</U></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Dr.
    Steve N. Slilaty, Chief Executive Officer</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>sunshine_ex3102.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>Exhibit 31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>18
USC, SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>SECTION
302 OF THE SARBANES OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">I,
Camille Sebaaly, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">I have reviewed this quarterly
    report on Form 10-Q of Sunshine Biopharma Inc.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Based on my knowledge, this
    report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements
    made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
    report.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Based on my knowledge, the
    financial statements, and other financial information included in this report, fairly present in all material respects the financial
    condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The registrant&rsquo;s other
    certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange
    Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and
    15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Designed such disclosure
    controls and procedures, or caused such disclosure controls and procedure to be designed under our supervision, to ensure that material
    information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
    particularly during the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Designed such internal control
    over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
    reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes
    in accordance with generally accepted accounting principles;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Evaluated the effectiveness
    of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
    disclosure controls and procedures, as of the end of the period covered by this report based upon such evaluation; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Disclosed in this report
    any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent
    fiscal quarter (the registrant&rsquo;s fourth quarter in the case of an annual report) that has materially affected, or is reasonably
    likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The registrant&rsquo;s other
    certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to
    the registrant's auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent
    functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">All significant deficiencies
    and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
    affect the registrant's ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Any fraud, whether or not
    material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over
    financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Dated: May 13,
    2026</FONT></TD>
    <TD STYLE="width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><U>/s/
    Camille Sebaaly</U></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Camille
    Sebaaly, Chief Financial Officer</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>sunshine_ex3201.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>Exhibit 32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>18
USC, SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">In
connection with this quarterly report of Sunshine Biopharma Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the quarterly period ended
March 31, 2026, as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), we, the undersigned,
in the capacities and on the date indicated below, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The Report fully complies
    with the requirements of Rule 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The information contained
    in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Dated: May 13,
    2026</FONT></TD>
    <TD STYLE="width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><U>/s/
    Dr. Steve N. Slilaty</U></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Dr.
    Steve N. Slilaty, Chief Executive Officer</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Dated: May 13, 2026</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><U>/s/
    Camille Sebaaly</U></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Camille
    Sebaaly, Chief Financial Officer</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>sbfm-20260331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +Kopo7xRiXgen8uEbXpMOaCJSaPty552WYkxvmR5fYnqvyYoJK2CjSeQctRGsWUB -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:SBFM="http://sunshinebiopharma.com/20260331" elementFormDefault="qualified" targetNamespace="http://sunshinebiopharma.com/20260331">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" id="StatementsOfOperationsAndComprehensiveLoss">
          <link:definition>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000005 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity" id="StatementsOfShareholdersEquity">
          <link:definition>00000006 - Statement - Consolidated Statements of Shareholders' Equity (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/DescriptionOfBusiness" id="DescriptionOfBusiness">
          <link:definition>999012 - Disclosure - Description of Business</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/BasisOfPresentation" id="BasisOfPresentation">
          <link:definition>999013 - Disclosure - Basis of Presentation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/ReverseStockSplits" id="ReverseStockSplits">
          <link:definition>999014 - Disclosure - Reverse Stock Splits</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc." id="AcquisitionOfNoraPharmaInc.">
          <link:definition>999015 - Disclosure - Acquisition of Nora Pharma Inc.</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/IntangibleAssets" id="IntangibleAssets">
          <link:definition>999016 - Disclosure - Intangible Assets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/PlantPropertyAndEquipment" id="PlantPropertyAndEquipment">
          <link:definition>999017 - Disclosure - Plant, Property and Equipment</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/Inventory" id="Inventory">
          <link:definition>999018 - Disclosure - Inventory</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/Leases" id="Leases">
          <link:definition>999019 - Disclosure - Leases</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>999020 - Disclosure - Income Taxes</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation" id="ManagementAndDirectorCompensation">
          <link:definition>999021 - Disclosure - Management and Director Compensation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/CapitalStock" id="CapitalStock">
          <link:definition>999022 - Disclosure - Capital Stock</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/Warrants" id="Warrants">
          <link:definition>999023 - Disclosure - Warrants</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/EarningsPerShare" id="EarningsPerShare">
          <link:definition>999024 - Disclosure - Earnings Per Share</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/SegmentReporting" id="SegmentReporting">
          <link:definition>999025 - Disclosure - Segment Reporting</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/LegalMatters" id="LegalMatters">
          <link:definition>999026 - Disclosure - Legal Matters</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999027 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
          <link:definition>999028 - Disclosure - Intangible Assets (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentTables" id="PlantPropertyAndEquipmentTables">
          <link:definition>999029 - Disclosure - Plant, Property and Equipment (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/InventoryTables" id="InventoryTables">
          <link:definition>999030 - Disclosure - Inventory (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/LeasesTables" id="LeasesTables">
          <link:definition>999031 - Disclosure - Leases (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/WarrantsTables" id="WarrantsTables">
          <link:definition>999032 - Disclosure - Warrants (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/EarningsPerShareTables" id="EarningsPerShareTables">
          <link:definition>999033 - Disclosure - Earnings Per Share (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/DescriptionOfBusinessDetailsNarrative" id="DescriptionOfBusinessDetailsNarrative">
          <link:definition>999034 - Disclosure - Description of Business (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative" id="ReverseStockSplitsDetailsNarrative">
          <link:definition>999035 - Disclosure - Reverse Stock Splits (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative" id="AcquisitionOfNoraPharmaInc.DetailsNarrative">
          <link:definition>999036 - Disclosure - Acquisition of Nora Pharma Inc. (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/IntangibleAssetsDetails-IntangibleAssets" id="IntangibleAssetsDetails-IntangibleAssets">
          <link:definition>999037 - Disclosure - Intangible Assets (Details - Intangible assets)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails" id="PlantPropertyAndEquipmentDetails">
          <link:definition>999038 - Disclosure - Plant, Property and Equipment (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/InventoryDetails" id="InventoryDetails">
          <link:definition>999039 - Disclosure - Inventory (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/LeasesDetails-LeaseInformation" id="LeasesDetails-LeaseInformation">
          <link:definition>999040 - Disclosure - Leases (Details - Lease information)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/LeasesDetails-MaturitiesOfLeasePayments" id="LeasesDetails-MaturitiesOfLeasePayments">
          <link:definition>999041 - Disclosure - Leases (Details - Maturities of lease payments)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>999042 - Disclosure - Income Taxes (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative" id="ManagementAndDirectorCompensationDetailsNarrative">
          <link:definition>999043 - Disclosure - Management and Director Compensation (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" id="CapitalStockDetailsNarrative">
          <link:definition>999044 - Disclosure - Capital Stock (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing" id="WarrantsDetails-WarrantsIssuedWithFinancing">
          <link:definition>999045 - Disclosure - Warrants (Details - Warrants issued with financing)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding" id="WarrantsDetails-WarrantsOutstanding">
          <link:definition>999046 - Disclosure - Warrants (Details - Warrants outstanding)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" id="WarrantsDetailsNarrative">
          <link:definition>999047 - Disclosure - Warrants (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/EarningsPerShareDetails" id="EarningsPerShareDetails">
          <link:definition>999048 - Disclosure - Earnings Per Share (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="sbfm-20260331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="sbfm-20260331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="sbfm-20260331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="sbfm-20260331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
    <element id="SBFM_NoraPharmaMember" name="NoraPharmaMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_MalekChamounMember" name="MalekChamounMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_AllDirectorsMember" name="AllDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_Director1Member" name="Director1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_Director2Member" name="Director2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_Director3Member" name="Director3Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_Director4Member" name="Director4Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_Director5Member" name="Director5Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_SeriesBWarrantsMember" name="SeriesBWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_RegisteredDirectOfferingMember" name="RegisteredDirectOfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_TradeableWarrantsMember" name="TradeableWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_PreFunded2022WarrantsMember" name="PreFunded2022WarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_InvestorWarrantsMember" name="InvestorWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_AprilWarrantsMember" name="AprilWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_MayPreFundedWarrantsMember" name="MayPreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_MayInvestorWarrantsMember" name="MayInvestorWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_PreFunded2024WarrantsMember" name="PreFunded2024WarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_SeriesAWarrantsMember" name="SeriesAWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_PreFunded2025WarrantsMember" name="PreFunded2025WarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_AprilWarrantsAndMayInvestorWarrantsMember" name="AprilWarrantsAndMayInvestorWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_TradeableWarrants1Member" name="TradeableWarrants1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_InvestorWarrants1Member" name="InvestorWarrants1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_SeriesBWarrants1Member" name="SeriesBWarrants1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_EarnoutPayable" name="EarnoutPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_Taxes" name="Taxes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_IncreaseDecreaseInReductionInRightofuseAsset" name="IncreaseDecreaseInReductionInRightofuseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_DisclosureReverseStockSplitsAbstract" name="DisclosureReverseStockSplitsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_ReverseStockSplitTextBlock" name="ReverseStockSplitTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_DisclosureManagementAndDirectorCompensationAbstract" name="DisclosureManagementAndDirectorCompensationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_CompensationRelatedCostsDisclosureTextBlock" name="CompensationRelatedCostsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_DisclosureWarrantsAbstract" name="DisclosureWarrantsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_WarrantsDisclosureTextBlock" name="WarrantsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_ScheduleOfWarrantsIssuedWithFinancingTableTextBlock" name="ScheduleOfWarrantsIssuedWithFinancingTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_EarnoutLiabilityExpenseFirstInstallment" name="EarnoutLiabilityExpenseFirstInstallment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_EarnoutLiabilityExpenseSecondInstallment" name="EarnoutLiabilityExpenseSecondInstallment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_EarnoutLiabilityBalance" name="EarnoutLiabilityBalance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_AllowanceForObsoleteInventory" name="AllowanceForObsoleteInventory" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_LesseeOperatingLeasesRemainingLeaseTerm" name="LesseeOperatingLeasesRemainingLeaseTerm" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_WarrantExpirationDate" name="WarrantExpirationDate" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>sbfm-20260331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#Cover" roleURI="http://sunshinebiopharma.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#BalanceSheets" roleURI="http://sunshinebiopharma.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#BalanceSheetsParenthetical" roleURI="http://sunshinebiopharma.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#StatementsOfOperationsAndComprehensiveLoss" roleURI="http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#StatementsOfCashFlows" roleURI="http://sunshinebiopharma.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#StatementsOfShareholdersEquity" roleURI="http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#DescriptionOfBusiness" roleURI="http://sunshinebiopharma.com/role/DescriptionOfBusiness" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#BasisOfPresentation" roleURI="http://sunshinebiopharma.com/role/BasisOfPresentation" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#ReverseStockSplits" roleURI="http://sunshinebiopharma.com/role/ReverseStockSplits" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#AcquisitionOfNoraPharmaInc." roleURI="http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc." />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#IntangibleAssets" roleURI="http://sunshinebiopharma.com/role/IntangibleAssets" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#PlantPropertyAndEquipment" roleURI="http://sunshinebiopharma.com/role/PlantPropertyAndEquipment" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#Inventory" roleURI="http://sunshinebiopharma.com/role/Inventory" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#Leases" roleURI="http://sunshinebiopharma.com/role/Leases" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#IncomeTaxes" roleURI="http://sunshinebiopharma.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#ManagementAndDirectorCompensation" roleURI="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#CapitalStock" roleURI="http://sunshinebiopharma.com/role/CapitalStock" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#Warrants" roleURI="http://sunshinebiopharma.com/role/Warrants" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#EarningsPerShare" roleURI="http://sunshinebiopharma.com/role/EarningsPerShare" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#SegmentReporting" roleURI="http://sunshinebiopharma.com/role/SegmentReporting" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#LegalMatters" roleURI="http://sunshinebiopharma.com/role/LegalMatters" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#SubsequentEvents" roleURI="http://sunshinebiopharma.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#IntangibleAssetsTables" roleURI="http://sunshinebiopharma.com/role/IntangibleAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#PlantPropertyAndEquipmentTables" roleURI="http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#InventoryTables" roleURI="http://sunshinebiopharma.com/role/InventoryTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#LeasesTables" roleURI="http://sunshinebiopharma.com/role/LeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#WarrantsTables" roleURI="http://sunshinebiopharma.com/role/WarrantsTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#EarningsPerShareTables" roleURI="http://sunshinebiopharma.com/role/EarningsPerShareTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#DescriptionOfBusinessDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/DescriptionOfBusinessDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#ReverseStockSplitsDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#AcquisitionOfNoraPharmaInc.DetailsNarrative" roleURI="http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#IntangibleAssetsDetails-IntangibleAssets" roleURI="http://sunshinebiopharma.com/role/IntangibleAssetsDetails-IntangibleAssets" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#PlantPropertyAndEquipmentDetails" roleURI="http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#InventoryDetails" roleURI="http://sunshinebiopharma.com/role/InventoryDetails" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#LeasesDetails-LeaseInformation" roleURI="http://sunshinebiopharma.com/role/LeasesDetails-LeaseInformation" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#LeasesDetails-MaturitiesOfLeasePayments" roleURI="http://sunshinebiopharma.com/role/LeasesDetails-MaturitiesOfLeasePayments" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#IncomeTaxesDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#ManagementAndDirectorCompensationDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#CapitalStockDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#WarrantsDetails-WarrantsIssuedWithFinancing" roleURI="http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#WarrantsDetails-WarrantsOutstanding" roleURI="http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#WarrantsDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#EarningsPerShareDetails" roleURI="http://sunshinebiopharma.com/role/EarningsPerShareDetails" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaapDepositAssets" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapDepositAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_EarnoutPayable" xlink:label="loc_SBFMEarnoutPayable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_SBFMEarnoutPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaapAccruedIncomeTaxesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedIncomeTaxesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="loc_us-gaapProfessionalAndContractServicesExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapProfessionalAndContractServicesExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseDirectorsFees" xlink:label="loc_us-gaapNoninterestExpenseDirectorsFees" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapNoninterestExpenseDirectorsFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketingExpense" xlink:label="loc_us-gaapMarketingExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapMarketingExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherGeneralAndAdministrativeExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapOtherGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapSalariesAndWages" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_Taxes" xlink:label="loc_SBFMTaxes" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_SBFMTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeDebtSecuritiesOperating" xlink:label="loc_us-gaapInterestIncomeDebtSecuritiesOperating" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeDebtSecuritiesOperating" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInDepositOtherAssets" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDepositOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_IncreaseDecreaseInReductionInRightofuseAsset" xlink:label="loc_SBFMIncreaseDecreaseInReductionInRightofuseAsset" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SBFMIncreaseDecreaseInReductionInRightofuseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedIncomeTaxesPayable" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity" xlink:title="00000006 - Statement - Consolidated Statements of Shareholders&apos; Equity (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/DescriptionOfBusiness" xlink:title="999012 - Disclosure - Description of Business" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/BasisOfPresentation" xlink:title="999013 - Disclosure - Basis of Presentation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ReverseStockSplits" xlink:title="999014 - Disclosure - Reverse Stock Splits" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc." xlink:title="999015 - Disclosure - Acquisition of Nora Pharma Inc." />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IntangibleAssets" xlink:title="999016 - Disclosure - Intangible Assets" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/PlantPropertyAndEquipment" xlink:title="999017 - Disclosure - Plant, Property and Equipment" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/Inventory" xlink:title="999018 - Disclosure - Inventory" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/Leases" xlink:title="999019 - Disclosure - Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IncomeTaxes" xlink:title="999020 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation" xlink:title="999021 - Disclosure - Management and Director Compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/CapitalStock" xlink:title="999022 - Disclosure - Capital Stock" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/Warrants" xlink:title="999023 - Disclosure - Warrants" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/EarningsPerShare" xlink:title="999024 - Disclosure - Earnings Per Share" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SegmentReporting" xlink:title="999025 - Disclosure - Segment Reporting" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/LegalMatters" xlink:title="999026 - Disclosure - Legal Matters" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SubsequentEvents" xlink:title="999027 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IntangibleAssetsTables" xlink:title="999028 - Disclosure - Intangible Assets (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentTables" xlink:title="999029 - Disclosure - Plant, Property and Equipment (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/InventoryTables" xlink:title="999030 - Disclosure - Inventory (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/LeasesTables" xlink:title="999031 - Disclosure - Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/WarrantsTables" xlink:title="999032 - Disclosure - Warrants (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/EarningsPerShareTables" xlink:title="999033 - Disclosure - Earnings Per Share (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/DescriptionOfBusinessDetailsNarrative" xlink:title="999034 - Disclosure - Description of Business (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative" xlink:title="999035 - Disclosure - Reverse Stock Splits (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative" xlink:title="999036 - Disclosure - Acquisition of Nora Pharma Inc. (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IntangibleAssetsDetails-IntangibleAssets" xlink:title="999037 - Disclosure - Intangible Assets (Details - Intangible assets)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails" xlink:title="999038 - Disclosure - Plant, Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/InventoryDetails" xlink:title="999039 - Disclosure - Inventory (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/LeasesDetails-LeaseInformation" xlink:title="999040 - Disclosure - Leases (Details - Lease information)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/LeasesDetails-MaturitiesOfLeasePayments" xlink:title="999041 - Disclosure - Leases (Details - Maturities of lease payments)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="999042 - Disclosure - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative" xlink:title="999043 - Disclosure - Management and Director Compensation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" xlink:title="999044 - Disclosure - Capital Stock (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing" xlink:title="999045 - Disclosure - Warrants (Details - Warrants issued with financing)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding" xlink:title="999046 - Disclosure - Warrants (Details - Warrants outstanding)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" xlink:title="999047 - Disclosure - Warrants (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/EarningsPerShareDetails" xlink:title="999048 - Disclosure - Earnings Per Share (Details)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>sbfm-20260331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#Cover" roleURI="http://sunshinebiopharma.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#BalanceSheets" roleURI="http://sunshinebiopharma.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#BalanceSheetsParenthetical" roleURI="http://sunshinebiopharma.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#StatementsOfOperationsAndComprehensiveLoss" roleURI="http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#StatementsOfCashFlows" roleURI="http://sunshinebiopharma.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#StatementsOfShareholdersEquity" roleURI="http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#DescriptionOfBusiness" roleURI="http://sunshinebiopharma.com/role/DescriptionOfBusiness" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#BasisOfPresentation" roleURI="http://sunshinebiopharma.com/role/BasisOfPresentation" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#ReverseStockSplits" roleURI="http://sunshinebiopharma.com/role/ReverseStockSplits" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#AcquisitionOfNoraPharmaInc." roleURI="http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc." />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#IntangibleAssets" roleURI="http://sunshinebiopharma.com/role/IntangibleAssets" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#PlantPropertyAndEquipment" roleURI="http://sunshinebiopharma.com/role/PlantPropertyAndEquipment" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#Inventory" roleURI="http://sunshinebiopharma.com/role/Inventory" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#Leases" roleURI="http://sunshinebiopharma.com/role/Leases" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#IncomeTaxes" roleURI="http://sunshinebiopharma.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#ManagementAndDirectorCompensation" roleURI="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#CapitalStock" roleURI="http://sunshinebiopharma.com/role/CapitalStock" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#Warrants" roleURI="http://sunshinebiopharma.com/role/Warrants" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#EarningsPerShare" roleURI="http://sunshinebiopharma.com/role/EarningsPerShare" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#SegmentReporting" roleURI="http://sunshinebiopharma.com/role/SegmentReporting" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#LegalMatters" roleURI="http://sunshinebiopharma.com/role/LegalMatters" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#SubsequentEvents" roleURI="http://sunshinebiopharma.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#IntangibleAssetsTables" roleURI="http://sunshinebiopharma.com/role/IntangibleAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#PlantPropertyAndEquipmentTables" roleURI="http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#InventoryTables" roleURI="http://sunshinebiopharma.com/role/InventoryTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#LeasesTables" roleURI="http://sunshinebiopharma.com/role/LeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#WarrantsTables" roleURI="http://sunshinebiopharma.com/role/WarrantsTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#EarningsPerShareTables" roleURI="http://sunshinebiopharma.com/role/EarningsPerShareTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#DescriptionOfBusinessDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/DescriptionOfBusinessDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#ReverseStockSplitsDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#AcquisitionOfNoraPharmaInc.DetailsNarrative" roleURI="http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#IntangibleAssetsDetails-IntangibleAssets" roleURI="http://sunshinebiopharma.com/role/IntangibleAssetsDetails-IntangibleAssets" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#PlantPropertyAndEquipmentDetails" roleURI="http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#InventoryDetails" roleURI="http://sunshinebiopharma.com/role/InventoryDetails" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#LeasesDetails-LeaseInformation" roleURI="http://sunshinebiopharma.com/role/LeasesDetails-LeaseInformation" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#LeasesDetails-MaturitiesOfLeasePayments" roleURI="http://sunshinebiopharma.com/role/LeasesDetails-MaturitiesOfLeasePayments" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#IncomeTaxesDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#ManagementAndDirectorCompensationDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#CapitalStockDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#WarrantsDetails-WarrantsIssuedWithFinancing" roleURI="http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#WarrantsDetails-WarrantsOutstanding" roleURI="http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#WarrantsDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#EarningsPerShareDetails" roleURI="http://sunshinebiopharma.com/role/EarningsPerShareDetails" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpExecutiveCategoriesOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpAdjustmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#IndividualsOnly" roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTypeOnly" roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TradingArrangmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_50" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_50" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_50" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_50" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_50" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_50" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_50" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_50" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_50" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_50" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_50" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_50" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_50" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_50" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_50" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_50" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_50" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_50" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_50" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_50" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_50" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_50" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_50" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_50" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_50" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_50" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_50" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_50" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_50" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_50" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_50" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_50" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_50" xlink:type="arc" order="57" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - Consolidated Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity" xlink:title="00000006 - Statement - Consolidated Statements of Shareholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeMember" xlink:label="loc_us-gaapComprehensiveIncomeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapComprehensiveIncomeMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax_70" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/DescriptionOfBusiness" xlink:title="999012 - Disclosure - Description of Business" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/BasisOfPresentation" xlink:title="999013 - Disclosure - Basis of Presentation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ReverseStockSplits" xlink:title="999014 - Disclosure - Reverse Stock Splits" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc." xlink:title="999015 - Disclosure - Acquisition of Nora Pharma Inc." />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IntangibleAssets" xlink:title="999016 - Disclosure - Intangible Assets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/PlantPropertyAndEquipment" xlink:title="999017 - Disclosure - Plant, Property and Equipment" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/Inventory" xlink:title="999018 - Disclosure - Inventory" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/Leases" xlink:title="999019 - Disclosure - Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IncomeTaxes" xlink:title="999020 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation" xlink:title="999021 - Disclosure - Management and Director Compensation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/CapitalStock" xlink:title="999022 - Disclosure - Capital Stock" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/Warrants" xlink:title="999023 - Disclosure - Warrants" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/EarningsPerShare" xlink:title="999024 - Disclosure - Earnings Per Share" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SegmentReporting" xlink:title="999025 - Disclosure - Segment Reporting" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/LegalMatters" xlink:title="999026 - Disclosure - Legal Matters" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SubsequentEvents" xlink:title="999027 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IntangibleAssetsTables" xlink:title="999028 - Disclosure - Intangible Assets (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentTables" xlink:title="999029 - Disclosure - Plant, Property and Equipment (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/InventoryTables" xlink:title="999030 - Disclosure - Inventory (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/LeasesTables" xlink:title="999031 - Disclosure - Leases (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/WarrantsTables" xlink:title="999032 - Disclosure - Warrants (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/EarningsPerShareTables" xlink:title="999033 - Disclosure - Earnings Per Share (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/DescriptionOfBusinessDetailsNarrative" xlink:title="999034 - Disclosure - Description of Business (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative" xlink:title="999035 - Disclosure - Reverse Stock Splits (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative" xlink:title="999036 - Disclosure - Acquisition of Nora Pharma Inc. (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_NoraPharmaMember" xlink:label="loc_SBFMNoraPharmaMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_SBFMNoraPharmaMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_MalekChamounMember" xlink:label="loc_SBFMMalekChamounMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_SBFMMalekChamounMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaapPaymentsToAcquireBusinessesGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapPaymentsToAcquireBusinessesGross_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_EarnoutPayable" xlink:label="loc_SBFMEarnoutPayable_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_SBFMEarnoutPayable_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_EarnoutLiabilityExpenseFirstInstallment" xlink:label="loc_SBFMEarnoutLiabilityExpenseFirstInstallment_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_SBFMEarnoutLiabilityExpenseFirstInstallment_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_EarnoutLiabilityExpenseSecondInstallment" xlink:label="loc_SBFMEarnoutLiabilityExpenseSecondInstallment_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_SBFMEarnoutLiabilityExpenseSecondInstallment_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_EarnoutLiabilityBalance" xlink:label="loc_SBFMEarnoutLiabilityBalance_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_SBFMEarnoutLiabilityBalance_60" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IntangibleAssetsDetails-IntangibleAssets" xlink:title="999037 - Disclosure - Intangible Assets (Details - Intangible assets)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails" xlink:title="999038 - Disclosure - Plant, Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VehiclesMember" xlink:label="loc_us-gaapVehiclesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapVehiclesMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_130" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/InventoryDetails" xlink:title="999039 - Disclosure - Inventory (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/LeasesDetails-LeaseInformation" xlink:title="999040 - Disclosure - Leases (Details - Lease information)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/LeasesDetails-MaturitiesOfLeasePayments" xlink:title="999041 - Disclosure - Leases (Details - Maturities of lease payments)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="999042 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="loc_countryUS_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_countryUS_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative" xlink:title="999043 - Disclosure - Management and Director Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_AllDirectorsMember" xlink:label="loc_SBFMAllDirectorsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_SBFMAllDirectorsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_Director1Member" xlink:label="loc_SBFMDirector1Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_SBFMDirector1Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_Director2Member" xlink:label="loc_SBFMDirector2Member_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_SBFMDirector2Member_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_Director3Member" xlink:label="loc_SBFMDirector3Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_SBFMDirector3Member_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_Director4Member" xlink:label="loc_SBFMDirector4Member_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_SBFMDirector4Member_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_Director5Member" xlink:label="loc_SBFMDirector5Member_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_SBFMDirector5Member_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaapSalariesWagesAndOfficersCompensation_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSalariesWagesAndOfficersCompensation_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseDirectorsFees" xlink:label="loc_us-gaapNoninterestExpenseDirectorsFees_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNoninterestExpenseDirectorsFees_150" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" xlink:title="999044 - Disclosure - Capital Stock (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_SeriesBWarrantsMember" xlink:label="loc_SBFMSeriesBWarrantsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_SBFMSeriesBWarrantsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_RegisteredDirectOfferingMember" xlink:label="loc_SBFMRegisteredDirectOfferingMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_SBFMRegisteredDirectOfferingMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_150" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_150" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_150" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_150" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_150" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_150" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_150" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_150" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing" xlink:title="999045 - Disclosure - Warrants (Details - Warrants issued with financing)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_TradeableWarrantsMember" xlink:label="loc_SBFMTradeableWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMTradeableWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_PreFunded2022WarrantsMember" xlink:label="loc_SBFMPreFunded2022WarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMPreFunded2022WarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_InvestorWarrantsMember" xlink:label="loc_SBFMInvestorWarrantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMInvestorWarrantsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_AprilWarrantsMember" xlink:label="loc_SBFMAprilWarrantsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMAprilWarrantsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_MayPreFundedWarrantsMember" xlink:label="loc_SBFMMayPreFundedWarrantsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMMayPreFundedWarrantsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_MayInvestorWarrantsMember" xlink:label="loc_SBFMMayInvestorWarrantsMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMMayInvestorWarrantsMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_PreFunded2024WarrantsMember" xlink:label="loc_SBFMPreFunded2024WarrantsMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMPreFunded2024WarrantsMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_SeriesAWarrantsMember" xlink:label="loc_SBFMSeriesAWarrantsMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMSeriesAWarrantsMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_SeriesBWarrantsMember" xlink:label="loc_SBFMSeriesBWarrantsMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMSeriesBWarrantsMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_PreFunded2025WarrantsMember" xlink:label="loc_SBFMPreFunded2025WarrantsMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMPreFunded2025WarrantsMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_210" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_210" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_WarrantExpirationDate" xlink:label="loc_SBFMWarrantExpirationDate_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_SBFMWarrantExpirationDate_210" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding" xlink:title="999046 - Disclosure - Warrants (Details - Warrants outstanding)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_TradeableWarrants1Member" xlink:label="loc_SBFMTradeableWarrants1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMTradeableWarrants1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_InvestorWarrants1Member" xlink:label="loc_SBFMInvestorWarrants1Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMInvestorWarrants1Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_SeriesBWarrants1Member" xlink:label="loc_SBFMSeriesBWarrants1Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMSeriesBWarrants1Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_WarrantExpirationDate" xlink:label="loc_SBFMWarrantExpirationDate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_SBFMWarrantExpirationDate_70" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" xlink:title="999047 - Disclosure - Warrants (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_AprilWarrantsAndMayInvestorWarrantsMember" xlink:label="loc_SBFMAprilWarrantsAndMayInvestorWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMAprilWarrantsAndMayInvestorWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_TradeableWarrantsMember" xlink:label="loc_SBFMTradeableWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMTradeableWarrantsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_InvestorWarrantsMember" xlink:label="loc_SBFMInvestorWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMInvestorWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_SeriesBWarrantsMember" xlink:label="loc_SBFMSeriesBWarrantsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMSeriesBWarrantsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="loc_us-gaapPaymentsForRepurchaseOfWarrants_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfWarrants_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/EarningsPerShareDetails" xlink:title="999048 - Disclosure - Earnings Per Share (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_TradeableWarrantsMember" xlink:label="loc_SBFMTradeableWarrantsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMTradeableWarrantsMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_PreFunded2022WarrantsMember" xlink:label="loc_SBFMPreFunded2022WarrantsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMPreFunded2022WarrantsMember" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_InvestorWarrantsMember" xlink:label="loc_SBFMInvestorWarrantsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMInvestorWarrantsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_AprilWarrantsMember" xlink:label="loc_SBFMAprilWarrantsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMAprilWarrantsMember" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_MayPreFundedWarrantsMember" xlink:label="loc_SBFMMayPreFundedWarrantsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMMayPreFundedWarrantsMember" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_MayInvestorWarrantsMember" xlink:label="loc_SBFMMayInvestorWarrantsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMMayInvestorWarrantsMember" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_PreFunded2024WarrantsMember" xlink:label="loc_SBFMPreFunded2024WarrantsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMPreFunded2024WarrantsMember" xlink:type="arc" order="60" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_SeriesAWarrantsMember" xlink:label="loc_SBFMSeriesAWarrantsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMSeriesAWarrantsMember" xlink:type="arc" order="70" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_SeriesBWarrantsMember" xlink:label="loc_SBFMSeriesBWarrantsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMSeriesBWarrantsMember" xlink:type="arc" order="80" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_PreFunded2025WarrantsMember" xlink:label="loc_SBFMPreFunded2025WarrantsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMPreFunded2025WarrantsMember" xlink:type="arc" order="90" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_AprilWarrantsAndMayInvestorWarrantsMember" xlink:label="loc_SBFMAprilWarrantsAndMayInvestorWarrantsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMAprilWarrantsAndMayInvestorWarrantsMember" xlink:type="arc" order="100" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_TradeableWarrants1Member" xlink:label="loc_SBFMTradeableWarrants1Member" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMTradeableWarrants1Member" xlink:type="arc" order="110" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_InvestorWarrants1Member" xlink:label="loc_SBFMInvestorWarrants1Member" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMInvestorWarrants1Member" xlink:type="arc" order="120" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_SeriesBWarrants1Member" xlink:label="loc_SBFMSeriesBWarrants1Member" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMSeriesBWarrants1Member" xlink:type="arc" order="130" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>sbfm-20260331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeMember" xlink:label="us-gaap_ComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeMember" xlink:to="us-gaap_ComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeMember_lbl" xml:lang="en-US">Comprehensive Income [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Combination [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_NoraPharmaMember" xlink:label="SBFM_NoraPharmaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_NoraPharmaMember" xlink:to="SBFM_NoraPharmaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_NoraPharmaMember_lbl" xml:lang="en-US">Nora Pharma [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_MalekChamounMember" xlink:label="SBFM_MalekChamounMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_MalekChamounMember" xlink:to="SBFM_MalekChamounMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_MalekChamounMember_lbl" xml:lang="en-US">Malek Chamoun [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VehiclesMember_lbl" xml:lang="en-US">Vehicles [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="country_US" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US">UNITED STATES</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_AllDirectorsMember" xlink:label="SBFM_AllDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_AllDirectorsMember" xlink:to="SBFM_AllDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_AllDirectorsMember_lbl" xml:lang="en-US">All Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_Director1Member" xlink:label="SBFM_Director1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_Director1Member" xlink:to="SBFM_Director1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_Director1Member_lbl" xml:lang="en-US">Director 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_Director2Member" xlink:label="SBFM_Director2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_Director2Member" xlink:to="SBFM_Director2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_Director2Member_lbl" xml:lang="en-US">Director 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_Director3Member" xlink:label="SBFM_Director3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_Director3Member" xlink:to="SBFM_Director3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_Director3Member_lbl" xml:lang="en-US">Director 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_Director4Member" xlink:label="SBFM_Director4Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_Director4Member" xlink:to="SBFM_Director4Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_Director4Member_lbl" xml:lang="en-US">Director 4 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_Director5Member" xlink:label="SBFM_Director5Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_Director5Member" xlink:to="SBFM_Director5Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_Director5Member_lbl" xml:lang="en-US">Director 5 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_SeriesBWarrantsMember" xlink:label="SBFM_SeriesBWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_SeriesBWarrantsMember" xlink:to="SBFM_SeriesBWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_SeriesBWarrantsMember_lbl" xml:lang="en-US">Series B Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_RegisteredDirectOfferingMember" xlink:label="SBFM_RegisteredDirectOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_RegisteredDirectOfferingMember" xlink:to="SBFM_RegisteredDirectOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_RegisteredDirectOfferingMember_lbl" xml:lang="en-US">Registered Direct Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_TradeableWarrantsMember" xlink:label="SBFM_TradeableWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_TradeableWarrantsMember" xlink:to="SBFM_TradeableWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_TradeableWarrantsMember_lbl" xml:lang="en-US">Tradeable Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_PreFunded2022WarrantsMember" xlink:label="SBFM_PreFunded2022WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_PreFunded2022WarrantsMember" xlink:to="SBFM_PreFunded2022WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_PreFunded2022WarrantsMember_lbl" xml:lang="en-US">2022 Pre-Funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_InvestorWarrantsMember" xlink:label="SBFM_InvestorWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_InvestorWarrantsMember" xlink:to="SBFM_InvestorWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_InvestorWarrantsMember_lbl" xml:lang="en-US">Investor Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_AprilWarrantsMember" xlink:label="SBFM_AprilWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_AprilWarrantsMember" xlink:to="SBFM_AprilWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_AprilWarrantsMember_lbl" xml:lang="en-US">April Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_MayPreFundedWarrantsMember" xlink:label="SBFM_MayPreFundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_MayPreFundedWarrantsMember" xlink:to="SBFM_MayPreFundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_MayPreFundedWarrantsMember_lbl" xml:lang="en-US">May Pre-Funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_MayInvestorWarrantsMember" xlink:label="SBFM_MayInvestorWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_MayInvestorWarrantsMember" xlink:to="SBFM_MayInvestorWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_MayInvestorWarrantsMember_lbl" xml:lang="en-US">May Investor Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_PreFunded2024WarrantsMember" xlink:label="SBFM_PreFunded2024WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_PreFunded2024WarrantsMember" xlink:to="SBFM_PreFunded2024WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_PreFunded2024WarrantsMember_lbl" xml:lang="en-US">2024 Pre-Funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_SeriesAWarrantsMember" xlink:label="SBFM_SeriesAWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_SeriesAWarrantsMember" xlink:to="SBFM_SeriesAWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_SeriesAWarrantsMember_lbl" xml:lang="en-US">Series A Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_PreFunded2025WarrantsMember" xlink:label="SBFM_PreFunded2025WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_PreFunded2025WarrantsMember" xlink:to="SBFM_PreFunded2025WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_PreFunded2025WarrantsMember_lbl" xml:lang="en-US">2025 Pre-Funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_AprilWarrantsAndMayInvestorWarrantsMember" xlink:label="SBFM_AprilWarrantsAndMayInvestorWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_AprilWarrantsAndMayInvestorWarrantsMember" xlink:to="SBFM_AprilWarrantsAndMayInvestorWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_AprilWarrantsAndMayInvestorWarrantsMember_lbl" xml:lang="en-US">April Warrants And May Investor Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_TradeableWarrants1Member" xlink:label="SBFM_TradeableWarrants1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_TradeableWarrants1Member" xlink:to="SBFM_TradeableWarrants1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_TradeableWarrants1Member_lbl" xml:lang="en-US">Tradeable Warrants 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_InvestorWarrants1Member" xlink:label="SBFM_InvestorWarrants1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_InvestorWarrants1Member" xlink:to="SBFM_InvestorWarrants1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_InvestorWarrants1Member_lbl" xml:lang="en-US">Investor Warrants 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_SeriesBWarrants1Member" xlink:label="SBFM_SeriesBWarrants1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_SeriesBWarrants1Member" xlink:to="SBFM_SeriesBWarrants1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_SeriesBWarrants1Member_lbl" xml:lang="en-US">Series B Warrants 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositAssets" xlink:label="us-gaap_DepositAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositAssets" xlink:to="us-gaap_DepositAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositAssets_lbl" xml:lang="en-US">Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Long-Term Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property &amp; equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use-asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total Long-Term Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US">LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable &amp; accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_EarnoutPayable" xlink:label="SBFM_EarnoutPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_EarnoutPayable" xlink:to="SBFM_EarnoutPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_EarnoutPayable_lbl" xml:lang="en-US">Earnout payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US">Income tax payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Right-of-use-liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Long-Term Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Right-of-use-liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total Long-Term Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">SHAREHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock Series B $0.10 par value per share; 1,000,000 shares authorized 130,000 shares issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock $0.001 par value per share; 3,000,000,000 shares authorized 4,905,945 shares issued and outstanding at March 31, 2026 and December 31, 2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Capital paid in excess of par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated comprehensive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated (Deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL SHAREHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Sales</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of sales</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xml:lang="en-US">General &amp; Administrative Expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Accounting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalAndContractServicesExpense" xlink:to="us-gaap_ProfessionalAndContractServicesExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl" xml:lang="en-US">Consulting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseDirectorsFees" xlink:label="us-gaap_NoninterestExpenseDirectorsFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestExpenseDirectorsFees" xlink:to="us-gaap_NoninterestExpenseDirectorsFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoninterestExpenseDirectorsFees_lbl" xml:lang="en-US">Director fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Legal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketingExpense" xlink:label="us-gaap_MarketingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketingExpense" xlink:to="us-gaap_MarketingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketingExpense_lbl" xml:lang="en-US">Marketing</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Office</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">R&amp;D</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesAndWages" xlink:label="us-gaap_SalariesAndWages" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesAndWages" xlink:to="us-gaap_SalariesAndWages_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesAndWages_lbl" xml:lang="en-US">Salaries</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_Taxes" xlink:label="SBFM_Taxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_Taxes" xlink:to="SBFM_Taxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_Taxes_lbl" xml:lang="en-US">Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation &amp; amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Total General &amp; Administrative Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">(Loss) From Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign exchange</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeDebtSecuritiesOperating" xlink:label="us-gaap_InterestIncomeDebtSecuritiesOperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeDebtSecuritiesOperating" xlink:to="us-gaap_InterestIncomeDebtSecuritiesOperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeDebtSecuritiesOperating_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Other income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Net (loss) before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_lbl" xml:lang="en-US">Foreign exchange translation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">(Loss) per common share (Basic)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding (Basic)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Operating Activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_2_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl" xml:lang="en-US">Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_IncreaseDecreaseInReductionInRightofuseAsset" xlink:label="SBFM_IncreaseDecreaseInReductionInRightofuseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_IncreaseDecreaseInReductionInRightofuseAsset" xlink:to="SBFM_IncreaseDecreaseInReductionInRightofuseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_IncreaseDecreaseInReductionInRightofuseAsset_lbl" xml:lang="en-US">Reduction in right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts Payable &amp; accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xml:lang="en-US">Income tax payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Flows (Used In) Operating Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Investing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Purchase of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Flows (Used In) Investing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Financing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Flows Provided by Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash and Cash Equivalents at Beginning of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Effect of exchange rate changes on cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash and Cash Equivalents at End of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplementary Disclosure of Cash Flow Information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Cash paid for income taxes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Exercise of warrants, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Net (loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xml:lang="en-US">Aggregate Available</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Description of Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_DisclosureReverseStockSplitsAbstract" xlink:label="SBFM_DisclosureReverseStockSplitsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_DisclosureReverseStockSplitsAbstract" xlink:to="SBFM_DisclosureReverseStockSplitsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_DisclosureReverseStockSplitsAbstract_lbl" xml:lang="en-US">Reverse Stock Splits</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_ReverseStockSplitTextBlock" xlink:label="SBFM_ReverseStockSplitTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_ReverseStockSplitTextBlock" xlink:to="SBFM_ReverseStockSplitTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SBFM_ReverseStockSplitTextBlock_lbl" xml:lang="en-US">Reverse Stock Splits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xml:lang="en-US">Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl" xml:lang="en-US">Acquisition of Nora Pharma Inc.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Plant, Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_DisclosureLeasesAbstract" xlink:label="SBFM_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_DisclosureLeasesAbstract" xlink:to="SBFM_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_DisclosureManagementAndDirectorCompensationAbstract" xlink:label="SBFM_DisclosureManagementAndDirectorCompensationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_DisclosureManagementAndDirectorCompensationAbstract" xlink:to="SBFM_DisclosureManagementAndDirectorCompensationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_DisclosureManagementAndDirectorCompensationAbstract_lbl" xml:lang="en-US">Management And Director Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_CompensationRelatedCostsDisclosureTextBlock" xlink:label="SBFM_CompensationRelatedCostsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_CompensationRelatedCostsDisclosureTextBlock" xlink:to="SBFM_CompensationRelatedCostsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_CompensationRelatedCostsDisclosureTextBlock_lbl" xml:lang="en-US">Management and Director Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Capital Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_DisclosureWarrantsAbstract" xlink:label="SBFM_DisclosureWarrantsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_DisclosureWarrantsAbstract" xlink:to="SBFM_DisclosureWarrantsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_DisclosureWarrantsAbstract_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_WarrantsDisclosureTextBlock" xlink:label="SBFM_WarrantsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_WarrantsDisclosureTextBlock" xlink:to="SBFM_WarrantsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SBFM_WarrantsDisclosureTextBlock_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Segment Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="us-gaap_LegalMattersAndContingenciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock_lbl" xml:lang="en-US">Legal Matters</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of plant property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of lease information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of maturities of lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_ScheduleOfWarrantsIssuedWithFinancingTableTextBlock" xlink:label="SBFM_ScheduleOfWarrantsIssuedWithFinancingTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_ScheduleOfWarrantsIssuedWithFinancingTableTextBlock" xlink:to="SBFM_ScheduleOfWarrantsIssuedWithFinancingTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_ScheduleOfWarrantsIssuedWithFinancingTableTextBlock_lbl" xml:lang="en-US">Schedule of warrants issued with financing</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of computation of basic and diluted net income per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of operating segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of reportable segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US">Business Combination [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US">Business Combination [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US">Purchase price of shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xml:lang="en-US">Payments to acquire shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Stock issued for acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US">Stock issued for acquisition, value</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_EarnoutLiabilityExpenseFirstInstallment" xlink:label="SBFM_EarnoutLiabilityExpenseFirstInstallment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_EarnoutLiabilityExpenseFirstInstallment" xlink:to="SBFM_EarnoutLiabilityExpenseFirstInstallment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_EarnoutLiabilityExpenseFirstInstallment_lbl" xml:lang="en-US">Earnout liability expense, first installment</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_EarnoutLiabilityExpenseSecondInstallment" xlink:label="SBFM_EarnoutLiabilityExpenseSecondInstallment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_EarnoutLiabilityExpenseSecondInstallment" xlink:to="SBFM_EarnoutLiabilityExpenseSecondInstallment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_EarnoutLiabilityExpenseSecondInstallment_lbl" xml:lang="en-US">Earnout liability expense, second installment</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_EarnoutLiabilityBalance" xlink:label="SBFM_EarnoutLiabilityBalance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_EarnoutLiabilityBalance" xlink:to="SBFM_EarnoutLiabilityBalance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_EarnoutLiabilityBalance_lbl" xml:lang="en-US">Remaining earnout balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Intangible assets at beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:to="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Purchase of additional intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Intangible assets at ending of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xml:lang="en-US">Less impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Less accumulated amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Plant, property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished goods</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_AllowanceForObsoleteInventory" xlink:label="SBFM_AllowanceForObsoleteInventory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_AllowanceForObsoleteInventory" xlink:to="SBFM_AllowanceForObsoleteInventory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_AllowanceForObsoleteInventory_lbl" xml:lang="en-US">Allowance for obsolete inventory</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryNet_2_lbl" xml:lang="en-US">Total Inventory, net of allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Operating lease ROU asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Operating Lease liability - Short-term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Operating lease liability - Long-term</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_LesseeOperatingLeasesRemainingLeaseTerm" xlink:label="SBFM_LesseeOperatingLeasesRemainingLeaseTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_LesseeOperatingLeasesRemainingLeaseTerm" xlink:to="SBFM_LesseeOperatingLeasesRemainingLeaseTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_LesseeOperatingLeasesRemainingLeaseTerm_lbl" xml:lang="en-US">Remaining lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2028</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2029</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:label="SBFM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:to="SBFM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income tax (expense) / benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesWagesAndOfficersCompensation" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xml:lang="en-US">Officers compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestExpenseDirectorsFees" xlink:to="us-gaap_NoninterestExpenseDirectorsFees_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NoninterestExpenseDirectorsFees_2_lbl" xml:lang="en-US">Directors cash compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Stock converted, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Stock converted, shares converted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_2_lbl" xml:lang="en-US">Net proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Aggregate shares Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_WarrantExpirationDate" xlink:label="SBFM_WarrantExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_WarrantExpirationDate" xlink:to="SBFM_WarrantExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_WarrantExpirationDate_lbl" xml:lang="en-US">Warrant expiration date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Number of warrants outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Warrant exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_WarrantExpirationDate" xlink:to="SBFM_WarrantExpirationDate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SBFM_WarrantExpirationDate_2_lbl" xml:lang="en-US">Expiry date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfWarrants" xlink:to="us-gaap_PaymentsForRepurchaseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants_lbl" xml:lang="en-US">Payments for repurchase of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_3_lbl" xml:lang="en-US">Proceeds from warrant exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net gain (loss) attributable to common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Weighted average outstanding shares of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_2_lbl" xml:lang="en-US">Net gain (loss) per share attributable to common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_CompensationRelatedCostsDisclosureTextBlock" xlink:to="SBFM_CompensationRelatedCostsDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SBFM_CompensationRelatedCostsDisclosureTextBlock_doc" xml:lang="en-US">Compensation Related Costs Disclosure [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="SBFM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="SBFM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SBFM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_doc" xml:lang="en-US">Lessee Operating Lease Liability Payments Due After Year Four</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">General and Administrative Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Deposit Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2_lbl" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_ReverseStockSplitTextBlock" xlink:to="SBFM_ReverseStockSplitTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_ReverseStockSplitTextBlock_2_lbl" xml:lang="en-US">ReverseStockSplitTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_2_lbl" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_WarrantsDisclosureTextBlock" xlink:to="SBFM_WarrantsDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_WarrantsDisclosureTextBlock_2_lbl" xml:lang="en-US">WarrantsDisclosureTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>sbfm-20260331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#Cover" roleURI="http://sunshinebiopharma.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#BalanceSheets" roleURI="http://sunshinebiopharma.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#BalanceSheetsParenthetical" roleURI="http://sunshinebiopharma.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#StatementsOfOperationsAndComprehensiveLoss" roleURI="http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#StatementsOfCashFlows" roleURI="http://sunshinebiopharma.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#StatementsOfShareholdersEquity" roleURI="http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#DescriptionOfBusiness" roleURI="http://sunshinebiopharma.com/role/DescriptionOfBusiness" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#BasisOfPresentation" roleURI="http://sunshinebiopharma.com/role/BasisOfPresentation" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#ReverseStockSplits" roleURI="http://sunshinebiopharma.com/role/ReverseStockSplits" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#AcquisitionOfNoraPharmaInc." roleURI="http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc." />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#IntangibleAssets" roleURI="http://sunshinebiopharma.com/role/IntangibleAssets" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#PlantPropertyAndEquipment" roleURI="http://sunshinebiopharma.com/role/PlantPropertyAndEquipment" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#Inventory" roleURI="http://sunshinebiopharma.com/role/Inventory" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#Leases" roleURI="http://sunshinebiopharma.com/role/Leases" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#IncomeTaxes" roleURI="http://sunshinebiopharma.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#ManagementAndDirectorCompensation" roleURI="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#CapitalStock" roleURI="http://sunshinebiopharma.com/role/CapitalStock" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#Warrants" roleURI="http://sunshinebiopharma.com/role/Warrants" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#EarningsPerShare" roleURI="http://sunshinebiopharma.com/role/EarningsPerShare" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#SegmentReporting" roleURI="http://sunshinebiopharma.com/role/SegmentReporting" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#LegalMatters" roleURI="http://sunshinebiopharma.com/role/LegalMatters" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#SubsequentEvents" roleURI="http://sunshinebiopharma.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#IntangibleAssetsTables" roleURI="http://sunshinebiopharma.com/role/IntangibleAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#PlantPropertyAndEquipmentTables" roleURI="http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#InventoryTables" roleURI="http://sunshinebiopharma.com/role/InventoryTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#LeasesTables" roleURI="http://sunshinebiopharma.com/role/LeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#WarrantsTables" roleURI="http://sunshinebiopharma.com/role/WarrantsTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#EarningsPerShareTables" roleURI="http://sunshinebiopharma.com/role/EarningsPerShareTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#DescriptionOfBusinessDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/DescriptionOfBusinessDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#ReverseStockSplitsDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#AcquisitionOfNoraPharmaInc.DetailsNarrative" roleURI="http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#IntangibleAssetsDetails-IntangibleAssets" roleURI="http://sunshinebiopharma.com/role/IntangibleAssetsDetails-IntangibleAssets" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#PlantPropertyAndEquipmentDetails" roleURI="http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#InventoryDetails" roleURI="http://sunshinebiopharma.com/role/InventoryDetails" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#LeasesDetails-LeaseInformation" roleURI="http://sunshinebiopharma.com/role/LeasesDetails-LeaseInformation" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#LeasesDetails-MaturitiesOfLeasePayments" roleURI="http://sunshinebiopharma.com/role/LeasesDetails-MaturitiesOfLeasePayments" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#IncomeTaxesDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#ManagementAndDirectorCompensationDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#CapitalStockDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#WarrantsDetails-WarrantsIssuedWithFinancing" roleURI="http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#WarrantsDetails-WarrantsOutstanding" roleURI="http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#WarrantsDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20260331.xsd#EarningsPerShareDetails" roleURI="http://sunshinebiopharma.com/role/EarningsPerShareDetails" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosureWithAdditionalMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpTable" roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpAdjustmentsToCompensation" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TabularListsByExecutiveCategory" roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TabularListMeasures" roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpPensionBenefitsAdjustments" roleURI="http://xbrl.sec.gov/ecd/role/PvpPensionBenefitsAdjustments" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ForgoneRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#OutstandingRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardsCloseToMnpiDisc" roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangemenstByInd" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#Defaults" roleURI="http://xbrl.sec.gov/ecd/role/Defaults" />
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaapDepositAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapDepositAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaapLiabilitiesAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_EarnoutPayable" xlink:label="loc_SBFMEarnoutPayable" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_SBFMEarnoutPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaapAccruedIncomeTaxesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedIncomeTaxesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="loc_us-gaapProfessionalAndContractServicesExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapProfessionalAndContractServicesExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseDirectorsFees" xlink:label="loc_us-gaapNoninterestExpenseDirectorsFees" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapNoninterestExpenseDirectorsFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketingExpense" xlink:label="loc_us-gaapMarketingExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapMarketingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherGeneralAndAdministrativeExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapOtherGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapSalariesAndWages" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_Taxes" xlink:label="loc_SBFMTaxes" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_SBFMTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeDebtSecuritiesOperating" xlink:label="loc_us-gaapInterestIncomeDebtSecuritiesOperating" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeDebtSecuritiesOperating" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapOtherIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInDepositOtherAssets" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDepositOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_IncreaseDecreaseInReductionInRightofuseAsset" xlink:label="loc_SBFMIncreaseDecreaseInReductionInRightofuseAsset" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_SBFMIncreaseDecreaseInReductionInRightofuseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedIncomeTaxesPayable" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity" xlink:title="00000006 - Statement - Consolidated Statements of Shareholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeMember" xlink:label="loc_us-gaapComprehensiveIncomeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="loc_ecdEqtyAwrdsAdjFnTextBlock" />
      <link:presentationArc order="2290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdEqtyAwrdsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="loc_ecdTrdArrSecuritiesAggAvailAmt" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrSecuritiesAggAvailAmt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/DescriptionOfBusiness" xlink:title="999012 - Disclosure - Description of Business">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/BasisOfPresentation" xlink:title="999013 - Disclosure - Basis of Presentation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ReverseStockSplits" xlink:title="999014 - Disclosure - Reverse Stock Splits">
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_DisclosureReverseStockSplitsAbstract" xlink:label="loc_SBFMDisclosureReverseStockSplitsAbstract" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_ReverseStockSplitTextBlock" xlink:label="loc_SBFMReverseStockSplitTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureReverseStockSplitsAbstract" xlink:to="loc_SBFMReverseStockSplitTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc." xlink:title="999015 - Disclosure - Acquisition of Nora Pharma Inc.">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:label="loc_us-gaapMergersAcquisitionsAndDispositionsDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapMergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IntangibleAssets" xlink:title="999016 - Disclosure - Intangible Assets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/PlantPropertyAndEquipment" xlink:title="999017 - Disclosure - Plant, Property and Equipment">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/Inventory" xlink:title="999018 - Disclosure - Inventory">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/Leases" xlink:title="999019 - Disclosure - Leases">
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_DisclosureLeasesAbstract" xlink:label="loc_SBFMDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IncomeTaxes" xlink:title="999020 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation" xlink:title="999021 - Disclosure - Management and Director Compensation">
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_DisclosureManagementAndDirectorCompensationAbstract" xlink:label="loc_SBFMDisclosureManagementAndDirectorCompensationAbstract" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_CompensationRelatedCostsDisclosureTextBlock" xlink:label="loc_SBFMCompensationRelatedCostsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureManagementAndDirectorCompensationAbstract" xlink:to="loc_SBFMCompensationRelatedCostsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/CapitalStock" xlink:title="999022 - Disclosure - Capital Stock">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/Warrants" xlink:title="999023 - Disclosure - Warrants">
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_DisclosureWarrantsAbstract" xlink:label="loc_SBFMDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_WarrantsDisclosureTextBlock" xlink:label="loc_SBFMWarrantsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureWarrantsAbstract" xlink:to="loc_SBFMWarrantsDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/EarningsPerShare" xlink:title="999024 - Disclosure - Earnings Per Share">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SegmentReporting" xlink:title="999025 - Disclosure - Segment Reporting">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/LegalMatters" xlink:title="999026 - Disclosure - Legal Matters">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaapLegalMattersAndContingenciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLegalMattersAndContingenciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SubsequentEvents" xlink:title="999027 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IntangibleAssetsTables" xlink:title="999028 - Disclosure - Intangible Assets (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentTables" xlink:title="999029 - Disclosure - Plant, Property and Equipment (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/InventoryTables" xlink:title="999030 - Disclosure - Inventory (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/LeasesTables" xlink:title="999031 - Disclosure - Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_DisclosureLeasesAbstract" xlink:label="loc_SBFMDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/WarrantsTables" xlink:title="999032 - Disclosure - Warrants (Tables)">
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_DisclosureWarrantsAbstract" xlink:label="loc_SBFMDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_ScheduleOfWarrantsIssuedWithFinancingTableTextBlock" xlink:label="loc_SBFMScheduleOfWarrantsIssuedWithFinancingTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureWarrantsAbstract" xlink:to="loc_SBFMScheduleOfWarrantsIssuedWithFinancingTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureWarrantsAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/EarningsPerShareTables" xlink:title="999033 - Disclosure - Earnings Per Share (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/DescriptionOfBusinessDetailsNarrative" xlink:title="999034 - Disclosure - Description of Business (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNumberOfOperatingSegments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNumberOfReportableSegments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative" xlink:title="999035 - Disclosure - Reverse Stock Splits (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_DisclosureReverseStockSplitsAbstract" xlink:label="loc_SBFMDisclosureReverseStockSplitsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureReverseStockSplitsAbstract" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative" xlink:title="999036 - Disclosure - Acquisition of Nora Pharma Inc. (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_NoraPharmaMember" xlink:label="loc_SBFMNoraPharmaMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_SBFMNoraPharmaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_srtCounterpartyNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_MalekChamounMember" xlink:label="loc_SBFMMalekChamounMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_SBFMMalekChamounMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaapPaymentsToAcquireBusinessesGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapPaymentsToAcquireBusinessesGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_EarnoutPayable" xlink:label="loc_SBFMEarnoutPayable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_SBFMEarnoutPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_EarnoutLiabilityExpenseFirstInstallment" xlink:label="loc_SBFMEarnoutLiabilityExpenseFirstInstallment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_SBFMEarnoutLiabilityExpenseFirstInstallment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_EarnoutLiabilityExpenseSecondInstallment" xlink:label="loc_SBFMEarnoutLiabilityExpenseSecondInstallment" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_SBFMEarnoutLiabilityExpenseSecondInstallment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_EarnoutLiabilityBalance" xlink:label="loc_SBFMEarnoutLiabilityBalance" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_SBFMEarnoutLiabilityBalance" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IntangibleAssetsDetails-IntangibleAssets" xlink:title="999037 - Disclosure - Intangible Assets (Details - Intangible assets)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsPeriodIncreaseDecrease" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_2" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails" xlink:title="999038 - Disclosure - Plant, Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VehiclesMember" xlink:label="loc_us-gaapVehiclesMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapVehiclesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/InventoryDetails" xlink:title="999039 - Disclosure - Inventory (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_AllowanceForObsoleteInventory" xlink:label="loc_SBFMAllowanceForObsoleteInventory" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_SBFMAllowanceForObsoleteInventory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/LeasesDetails-LeaseInformation" xlink:title="999040 - Disclosure - Leases (Details - Lease information)">
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_DisclosureLeasesAbstract" xlink:label="loc_SBFMDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_LesseeOperatingLeasesRemainingLeaseTerm" xlink:label="loc_SBFMLesseeOperatingLeasesRemainingLeaseTerm" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureLeasesAbstract" xlink:to="loc_SBFMLesseeOperatingLeasesRemainingLeaseTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/LeasesDetails-MaturitiesOfLeasePayments" xlink:title="999041 - Disclosure - Leases (Details - Maturities of lease payments)">
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_DisclosureLeasesAbstract" xlink:label="loc_SBFMDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:label="loc_SBFMLesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureLeasesAbstract" xlink:to="loc_SBFMLesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="999042 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="loc_countryUS" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_countryUS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative" xlink:title="999043 - Disclosure - Management and Director Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_DisclosureManagementAndDirectorCompensationAbstract" xlink:label="loc_SBFMDisclosureManagementAndDirectorCompensationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureManagementAndDirectorCompensationAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtCounterpartyNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_AllDirectorsMember" xlink:label="loc_SBFMAllDirectorsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_SBFMAllDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_Director1Member" xlink:label="loc_SBFMDirector1Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_SBFMDirector1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_Director2Member" xlink:label="loc_SBFMDirector2Member" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_SBFMDirector2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_Director3Member" xlink:label="loc_SBFMDirector3Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_SBFMDirector3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_Director4Member" xlink:label="loc_SBFMDirector4Member" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_SBFMDirector4Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_Director5Member" xlink:label="loc_SBFMDirector5Member" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_SBFMDirector5Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaapSalariesWagesAndOfficersCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSalariesWagesAndOfficersCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseDirectorsFees" xlink:label="loc_us-gaapNoninterestExpenseDirectorsFees" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNoninterestExpenseDirectorsFees" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" xlink:title="999044 - Disclosure - Capital Stock (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_SeriesBWarrantsMember" xlink:label="loc_SBFMSeriesBWarrantsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_SBFMSeriesBWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_RegisteredDirectOfferingMember" xlink:label="loc_SBFMRegisteredDirectOfferingMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_SBFMRegisteredDirectOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing" xlink:title="999045 - Disclosure - Warrants (Details - Warrants issued with financing)">
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_DisclosureWarrantsAbstract" xlink:label="loc_SBFMDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureWarrantsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_TradeableWarrantsMember" xlink:label="loc_SBFMTradeableWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMTradeableWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_PreFunded2022WarrantsMember" xlink:label="loc_SBFMPreFunded2022WarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMPreFunded2022WarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_InvestorWarrantsMember" xlink:label="loc_SBFMInvestorWarrantsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMInvestorWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_AprilWarrantsMember" xlink:label="loc_SBFMAprilWarrantsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMAprilWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_MayPreFundedWarrantsMember" xlink:label="loc_SBFMMayPreFundedWarrantsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMMayPreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_MayInvestorWarrantsMember" xlink:label="loc_SBFMMayInvestorWarrantsMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMMayInvestorWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_PreFunded2024WarrantsMember" xlink:label="loc_SBFMPreFunded2024WarrantsMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMPreFunded2024WarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_SeriesAWarrantsMember" xlink:label="loc_SBFMSeriesAWarrantsMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMSeriesAWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_SeriesBWarrantsMember" xlink:label="loc_SBFMSeriesBWarrantsMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMSeriesBWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_PreFunded2025WarrantsMember" xlink:label="loc_SBFMPreFunded2025WarrantsMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMPreFunded2025WarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_WarrantExpirationDate" xlink:label="loc_SBFMWarrantExpirationDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_SBFMWarrantExpirationDate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding" xlink:title="999046 - Disclosure - Warrants (Details - Warrants outstanding)">
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_DisclosureWarrantsAbstract" xlink:label="loc_SBFMDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureWarrantsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_TradeableWarrants1Member" xlink:label="loc_SBFMTradeableWarrants1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMTradeableWarrants1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_InvestorWarrants1Member" xlink:label="loc_SBFMInvestorWarrants1Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMInvestorWarrants1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_SeriesBWarrants1Member" xlink:label="loc_SBFMSeriesBWarrants1Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMSeriesBWarrants1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_WarrantExpirationDate" xlink:label="loc_SBFMWarrantExpirationDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_SBFMWarrantExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" xlink:title="999047 - Disclosure - Warrants (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_DisclosureWarrantsAbstract" xlink:label="loc_SBFMDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureWarrantsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_AprilWarrantsAndMayInvestorWarrantsMember" xlink:label="loc_SBFMAprilWarrantsAndMayInvestorWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMAprilWarrantsAndMayInvestorWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_TradeableWarrantsMember" xlink:label="loc_SBFMTradeableWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMTradeableWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_InvestorWarrantsMember" xlink:label="loc_SBFMInvestorWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMInvestorWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20260331.xsd#SBFM_SeriesBWarrantsMember" xlink:label="loc_SBFMSeriesBWarrantsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMSeriesBWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="loc_us-gaapPaymentsForRepurchaseOfWarrants" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/EarningsPerShareDetails" xlink:title="999048 - Disclosure - Earnings Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !L /H# 2(  A$! Q$!_\0
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M.'_Y^8+_ ,!F>ASR[5"OY'A7_GI>_K2^1X5_YZ7OZU/]M\(_\^%Q_P!]O_\
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MO&<4C$#OBOE?X_\ PNTG7/VC?A(CS:E!%XBNM0358K;4YXEN5MK/S8AM5_E
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944 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>May 13, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SUNSHINE BIOPHARMA INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001402328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-5566275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">CO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">333 Las Olas Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">CU4 Suite 433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Fort Lauderdale<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">330-0684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,005,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SBFM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock Purchase Warrants<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SBFMW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 6,913,013<span></span>
</td>
<td class="nump">$ 9,123,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">4,011,632<span></span>
</td>
<td class="nump">3,459,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">13,168,430<span></span>
</td>
<td class="nump">13,472,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositAssets', window );">Deposits</a></td>
<td class="nump">71,740<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">618,361<span></span>
</td>
<td class="nump">798,384<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">24,783,176<span></span>
</td>
<td class="nump">26,853,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Long-Term Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property &amp; equipment</a></td>
<td class="nump">516,349<span></span>
</td>
<td class="nump">557,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">1,917,812<span></span>
</td>
<td class="nump">1,889,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use-asset</a></td>
<td class="nump">713,038<span></span>
</td>
<td class="nump">778,846<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total Long-Term Assets</a></td>
<td class="nump">3,147,199<span></span>
</td>
<td class="nump">3,225,586<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">27,930,375<span></span>
</td>
<td class="nump">30,079,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable &amp; accrued expenses</a></td>
<td class="nump">5,104,868<span></span>
</td>
<td class="nump">5,664,212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_EarnoutPayable', window );">Earnout payable</a></td>
<td class="nump">295,797<span></span>
</td>
<td class="nump">295,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income tax payable</a></td>
<td class="nump">268,276<span></span>
</td>
<td class="nump">268,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Right-of-use-liability</a></td>
<td class="nump">209,226<span></span>
</td>
<td class="nump">215,637<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">5,878,167<span></span>
</td>
<td class="nump">6,443,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-Term Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Right-of-use-liability</a></td>
<td class="nump">535,614<span></span>
</td>
<td class="nump">596,785<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total Long-Term Liabilities</a></td>
<td class="nump">535,614<span></span>
</td>
<td class="nump">596,785<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">6,413,781<span></span>
</td>
<td class="nump">7,040,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock Series B $0.10 par value per share; 1,000,000 shares authorized 130,000 shares issued and outstanding</a></td>
<td class="nump">13,000<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock $0.001 par value per share; 3,000,000,000 shares authorized 4,905,945 shares issued and outstanding at March 31, 2026 and December 31, 2025</a></td>
<td class="nump">4,905<span></span>
</td>
<td class="nump">4,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Capital paid in excess of par value</a></td>
<td class="nump">98,100,990<span></span>
</td>
<td class="nump">98,100,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated comprehensive income</a></td>
<td class="num">(343,306)<span></span>
</td>
<td class="num">(65,309)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated (Deficit)</a></td>
<td class="num">(76,258,995)<span></span>
</td>
<td class="num">(75,015,126)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL SHAREHOLDERS' EQUITY</a></td>
<td class="nump">21,516,594<span></span>
</td>
<td class="nump">23,038,460<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</a></td>
<td class="nump">$ 27,930,375<span></span>
</td>
<td class="nump">$ 30,079,167<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_EarnoutPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_EarnoutPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">3,000,000,000<span></span>
</td>
<td class="nump">3,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">4,905,945<span></span>
</td>
<td class="nump">4,905,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">4,905,945<span></span>
</td>
<td class="nump">4,905,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">130,000<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">130,000<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 8,088,765<span></span>
</td>
<td class="nump">$ 8,901,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of sales</a></td>
<td class="nump">5,907,775<span></span>
</td>
<td class="nump">6,170,915<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">2,180,990<span></span>
</td>
<td class="nump">2,730,426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General &amp; Administrative Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Accounting</a></td>
<td class="nump">175,809<span></span>
</td>
<td class="nump">293,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalAndContractServicesExpense', window );">Consulting</a></td>
<td class="nump">143,148<span></span>
</td>
<td class="nump">365,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseDirectorsFees', window );">Director fees</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal</a></td>
<td class="nump">89,076<span></span>
</td>
<td class="nump">27,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketingExpense', window );">Marketing</a></td>
<td class="nump">250,223<span></span>
</td>
<td class="nump">398,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Office</a></td>
<td class="nump">871,608<span></span>
</td>
<td class="nump">925,878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">R&amp;D</a></td>
<td class="nump">31,724<span></span>
</td>
<td class="nump">215,277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Salaries</a></td>
<td class="nump">1,708,484<span></span>
</td>
<td class="nump">1,525,446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_Taxes', window );">Taxes</a></td>
<td class="nump">129,656<span></span>
</td>
<td class="nump">110,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation &amp; amortization</a></td>
<td class="nump">76,859<span></span>
</td>
<td class="nump">64,793<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total General &amp; Administrative Expenses</a></td>
<td class="nump">3,576,587<span></span>
</td>
<td class="nump">4,026,176<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">(Loss) From Operations</a></td>
<td class="num">(1,395,597)<span></span>
</td>
<td class="num">(1,295,750)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange</a></td>
<td class="num">(18)<span></span>
</td>
<td class="nump">451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeDebtSecuritiesOperating', window );">Interest income</a></td>
<td class="nump">48,426<span></span>
</td>
<td class="nump">75,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="nump">103,320<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other Income</a></td>
<td class="nump">151,728<span></span>
</td>
<td class="nump">75,818<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net (loss) before income taxes</a></td>
<td class="num">(1,243,869)<span></span>
</td>
<td class="num">(1,219,932)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(40,161)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (Loss)</a></td>
<td class="num">(1,243,869)<span></span>
</td>
<td class="num">(1,179,771)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax', window );">Foreign exchange translation</a></td>
<td class="num">(277,997)<span></span>
</td>
<td class="nump">26,189<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (Loss)</a></td>
<td class="num">$ (1,521,866)<span></span>
</td>
<td class="num">$ (1,153,582)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">(Loss) per common share (Basic)</a></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.44)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding (Basic)</a></td>
<td class="nump">4,905,945<span></span>
</td>
<td class="nump">2,703,293<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_Taxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_Taxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeDebtSecuritiesOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income, amortization of premium and accretion of discount, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading); classified as operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeDebtSecuritiesOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestExpenseDirectorsFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for service provided by entity's director.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestExpenseDirectorsFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalAndContractServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalAndContractServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (Loss)</a></td>
<td class="num">$ (1,243,869)<span></span>
</td>
<td class="num">$ (1,179,771)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">76,859<span></span>
</td>
<td class="nump">64,793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(609,601)<span></span>
</td>
<td class="nump">426,673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">78,399<span></span>
</td>
<td class="num">(568,834)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDepositOtherAssets', window );">Deposits</a></td>
<td class="num">(71,740)<span></span>
</td>
<td class="num">(70,457)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">154,726<span></span>
</td>
<td class="nump">139,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_IncreaseDecreaseInReductionInRightofuseAsset', window );">Reduction in right-of-use asset</a></td>
<td class="nump">52,788<span></span>
</td>
<td class="nump">35,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts Payable &amp; accrued expenses</a></td>
<td class="num">(455,836)<span></span>
</td>
<td class="num">(486,009)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liability</a></td>
<td class="num">(54,001)<span></span>
</td>
<td class="num">(17,160)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income tax payable</a></td>
<td class="nump">175<span></span>
</td>
<td class="num">(40,161)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Flows (Used In) Operating Activities</a></td>
<td class="num">(2,072,100)<span></span>
</td>
<td class="num">(1,695,002)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of intangible assets</a></td>
<td class="num">(99,389)<span></span>
</td>
<td class="num">(204,527)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of equipment</a></td>
<td class="num">(5,129)<span></span>
</td>
<td class="num">(7,490)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Flows (Used In) Investing Activities</a></td>
<td class="num">(104,518)<span></span>
</td>
<td class="num">(212,017)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">355,297<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Flows Provided by Financing Activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">355,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash Equivalents at Beginning of Period</a></td>
<td class="nump">9,123,308<span></span>
</td>
<td class="nump">9,686,529<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(2,176,618)<span></span>
</td>
<td class="num">(1,551,722)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="num">(33,677)<span></span>
</td>
<td class="num">(10,197)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash Equivalents at End of Period</a></td>
<td class="nump">6,913,013<span></span>
</td>
<td class="nump">8,124,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary Disclosure of Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_IncreaseDecreaseInReductionInRightofuseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_IncreaseDecreaseInReductionInRightofuseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDepositOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDepositOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Comprehensive Income [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2024</a></td>
<td class="nump">$ 2,580<span></span>
</td>
<td class="nump">$ 93,354,907<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="num">$ (829,959)<span></span>
</td>
<td class="num">$ (69,039,774)<span></span>
</td>
<td class="nump">$ 23,500,754<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2024</a></td>
<td class="nump">2,580,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Exercise of warrants</a></td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">355,171<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">355,298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Exercise of warrants, shares</a></td>
<td class="nump">127,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">26,189<span></span>
</td>
<td class="num">(1,179,771)<span></span>
</td>
<td class="num">(1,153,582)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2025</a></td>
<td class="nump">$ 2,707<span></span>
</td>
<td class="nump">93,710,078<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="num">(803,770)<span></span>
</td>
<td class="num">(70,219,545)<span></span>
</td>
<td class="nump">22,702,470<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2025</a></td>
<td class="nump">2,707,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2025</a></td>
<td class="nump">$ 4,905<span></span>
</td>
<td class="nump">98,100,990<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="num">(65,309)<span></span>
</td>
<td class="num">(75,015,126)<span></span>
</td>
<td class="nump">23,038,460<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2025</a></td>
<td class="nump">4,905,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(277,997)<span></span>
</td>
<td class="num">(1,243,869)<span></span>
</td>
<td class="num">(1,521,866)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2026</a></td>
<td class="nump">$ 4,905<span></span>
</td>
<td class="nump">$ 98,100,990<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="num">$ (343,306)<span></span>
</td>
<td class="num">$ (76,258,995)<span></span>
</td>
<td class="nump">$ 21,516,594<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2026</a></td>
<td class="nump">4,905,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (1,243,869)<span></span>
</td>
<td class="num">$ (1,179,771)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Business</a></td>
<td class="text"><p id="xdx_802_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z2DeaOnl6Xod" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b><span style="text-decoration: underline">Note
1 &#8211;&#160;<span id="xdx_823_z8EtEQjhjm5g">Description of Business</span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
Company was incorporated under the name Mountain West Business Solutions, Inc. on August 31, 2006, in the State of Colorado. Effective
October 15, 2009, the Company acquired Sunshine Biopharma Inc. in a transaction classified as a reverse acquisition. Upon completion
of the reverse acquisition, the Company changed its name to Sunshine Biopharma Inc. and began operating as a pharmaceutical
company.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Sunshine
Biopharma has two wholly owned subsidiaries: (i) Nora Pharma Inc. (&#8220;Nora Pharma&#8221;), a Canadian corporation with a portfolio
of pharmaceutical products consisting of 60 generic prescription drugs on the market in Canada, and (ii) Sunshine Biopharma Canada Inc.
(&#8220;Sunshine Canada&#8221;), a Canadian corporation which develops and sells nonprescription, over-the-counter (&#8220;OTC&#8221;)
supplements. The Company operates the two subsidiaries as a <span id="xdx_901_eus-gaap--NumberOfOperatingSegments_dxL_uSegment_c20260101__20260331_zNOp7mPIYGI" title="Number of operating segments::XDX::1"><span id="xdx_90A_eus-gaap--NumberOfReportableSegments_dxL_uSegment_c20260101__20260331_zb7KR8S8GwB8" title="Number of reportable segments::XDX::1"><span style="-sec-ix-hidden: xdx2ixbrl0408"><span style="-sec-ix-hidden: xdx2ixbrl0410">single</span></span></span></span> business segment. Sales of the OTC supplements represent less than
3% of the Company&#8217;s total annual sales.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
Company is not subject to material customer concentration risks as it sells its products directly to pharmacies in several Canadian Provinces.
However, Provincial governments in Canada reimburse patients for their prescription drug expenditures to various degrees under drug reimbursement
programs, making generic drugs prices highly dependent on government policies which may change over time. The most recent negotiations
between the pan-Canadian Pharmaceutical Alliance (&#8220;pCPA&#8221;), the entity that negotiates drug prices on behalf of the government,
and the Canadian Generic Pharmaceutical Association (&#8220;CGPA&#8221;) resulted in updated generic pricing for certain products which
took effect on October 1, 2023. The updated prices are valid for three years and the agreement contains an option to extend for an additional
two years. On February 10, 2024, the Canadian federal government joined the generic drug reimbursement program as a payor under the Pharmacare
Act. This development further strengthened the Canadian generic drug market, which is the Company&#8217;s current focus.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">In
addition, the Company is engaged in the development of the following proprietary drugs:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">K1.1 mRNA, a lipid nano-particle
    (LNP) targeted for liver cancer</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">SBFM-PL4, a protease inhibitor
    for treatment of SARS Coronavirus infections</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zzs47lfM0e63" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b><span style="text-decoration: underline">Note
2 &#8211;&#160;<span id="xdx_82A_zp5BfBoUACYi">Basis of Presentation</span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
unaudited financial statements of the Company for the three month periods ended March 31, 2026 and 2025 have been prepared in accordance
with accounting principles generally accepted in the United States of America for interim financial information and pursuant to the requirements
for reporting on Form 10-Q and Regulation S-X. Accordingly, they do not include all the information and footnotes required by accounting
principles generally accepted in the United States of America for complete financial statements. However, such information reflects all
adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation
of the financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results
to be obtained for a full fiscal year. The balance sheet information as of December 31, 2025, was derived from the audited financial
statements included in the Company's financial statements as of and for the year ended December 31, 2025, included in the Company&#8217;s
Annual Report on Form 10-K filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on April 3, 2026. These financial
statements should be read in conjunction with that report.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>











<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reverse Stock Splits<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_DisclosureReverseStockSplitsAbstract', window );"><strong>Reverse Stock Splits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_ReverseStockSplitTextBlock', window );">Reverse Stock Splits</a></td>
<td class="text"><p id="xdx_80C_ecustom--ReverseStockSplitTextBlock_zMBrGX1JIYm7" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b><span style="text-decoration: underline">Note
3 &#8211;&#160;<span id="xdx_82C_zqhTk9skmFO9">Reverse Stock Splits</span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Effective
April 17, 2024 and August 8, 2024, the Company completed <span id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20240416__20240417_zZEm5MJxDUae" title="Reverse stock split">1-for-100</span> and <span id="xdx_907_eus-gaap--StockholdersEquityReverseStockSplit_c20240807__20240808_zEdhenjeYUZf" title="Reverse stock split">1-for-20</span> reverse splits of its common stock, respectively. The
Company had previously completed three (3) reverse stock splits including a 1-for-200 reverse split on February 9, 2022, and two 1-for-20
reverse splits, one in 2019 and the other in 2020. The Company&#8217;s financial statements included in this report reflect all five
(5) reverse stock splits on a retroactive basis for all periods presented and for all references to common stock, unless specifically
stated otherwise.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; background-color: white">On
February 18, 2026, Dr. Steve N. Slilaty, the Company&#8217;s chief executive officer and holder of the majority of the voting power of
the stockholders of the Company, approved by written consent an authorization of the Company&#8217;s board of directors to effect a reverse
split of the Company&#8217;s issued and outstanding common stock in a ratio of up to 1-for-10, with the board of directors having the
discretion as to whether or not to effect the reverse split and at what ratio. The shareholder consent became effective March 23, 2026
(20 days after the definitive information statement relating to such consent was mailed to stockholders).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_DisclosureReverseStockSplitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_DisclosureReverseStockSplitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_ReverseStockSplitTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_ReverseStockSplitTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Nora Pharma Inc.<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Acquisition of Nora Pharma Inc.</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--MergersAcquisitionsAndDispositionsDisclosuresTextBlock_zkAWd58ZUlv3" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b><span style="text-decoration: underline">Note
4 &#8211;&#160;<span id="xdx_827_zq1M8UeYyyqf">Acquisition of Nora Pharma Inc.</span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">On
October 20, 2022, the Company acquired all of the issued and outstanding shares of Nora Pharma Inc. (&#8220;Nora Pharma&#8221;), a Canadian
privately held pharmaceutical company. The purchase price for the shares was $<span id="xdx_906_eus-gaap--BusinessCombinationConsiderationTransferred1_pp0p0_c20221019__20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zkeRq1qaKeY5" title="Purchase price of shares">18,860,637</span> which was paid in cash ($<span id="xdx_90D_eus-gaap--PaymentsToAcquireBusinessesGross_pp0p0_c20221019__20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zBLZdlIByqbl" title="Payments to acquire shares">14,346,637</span>) and by
the issuance of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20221019__20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zhy3BozGrXO4" title="Stock issued for acquisition">1,850</span> shares of the Company&#8217;s common stock valued at $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pp0p0_c20221019__20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zQYFB46JHll9" title="Stock issued for acquisition, value">4,514,000</span> or $2,440.00 per share. Nora Pharma sells generic
pharmaceutical products in Canada. Nora Pharma&#8217;s operations are authorized by a Drug Establishment License issued by Health Canada.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">As
part of the consideration for Nora Pharma, the Company agreed to a $<span id="xdx_905_ecustom--EarnoutPayable_iI_uCAD_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember__srt--CounterpartyNameAxis__custom--MalekChamounMember_zb2Li8AFI7L6" title="Earnout payable">5,000,000</span> CAD ($<span id="xdx_90A_ecustom--EarnoutPayable_iI_uUSD_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember__srt--CounterpartyNameAxis__custom--MalekChamounMember_zOnq5VD5kxf6" title="Earnout payable">3,632,000</span> USD) earnout amount payable to Mr. Malek
Chamoun, the seller of Nora Pharma. The earnout is payable in the form of twenty (20) payments of $250,000 CAD for every $1,000,000 CAD
increase in gross sales (as defined in the Purchase Agreement) above Nora Pharma&#8217;s June 30, 2022 gross sales, provided that his
employment with the Company is not terminated pursuant to the Company&#8217;s employment agreement with him. The total earnout amount
of $3,632,000 has been recorded as a salary payable. During the fiscal year ended December 31, 2023, the Company paid an earnout amount
of $<span id="xdx_905_ecustom--EarnoutLiabilityExpenseFirstInstallment_uCAD_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zY3tWokHGfld" title="Earnout liability expense, first installment">1,426,914</span> CAD (approximately $<span id="xdx_903_ecustom--EarnoutLiabilityExpenseFirstInstallment_uUSD_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zs0NxXrA9d3">1,036,500</span> USD) for the fiscal year ended December 31, 2022. On April 22, 2024, the Company paid another
earnout amount of $<span id="xdx_90E_ecustom--EarnoutLiabilityExpenseSecondInstallment_uCAD_c20240421__20240422__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zfZrJ5g5oqC1" title="Earnout liability expense, second installment">3,093,878</span> CAD (approximately $<span id="xdx_902_ecustom--EarnoutLiabilityExpenseSecondInstallment_uUSD_c20240421__20240422__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zGaPIbLfbqY2">2,247,400</span> USD) for the fiscal year ended December 31, 2023. As of December 31, 2025,
the remaining earnout balance was $<span id="xdx_906_ecustom--EarnoutLiabilityBalance_uCAD_c20250101__20251231__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zuOeX3DLC4ni" title="Remaining earnout balance">479,208</span> CAD ($<span id="xdx_901_ecustom--EarnoutLiabilityBalance_uUSD_c20250101__20251231__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_z2Y22ItIazQc">295,797</span> USD). This remaining earnout amount is currently in dispute following dismissal
of Mr. Chamoun by the Company on April 14, 2025 (See Note 15).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-20/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text"><p id="xdx_801_eus-gaap--IntangibleAssetsDisclosureTextBlock_zRMSdqXcZ4Z2" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b><span style="text-decoration: underline">Note
5 &#8211;&#160;<span id="xdx_823_zwxlD5TNgw8b">Intangible Assets</span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">Intangible assets
consisted of the following:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zrHEKQakZ3Sc" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details - Intangible assets)">
  <tr style="border-bottom: Black 1pt solid; vertical-align: bottom">
    <td><span id="xdx_8BC_zjUH5gaAFaSf" style="display: none">Schedule of intangible assets</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Period Ended</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left">Intangible assets at beginning of period, net</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_c20260101__20260331_zD5wRK6fN5Z5" style="width: 15%; text-align: right" title="Intangible assets at beginning of period">1,889,370</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_c20250101__20251231_zdMKpexTbQc5" style="width: 15%; text-align: right" title="Intangible assets at beginning of period">3,019,717</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left">Purchase of additional intangible assets (drug licenses &amp; dossiers)</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_c20260101__20260331_zDAq4Jptygvk" style="border-bottom: Black 1pt solid; text-align: right" title="Purchase of additional intangible assets">68,147</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_c20250101__20251231_zn7s50IPzU4d" style="border-bottom: Black 1pt solid; text-align: right" title="Purchase of additional intangible assets">774,355</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_c20260101__20260331_zBoFOLvWnGf7" style="text-align: right" title="Intangible assets at ending of period">1,957,517</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_c20250101__20251231_zRrJJxlOcb3b" style="text-align: right" title="Intangible assets at ending of period">3,794,072</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less impairment*</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_d0_c20260101__20260331_zucHPxh3hrYc" style="text-align: right" title="Less impairment">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_d0_c20250101__20251231_z8WFuNRTXsY8" style="text-align: right" title="Less impairment">(1,748,247</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">Less accumulated amortization</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20260331_zBjftBibnAV4" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated amortization">(39,705</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20251231_z0qHyqKRU3h7" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated amortization">(156,455</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left">Intangible assets, net</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20260331_zv2kVbMPjWMg" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">1,917,812</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20251231_zzC3glplQt55" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">1,889,370</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">*
The impairment was a result of the determination by the Company that certain product licenses could not be commercialized</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<p id="xdx_8A5_zLMyeyqstI9l" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>











<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Plant, Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Plant, Property and Equipment</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zMIx7KkCNkCd" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b><span style="text-decoration: underline">Note
6 &#8211;&#160;<span id="xdx_823_zbYbj6wcgaPi">Plant, Property and Equipment</span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Property,
plant and equipment are stated at cost. Depreciation of property, plant and equipment begins in the month when the asset is placed into
service and is provided using the straight-line method for financial reporting purposes at rates based on the estimated useful lives
of the assets. Estimated useful lives range from three to twenty years. Property, plant and equipment consist of the following:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--PropertyPlantAndEquipmentTextBlock_z6mp9R2mdPu1" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Plant, Property and Equipment (Details)">
  <tr style="border-bottom: Black 1pt solid; vertical-align: bottom">
    <td><span id="xdx_8B6_z40TVLdXvfu8" style="display: none">Schedule
    of plant property and equipment</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49C_20260331_z72JAJAYhzSe" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_492_20251231_zAyr9df3LW6j" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Period Ended</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zjMYTRzIS1O3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%">Equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">352,278</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">335,464</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zJ0IJRA1hAe7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Computer equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79,029</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69,139</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zq5fmfY3cMEf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44,702</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,462</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_d0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z22PQyDrIIFa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91,157</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">92,706</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zZwQlgZRqdcl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid">Vehicles</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">498,995</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">507,478</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzbhx_zBlydmVUX0ye" style="vertical-align: bottom; background-color: White">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,066,161</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,070,249</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzbhx_zeiRvQSraykh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">Less accumulated depreciation</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(549,812</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(512,879</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzbhx_zBsJlbwC3TO3" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left">Plant, property and equipment, net</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">516,349</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">557,370</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--InventoryDisclosureTextBlock_z8d6pnAaH0r9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b><span style="text-decoration: underline">Note
7 &#8211;&#160;<span id="xdx_82E_zx5ntqyfPwBi">Inventory</span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Inventory
consists solely of finished goods purchased for resale. Inventory is stated at cost which represents the amount paid to acquire the finished
goods. The Company evaluates inventory for potential obsolescence based on a combination of factors, including (i) aging, (ii) historical
sell-through patterns, and (iii) product-specific considerations. When estimated net realizable value is lower than cost, the Company
records an allowance for obsolescence for the difference. Write-downs are recorded within cost of goods sold and are not subsequently
reversed.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">Inventory is comprised
of the following:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zU4MbZn7yvg4" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Inventory (Details)">
  <tr style="border-bottom: Black 1pt solid; vertical-align: bottom">
    <td><span id="xdx_8B5_zETUbe8XGd6i" style="display: none">Schedule of inventory</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_490_20260331_zHkpY92a1YUi" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_495_20251231_zPXaqC6zP3Lc" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Period Ended</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--InventoryFinishedGoods_iI_zn2V82HAaZ93" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left">Finished goods</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">14,035,748</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">13,947,178</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--AllowanceForObsoleteInventory_iI_d0_msARNCzj7C_zCBCR87CSehl" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left">Allowance for obsolete inventory</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(867,318</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(475,797</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--InventoryNet_iI_zdZJYi514ez" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left">Total Inventory, net of allowance</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,168,430</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,472,025</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>













<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_807_eus-gaap--LesseeOperatingLeasesTextBlock_zWCY5Y0Zbhkh" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b><span style="text-decoration: underline">Note
8 &#8211;&#160;<span id="xdx_821_zuZsUxx7hggb">Leases</span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
Company has obligations as a lessee for warehouse and office space with initial non-cancellable terms in excess of one year. The Company
classified the lease as an operating lease. The lease contains a renewal option for a period of five years. Because the Company is certain
to exercise the renewal option, the optional period is included in determining the lease term, and associated payments under the renewal
option are included in the lease payments. The Company&#8217;s lease does not include termination options for either party to the lease
or restrictive financial or other covenants. Payments due under the lease contract include fixed payments plus a variable payment. The
Company&#8217;s office space lease requires it to make variable payments for the Company&#8217;s proportionate share of building&#8217;s
property taxes, insurance, and common area maintenance. These variable lease payments are not included in lease payments used to determine
lease liability and are recognized as variable costs when incurred.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Amounts
reported on the balance sheet as of March 31, 2026 were as follows:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--LeaseCostTableTextBlock_zYThboU7nwxk" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Lease information)">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;<span id="xdx_8BE_zIKgWA6AvVpa" style="display: none">Schedule of lease information</span></span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 83%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Operating lease ROU asset</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><span id="xdx_905_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20260331_zafwhQI5qDgk" title="Operating lease ROU asset">713,038</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Operating Lease liability - Short-term</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><span id="xdx_902_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20260331_zaa4VAJ76ZH5" title="Operating Lease liability - Short-term">209,226</span></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Operating lease liability - Long-term</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><span id="xdx_90D_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20260331_zAo3Rz0ElP16" title="Operating lease liability - Long-term">535,614</span></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Remaining lease term</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_90F_ecustom--LesseeOperatingLeasesRemainingLeaseTerm_c20260101__20260331_zDtTkwGTbcG4" title="Remaining lease term">4
                                            Years 6 Months</span></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Discount rate</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20260331_zHglqOXb5u6k" title="Discount rate">6</span>%</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Amounts
disclosed for ROU assets obtained in exchange for lease obligations and reductions of ROU assets resulting from reductions of lease obligations
include amounts reduced from the carrying amount of ROU assets resulting from deferred rent.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Maturities
of lease liabilities under non-cancellable operating leases at March 31, 2026 are as follows:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zWPaPM7ACZnd" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Maturities of lease payments)">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;<span id="xdx_8B5_zeE9O9ujvNoc" style="display: none">Schedule of maturities of lease liabilities</span></span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20260331_z7gTOmIqKAi2" style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_zIzx0IxDJXNf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 83%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2026</span></td>
    <td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">158,031</span></td>
    <td style="width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_z6p3oWnArCyk" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2027</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">201,011</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_zeo1i9pHWJ52" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2028</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">190,554</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_zlYLJ4n2U9Yb" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2029</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">180,634</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_iI_zIjglAIRDXOe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Thereafter</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">14,610</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>














<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_806_eus-gaap--IncomeTaxDisclosureTextBlock_zMc8Je7sKiSh" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b><span style="text-decoration: underline">Note
9 &#8211; <span id="xdx_825_zF0exUUgRsdc">Income Taxes</span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
Company&#8217;s income tax (expense) / benefit of $<span id="xdx_900_eus-gaap--IncomeTaxExpenseBenefit_c20260101__20260331__us-gaap--IncomeTaxAuthorityAxis__country--US_z5Gq1oSxMVc5" title="Income tax (expense) / benefit">0</span> and $<span id="xdx_908_eus-gaap--IncomeTaxExpenseBenefit_c20250101__20250331__us-gaap--IncomeTaxAuthorityAxis__country--US_ztyyHlDXBy2i" title="Income tax (expense) / benefit">40,161</span> for the three months ended March 31, 2026 and March 31, 2025, respectively,
is primarily due to operations outside of the United States and changes in valuation allowance related to certain deferred tax assets
generated or utilized in the applicable period.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Deferred
tax assets are regularly reviewed for recoverability by jurisdiction and valuation allowances are established based on historical and
projected future taxable losses and the expected timing of the reversal of existing temporary differences. The Company has recorded valuation
allowances against the majority of its deferred tax assets of March 31, 2026, and the Company expects to maintain these valuation allowances
until there is sufficient evidence that future earnings can be achieved, which is uncertain at this time.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
Company's consolidated financial statements contain various tax related entries as a result of operations of the two Canadian subsidiaries
and are in compliance with Canadian tax laws.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
Company only recognizes tax benefits from an uncertain tax position if it is more likely than not that the tax position will be sustained
on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial
statement from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized
upon ultimate resolution. To date, the Company has not recognized such tax benefits in its financial statements.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">On
July 4, 2025, the One Big Beautiful Bill Act ("OBBBA") was enacted in the U.S. The OBBBA makes permanent key elements of the
Tax Cuts and Jobs Act, including 100% bonus depreciation, domestic research cost expensing, and the business interest expense limitation.
<i>ASC Topic 740, Income Taxes</i>, requires the tax effects of changes in tax rates and laws to be recognized in the period in which
the legislation is enacted. Those effects, both current tax and deferred tax, are reported as part of continuing operations. The Company
is currently assessing the impact of OBBBA on its Consolidated Financial Statements but does not believe that the OBBBA will
have a material impact on the Company's income tax expense.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In July 2025, OBBBA amended section 951A for
taxable years beginning after December 31, 2025, replacing the prior Global Intangible Low-Taxed Income (&#8220;GILTI&#8221;) regime
with a net Controlled Foreign Corporation (&#8220;CFC&#8221;) tested income inclusion framework. The legislation also modified related
provisions, including the deduction under section 250 for amounts included under section 951A. The Company has evaluated the impact of
these changes on its income tax accounting and related disclosures under <i>ASC 740</i>, including the effect on its estimated annual
effective tax rate and taxes on foreign earnings. The Company does not expect the impact of these changes to be material to its financial
statements.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Management and Director Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_DisclosureManagementAndDirectorCompensationAbstract', window );"><strong>Management And Director Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_CompensationRelatedCostsDisclosureTextBlock', window );">Management and Director Compensation</a></td>
<td class="text"><p id="xdx_803_ecustom--CompensationRelatedCostsDisclosureTextBlock_z9wSjC2uBp6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b><span style="text-decoration: underline">Note
10 &#8211;&#160;<span id="xdx_826_zMBjyqxfVry">Management and Director Compensation</span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
Company paid its officers aggregate cash compensation of $<span id="xdx_905_eus-gaap--SalariesWagesAndOfficersCompensation_c20260101__20260331_zGCm2NvkgRMl" title="Officers compensation">251,160</span> and $<span id="xdx_907_eus-gaap--SalariesWagesAndOfficersCompensation_c20250101__20250331_zuoDamZJ3KJj" title="Officers compensation">269,496</span> for the three-month periods ended March 31, 2026 and 2025,
respectively.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
Company paid its directors aggregate cash compensation of $<span id="xdx_901_eus-gaap--NoninterestExpenseDirectorsFees_c20260101__20260331__srt--CounterpartyNameAxis__custom--AllDirectorsMember_zlSSZTZ77nnk" title="Directors cash compensation"><span id="xdx_90E_eus-gaap--NoninterestExpenseDirectorsFees_c20250101__20250331__srt--CounterpartyNameAxis__custom--AllDirectorsMember_zdjOyJoq1LAl">100,000</span></span> for each of the three-month periods ended March 31, 2026 and 2025
($<span id="xdx_90A_eus-gaap--NoninterestExpenseDirectorsFees_c20260101__20260331__srt--CounterpartyNameAxis__custom--Director1Member_z3Qm1mGxeSNk" title="Directors cash compensation"><span id="xdx_908_eus-gaap--NoninterestExpenseDirectorsFees_c20260101__20260331__srt--CounterpartyNameAxis__custom--Director2Member_zuqpt13lVj0c"><span id="xdx_90B_eus-gaap--NoninterestExpenseDirectorsFees_c20260101__20260331__srt--CounterpartyNameAxis__custom--Director3Member_zyo0TTG5Sj88"><span id="xdx_90F_eus-gaap--NoninterestExpenseDirectorsFees_c20260101__20260331__srt--CounterpartyNameAxis__custom--Director4Member_zP4Nmu8XVkik"><span id="xdx_901_eus-gaap--NoninterestExpenseDirectorsFees_c20260101__20260331__srt--CounterpartyNameAxis__custom--Director5Member_zpK3tJmPkAG2"><span id="xdx_905_eus-gaap--NoninterestExpenseDirectorsFees_c20250101__20250331__srt--CounterpartyNameAxis__custom--Director1Member_zj22bX0PRrge"><span id="xdx_905_eus-gaap--NoninterestExpenseDirectorsFees_c20250101__20250331__srt--CounterpartyNameAxis__custom--Director2Member_z3oiYXci0MBa"><span id="xdx_901_eus-gaap--NoninterestExpenseDirectorsFees_c20250101__20250331__srt--CounterpartyNameAxis__custom--Director3Member_z6NziEE1ATjd"><span id="xdx_90A_eus-gaap--NoninterestExpenseDirectorsFees_c20250101__20250331__srt--CounterpartyNameAxis__custom--Director4Member_z8kxXIQCgCra"><span id="xdx_903_eus-gaap--NoninterestExpenseDirectorsFees_c20250101__20250331__srt--CounterpartyNameAxis__custom--Director5Member_z43cJtQsHaTk">20,000</span></span></span></span></span></span></span></span></span></span> per director).&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_CompensationRelatedCostsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Compensation Related Costs Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_CompensationRelatedCostsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_DisclosureManagementAndDirectorCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_DisclosureManagementAndDirectorCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Capital Stock</a></td>
<td class="text"><p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z0cSDmzvLXij" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b><span style="text-decoration: underline">Note
11 &#8211;&#160;<span id="xdx_827_zqlYsOhx7Gna">Capital Stock</span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
Company&#8217;s authorized capital is comprised of <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_c20260331_zfHywfOGgZH1" title="Common stock, shares authorized">3,000,000,000</span> shares of common stock, par value $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20260331_zW4mXuAL7lF8" title="Common stock, par value">0.001</span>, and <span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_c20260331__srt--TitleOfIndividualAxis__srt--DirectorMember_zBZOto6NZHY9" title="Preferred stock, shares authorized">30,000,000</span> shares of preferred
stock, $<span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20260331__srt--TitleOfIndividualAxis__srt--DirectorMember_zTpXD9DWYBAl" title="Preferred stock, par value">0.10</span> par value. As of March 31, 2026, the Company had authorized <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zzIBLwDJDn9k" title="Preferred stock, shares authorized"><span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zmVXkKzxpwT8" title="Preferred stock, shares authorized">1,000,000</span></span> shares of Series B Preferred Stock. The Series B Preferred
Stock is non-convertible and non-redeemable. It has a liquidation preference equal to the stated value of $0.10 per share, relative to
the common stock and gives the holder the right to 1,000 votes per share. As of March 31, 2026, <span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zrqXSQEvdD5a" title="Preferred stock, shares outstanding"><span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zVGPa0S5ZXY9" title="Preferred stock, shares outstanding">130,000</span></span> shares of Series B Preferred
Stock were outstanding and held by the Company&#8217;s Chief Executive Officer.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">On
January 3, 2025, the Company issued <span id="xdx_907_eus-gaap--ConversionOfStockSharesIssued1_c20250102__20250103__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zP5cXv0nejl" title="Stock converted, shares issued">127,443</span> shares of common stock upon the exercise of <span id="xdx_900_eus-gaap--ConversionOfStockSharesConverted1_c20250102__20250103__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zwkYoJyH51B3" title="Stock converted, shares converted">127,443</span> Series B Warrants and received $<span id="xdx_90A_eus-gaap--ProceedsFromWarrantExercises_c20250102__20250103__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zsZN3W3qXy4j" title="Proceeds from warrant exercise">355,298</span>
in net proceeds.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">On
April 2, 2025, the Company issued <span id="xdx_905_eus-gaap--ConversionOfStockSharesIssued1_c20250401__20250402__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zc3jPVyy4ktd" title="Stock converted, shares issued">660,000</span> shares of common stock upon the exercise of <span id="xdx_90F_eus-gaap--ConversionOfStockSharesConverted1_c20250401__20250402__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zfKECF2GVxvh" title="Stock converted, shares converted">660,000</span> Series B Warrants and received $<span id="xdx_905_eus-gaap--ProceedsFromWarrantExercises_c20250401__20250402__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zU8k8UuhPru4" title="Proceeds from warrant exercise">1,840,014</span>
in net proceeds.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">On
April 3, 2025, the Company issued an aggregate of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250401__20250403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember_zbpIFmjAnzuc" title="Aggregate shares Issued">1,188,404</span> shares of common stock in connection with a registered direct offering and
received $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250401__20250403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember_zqNlYkY17PZf" title="Net proceeds">1,828,596</span> in net proceeds.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">On
October 16, 2025, the Company issued <span id="xdx_90F_eus-gaap--ConversionOfStockSharesIssued1_c20251015__20251016__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zc3yksZ0fY8" title="Stock converted, shares issued">350,000</span> shares of common stock upon the exercise of <span id="xdx_901_eus-gaap--ConversionOfStockSharesConverted1_c20251015__20251016__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zEQoAFSHTUmf" title="Stock converted, shares converted">350,000</span> Series B Warrants and received net proceeds
of $<span id="xdx_90F_eus-gaap--ProceedsFromWarrantExercises_c20251015__20251016__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zbOxhfV3BFd3" title="Net proceeds">724,500</span>.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">As
of March 31, 2026 and December 31, 2025, the Company had <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_c20260331_zufR67krgkK5"><span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_c20260331_zF266wFxJ4X4"><span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_c20251231_z42oS2fULTXd" title="Common stock, shares issued"><span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_c20251231_zyRqUKWfpyL9" title="Common stock, shares outstanding">4,905,945</span></span></span></span> shares of common stock issued and outstanding.</span></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
Company has declared no dividends since inception.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_DisclosureWarrantsAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_WarrantsDisclosureTextBlock', window );">Warrants</a></td>
<td class="text"><p id="xdx_804_ecustom--WarrantsDisclosureTextBlock_zgefdF98JNlb" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b><span style="text-decoration: underline">Note
12 &#8211;&#160;<span id="xdx_82D_z41R79xKmNGg">Warrants</span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
Company accounts for issued warrants either as a liability or equity in accordance with <i>ASC 480-10</i> or <i>ASC 815-40</i>. Under
<i>ASC 480-10</i>, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other
assets, or a variable number of shares. If warrants do not meet liability classification under <i>ASC 480-10</i>, the Company considers
the requirements of <i>ASC 815-40</i> to determine whether the warrants should be classified as a liability or as equity. Under <i>ASC
815-40</i>, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering
event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change
in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss.
If warrants do not require liability classification under <i>ASC 815-40</i>, in order to conclude warrants should be classified as equity,
the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under <i>ASC
815-40</i> or other applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no
changes in fair value recognized after the issuance date.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>











<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">In
2022, 2023, 2024, and 2025, the Company completed six (6) financing events, and in connection therewith, it issued warrants as follows:</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--ScheduleOfWarrantsIssuedWithFinancingTableTextBlock_z3kLv63CZYD2" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Warrants (Details - Warrants issued with financing)">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 9pt">&#160;<span id="xdx_8B7_zQgPJrzqilac" style="display: none">Schedule of warrants issued with financing</span></span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"><span style="font-size: 9pt">Issuance Date/Type</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Number</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Exercise
    Price</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"><span style="font-size: 9pt">Expiry Date</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 47%; text-align: justify"><span style="font-size: 9pt">Feb 17, 2022 (&#8220;Tradeable Warrants&#8221;)*</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_fKg_____zFNlPbkCNnu4" style="width: 13%; text-align: right" title="Warrants outstanding"><span style="font-size: 9pt">2,051</span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_z3XURb75j5Hd" title="Warrant expiration date">4,440.00</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 17%; text-align: justify"><span style="font-size: 9pt"><span id="xdx_90B_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_zwd5RSFiipmf" title="Warrant expiration date">February 2027</span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-size: 9pt">Mar 14, 2022 (&#8220;2022 Pre-Funded Warrants&#8221;)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--PreFunded2022WarrantsMember_zSDVm8DZs7Z9" style="text-align: right" title="Warrants outstanding"><span style="font-size: 9pt">1,846</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--PreFunded2022WarrantsMember_zsWwnKfq3Aek" title="Warrant expiration date">2.00</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt"><span id="xdx_909_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--PreFunded2022WarrantsMember_zbHvGRYNtgc2" title="Warrant expiration date">Unlimited</span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 9pt">Mar 14, 2022 (&#8220;Investor Warrants&#8221;)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_zlpEKgtvk7fa">1,801</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_zXXBuzTZihpa">4,440.00</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt"><span id="xdx_909_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_zhehrWq1HAKl">March 2027</span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-size: 9pt">Apr 28, 2022 (&#8220;April Warrants&#8221;)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_z9UtQ5ylKBDb" style="text-align: right"><span style="font-size: 9pt">4,862</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_z3tX4rpVkpkf">7,520.00</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt"><span id="xdx_908_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_zDrzvMaDeGwk">April 2027</span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 9pt">May 16, 2023 (&#8220;May Pre-Funded Warrants&#8221;)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_zzCltop3CFh3" style="text-align: right"><span style="font-size: 9pt">1,751</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_zPq6QUFjLh2">2.00</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt"><span id="xdx_90C_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_z6WLCW2CXcei">Unlimited</span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-size: 9pt">May 16, 2023 (&#8220;May Investor Warrants&#8221;)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_zfITJ50GfMAl" style="text-align: right"><span style="font-size: 9pt">5,952</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_zCZUCd9cxTtk">1,180.00</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt"><span id="xdx_903_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_znIgoCy4VMBd">November 2028</span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 9pt">Feb 15, 2024 (&#8220;2024 Pre-Funded Warrants&#8221;)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--PreFunded2024WarrantsMember_zy1UPEFRHGt5" style="text-align: right"><span style="font-size: 9pt">22,500</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--PreFunded2024WarrantsMember_zajtJ1lI2685">2.00</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt"><span id="xdx_905_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--PreFunded2024WarrantsMember_znK4aYMNJJQ3">Unlimited</span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-size: 9pt">Feb 15, 2024 (&#8220;Series A Warrants&#8221;)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsMember_fKio___zn90kykWzd14">3,986</span></span></td><td style="text-align: left"><span style="font-size: 9pt">**</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsMember_zPt1hEIIFu19">4,200.00</span></span></td><td style="text-align: left"><span style="font-size: 9pt">**</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt"><span id="xdx_90A_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsMember_zpfrT5HPcF73">August 2026</span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 9pt">Feb 15, 2024 (&#8220;Series B Warrants&#8221;)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_fKio___zvirEpFfnwld">7,973</span></span></td><td style="text-align: left"><span style="font-size: 9pt">**</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_zzQ60PND3ey1">4,760.00</span></span></td><td style="text-align: left"><span style="font-size: 9pt">**</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt"><span id="xdx_909_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_zsdf2Nigsi07">February 2029</span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 9pt">Apr 3, 2025 (&#8220;2025 Pre-Funded
    Warrants&#8221;)</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--PreFunded2025WarrantsMember_zT99q5RoPUIb" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">260,000</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--PreFunded2025WarrantsMember_zyrbsgWJ1hO4" title="Exercise price">0.001</span></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 9pt"><span id="xdx_906_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--PreFunded2025WarrantsMember_z6t3H9lj4OE9">Unlimited</span></span></td></tr>
  </table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13px; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">These warrants trade on Nasdaq
    under the symbol SBFMW.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">**</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Subject to adjustment.</span></td></tr>
  </table>
<p id="xdx_8AD_z5HcTIeerYsd" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">On
February 11, 2024, the Company redeemed all of the April Warrants and all of the May Investor Warrants for an aggregate purchase price
of $<span id="xdx_906_eus-gaap--PaymentsForRepurchaseOfWarrants_pp0p0_c20240210__20240211__us-gaap--AwardTypeAxis__custom--AprilWarrantsAndMayInvestorWarrantsMember_zivYVWX2iQEh" title="Payments for repurchase of warrants">3,139,651</span>.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">As
of March 31, 2026, all of the 2022 Pre-Funded Warrants, all of the May Pre-Funded Warrants, all of the 2024 Pre-Funded Warrants, all
of the 2025 Pre-Funded Warrants, a total of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20260101__20260331__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_zQbLPOgNWyLi" title="Warrants exercised">1,569</span> Tradeable Warrants, <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20260101__20260331__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_zX9mPRLxsq5i" title="Warrants exercised">1,401</span> Investor Warrants, all of the Series A Warrants, and <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20260101__20260331__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_zjnNEqsQfuy4" title="Warrants exercised">2,269,303</span>
Series B Warrants (as adjusted) were exercised resulting in aggregate net proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromWarrantExercises_c20260101__20260331__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_zex3fqzh3ESj" title="Proceeds from warrant exercises">18,136,992</span> received by the Company.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
Company&#8217;s outstanding warrants as of March 31, 2026 consisted of the following:</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zwjN9QTuTio2" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Warrants (Details - Warrants outstanding)">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 9pt">&#160;<span id="xdx_8BA_z3oHWhyX2Sh1" style="display: none">Schedule of warrants outstanding</span></span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"><span style="font-size: 9pt">Type</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Number</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Exercise
    Price</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"><span style="font-size: 9pt">Expiry Date</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 47%; text-align: justify"><span style="font-size: 9pt">Tradeable Warrants</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--TradeableWarrants1Member_zCi5SgCW8vCl" style="width: 13%; text-align: right" title="Number of warrants outstanding"><span style="font-size: 9pt">482</span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--TradeableWarrants1Member_zFGms0kom2ek" style="width: 13%; text-align: right" title="Warrant exercise price"><span style="font-size: 9pt">220.00</span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 17%; text-align: justify"><span style="font-size: 9pt"><span id="xdx_90D_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--TradeableWarrants1Member_zhugGfv1zUD1" title="Expiry date">February 2027</span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-size: 9pt">Investor Warrants</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--InvestorWarrants1Member_zTfNuEF7Cyg1">400</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--InvestorWarrants1Member_zroxUTMCZRul">4,000.00</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt"><span id="xdx_901_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--InvestorWarrants1Member_zWW4t5pyMry">March 2027</span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 9pt">Series B Warrants</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesBWarrants1Member_fKg_____zOtM0PWEXcO6">15,227,962</span></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">*</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesBWarrants1Member_fKg_____zbY4R4eA4br9">2.07</span></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">*</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 9pt"><span id="xdx_903_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--SeriesBWarrants1Member_zXvA6KIeZgL7" title="Expiry date">February 2029</span></span></td></tr>
  </table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 12px"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">As adjusted following the
    financing event of April 3, 2025 and subject to further adjustment of the number of warrants and exercise price upon certain corporate
    actions such that the aggregate exercise price of the warrants remains unchanged</span></td></tr>
  </table>
<p id="xdx_8A6_zR3R2HostCad" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;&#160;</span></p>













<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_DisclosureWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_DisclosureWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_WarrantsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_WarrantsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text"><p id="xdx_802_eus-gaap--EarningsPerShareTextBlock_zO7Ldk3ifIx9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b><span style="text-decoration: underline">Note
13 &#8211;&#160;<span id="xdx_829_zKfKVMw6O033">Earnings Per Share</span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
following table sets forth the computation of basic* net income (loss) per share:</span></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zpQEZ9JHPha3" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Earnings Per Share (Details)">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: justify"><span id="xdx_8B1_zECYMIfCWOZb" style="display: none">Schedule of computation of basic and diluted net income per share</span></td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td colspan="2" id="xdx_490_20260101__20260331_zlIAU8PI8XT6" style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td colspan="2" id="xdx_491_20250101__20250331_zQ3KM1lhh95" style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Quarter Ended March 31,</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zorBPa59UqDf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: justify">Net gain (loss) attributable to common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(1,243,869</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(1,179,771</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Weighted average outstanding shares of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331_zF5Bz74xNNWl" title="Weighted average outstanding shares of common stock">4,905,945</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250331_zVHfdv2NhM6c" title="Weighted average outstanding shares of common stock">2,703,293</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: justify">Net gain (loss) per share attributable to common stock</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20260101__20260331_zGmiQVdh5BBg" title="Net gain (loss) per share attributable to common stock">(0.25</span></td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20250101__20250331_zSQMIZwOmeuh" title="Net gain (loss) per share attributable to common stock">(0.44</span></td><td style="border-bottom: Black 1pt solid; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">*
Diluted net income (loss) per share is not included in this table as the Company incurred net losses for the years ended December
31, 2026 and 2025 and inclusion of dilutive instruments would have an anti-dilutive effect.</span></p>

<p id="xdx_8A7_zbApCWCEJAw" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p id="xdx_801_eus-gaap--SegmentReportingDisclosureTextBlock_zLl9MK93R4X5" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b><span style="text-decoration: underline">Note 14 &#8211; <span id="xdx_827_z9UtBIoYlVqj">Segment Reporting</span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company operates as one operating segment,
which is also its one reportable segment, as the Chief Executive Officer, acting as the Chief Operating Decision Maker (&#8220;CODM&#8221;),
evaluates financial performance and allocates resources on a consolidated, enterprise-wide basis. The Company&#8217;s operations are managed
as an integrated pharmaceutical business focused on the research, development, and commercialization of prescription drugs and supplements.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Although the Company conducts activities through
multiple legal entities &#8212; including Sunshine Biopharma Inc. (U.S.), Sunshine Biopharma Canada Inc. (Canada), and Nora Pharma Inc.
(Canada) &#8212; these entities operate under a unified management structure with shared economic characteristics, common product development
objectives, and centralized decision making. As such, they do not meet the criteria for separate operating segments under <i>ASC 280 &#8211;
Segment Reporting</i>.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In accordance with <i>ASU 2023-07</i>, the Company
provides the following information regarding its single reportable segment:</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Measure of Segment Profit (Loss): The CODM evaluates performance using consolidated operating income (loss), which is consistent with the amounts presented in the accompanying consolidated financial statements.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Significant Segment Expenses: Research and development expenses, and supply chain costs, selling and marketing expenses, and general and administrative expenses are all incurred and reviewed on a consolidated basis.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Other Segment Items: Interest income, interest expense, foreign exchange gains and losses, and other non-operating items are also managed and reviewed on a consolidated basis.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Reconciliation: As the Company has only one reportable segment, no additional reconciliation to consolidated totals is required beyond what is presented in the consolidated statements of operations.</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s operations are conducted in
Canada and substantially all long-lived assets are located in this jurisdiction. Revenues are generated from customers located in Canada.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Matters<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Legal Matters</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--LegalMattersAndContingenciesTextBlock_zqyHjRQr0Yyd" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b><span style="text-decoration: underline">Note
15 &#8211; <span id="xdx_828_zSMDigiWGpV8">Legal Matters</span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On April 14, 2025, the Company terminated the
employment of Mr. Malek Chamoun, president of the Company&#8217;s wholly owned Canadian subsidiary, Nora Pharma. On April 17, 2025, the
Company received a demand letter from the attorneys of Mr. Chamoun requesting that the Company pay to Mr. Chamoun $7,307,025 CAD (approximately
$5,300,000 USD) within five (5) days. In response to the demand letter, the Company sent a letter on May 1, 2025 stating that the demands
contained in the demand letter, including the sum of $7,307,025 CAD (approximately $5,300,000 USD), are completely unfounded and that
it intends to defend itself vigorously. Following a series of communications between the parties&#8217; legal counsels, there has been
no response to the Company&#8217;s letter dated October 14, 2025, nor any action taken by Mr. Chamoun&#8217;s attorneys since that date.
No provision or accrual was made in the financial statements for any litigation liability or legal expense which the Company may incur
in connection with this alleged claim.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zFW9S4GQ5LG9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b><span style="text-decoration: underline">Note
16 &#8211;&#160;<span id="xdx_82F_zDERCYJHIBVg">Subsequent Events</span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">On
April 14, 2026, the Company issued 100,000 restricted shares of common stock under the Company&#8217;s 2023 Equity Incentive Plan to
one of its directors for services.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of intangible assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zrHEKQakZ3Sc" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details - Intangible assets)">
  <tr style="border-bottom: Black 1pt solid; vertical-align: bottom">
    <td><span id="xdx_8BC_zjUH5gaAFaSf" style="display: none">Schedule of intangible assets</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Period Ended</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left">Intangible assets at beginning of period, net</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_c20260101__20260331_zD5wRK6fN5Z5" style="width: 15%; text-align: right" title="Intangible assets at beginning of period">1,889,370</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_c20250101__20251231_zdMKpexTbQc5" style="width: 15%; text-align: right" title="Intangible assets at beginning of period">3,019,717</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left">Purchase of additional intangible assets (drug licenses &amp; dossiers)</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_c20260101__20260331_zDAq4Jptygvk" style="border-bottom: Black 1pt solid; text-align: right" title="Purchase of additional intangible assets">68,147</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_c20250101__20251231_zn7s50IPzU4d" style="border-bottom: Black 1pt solid; text-align: right" title="Purchase of additional intangible assets">774,355</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_c20260101__20260331_zBoFOLvWnGf7" style="text-align: right" title="Intangible assets at ending of period">1,957,517</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_c20250101__20251231_zRrJJxlOcb3b" style="text-align: right" title="Intangible assets at ending of period">3,794,072</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less impairment*</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_d0_c20260101__20260331_zucHPxh3hrYc" style="text-align: right" title="Less impairment">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_d0_c20250101__20251231_z8WFuNRTXsY8" style="text-align: right" title="Less impairment">(1,748,247</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">Less accumulated amortization</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20260331_zBjftBibnAV4" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated amortization">(39,705</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20251231_z0qHyqKRU3h7" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated amortization">(156,455</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left">Intangible assets, net</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20260331_zv2kVbMPjWMg" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">1,917,812</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20251231_zzC3glplQt55" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">1,889,370</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">*
The impairment was a result of the determination by the Company that certain product licenses could not be commercialized</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Plant, Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of plant property and equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--PropertyPlantAndEquipmentTextBlock_z6mp9R2mdPu1" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Plant, Property and Equipment (Details)">
  <tr style="border-bottom: Black 1pt solid; vertical-align: bottom">
    <td><span id="xdx_8B6_z40TVLdXvfu8" style="display: none">Schedule
    of plant property and equipment</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49C_20260331_z72JAJAYhzSe" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_492_20251231_zAyr9df3LW6j" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Period Ended</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zjMYTRzIS1O3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%">Equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">352,278</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">335,464</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zJ0IJRA1hAe7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Computer equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79,029</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69,139</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zq5fmfY3cMEf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44,702</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,462</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_d0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z22PQyDrIIFa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91,157</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">92,706</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zZwQlgZRqdcl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid">Vehicles</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">498,995</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">507,478</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzbhx_zBlydmVUX0ye" style="vertical-align: bottom; background-color: White">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,066,161</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,070,249</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzbhx_zeiRvQSraykh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">Less accumulated depreciation</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(549,812</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(512,879</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzbhx_zBsJlbwC3TO3" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left">Plant, property and equipment, net</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">516,349</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">557,370</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventory</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zU4MbZn7yvg4" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Inventory (Details)">
  <tr style="border-bottom: Black 1pt solid; vertical-align: bottom">
    <td><span id="xdx_8B5_zETUbe8XGd6i" style="display: none">Schedule of inventory</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_490_20260331_zHkpY92a1YUi" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_495_20251231_zPXaqC6zP3Lc" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Period Ended</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--InventoryFinishedGoods_iI_zn2V82HAaZ93" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left">Finished goods</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">14,035,748</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">13,947,178</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--AllowanceForObsoleteInventory_iI_d0_msARNCzj7C_zCBCR87CSehl" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left">Allowance for obsolete inventory</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(867,318</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(475,797</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--InventoryNet_iI_zdZJYi514ez" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left">Total Inventory, net of allowance</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,168,430</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,472,025</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of lease information</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--LeaseCostTableTextBlock_zYThboU7nwxk" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Lease information)">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;<span id="xdx_8BE_zIKgWA6AvVpa" style="display: none">Schedule of lease information</span></span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 83%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Operating lease ROU asset</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><span id="xdx_905_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20260331_zafwhQI5qDgk" title="Operating lease ROU asset">713,038</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Operating Lease liability - Short-term</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><span id="xdx_902_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20260331_zaa4VAJ76ZH5" title="Operating Lease liability - Short-term">209,226</span></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Operating lease liability - Long-term</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><span id="xdx_90D_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20260331_zAo3Rz0ElP16" title="Operating lease liability - Long-term">535,614</span></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Remaining lease term</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_90F_ecustom--LesseeOperatingLeasesRemainingLeaseTerm_c20260101__20260331_zDtTkwGTbcG4" title="Remaining lease term">4
                                            Years 6 Months</span></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Discount rate</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20260331_zHglqOXb5u6k" title="Discount rate">6</span>%</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of lease liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zWPaPM7ACZnd" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Maturities of lease payments)">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;<span id="xdx_8B5_zeE9O9ujvNoc" style="display: none">Schedule of maturities of lease liabilities</span></span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20260331_z7gTOmIqKAi2" style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_zIzx0IxDJXNf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 83%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2026</span></td>
    <td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">158,031</span></td>
    <td style="width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_z6p3oWnArCyk" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2027</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">201,011</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_zeo1i9pHWJ52" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2028</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">190,554</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_zlYLJ4n2U9Yb" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2029</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">180,634</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_iI_zIjglAIRDXOe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Thereafter</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">14,610</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>














<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_DisclosureWarrantsAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_ScheduleOfWarrantsIssuedWithFinancingTableTextBlock', window );">Schedule of warrants issued with financing</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--ScheduleOfWarrantsIssuedWithFinancingTableTextBlock_z3kLv63CZYD2" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Warrants (Details - Warrants issued with financing)">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 9pt">&#160;<span id="xdx_8B7_zQgPJrzqilac" style="display: none">Schedule of warrants issued with financing</span></span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"><span style="font-size: 9pt">Issuance Date/Type</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Number</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Exercise
    Price</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"><span style="font-size: 9pt">Expiry Date</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 47%; text-align: justify"><span style="font-size: 9pt">Feb 17, 2022 (&#8220;Tradeable Warrants&#8221;)*</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_fKg_____zFNlPbkCNnu4" style="width: 13%; text-align: right" title="Warrants outstanding"><span style="font-size: 9pt">2,051</span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_z3XURb75j5Hd" title="Warrant expiration date">4,440.00</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 17%; text-align: justify"><span style="font-size: 9pt"><span id="xdx_90B_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_zwd5RSFiipmf" title="Warrant expiration date">February 2027</span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-size: 9pt">Mar 14, 2022 (&#8220;2022 Pre-Funded Warrants&#8221;)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--PreFunded2022WarrantsMember_zSDVm8DZs7Z9" style="text-align: right" title="Warrants outstanding"><span style="font-size: 9pt">1,846</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--PreFunded2022WarrantsMember_zsWwnKfq3Aek" title="Warrant expiration date">2.00</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt"><span id="xdx_909_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--PreFunded2022WarrantsMember_zbHvGRYNtgc2" title="Warrant expiration date">Unlimited</span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 9pt">Mar 14, 2022 (&#8220;Investor Warrants&#8221;)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_zlpEKgtvk7fa">1,801</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_zXXBuzTZihpa">4,440.00</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt"><span id="xdx_909_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_zhehrWq1HAKl">March 2027</span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-size: 9pt">Apr 28, 2022 (&#8220;April Warrants&#8221;)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_z9UtQ5ylKBDb" style="text-align: right"><span style="font-size: 9pt">4,862</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_z3tX4rpVkpkf">7,520.00</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt"><span id="xdx_908_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_zDrzvMaDeGwk">April 2027</span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 9pt">May 16, 2023 (&#8220;May Pre-Funded Warrants&#8221;)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_zzCltop3CFh3" style="text-align: right"><span style="font-size: 9pt">1,751</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_zPq6QUFjLh2">2.00</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt"><span id="xdx_90C_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_z6WLCW2CXcei">Unlimited</span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-size: 9pt">May 16, 2023 (&#8220;May Investor Warrants&#8221;)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_zfITJ50GfMAl" style="text-align: right"><span style="font-size: 9pt">5,952</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_zCZUCd9cxTtk">1,180.00</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt"><span id="xdx_903_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_znIgoCy4VMBd">November 2028</span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 9pt">Feb 15, 2024 (&#8220;2024 Pre-Funded Warrants&#8221;)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--PreFunded2024WarrantsMember_zy1UPEFRHGt5" style="text-align: right"><span style="font-size: 9pt">22,500</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--PreFunded2024WarrantsMember_zajtJ1lI2685">2.00</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt"><span id="xdx_905_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--PreFunded2024WarrantsMember_znK4aYMNJJQ3">Unlimited</span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-size: 9pt">Feb 15, 2024 (&#8220;Series A Warrants&#8221;)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsMember_fKio___zn90kykWzd14">3,986</span></span></td><td style="text-align: left"><span style="font-size: 9pt">**</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsMember_zPt1hEIIFu19">4,200.00</span></span></td><td style="text-align: left"><span style="font-size: 9pt">**</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt"><span id="xdx_90A_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsMember_zpfrT5HPcF73">August 2026</span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 9pt">Feb 15, 2024 (&#8220;Series B Warrants&#8221;)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_fKio___zvirEpFfnwld">7,973</span></span></td><td style="text-align: left"><span style="font-size: 9pt">**</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_zzQ60PND3ey1">4,760.00</span></span></td><td style="text-align: left"><span style="font-size: 9pt">**</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt"><span id="xdx_909_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_zsdf2Nigsi07">February 2029</span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 9pt">Apr 3, 2025 (&#8220;2025 Pre-Funded
    Warrants&#8221;)</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--PreFunded2025WarrantsMember_zT99q5RoPUIb" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">260,000</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--PreFunded2025WarrantsMember_zyrbsgWJ1hO4" title="Exercise price">0.001</span></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 9pt"><span id="xdx_906_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--PreFunded2025WarrantsMember_z6t3H9lj4OE9">Unlimited</span></span></td></tr>
  </table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13px; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">These warrants trade on Nasdaq
    under the symbol SBFMW.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">**</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Subject to adjustment.</span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrants outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zwjN9QTuTio2" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Warrants (Details - Warrants outstanding)">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 9pt">&#160;<span id="xdx_8BA_z3oHWhyX2Sh1" style="display: none">Schedule of warrants outstanding</span></span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"><span style="font-size: 9pt">Type</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Number</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Exercise
    Price</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"><span style="font-size: 9pt">Expiry Date</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 47%; text-align: justify"><span style="font-size: 9pt">Tradeable Warrants</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--TradeableWarrants1Member_zCi5SgCW8vCl" style="width: 13%; text-align: right" title="Number of warrants outstanding"><span style="font-size: 9pt">482</span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--TradeableWarrants1Member_zFGms0kom2ek" style="width: 13%; text-align: right" title="Warrant exercise price"><span style="font-size: 9pt">220.00</span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 17%; text-align: justify"><span style="font-size: 9pt"><span id="xdx_90D_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--TradeableWarrants1Member_zhugGfv1zUD1" title="Expiry date">February 2027</span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-size: 9pt">Investor Warrants</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--InvestorWarrants1Member_zTfNuEF7Cyg1">400</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--InvestorWarrants1Member_zroxUTMCZRul">4,000.00</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 9pt"><span id="xdx_901_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--InvestorWarrants1Member_zWW4t5pyMry">March 2027</span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 9pt">Series B Warrants</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesBWarrants1Member_fKg_____zOtM0PWEXcO6">15,227,962</span></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">*</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesBWarrants1Member_fKg_____zbY4R4eA4br9">2.07</span></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">*</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 9pt"><span id="xdx_903_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--SeriesBWarrants1Member_zXvA6KIeZgL7" title="Expiry date">February 2029</span></span></td></tr>
  </table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 12px"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">As adjusted following the
    financing event of April 3, 2025 and subject to further adjustment of the number of warrants and exercise price upon certain corporate
    actions such that the aggregate exercise price of the warrants remains unchanged</span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_DisclosureWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_DisclosureWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_ScheduleOfWarrantsIssuedWithFinancingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_ScheduleOfWarrantsIssuedWithFinancingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of computation of basic and diluted net income per share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zpQEZ9JHPha3" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Earnings Per Share (Details)">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: justify"><span id="xdx_8B1_zECYMIfCWOZb" style="display: none">Schedule of computation of basic and diluted net income per share</span></td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td colspan="2" id="xdx_490_20260101__20260331_zlIAU8PI8XT6" style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td colspan="2" id="xdx_491_20250101__20250331_zQ3KM1lhh95" style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Quarter Ended March 31,</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zorBPa59UqDf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: justify">Net gain (loss) attributable to common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(1,243,869</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(1,179,771</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Weighted average outstanding shares of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331_zF5Bz74xNNWl" title="Weighted average outstanding shares of common stock">4,905,945</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250331_zVHfdv2NhM6c" title="Weighted average outstanding shares of common stock">2,703,293</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: justify">Net gain (loss) per share attributable to common stock</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20260101__20260331_zGmiQVdh5BBg" title="Net gain (loss) per share attributable to common stock">(0.25</span></td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20250101__20250331_zSQMIZwOmeuh" title="Net gain (loss) per share attributable to common stock">(0.44</span></td><td style="border-bottom: Black 1pt solid; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">*
Diluted net income (loss) per share is not included in this table as the Company incurred net losses for the years ended December
31, 2026 and 2025 and inclusion of dilutive instruments would have an anti-dilutive effect.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Reverse Stock Splits (Details Narrative)<br></strong></div></th>
<th class="th"><div>Aug. 08, 2024</div></th>
<th class="th"><div>Apr. 17, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_DisclosureReverseStockSplitsAbstract', window );"><strong>Reverse Stock Splits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">1-for-20<span></span>
</td>
<td class="text">1-for-100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_DisclosureReverseStockSplitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_DisclosureReverseStockSplitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Nora Pharma Inc. (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 22, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 22, 2024 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Oct. 20, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 20, 2022 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_EarnoutPayable', window );">Earnout payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 295,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 295,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=SBFM_NoraPharmaMember', window );">Nora Pharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Purchase price of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,860,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,346,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued for acquisition | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock issued for acquisition, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,514,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_EarnoutLiabilityExpenseFirstInstallment', window );">Earnout liability expense, first installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,036,500<span></span>
</td>
<td class="nump">$ 1,426,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_EarnoutLiabilityExpenseSecondInstallment', window );">Earnout liability expense, second installment</a></td>
<td class="nump">$ 2,247,400<span></span>
</td>
<td class="nump">$ 3,093,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_EarnoutLiabilityBalance', window );">Remaining earnout balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 295,797<span></span>
</td>
<td class="nump">$ 479,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=SBFM_NoraPharmaMember', window );">Nora Pharma [Member] | Malek Chamoun [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_EarnoutPayable', window );">Earnout payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,632,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_EarnoutLiabilityBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_EarnoutLiabilityBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_EarnoutLiabilityExpenseFirstInstallment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_EarnoutLiabilityExpenseFirstInstallment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_EarnoutLiabilityExpenseSecondInstallment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_EarnoutLiabilityExpenseSecondInstallment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_EarnoutPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_EarnoutPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-47<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 37: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=SBFM_NoraPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=SBFM_NoraPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=SBFM_MalekChamounMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=SBFM_MalekChamounMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Details - Intangible assets) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets at beginning of period</a></td>
<td class="nump">$ 1,889,370<span></span>
</td>
<td class="nump">$ 3,019,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Purchase of additional intangible assets</a></td>
<td class="nump">68,147<span></span>
</td>
<td class="nump">774,355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets at ending of period</a></td>
<td class="nump">1,957,517<span></span>
</td>
<td class="nump">3,794,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Less impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,748,247)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated amortization</a></td>
<td class="num">(39,705)<span></span>
</td>
<td class="num">(156,455)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">$ 1,917,812<span></span>
</td>
<td class="nump">$ 1,889,370<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Plant, Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 1,066,161<span></span>
</td>
<td class="nump">$ 1,070,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(549,812)<span></span>
</td>
<td class="num">(512,879)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Plant, property and equipment, net</a></td>
<td class="nump">516,349<span></span>
</td>
<td class="nump">557,370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">352,278<span></span>
</td>
<td class="nump">335,464<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">79,029<span></span>
</td>
<td class="nump">69,139<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">44,702<span></span>
</td>
<td class="nump">45,462<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">91,157<span></span>
</td>
<td class="nump">92,706<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 498,995<span></span>
</td>
<td class="nump">$ 507,478<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">$ 14,035,748<span></span>
</td>
<td class="nump">$ 13,947,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_AllowanceForObsoleteInventory', window );">Allowance for obsolete inventory</a></td>
<td class="num">(867,318)<span></span>
</td>
<td class="num">(475,797)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total Inventory, net of allowance</a></td>
<td class="nump">$ 13,168,430<span></span>
</td>
<td class="nump">$ 13,472,025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_AllowanceForObsoleteInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_AllowanceForObsoleteInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details - Lease information) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease ROU asset</a></td>
<td class="nump">$ 713,038<span></span>
</td>
<td class="nump">$ 778,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating Lease liability - Short-term</a></td>
<td class="nump">209,226<span></span>
</td>
<td class="nump">215,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability - Long-term</a></td>
<td class="nump">$ 535,614<span></span>
</td>
<td class="nump">$ 596,785<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_LesseeOperatingLeasesRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">4
                                            Years 6 Months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Discount rate</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_LesseeOperatingLeasesRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_LesseeOperatingLeasesRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details - Maturities of lease payments)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2026</a></td>
<td class="nump">$ 158,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2027</a></td>
<td class="nump">201,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2028</a></td>
<td class="nump">190,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2029</a></td>
<td class="nump">180,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree', window );">Thereafter</a></td>
<td class="nump">$ 14,610<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) / benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (40,161)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) / benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 40,161<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Management and Director Compensation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Officers compensation</a></td>
<td class="nump">$ 251,160<span></span>
</td>
<td class="nump">$ 269,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseDirectorsFees', window );">Directors cash compensation</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=SBFM_AllDirectorsMember', window );">All Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseDirectorsFees', window );">Directors cash compensation</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=SBFM_Director1Member', window );">Director 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseDirectorsFees', window );">Directors cash compensation</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=SBFM_Director2Member', window );">Director 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseDirectorsFees', window );">Directors cash compensation</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=SBFM_Director3Member', window );">Director 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseDirectorsFees', window );">Directors cash compensation</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=SBFM_Director4Member', window );">Director 4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseDirectorsFees', window );">Directors cash compensation</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=SBFM_Director5Member', window );">Director 5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseDirectorsFees', window );">Directors cash compensation</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestExpenseDirectorsFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for service provided by entity's director.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestExpenseDirectorsFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesWagesAndOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesWagesAndOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=SBFM_AllDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=SBFM_AllDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=SBFM_Director1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=SBFM_Director1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=SBFM_Director2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=SBFM_Director2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=SBFM_Director3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=SBFM_Director3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=SBFM_Director4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=SBFM_Director4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=SBFM_Director5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=SBFM_Director5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 16, 2025</div></th>
<th class="th"><div>Apr. 03, 2025</div></th>
<th class="th"><div>Apr. 02, 2025</div></th>
<th class="th"><div>Jan. 03, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 355,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,905,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,905,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,905,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,905,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=SBFM_SeriesBWarrantsMember', window );">Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Stock converted, shares converted</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">660,000<span></span>
</td>
<td class="nump">127,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Net proceeds</a></td>
<td class="nump">$ 724,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,840,014<span></span>
</td>
<td class="nump">$ 355,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Stock converted, shares issued</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">660,000<span></span>
</td>
<td class="nump">127,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Registered Direct Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,188,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,828,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member] | Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=SBFM_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=SBFM_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=SBFM_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=SBFM_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Details - Warrants issued with financing)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SBFM_TradeableWarrantsMember', window );">Tradeable Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding | shares</a></td>
<td class="nump">2,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 4,440.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_WarrantExpirationDate', window );">Warrant expiration date</a></td>
<td class="text">February 2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SBFM_PreFunded2022WarrantsMember', window );">2022 Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding | shares</a></td>
<td class="nump">1,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 2.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_WarrantExpirationDate', window );">Warrant expiration date</a></td>
<td class="text">Unlimited<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SBFM_InvestorWarrantsMember', window );">Investor Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding | shares</a></td>
<td class="nump">1,801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 4,440.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_WarrantExpirationDate', window );">Warrant expiration date</a></td>
<td class="text">March 2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SBFM_AprilWarrantsMember', window );">April Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding | shares</a></td>
<td class="nump">4,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 7,520.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_WarrantExpirationDate', window );">Warrant expiration date</a></td>
<td class="text">April 2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SBFM_MayPreFundedWarrantsMember', window );">May Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding | shares</a></td>
<td class="nump">1,751<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 2.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_WarrantExpirationDate', window );">Warrant expiration date</a></td>
<td class="text">Unlimited<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SBFM_MayInvestorWarrantsMember', window );">May Investor Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding | shares</a></td>
<td class="nump">5,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 1,180.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_WarrantExpirationDate', window );">Warrant expiration date</a></td>
<td class="text">November 2028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SBFM_PreFunded2024WarrantsMember', window );">2024 Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding | shares</a></td>
<td class="nump">22,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 2.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_WarrantExpirationDate', window );">Warrant expiration date</a></td>
<td class="text">Unlimited<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SBFM_SeriesAWarrantsMember', window );">Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding | shares</a></td>
<td class="nump">3,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 4,200.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_WarrantExpirationDate', window );">Warrant expiration date</a></td>
<td class="text">August 2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SBFM_SeriesBWarrantsMember', window );">Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding | shares</a></td>
<td class="nump">7,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 4,760.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_WarrantExpirationDate', window );">Warrant expiration date</a></td>
<td class="text">February 2029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SBFM_PreFunded2025WarrantsMember', window );">2025 Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding | shares</a></td>
<td class="nump">260,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_WarrantExpirationDate', window );">Warrant expiration date</a></td>
<td class="text">Unlimited<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_WarrantExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_WarrantExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SBFM_TradeableWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SBFM_TradeableWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SBFM_PreFunded2022WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SBFM_PreFunded2022WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SBFM_InvestorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SBFM_InvestorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SBFM_AprilWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SBFM_AprilWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SBFM_MayPreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SBFM_MayPreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SBFM_MayInvestorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SBFM_MayInvestorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SBFM_PreFunded2024WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SBFM_PreFunded2024WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SBFM_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SBFM_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SBFM_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SBFM_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SBFM_PreFunded2025WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SBFM_PreFunded2025WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Details - Warrants outstanding)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SBFM_TradeableWarrants1Member', window );">Tradeable Warrants 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding | shares</a></td>
<td class="nump">482<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price | $ / shares</a></td>
<td class="nump">$ 220.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_WarrantExpirationDate', window );">Expiry date</a></td>
<td class="text">February 2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SBFM_InvestorWarrants1Member', window );">Investor Warrants 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding | shares</a></td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price | $ / shares</a></td>
<td class="nump">$ 4,000.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_WarrantExpirationDate', window );">Expiry date</a></td>
<td class="text">March 2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SBFM_SeriesBWarrants1Member', window );">Series B Warrants 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding | shares</a></td>
<td class="nump">15,227,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price | $ / shares</a></td>
<td class="nump">$ 2.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_WarrantExpirationDate', window );">Expiry date</a></td>
<td class="text">February 2029<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_WarrantExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_WarrantExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SBFM_TradeableWarrants1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SBFM_TradeableWarrants1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SBFM_InvestorWarrants1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SBFM_InvestorWarrants1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SBFM_SeriesBWarrants1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SBFM_SeriesBWarrants1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 11, 2024</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 355,297<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SBFM_AprilWarrantsAndMayInvestorWarrantsMember', window );">April Warrants And May Investor Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Payments for repurchase of warrants</a></td>
<td class="nump">$ 3,139,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SBFM_TradeableWarrantsMember', window );">Tradeable Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SBFM_InvestorWarrantsMember', window );">Investor Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SBFM_SeriesBWarrantsMember', window );">Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,269,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,136,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SBFM_AprilWarrantsAndMayInvestorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SBFM_AprilWarrantsAndMayInvestorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SBFM_TradeableWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SBFM_TradeableWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SBFM_InvestorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SBFM_InvestorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SBFM_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SBFM_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net gain (loss) attributable to common stock</a></td>
<td class="num">$ (1,243,869)<span></span>
</td>
<td class="num">$ (1,179,771)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average outstanding shares of common stock</a></td>
<td class="nump">4,905,945<span></span>
</td>
<td class="nump">2,703,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net gain (loss) per share attributable to common stock</a></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.44)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>109</ContextCount>
  <ElementCount>176</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>40</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Shareholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>999012 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/DescriptionOfBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>999013 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/BasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999014 - Disclosure - Reverse Stock Splits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/ReverseStockSplits</Role>
      <ShortName>Reverse Stock Splits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999015 - Disclosure - Acquisition of Nora Pharma Inc.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.</Role>
      <ShortName>Acquisition of Nora Pharma Inc.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999016 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999017 - Disclosure - Plant, Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/PlantPropertyAndEquipment</Role>
      <ShortName>Plant, Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999018 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999019 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999020 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999021 - Disclosure - Management and Director Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation</Role>
      <ShortName>Management and Director Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999022 - Disclosure - Capital Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/CapitalStock</Role>
      <ShortName>Capital Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999023 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999024 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999025 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999026 - Disclosure - Legal Matters</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/LegalMatters</Role>
      <ShortName>Legal Matters</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999027 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999028 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/IntangibleAssets</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999029 - Disclosure - Plant, Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentTables</Role>
      <ShortName>Plant, Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/PlantPropertyAndEquipment</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999030 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/Inventory</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999031 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/Leases</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999032 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/WarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/Warrants</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999033 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/EarningsPerShare</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999034 - Disclosure - Description of Business (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/DescriptionOfBusinessDetailsNarrative</Role>
      <ShortName>Description of Business (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/DescriptionOfBusiness</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999035 - Disclosure - Reverse Stock Splits (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative</Role>
      <ShortName>Reverse Stock Splits (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/ReverseStockSplits</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999036 - Disclosure - Acquisition of Nora Pharma Inc. (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative</Role>
      <ShortName>Acquisition of Nora Pharma Inc. (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999037 - Disclosure - Intangible Assets (Details - Intangible assets)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/IntangibleAssetsDetails-IntangibleAssets</Role>
      <ShortName>Intangible Assets (Details - Intangible assets)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/IntangibleAssetsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999038 - Disclosure - Plant, Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails</Role>
      <ShortName>Plant, Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999039 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/InventoryTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999040 - Disclosure - Leases (Details - Lease information)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/LeasesDetails-LeaseInformation</Role>
      <ShortName>Leases (Details - Lease information)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/LeasesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999041 - Disclosure - Leases (Details - Maturities of lease payments)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/LeasesDetails-MaturitiesOfLeasePayments</Role>
      <ShortName>Leases (Details - Maturities of lease payments)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/LeasesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999042 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/IncomeTaxes</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999043 - Disclosure - Management and Director Compensation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative</Role>
      <ShortName>Management and Director Compensation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999044 - Disclosure - Capital Stock (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative</Role>
      <ShortName>Capital Stock (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/CapitalStock</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999045 - Disclosure - Warrants (Details - Warrants issued with financing)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing</Role>
      <ShortName>Warrants (Details - Warrants issued with financing)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/WarrantsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999046 - Disclosure - Warrants (Details - Warrants outstanding)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding</Role>
      <ShortName>Warrants (Details - Warrants outstanding)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/WarrantsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999047 - Disclosure - Warrants (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/WarrantsDetailsNarrative</Role>
      <ShortName>Warrants (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/WarrantsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="sunshine_i10q-033126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999048 - Disclosure - Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/EarningsPerShareTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>sbfm-20260331.xsd</File>
    <File>sbfm-20260331_cal.xml</File>
    <File>sbfm-20260331_def.xml</File>
    <File>sbfm-20260331_lab.xml</File>
    <File>sbfm-20260331_pre.xml</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="sunshine_i10q-033126.htm">sunshine_i10q-033126.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>logo.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="353">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="33">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>63
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "sunshine_i10q-033126.htm": {
   "nsprefix": "SBFM",
   "nsuri": "http://sunshinebiopharma.com/20260331",
   "dts": {
    "schema": {
     "local": [
      "sbfm-20260331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "sbfm-20260331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sbfm-20260331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "sbfm-20260331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sbfm-20260331_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "sunshine_i10q-033126.htm"
     ]
    }
   },
   "keyStandard": 162,
   "keyCustom": 14,
   "axisStandard": 10,
   "axisCustom": 0,
   "memberStandard": 15,
   "memberCustom": 23,
   "hidden": {
    "total": 16,
    "http://fasb.org/us-gaap/2025": 11,
    "http://xbrl.sec.gov/dei/2025": 5
   },
   "contextCount": 109,
   "entityCount": 1,
   "segmentCount": 40,
   "elementCount": 391,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 353,
    "http://xbrl.sec.gov/dei/2025": 33,
    "http://xbrl.sec.gov/ecd/2025": 4
   },
   "report": {
    "R1": {
     "role": "http://sunshinebiopharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://sunshinebiopharma.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31_us-gaap_SeriesBPreferredStockMember",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss",
     "longName": "00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://sunshinebiopharma.com/role/StatementsOfCashFlows",
     "longName": "00000005 - Statement - Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:IncreaseDecreaseInAccountsReceivable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity",
     "longName": "00000006 - Statement - Consolidated Statements of Shareholders' Equity (Unaudited)",
     "shortName": "Consolidated Statements of Shareholders' Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://sunshinebiopharma.com/role/DescriptionOfBusiness",
     "longName": "999012 - Disclosure - Description of Business",
     "shortName": "Description of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://sunshinebiopharma.com/role/BasisOfPresentation",
     "longName": "999013 - Disclosure - Basis of Presentation",
     "shortName": "Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://sunshinebiopharma.com/role/ReverseStockSplits",
     "longName": "999014 - Disclosure - Reverse Stock Splits",
     "shortName": "Reverse Stock Splits",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "SBFM:ReverseStockSplitTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "SBFM:ReverseStockSplitTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.",
     "longName": "999015 - Disclosure - Acquisition of Nora Pharma Inc.",
     "shortName": "Acquisition of Nora Pharma Inc.",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://sunshinebiopharma.com/role/IntangibleAssets",
     "longName": "999016 - Disclosure - Intangible Assets",
     "shortName": "Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://sunshinebiopharma.com/role/PlantPropertyAndEquipment",
     "longName": "999017 - Disclosure - Plant, Property and Equipment",
     "shortName": "Plant, Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://sunshinebiopharma.com/role/Inventory",
     "longName": "999018 - Disclosure - Inventory",
     "shortName": "Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://sunshinebiopharma.com/role/Leases",
     "longName": "999019 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://sunshinebiopharma.com/role/IncomeTaxes",
     "longName": "999020 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation",
     "longName": "999021 - Disclosure - Management and Director Compensation",
     "shortName": "Management and Director Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "SBFM:CompensationRelatedCostsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "SBFM:CompensationRelatedCostsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://sunshinebiopharma.com/role/CapitalStock",
     "longName": "999022 - Disclosure - Capital Stock",
     "shortName": "Capital Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://sunshinebiopharma.com/role/Warrants",
     "longName": "999023 - Disclosure - Warrants",
     "shortName": "Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "SBFM:WarrantsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "SBFM:WarrantsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://sunshinebiopharma.com/role/EarningsPerShare",
     "longName": "999024 - Disclosure - Earnings Per Share",
     "shortName": "Earnings Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://sunshinebiopharma.com/role/SegmentReporting",
     "longName": "999025 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://sunshinebiopharma.com/role/LegalMatters",
     "longName": "999026 - Disclosure - Legal Matters",
     "shortName": "Legal Matters",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://sunshinebiopharma.com/role/SubsequentEvents",
     "longName": "999027 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://sunshinebiopharma.com/role/IntangibleAssetsTables",
     "longName": "999028 - Disclosure - Intangible Assets (Tables)",
     "shortName": "Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentTables",
     "longName": "999029 - Disclosure - Plant, Property and Equipment (Tables)",
     "shortName": "Plant, Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://sunshinebiopharma.com/role/InventoryTables",
     "longName": "999030 - Disclosure - Inventory (Tables)",
     "shortName": "Inventory (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://sunshinebiopharma.com/role/LeasesTables",
     "longName": "999031 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://sunshinebiopharma.com/role/WarrantsTables",
     "longName": "999032 - Disclosure - Warrants (Tables)",
     "shortName": "Warrants (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "SBFM:ScheduleOfWarrantsIssuedWithFinancingTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "SBFM:WarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "SBFM:ScheduleOfWarrantsIssuedWithFinancingTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "SBFM:WarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://sunshinebiopharma.com/role/EarningsPerShareTables",
     "longName": "999033 - Disclosure - Earnings Per Share (Tables)",
     "shortName": "Earnings Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://sunshinebiopharma.com/role/DescriptionOfBusinessDetailsNarrative",
     "longName": "999034 - Disclosure - Description of Business (Details Narrative)",
     "shortName": "Description of Business (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R32": {
     "role": "http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative",
     "longName": "999035 - Disclosure - Reverse Stock Splits (Details Narrative)",
     "shortName": "Reverse Stock Splits (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2024-08-072024-08-08",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "SBFM:ReverseStockSplitTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-08-072024-08-08",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "SBFM:ReverseStockSplitTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative",
     "longName": "999036 - Disclosure - Acquisition of Nora Pharma Inc. (Details Narrative)",
     "shortName": "Acquisition of Nora Pharma Inc. (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "SBFM:EarnoutPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-192022-10-20_custom_NoraPharmaMember",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://sunshinebiopharma.com/role/IntangibleAssetsDetails-IntangibleAssets",
     "longName": "999037 - Disclosure - Intangible Assets (Details - Intangible assets)",
     "shortName": "Intangible Assets (Details - Intangible assets)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails",
     "longName": "999038 - Disclosure - Plant, Property and Equipment (Details)",
     "shortName": "Plant, Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://sunshinebiopharma.com/role/InventoryDetails",
     "longName": "999039 - Disclosure - Inventory (Details)",
     "shortName": "Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:InventoryFinishedGoods",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:InventoryFinishedGoods",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://sunshinebiopharma.com/role/LeasesDetails-LeaseInformation",
     "longName": "999040 - Disclosure - Leases (Details - Lease information)",
     "shortName": "Leases (Details - Lease information)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "SBFM:LesseeOperatingLeasesRemainingLeaseTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://sunshinebiopharma.com/role/LeasesDetails-MaturitiesOfLeasePayments",
     "longName": "999041 - Disclosure - Leases (Details - Maturities of lease payments)",
     "shortName": "Leases (Details - Maturities of lease payments)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative",
     "longName": "999042 - Disclosure - Income Taxes (Details Narrative)",
     "shortName": "Income Taxes (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-012026-03-31_country_US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative",
     "longName": "999043 - Disclosure - Management and Director Compensation (Details Narrative)",
     "shortName": "Management and Director Compensation (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:SalariesWagesAndOfficersCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "SBFM:CompensationRelatedCostsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:SalariesWagesAndOfficersCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "SBFM:CompensationRelatedCostsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative",
     "longName": "999044 - Disclosure - Capital Stock (Details Narrative)",
     "shortName": "Capital Stock (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-10-152025-10-16_custom_SeriesBWarrantsMember",
      "name": "us-gaap:ConversionOfStockSharesConverted1",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing",
     "longName": "999045 - Disclosure - Warrants (Details - Warrants issued with financing)",
     "shortName": "Warrants (Details - Warrants issued with financing)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31_custom_TradeableWarrantsMember",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "SBFM:ScheduleOfWarrantsIssuedWithFinancingTableTextBlock",
       "SBFM:WarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31_custom_TradeableWarrantsMember",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "SBFM:ScheduleOfWarrantsIssuedWithFinancingTableTextBlock",
       "SBFM:WarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding",
     "longName": "999046 - Disclosure - Warrants (Details - Warrants outstanding)",
     "shortName": "Warrants (Details - Warrants outstanding)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31_custom_TradeableWarrants1Member",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "SBFM:WarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31_custom_TradeableWarrants1Member",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "SBFM:WarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative",
     "longName": "999047 - Disclosure - Warrants (Details Narrative)",
     "shortName": "Warrants (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:ProceedsFromWarrantExercises",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-02-102024-02-11_custom_AprilWarrantsAndMayInvestorWarrantsMember",
      "name": "us-gaap:PaymentsForRepurchaseOfWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "SBFM:WarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://sunshinebiopharma.com/role/EarningsPerShareDetails",
     "longName": "999048 - Disclosure - Earnings Per Share (Details)",
     "shortName": "Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-01-01to2026-03-31",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10q-033126.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable &amp; accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r558"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax payable",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r68"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r93",
      "r423"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated comprehensive income",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r45",
      "r99",
      "r420",
      "r437",
      "r438",
      "r722"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital paid in excess of par value",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r558",
      "r734"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r689",
      "r690",
      "r691",
      "r692",
      "r723",
      "r739"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r589",
      "r600",
      "r610",
      "r636"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r592",
      "r603",
      "r613",
      "r639"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r625"
     ]
    },
    "SBFM_AllDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "AllDirectorsMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r632"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r593",
      "r604",
      "r614",
      "r632",
      "r640",
      "r644",
      "r652"
     ]
    },
    "SBFM_AllowanceForObsoleteInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "AllowanceForObsoleteInventory",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/InventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allowance for obsolete inventory"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "SBFM_AprilWarrantsAndMayInvestorWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "AprilWarrantsAndMayInvestorWarrantsMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "April Warrants And May Investor Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_AprilWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "AprilWarrantsMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "April Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r76",
      "r95",
      "r122",
      "r123",
      "r124",
      "r160",
      "r168",
      "r177",
      "r180",
      "r188",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r362",
      "r364",
      "r381",
      "r411",
      "r412",
      "r417",
      "r482",
      "r542",
      "r543",
      "r547",
      "r558",
      "r559",
      "r560",
      "r570",
      "r708",
      "r709",
      "r728"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r102",
      "r122",
      "r123",
      "r124",
      "r188",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r362",
      "r364",
      "r381",
      "r558",
      "r708",
      "r709",
      "r728"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Long-Term Assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r188",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r362",
      "r364",
      "r381",
      "r708",
      "r709",
      "r728"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r643"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing",
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding",
      "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r440",
      "r549",
      "r550",
      "r715",
      "r716",
      "r717"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r440",
      "r549",
      "r550",
      "r715",
      "r716",
      "r717"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r306",
      "r307",
      "r308",
      "r309",
      "r315",
      "r316",
      "r317",
      "r318",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r353",
      "r354",
      "r355",
      "r358",
      "r552",
      "r554",
      "r715",
      "r716",
      "r717"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase price of shares",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r355",
      "r552",
      "r553"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/BasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r682"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets",
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodStartLabel": "Cash and Cash Equivalents at Beginning of Period",
        "periodEndLabel": "Cash and Cash Equivalents at End of Period",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r54",
      "r121"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation",
        "documentation": "Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r54"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical",
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r96",
      "r97",
      "r98",
      "r122",
      "r124",
      "r149",
      "r150",
      "r153",
      "r155",
      "r162",
      "r163",
      "r188",
      "r208",
      "r210",
      "r211",
      "r212",
      "r215",
      "r216",
      "r221",
      "r222",
      "r224",
      "r225",
      "r227",
      "r230",
      "r233",
      "r234",
      "r237",
      "r240",
      "r247",
      "r381",
      "r444",
      "r445",
      "r446",
      "r447",
      "r450",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r470",
      "r490",
      "r509",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r661",
      "r685",
      "r686",
      "r693"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r162",
      "r224",
      "r233",
      "r234",
      "r235",
      "r237",
      "r240",
      "r245",
      "r247",
      "r366",
      "r444",
      "r445",
      "r446",
      "r447",
      "r548",
      "r661",
      "r683",
      "r685"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing",
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "verboseLabel": "Warrant exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r126",
      "r248"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing",
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding",
      "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing",
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants outstanding",
        "verboseLabel": "Number of warrants outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative",
      "http://sunshinebiopharma.com/role/Cover",
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r562",
      "r563",
      "r565",
      "r566",
      "r567",
      "r568",
      "r689",
      "r690",
      "r692",
      "r723",
      "r732",
      "r739"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical",
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical",
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r470"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical",
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical",
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r36",
      "r470",
      "r488",
      "r739",
      "r740"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock $0.001 par value per share; 3,000,000,000 shares authorized 4,905,945 shares issued and outstanding at March 31, 2026 and December 31, 2025",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r222",
      "r229",
      "r419",
      "r558"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "SBFM_CompensationRelatedCostsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "CompensationRelatedCostsDisclosureTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management and Director Compensation",
        "documentation": "Compensation Related Costs Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income [Member]",
        "documentation": "The change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss",
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive (Loss)",
        "label": "Net (loss)",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r104",
      "r106",
      "r111",
      "r409",
      "r428",
      "r429"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock converted, shares converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r18"
     ]
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock converted, shares issued",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r18"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of sales",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r122",
      "r123",
      "r124",
      "r188",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r381",
      "r542",
      "r708"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative",
      "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r122",
      "r128",
      "r129",
      "r217",
      "r235",
      "r402",
      "r405",
      "r416",
      "r528",
      "r529",
      "r530",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r718",
      "r719",
      "r720",
      "r721"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepositAssets",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits",
        "documentation": "The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows",
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation &amp; amortization",
        "verboseLabel": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r115",
      "r160",
      "r171",
      "r180",
      "r531",
      "r542",
      "r543"
     ]
    },
    "SBFM_Director1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "Director1Member",
     "presentation": [
      "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_Director2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "Director2Member",
     "presentation": [
      "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_Director3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "Director3Member",
     "presentation": [
      "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director 3 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_Director4Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "Director4Member",
     "presentation": [
      "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director 4 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_Director5Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "Director5Member",
     "presentation": [
      "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director 5 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "DirectorMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]"
       }
      }
     },
     "auth_ref": [
      "r701",
      "r733"
     ]
    },
    "SBFM_DisclosureLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "DisclosureLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_DisclosureManagementAndDirectorCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "DisclosureManagementAndDirectorCompensationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Management And Director Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_DisclosureReverseStockSplitsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "DisclosureReverseStockSplitsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse Stock Splits"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_DisclosureWarrantsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "DisclosureWarrantsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r582",
      "r584",
      "r596"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://sunshinebiopharma.com/role/EarningsPerShareDetails",
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(Loss) per common share (Basic)",
        "verboseLabel": "Net gain (loss) per share attributable to common stock",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r112",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r147",
      "r149",
      "r153",
      "r154",
      "r155",
      "r159",
      "r220",
      "r280",
      "r304",
      "r360",
      "r379",
      "r380",
      "r410",
      "r430",
      "r536"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/EarningsPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r156",
      "r157",
      "r158"
     ]
    },
    "SBFM_EarnoutLiabilityBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "EarnoutLiabilityBalance",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining earnout balance"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_EarnoutLiabilityExpenseFirstInstallment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "EarnoutLiabilityExpenseFirstInstallment",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnout liability expense, first installment"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_EarnoutLiabilityExpenseSecondInstallment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "EarnoutLiabilityExpenseSecondInstallment",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnout liability expense, second installment"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_EarnoutPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "EarnoutPayable",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative",
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnout payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r285",
      "r551"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r285",
      "r551"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquipmentMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover",
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r83",
      "r84",
      "r85",
      "r107",
      "r108",
      "r109",
      "r130",
      "r131",
      "r132",
      "r134",
      "r141",
      "r143",
      "r145",
      "r161",
      "r189",
      "r190",
      "r207",
      "r219",
      "r249",
      "r280",
      "r294",
      "r295",
      "r301",
      "r302",
      "r303",
      "r305",
      "r359",
      "r360",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r395",
      "r401",
      "r427",
      "r433",
      "r434",
      "r435",
      "r450",
      "r509"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r589",
      "r600",
      "r610",
      "r636"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r586",
      "r597",
      "r607",
      "r633"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IntangibleAssetsDetails-IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less accumulated amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r194",
      "r204",
      "r525"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IntangibleAssetsDetails-IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Intangible assets at ending of period",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r204",
      "r408",
      "r525"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IntangibleAssetsDetails-IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Intangible assets at beginning of period",
        "label": "Intangible assets, net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r705"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsPeriodIncreaseDecrease",
     "presentation": [
      "http://sunshinebiopharma.com/role/IntangibleAssetsDetails-IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of additional intangible assets",
        "documentation": "Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign exchange",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r382",
      "r383",
      "r384",
      "r385",
      "r506"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r593",
      "r604",
      "r614",
      "r640"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r593",
      "r604",
      "r614",
      "r640"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r593",
      "r604",
      "r614",
      "r640"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r593",
      "r604",
      "r614",
      "r640"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r593",
      "r604",
      "r614",
      "r640"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total General &amp; Administrative Expenses",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r493"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General &amp; Administrative Expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r48",
      "r75",
      "r122",
      "r123",
      "r124",
      "r188",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r381",
      "r538",
      "r542",
      "r695",
      "r697",
      "r698",
      "r699",
      "r700",
      "r708"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IntangibleAssetsDetails-IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less impairment",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r681",
      "r707"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (loss) before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r71",
      "r75",
      "r411",
      "r413",
      "r425",
      "r532",
      "r534",
      "r535",
      "r538",
      "r542",
      "r695",
      "r697",
      "r698",
      "r699",
      "r700"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r284",
      "r285",
      "r289",
      "r293",
      "r551",
      "r713"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r284",
      "r285",
      "r289",
      "r293",
      "r551",
      "r713"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r125",
      "r282",
      "r284",
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r296",
      "r298",
      "r299",
      "r300",
      "r415",
      "r439",
      "r449",
      "r551"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative",
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for income taxes",
        "verboseLabel": "Income tax (expense) / benefit",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r81",
      "r122",
      "r144",
      "r145",
      "r160",
      "r172",
      "r180",
      "r283",
      "r284",
      "r297",
      "r432",
      "r532",
      "r534",
      "r535",
      "r551"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for income taxes",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r120",
      "r292",
      "r293"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable &amp; accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income tax payable",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInDepositOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInDepositOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deposits",
        "label": "Increase (Decrease) in Deposit Assets",
        "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r662",
      "r680"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "SBFM_IncreaseDecreaseInReductionInRightofuseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "IncreaseDecreaseInReductionInRightofuseAsset",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reduction in right-of-use asset"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r593",
      "r604",
      "r614",
      "r632",
      "r640",
      "r644",
      "r652"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r585",
      "r656"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r585",
      "r656"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r585",
      "r656"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r205",
      "r206",
      "r523",
      "r524"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r705",
      "r706"
     ]
    },
    "us-gaap_InterestIncomeDebtSecuritiesOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestIncomeDebtSecuritiesOperating",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "Amount of interest income, amortization of premium and accretion of discount, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading); classified as operating."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r118",
      "r119"
     ]
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/Inventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventory",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/InventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finished goods",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets",
      "http://sunshinebiopharma.com/role/InventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory",
        "verboseLabel": "Total Inventory, net of allowance",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r526",
      "r558"
     ]
    },
    "SBFM_InvestorWarrants1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "InvestorWarrants1Member",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor Warrants 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_InvestorWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "InvestorWarrantsMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing",
      "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of lease information",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r400"
     ]
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LegalFees",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r663",
      "r736",
      "r738"
     ]
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LegalMattersAndContingenciesTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/LegalMatters"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Matters",
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of maturities of lease liabilities",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "SBFM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/LeasesDetails-MaturitiesOfLeasePayments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/LeasesDetails-MaturitiesOfLeasePayments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r684",
      "r688",
      "r731"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/LeasesDetails-MaturitiesOfLeasePayments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r684",
      "r688",
      "r731"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/LeasesDetails-MaturitiesOfLeasePayments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r684",
      "r688",
      "r731"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/LeasesDetails-MaturitiesOfLeasePayments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "SBFM_LesseeOperatingLeasesRemainingLeaseTerm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "LesseeOperatingLeasesRemainingLeaseTerm",
     "presentation": [
      "http://sunshinebiopharma.com/role/LeasesDetails-LeaseInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining lease term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r122",
      "r123",
      "r124",
      "r188",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r363",
      "r364",
      "r365",
      "r381",
      "r469",
      "r537",
      "r547",
      "r570",
      "r708",
      "r728",
      "r729"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r69",
      "r422",
      "r558",
      "r559",
      "r560",
      "r683",
      "r687",
      "r703",
      "r724"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r91",
      "r122",
      "r123",
      "r124",
      "r188",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r363",
      "r364",
      "r365",
      "r381",
      "r558",
      "r708",
      "r728",
      "r729"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Long-Term Liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r31",
      "r32",
      "r33",
      "r34",
      "r122",
      "r123",
      "r124",
      "r188",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r363",
      "r364",
      "r365",
      "r381",
      "r708",
      "r728",
      "r729"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_MalekChamounMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "MalekChamounMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Malek Chamoun [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketing",
        "documentation": "Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "SBFM_MayInvestorWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "MayInvestorWarrantsMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "May Investor Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_MayPreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "MayPreFundedWarrantsMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "May Pre-Funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc."
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition of Nora Pharma Inc.",
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r714"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Flows Provided by Financing Activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Financing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Flows (Used In) Investing Activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Investing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Flows (Used In) Operating Activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r56"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Operating Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows",
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (Loss)",
        "label": "Net (Loss)",
        "verboseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r56",
      "r72",
      "r85",
      "r89",
      "r103",
      "r105",
      "r109",
      "r122",
      "r123",
      "r124",
      "r127",
      "r133",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r144",
      "r145",
      "r151",
      "r188",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r220",
      "r223",
      "r226",
      "r231",
      "r280",
      "r304",
      "r360",
      "r380",
      "r381",
      "r426",
      "r489",
      "r507",
      "r508",
      "r532",
      "r534",
      "r535",
      "r569",
      "r708"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/EarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net gain (loss) attributable to common stock",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r113",
      "r137",
      "r138",
      "r139",
      "r140",
      "r147",
      "r148",
      "r152",
      "r155",
      "r223",
      "r226",
      "r231",
      "r360"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "us-gaap_NoninterestExpenseDirectorsFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoninterestExpenseDirectorsFees",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative",
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director fees",
        "verboseLabel": "Directors cash compensation",
        "documentation": "Amount of expense for service provided by entity's director."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r737",
      "r738"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Other Income",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "SBFM_NoraPharmaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "NoraPharmaMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nora Pharma [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://sunshinebiopharma.com/role/DescriptionOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r696"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://sunshinebiopharma.com/role/DescriptionOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of reportable segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r546",
      "r696"
     ]
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "(Loss) From Operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r532",
      "r535",
      "r538",
      "r695",
      "r697",
      "r698",
      "r699",
      "r700"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets",
      "http://sunshinebiopharma.com/role/LeasesDetails-LeaseInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use-liability",
        "verboseLabel": "Operating Lease liability - Short-term",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets",
      "http://sunshinebiopharma.com/role/LeasesDetails-LeaseInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Right-of-use-liability",
        "label": "Operating lease liability - Long-term",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets",
      "http://sunshinebiopharma.com/role/LeasesDetails-LeaseInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use-asset",
        "verboseLabel": "Operating lease ROU asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://sunshinebiopharma.com/role/LeasesDetails-LeaseInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r557"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/DescriptionOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Business",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r86",
      "r87",
      "r88",
      "r441",
      "r442"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign exchange translation",
        "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r45",
      "r427"
     ]
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r738"
     ]
    },
    "us-gaap_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income",
        "documentation": "Amount of revenue and income classified as other."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r491",
      "r514",
      "r515",
      "r516",
      "r559",
      "r560"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r591",
      "r602",
      "r612",
      "r638"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r594",
      "r605",
      "r615",
      "r641"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r594",
      "r605",
      "r615",
      "r641"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r619"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRepurchaseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for repurchase of warrants",
        "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to acquire shares",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r344",
      "r552",
      "r553",
      "r555"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of intangible assets",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "SBFM_PreFunded2022WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "PreFunded2022WarrantsMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2022 Pre-Funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_PreFunded2024WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "PreFunded2024WarrantsMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024 Pre-Funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_PreFunded2025WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "PreFunded2025WarrantsMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025 Pre-Funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r562",
      "r565",
      "r566",
      "r567",
      "r568",
      "r732",
      "r739"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical",
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r233"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical",
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r470"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r233"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical",
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r470",
      "r488",
      "r739",
      "r740"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Series B $0.10 par value per share; 1,000,000 shares authorized 130,000 shares issued and outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r222",
      "r228",
      "r418",
      "r558"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r192",
      "r193",
      "r527"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative",
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows",
      "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of warrants",
        "verboseLabel": "Net proceeds",
        "terseLabel": "Proceeds from warrant exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_ProfessionalAndContractServicesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfessionalAndContractServicesExpense",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting",
        "documentation": "Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r542",
      "r569",
      "r736",
      "r738"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r400"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/PlantPropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plant, Property and Equipment",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r78",
      "r79",
      "r80"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r92",
      "r424"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets",
      "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property &amp; equipment",
        "totalLabel": "Plant, property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r400",
      "r414",
      "r424",
      "r558"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of plant property and equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r400"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r586",
      "r597",
      "r607",
      "r633"
     ]
    },
    "SBFM_RegisteredDirectOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "RegisteredDirectOfferingMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registered Direct Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative",
      "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative"
     ],
     "auth_ref": [
      "r122",
      "r128",
      "r129",
      "r217",
      "r235",
      "r402",
      "r405",
      "r416",
      "r528",
      "r529",
      "r530",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r718",
      "r719",
      "r720",
      "r721"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "R&amp;D",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r524",
      "r532",
      "r533",
      "r542",
      "r730"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r587",
      "r598",
      "r608",
      "r634"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r588",
      "r599",
      "r609",
      "r635"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r595",
      "r606",
      "r616",
      "r642"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated (Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r64",
      "r421",
      "r436",
      "r438",
      "r448",
      "r471",
      "r558"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r130",
      "r131",
      "r132",
      "r134",
      "r141",
      "r143",
      "r145",
      "r189",
      "r190",
      "r207",
      "r219",
      "r280",
      "r294",
      "r295",
      "r301",
      "r302",
      "r303",
      "r305",
      "r359",
      "r360",
      "r367",
      "r369",
      "r370",
      "r372",
      "r378",
      "r393",
      "r395",
      "r433",
      "r435",
      "r450",
      "r739"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r74",
      "r110",
      "r122",
      "r123",
      "r124",
      "r160",
      "r169",
      "r170",
      "r176",
      "r180",
      "r183",
      "r185",
      "r186",
      "r188",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r381",
      "r411",
      "r413",
      "r542",
      "r556",
      "r559",
      "r560",
      "r708"
     ]
    },
    "SBFM_ReverseStockSplitTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "ReverseStockSplitTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/ReverseStockSplits"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Reverse Stock Splits",
        "label": "ReverseStockSplitTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "us-gaap_SalariesAndWages": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalariesAndWages",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Salaries",
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "us-gaap_SalariesWagesAndOfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalariesWagesAndOfficersCompensation",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officers compensation",
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r306",
      "r307",
      "r308",
      "r309",
      "r315",
      "r316",
      "r317",
      "r318",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r353",
      "r354",
      "r355",
      "r358",
      "r552",
      "r554",
      "r715",
      "r716",
      "r717"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/EarningsPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of computation of basic and diluted net income per share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of intangible assets",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r704"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/InventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of inventory",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r42",
      "r43",
      "r44"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r400"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing",
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding",
      "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r25",
      "r62",
      "r63",
      "r64",
      "r96",
      "r97",
      "r98",
      "r162",
      "r233",
      "r234",
      "r235",
      "r237",
      "r240",
      "r245",
      "r247",
      "r366",
      "r444",
      "r445",
      "r446",
      "r447",
      "r548",
      "r661",
      "r683",
      "r685"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of warrants outstanding",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "SBFM_ScheduleOfWarrantsIssuedWithFinancingTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "ScheduleOfWarrantsIssuedWithFinancingTableTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of warrants issued with financing"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r160",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r173",
      "r174",
      "r175",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r186",
      "r539",
      "r540",
      "r541",
      "r542",
      "r544",
      "r545",
      "r546"
     ]
    },
    "SBFM_SeriesAWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "SeriesAWarrantsMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical",
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r667",
      "r710",
      "r711"
     ]
    },
    "SBFM_SeriesBWarrants1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "SeriesBWarrants1Member",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Warrants 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_SeriesBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "SeriesBWarrantsMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative",
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing",
      "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing",
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding",
      "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, shares",
        "periodEndLabel": "Ending balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical",
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r96",
      "r97",
      "r98",
      "r122",
      "r124",
      "r149",
      "r150",
      "r153",
      "r155",
      "r162",
      "r163",
      "r188",
      "r208",
      "r210",
      "r211",
      "r212",
      "r215",
      "r216",
      "r221",
      "r222",
      "r224",
      "r225",
      "r227",
      "r230",
      "r233",
      "r234",
      "r237",
      "r240",
      "r247",
      "r381",
      "r444",
      "r445",
      "r446",
      "r447",
      "r450",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r470",
      "r490",
      "r509",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r661",
      "r685",
      "r686",
      "r693"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover",
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r36",
      "r39",
      "r40",
      "r83",
      "r84",
      "r85",
      "r107",
      "r108",
      "r109",
      "r130",
      "r131",
      "r132",
      "r134",
      "r141",
      "r143",
      "r145",
      "r161",
      "r189",
      "r190",
      "r207",
      "r219",
      "r249",
      "r280",
      "r294",
      "r295",
      "r301",
      "r302",
      "r303",
      "r305",
      "r359",
      "r360",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r395",
      "r401",
      "r427",
      "r433",
      "r434",
      "r435",
      "r450",
      "r509"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical",
      "http://sunshinebiopharma.com/role/Cover",
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r161",
      "r221",
      "r222",
      "r224",
      "r227",
      "r395",
      "r406",
      "r443",
      "r451",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r470",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r509",
      "r534",
      "r535",
      "r564",
      "r735"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical",
      "http://sunshinebiopharma.com/role/Cover",
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r161",
      "r187",
      "r221",
      "r222",
      "r224",
      "r227",
      "r395",
      "r406",
      "r443",
      "r451",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r470",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r509",
      "r534",
      "r535",
      "r564",
      "r735"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r590",
      "r601",
      "r611",
      "r637"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued for acquisition",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r64"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of warrants, shares",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r22",
      "r36",
      "r39",
      "r64",
      "r218"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate shares Issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r35",
      "r36",
      "r64",
      "r444",
      "r509",
      "r518"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued for acquisition, value",
        "documentation": "Value of stock issued pursuant to acquisitions during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r36",
      "r39",
      "r40",
      "r64"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise of warrants",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r36",
      "r39",
      "r40",
      "r64"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets",
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL SHAREHOLDERS' EQUITY",
        "periodStartLabel": "Beginning balance, value",
        "periodEndLabel": "Ending balance, value",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r39",
      "r40",
      "r57",
      "r472",
      "r488",
      "r510",
      "r511",
      "r558",
      "r570",
      "r683",
      "r686",
      "r687",
      "r703",
      "r724",
      "r739"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Stock",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r232",
      "r234",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r249",
      "r366",
      "r377",
      "r512",
      "r513",
      "r522"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplementary Disclosure of Cash Flow Information:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "SBFM_Taxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "Taxes",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r701",
      "r727"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "SBFM_TradeableWarrants1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "TradeableWarrants1Member",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tradeable Warrants 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_TradeableWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "TradeableWarrantsMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing",
      "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tradeable Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "US",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "us-gaap_VehiclesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VehiclesMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vehicles [Member]",
        "documentation": "Equipment used primarily for road transportation."
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_WarrantExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "WarrantExpirationDate",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing",
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant expiration date",
        "verboseLabel": "Expiry date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r562",
      "r565",
      "r566",
      "r567",
      "r568"
     ]
    },
    "SBFM_WarrantsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://sunshinebiopharma.com/20260331",
     "localname": "WarrantsDisclosureTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/Warrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants",
        "label": "WarrantsDisclosureTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://sunshinebiopharma.com/role/EarningsPerShareDetails",
      "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding (Basic)",
        "verboseLabel": "Weighted average outstanding shares of common stock",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r155"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-20/tableOfContent"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>64
<FILENAME>0001683168-26-003819-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001683168-26-003819-xbrl.zip
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M/HQ :M 7O/5R83#.W!+!)P@9/9F!;)Q:5-L%IO4S,B[9),U0 WY!K9)1?+U
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MQ_EX]SD3/Z=CRI4"-'&!A^<UVJEB[ZP4#E*ZQSK,$E_?J.!JZL4;57Z&!1+
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M!O%OA^$E#=C.$,;"?SV")X/HJ(9\_!-02P,$%     @ 4X*M7$3*1O[>#@
M3+0  !4   !S8F9M+3(P,C8P,S,Q7V-A;"YX;6SM7>EOVS@6_[[ _@_:++#H
M .N<;6>2:7>0LPB0PTC:Z7XK&(F.N95%EY1R[%^_)"79DGB(LB63!39 TUCF
M>_J]@WSOD13UX8^761P\04(13CYN[6WO;@4P"7&$DL>/6U_N1\?WIY>76P%-
M01*!&"?PXU:"M_[XUU__$K"?#W\;C8(+!./H*#C#X>@RF>#?@QLP@T?!)YA
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M@T]'1R\O+V]\\HQ>"/T>O+')3*W"^Q"%4;"L[>WKV_2_1/P7S_6_?^+_/*$
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M8'KMD9?-4>=J: /@/7LTGA+/89WQU1^1&RXV1BJJJBG(ESBPJ3OG[ W'YU'
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M!$!S*(H1")$J],P 631@(M&$PX,(XY:E*Y'$*(TM784*]"L-B.A0&V,4(G$
MU !U-&AR?WD:LB>91\^7"1=JNDACN>AL40F(]RL6"^VA9@ P(NF8&0(*$A?4
M#*U""DG<FL/616^[PVE]&<MID< 1BL7*KZB<7!A*RVB"2& N/ &9#4R/ZCTI
M(G5F4P 1)011W"Q)^(,JF_]<I3E]!_JOQ?I5EX'N4%,:("(EP>P _33(H_8/
M(FS(38Y%-.\GN/H^O&C>NXKF/6K1O-]'-///!1+1?)C@ZH?PHOG@*IH/J$7S
M82_1\(H/VM:<\C]OV+SXK-N<#2*#2$:EJA7,#H9/+@HWFUB$@8AGA$E(F<C
MZH;=LN(IS6,X9(;@000#D-:J9H3%)QT]09M^NH"XM0O:UM1!N?4E:6%A6IDA
M27T3T]SDB4XD0V+6QJ5&AY3$;5%64?9_TK5Q(*X'!Y&'EK!6) ,D/JGHZ-D$
M4]L0;A1B8-W(52QH:(^2C;[WMMJLH]4M,?>_1"$"'2-E,;F9/:E!OJM9:)31
M"&@1AE][JV0-J:Z.>]_AJ&*5D%+#\KWFF! O\E4A]D@]%CF\04"%^*IIB%Q;
MV^/O4=0X0&I<ZQ)&)"[0;/QS1?-2WWSWOO/6LX_I=!UY^P6*VAVS4;KI]GO/
MM?D+2RO^RZ?%:K7)FU4>W;Y! .>KEHTTVQK7@E#4OHG96 D-E@S!GF5Q7V1I
MG%;BEAD^^&1II/-*!_(E")A@JP85@4(*("TEDTL')"W2LPAN&14BI+PBY"%
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MS#F*"QT6NX7#N,;8(#_S$FC/#)-BG!=#+3:!=.2V+&HT0-,FN;"$%TA1C;2
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M\VA]3T='0_J)I:#1[][4U4M(.B'WMV+PQG-7A/$P,9XYF?>8:D?#"_&4S&Y
M6\Z+.RKJ)LWHP(UY<9BFY75^RN^%1:_WL(:W'1W^=]"\(J_HG'( ?O=3I"H(
M:W^,Y/P%%.LNXE/Q=RS:P@W_%7$;4[>T2J+@#>&K[H;VVVPZ7*X\B;5Q8[2X
MHPW5MF@N;B9NC#ZC]7\O\R8[0\E? 9H^10\9M)'"S=3S*INS,Z,E-ZN='TU^
M7VLRITN15]>R*NS*&<B_48J&IT$BU.%E_L0;R(+!]S=;;,(J3T/?++F> 7ZM
MJ635/8(U(OQ=\BI[WB0795K)A9=96=+*76$ZT[!"@YTQZTVUPR\[D+.FTQ7
M\)L,5!]N&17W:YHW*=K-PHI.[X19<$,;_&+3\M5<L2!O2Z4'.F($'(M5V=W1
M9",7@OF?8OJY6/!Q@GPG1@[N8>_MD.T^;G5G<:<8!Q]E[LM8.8_?&H@1(1,F
MQ\7BF!N12%@A;._::/,VVHI(4PR;XIAM^-NXN[%N<HQK+@S'F,/%8;=1B*FD
MX,H^"'UPB-+8MB>*:_N#M;:O(/=N-NA*_+OU%+HE<X)]6%%;W#+K&#!&+%TS
M8S7W%P>1K$4A5&7SXO6VB#<OUI27&2HA>'-K=LW:QNK-L4U"3J<.7!A01<]D
M70.#*]5]U?#%RXY8UX-?M@Z,:[/@9-ZZ%<C> O#7PIY<YM]H5X&QJE=,?96'
MV-U@+ B!FAT<=5"UH10T$<+>U&V[&[H27'<W^$F+'6V;A=!9_,<F%6?+*NY%
M*J)XTWRI@YW79-BN;@SR8-N,L,U<N1)6IJXXET<1N!8+DG8F]3Q"^+95\8J_
M>[P/J+:WW(F*CR7%M?8R@:'K8S$4$%245L>,Z@2MT<O4QMRD5]IB@^O4O6=X
M<=>"M<]_65__142P,&_G"%;7TV-5[T6:1WE\@ C66! "-3LXZJ!J0RG8(U@[
M=5L$VY6 *X)E14QI(E,F_!(Q%HE$QY3%:6FZ^,=@XOD2%ROYT=4M(!Z- !U(
MCJ76?B]Z_,^UR9?49+[X3<3:1+ZL:?PB.GR8MZ7#;PLB#UMMTQAHPZY@*/XG
M@NRG**-RGR!OY].8A^WB"QZ #S_H(77U_:("/6_QY<.,M$CNJXA5)BD<QB5M
M?RGV_<H_>A8DJL@)7::Y."(KFKA;23-X _>BQU#[,%ZK.'^.LTTB+TVILP[<
M\='B^6)!P7C2-PFOJ0*"/."#O;R3&>!J\(/XKNLTTJ84\G72E/.-V-03M^V%
M_(/N?CMXPU![=+/H>WF3'Z1G&=71J_R2U_P-K_>H!MD?#O\S:,8+K^>;,LR0
MOR2G%=ND.(S_&*G_+DE1OY3_/W(3C_!#@,CM/#?.+!_&H4EQ&V>$*&*[WZS7
MF<P$$&5M\H#+?%&P59T<RI+8P=7::XZ':2X-TCVXF:)IZ*;Q59) [*S9EIRE
M99P5Y8;104X(TBLO_-Q<FWWT-DJ3:V6_.H@*D01^1%&7[KV!H)&3GI>V=9,G
M%^J\G+4- FGT]K*9U:$"@R1T58AJ<[EV*$0R :C9E.*6P?4UNX:JB']_++*$
MLE)TR_I=R"H*YZ23@>>X)G:310\1_R*F1X2'))OPNSB5;%F0KRK.:TP!T1SH
M9@Q"*1J I(-BZJ1DX24C9']9EAN:G&T89UB'TC\+/9\6^1-_&WBL<K.H_Z[$
MSJ3=_22F5VG_,OVF,#N ^TISMV^!V+:Z'\*9+V(M$7"T?KT/_!HX%XK@/9CX
M !Q>!,<2T81G!W'#Y1UPZ1%><W;K<&F3\61;<V$)W[GQI875"&<$#2R5=Z).
MS.H>4>,+4$.,:VP5 )*T/?]7B$]+&G^[+)[>T#AI.N4XV?7%_!^_W3ZMYYK3
MD,.O?/2+.C*B\ON?!V_F-&24O=K1ECR58GY<SCMR?_M3D[]*T\-FI[57,N_]
MXHVX#_@TJNBR8-O9<SJ.H0PX7]5OI-EJ00M"(0P3,TT\4F-)"R:_"KAO95SR
M-N@I3391!DAB#/"E!3VQ5@3#;U'4OI:2>@ZY!86I[EGR[_-"Q&A ;8^^]U79
M6EIM70^^1%'5.D9PHE.1T52 >4Q<9\(,4O.?:"0Z(*#>!]_ZJG4-I;;.>U^A
MJ'&5S[B^&T28RFU#DCE]KDYX@;\;PI8>QG=8I] ;QW<= $6E0ZPF17Q'9'[P
M=!-V09P6]S2C8L]'H\OK2+D@VH#S)0PCS58<6A *@9B8Z:Z&BO(M:2U(VV (
M&\_J$#^9=!'HS6*1QI25%[FI^7"P\:4:9_JM@JP&*-3DRE*9/A-V9#>@:"V/
MR$515'E1^9;7+:7L1U9LUG(2UR8L(]I;#V6GW/55,!2%C.S\E/Z+6Q!I0AJ;
M8-(YE?M.D\X'LW2,:&]]F)URUY/!4!32L?-3>K7:@NPD%+#5*>;B (0<EZW&
MFZ>T"'^MBY;:KD49?(U""GI.2LMQ?D,D;#C G:U$!DO_]3^+JTV495NQJ\LH
M RW0HQH,1'NBT*"P: .FII-(BR8"CD J<OZ&>R&8F'L8$.EU9@RF.I@C4V$H
MY&+F9I@WFQ=$J*>OEV"]RW61<Q>NN?*?EI9N!H9Z&R!9R';C(@"'0C86<LHH
MJ,B/A5JN17O37$:*I6OJNR*]Z+6>=@UI+4)(R4!=IR@-')VP8(XN^AHJ:]#)
MA>O7.O<<>S<8[[6/L]$>]'00&(6^7!B:5XOZ6AMH+%#G5^\C$GM0ZV-99;E9
MK>6-<.EB01GEM6L6VM0"O&TXV,NQ;B?")&L4VMR+LK)W019"NE+(KABR*R?<
M'-*H3?^YE'& W)=5;XR[J\S32A,+\+=:LH]CNV64*=8HU+H79=W""]!)/Y7?
M-C%BKTAR1ZL-.^SUE/N(MKM^=9I4=6;A! H[ <M2M4$J1I#H1 F*_<]U0<%%
MIZQH3A.?R3R<".U.P6*$;9&*TDIXHCBA=6O/4M4T_#^7W4*%2:7.EKX$.M&5
M5IN.9BAD.8WK6)%0ETQ^+GL+3<';2GD5YU[-)& 9KH4TN@(WCEHS% *<QG5B
MDRB+"M4.1@^;+&)7:5E9=_P9L-[:.AO=KG6#@"CD9&.GM& UG@B#,!L -2VP
M?J89 @;L#37SRGH4#FV8J#EW;8&6S-L>V54M5@OO&[;<]&.!HQ"2&T?#YJT7
MB.L5:JF79;H>W%X5)90^>P?P?*36(2.#GI[N#'-SR>#75[:CS#XV?.O?7STL
MV'9OS9NJPZ!X/0W$G/=Z!VGE9;@J#B<8E:%%^1*&@6*K"PT$A2Q@7F-5U,.&
M_BF1QN0HX&HQO(UE^+7_DX"J!/K?H:A[#2'W8X"!:EVL2NO/ G7?>-P(J3OO
MTWR,HH:'7'1[&P,<WS$?Z0IRD,MP? O;H2W[4:T0)[**_$<>;#;<SF@9LU0N
MJ!N/9#D8>=PGYNA ;ZN8Q0*%7)QIZC:,_3B;W7;!7\_6>T^?I.)GH^R[M^^?
M=F=3S7O#K#;^8@)'^KM P6* 0EFN+-60HK4CW/#KIV]ZIXU]!Q-YF9_DBZKD
M88[EE!^$]!9LF*EVP8<>AD(P9F[JQ% NTN21$YK315J59!>*ACO?=_Y'M9U]
M9HE=,"#2W]Y (]7=)D M#(5@S-R ;7VSSQ&WP*$6QL2(Z8[&Q1-E6RA/F1[F
M32<&DIU(-!@<"H&)*?)@K,AIL2FS1B-T=)2K+210CC-QS4E4R>L@SOA_@40W
M6I0OJ1@HMDK10% (!>8UUDD/R4/>BK)5FM<"$89A\N/TV?<I"4869U5X"+5
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MW"Q^*NMI,EU=& WP58X;W7%M=59-9J6[FY_JN4 4M=3MUVF2ZMFK:6R!O9Y
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M[7]TQ?_B'[<?\?_WP#MX_LG_ U!+ P04    " !3@JU<YT6IG \U  !T2 ,
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MK]QV2P#Q'0I>]8JBPK:E,0JL4_Y]7^AP%I*%'-=&$2"P'U&1E9J%!6TM@L>
M\$Y)[-'9#FB)D4@CQ U=!&+_(539V* ?,A0BV&.TU2"B-1N)BFD4920LPH?U
M#.R6! +_Q0G@948BX?U_,L)2RL(U!/)682#J7YU 76$JUJJ$KX^*"$$(\NW2
M0.A_< )ZE;%(V-\^T# 4"UD2@=J]K#P0_S\[@;_:8 <8R*] G'!KX"341( \
M_,4Y'EIF(U$QHRR(?6X& Y#0*@R$_T<GX%>8B@K\:>1#8=\4!6^H'$*]82<2
MYF=!XI&PT.B,_T[F*:ZI+BD.Q1YW-VNT%Q7_?U#"P.C7"D.QQ]W@&FP=&?GC
MC+$=9;0#CKHT%'O<K:W)VI'!/XW2(%V+-$E7F<+7RXNU2T'!QMW.JJQ# ;ER
M9D2IR .E [I9$@HV[BY69R4*X,=<84;"\\BGS_]%USK$6T6AD./N7K5VHF ^
M8\&2L/5MX)G'DW99*.JX>U:]I2BPWY'G<Y^K'<R#(LF:&7VE")0$W TKR&X4
M+L2%.+:*:U[KXSCC/71]'/O:8=\@".4%=R=K@0$*.U/?Y[@EY?\)2S[J.)$6
M!Y]B.<"$QEY'\/]DA_\G./ZX.URCO8[@_]D._\]P_'%WN49[,?$_YC]>L[OX
M27%\KBP,Q1YWEVNP%1/Y7/]K-F/Q8U!DJ#7!WY* <N#"YE=O-6H7*%8$D/9?
ME80"[\)&6&XE)N"S.$E)^/^"E6DA*B\/!=^%+;'.XK'=FT4#$'X15:Q4HP@4
M:-Q=L-2NL;$55#-*U UZMP046=RMK<RJD8&]B,6AS$,<:=W"[5)0@''WJ"KK
MQAZ<Q26T1#DJU/X,#MK#'7J;]HR,YW<6I%P#$56?1:4_2'& IR@*Q1EW8ZFU
M<V3,;_/+H2*/ZB77G 4BE;\,<%DY*-JXVTBUA2-#/6-44$[Y\CV/6!,76-GU
M?*X:G77EH=#C[B+-%N-2D&>G8K9$2*2@=.!N**'6CST$44_DREM__'1_)VYD
M*P:@5BDHZ+B;295U(X-\%9?9 &[7R_LX5-^LD1:$0HV[==38.#+:.WK(<6X4
M@2*,NV>4VH4T7)P^>P\B-X<Z&$->$HHT[AY29R7:^+P C<\+R_$9=R^IL@X)
MY,VS!M?W8; @ZOMY6@'P724GH-?8//;UR/S:5"WG\!G_08Z_HB@4>>2KJ#H[
MQ\8\\X.4^H5*9998D0>W>D], ;]1"LH$\EU5H/4HYP[?:1C^5Q0_1;>4)'%$
M_6++H#MZ4(I Z7#AW--@-PH7W^(PXW"Q/!J6*7J%HB@4>Q?..Q5VX@2@%K'>
MF_FI>/E5![U* LJ "P>?>JN10O)2*I)W!8_TA*2DU%!'A$H"2H0+AZ!ZJ]$N
M&K!MCF U_HV"4-A=" R6VHB"]NV2A.'VB5(UVHV"4+1=B "6VHB"]NF2L@4?
M[WYF\5/Z4-ZAU:&N$("B[T*<K]9F'!:>MU?YBUN%6@HDI<$I(US 7VDM5G84
MSQ-Q(<6T'_F$*>#7E8<2X,8%5K7%(U-PG3Y05E]UY<H(]74Q'&8I*!VX&V&H
M]3@3<2VK@G8>WBD'!=Z%+:_,0IP+:-E]&'AG84RTZ_N=8E"@7=C?2NQ#P?F(
M1+^Q;)5Z:Y$7G%)QKI-L^A]@AP6L ,J-"SM?*TQP/!+;C*/Y4TJ[;U-I_!):
M.2A'+FR*(0@@K9V2[:TYZA^M;^B<,A%L<4>?TZ,P?U]<MY0"B$.)<B,G%!@/
M"5]_>]\RD'_RM^JOTC_NU-;UA8 C$A*N(Y\/:<W[OO-2P*?)V\D&B/RI@"B)
MP\ 79DY*^4E9 6[F\NOYYDAA%A>[#,U+ TV.M=(X>8V+IV#--C3+N9)Y%T!(
M(\^QW&+T!-.%6N64".6C5=R9O+U=>5$ @$[/,4D>Q']%1NU'$HK!^(9R'0./
MCU'B#]/(W_U%K:2:QCVKQ<X>K.<L[M-41]I!Z=S@JGN4*W<?TBN:JA?W%4Y:
M*>P,Q#8L0NQ')VGS-C?734W*;BGL;,0V),CL0P?]A&_K^$!?O2VO0KU1##L=
ML0WL4@O1<9\QNB*!?_HLWDREQJ%(41P[-[$-#UJ+T?G8L02X@',H-_&>"S<)
M#=P4OD]EU+\H0% JG&N;QBD)\Y*X!%[%D6>W&)=).)/JN"NM:AC0.]J,Q2O*
MTO4L)"(_OR^6BRMAJW;6UTLYDQO9GB\('.B<G7,LHT7 EXUE\Z+IZ;,79L+9
M^',<^T]!*+O>L5GW0*3=2;5L3Z(-/NAD7O/V1H0C_X*2A-X$BP=N\2])H;J:
M18.8.]F:[>D#(8+.6W-DAT]L+N5SWG]&>S%K%1.!+J6"[DK;"R#K(B#W0<A-
MI@"'N[2P.TFF[6G46(\^(M9T WO@=3+NY*?>BR=7G?&5$W)&UL(#"7:_-LNC
MY[0&8"UWO\HMWY>8Y'Z^%&C_\.'SYX\YXK='9Y>_GA(6Q5E:?E,"LRC5+(2>
MN1J.K4Q]=UHZRZ@OSOV7](X\4X!C22V"GLBZ2WO7VX_.T.Z2OS)P;:3))(>>
MW-J:*Q@2Z(2U[;*9XUW*==W'W/ZREM4V3EN#F#LIM?>BV6'_K6*\@/@E *+H
M*;EA)("&T!Y=%H^4W<>\:N<ZK&5'=2GO=T\=]&4-Q2 ^7<H<OA>++X"[/ +\
M(0XYWHDX.TK7D,A6M8P[J<GMF35C@3Y[SJKFE>OZC829;&>^C9AH%W8@?;D1
MY5;@A\IF=#YJUR@,9+1+.I#?W)()E;7H-$Q]/^_@O*N3P#^/CLDJ2*4Y>"L/
M@TK @=3HEJ08;,?GQO.R91:*6QWYY51Q.Y+1!Y$B^Y$6+IZ+.!%GWM?S._*L
M=7'95>1 %G9;+KMAA<[Q#4U)$%%?^%/%9;^:'2=T+O)&JVF%R#J0^-V223@B
MZ.2U;;-9^CF1+=Z2'+7%![R2KY^T1KX-J69)=U+4[W<"K<.E5^K=N'<YRZ%]
MH&G@U18$.Y<P/\,O84[^M%/?O[]>RAS(LCO%@6O3ACO8F6NK>;O60YL&U4,U
MD:FX:-[/UM!1*^L8)3L-2@5^3?WZ818R <<A29+K>3YL3Y\#" ]MD4.DHVU%
M[18ODK.CIM))O.3K6XV[0U+6,1I43:OI])!8LKWGCM0]*./+F:-=S]@E5:2W
MJ@S7"6%?(5>WK68',9N.OJ/:58ZOFJY9WNK\W&LVHRQ/N0)UW*KE74G'T)HE
MM1Y<$QZ.T5>DQYEFZ4/,@G]M5^0FVMIRV'VL(U\J )SD*4\Q;LE1)8.=5V$O
M?G8-=Y(;?9(MC6U=LFPA9@.$6N((5;53'?NI"B2,G64!3)D%%"[1!I^BM$+8
M61FZT.3LY-32T30S*06PDS1TI\6Q.<DRZZ/*JBZS$6(F09 92H;0'-G;MWNN
MYV6 9!P)#_[.F:@X#94[MK_H'-O;RB?Q?+*M?L+QF.Q\8"*^,/G3+Q$I7AA"
M\GH79[\;M<V.;J4 U@'Q(XTR77S@M@3RKM8 =>N<=]<P!P:Y)+V>EVKI1K6=
M8MA;4SO0I3:B(_\SXT/%C,5S7;3#3B'L#:<=ZA+[#OBX_&<:\5$_Y!/*U%\&
M42!,%T\$E?FES",LN +L#:LERW:XH/<ZT2!IDN0!<&=4-\.T2V+O2VVQ;J7^
MD5KN%"7Y@BW*S;BE[#'P:%):!R-*)X^]7^V//C-*Z*1>Q5$@'E*C25JJ=A(P
MZO$/)?IN9Q3$WM_N1R,0%W3^+NC"-$#6BF!O:_?CI&4K.OJ7A/U&Q14_X^#7
M+HF=37 _+E26HU.2!U@;;%/3!)/&3BRX'W4V"*'3><.1Y9\7^<1/^,8PC/,L
MB$8>#6+H607W8Q $"CIUMR0DK C/_4X6NAFJ71(];^!^!*E,'RBG3YY+10*O
M^&/Y-_14?QT!K9G@2+,^H1P[+\B1XS^'-(>0F[44#V']*_^]NJG#I-$S_.W7
M_&T@0N>S\UJAKV7"< G^]F/1?HEP:,["38:.[1T\S=)05A@]-^">2T$U  =,
MZUG,:+"(BJ1(WCI_0U@\%!]'/Y,@$D8>T3DOH[V6:E4)>N[!_9I!!\#0A^WS
MTCM3M-P3>I_>4B]C^86P3;/6':2"Q-$3'^Y'K!5(Z)3F&]-"5<,.O2J$G@.Q
MAYWXKL'H)%S%4;P[*Q@70AH1],2'=J=D1N,/>%;<3O%G'"1Q+A%$&;=S&R93
M#/*U])RGSQPL3E$0$;;.HY!$@BMQHA&'80Y1,;R8XE4&^BAZ\D:[QC4" 0??
M/+G598\[XB.K-N1"*8">[+%+LU :CC\AT!2R/6H40\_8:#GPRXP\X-ZD2S.C
M7NWS94S^K["@R?]GEJ0"/,!V:; /HF>&M&M( P.//AI(3#.G>-(*H2>-M U2
M- )PP.-&E=>HNA9S1)+ 4Q.K*(Z>+=*.4JW1Z#WN.Q4O3U%_^LB7B0MZE8D[
MT=?S5K2_@2K+:M#S2=I1V DD5^]%B.>RS\+X27$%XBO\"H2H:9)7A7_7H99)
M9F.@568?B13:BECH,F/Q8\"I/EK_DHA7+38.M2F?TQ^!+T-UJ<N5_  :(MO+
MZXZ(H0^_@VY_!MN"[@&XW<8(*S%LM4).[N(;ZL61%^2/UV]UO8M[ZZ/#? W[
MEDAO361(,M!;FD/1'H/M< <EL)?(D,-[%H-#Q\2S'R>T^/_SJ'KMC0-,@T=]
M+D"8-/8]EQ';C0V<]NWFQZ+=1'0AUM".M9OSZ)$C'#/M,QP&,>PK-:@M10+@
M"VLB?"05*3ESWZ/I$6&8-/;E'=0&HX;SA;6;&:,K$OC& WZS)/;%(M3V(H<1
MLZTHXL3;JM]0/\M/(/B/PH,6S[/& _>-<'*[*K#O.(W1+.Q1<61KHUY3E0_G
MBG5Y\60KZ"FPKO5AWZ9R8AD+@=S!%J-XX]"FD2BK0+^DA=HP#,@ZV!;:SSNK
M'QG7]0=5)>AWPK '"CVZ!^TN@3LC^SA*<> ZW(AMR1[; PY@4!@K? !)3V=S
MVKK0;^[U=SH'P Q]%N)C8-F'IM[O62""9U,2+0*QE#(X0@"BZ!?X]F FMC46
M?]?:?VO@P/%1+EW/0A*E?&TMGH;*[\I;- M-'>BW_X9K'T;D#KJAP''K8W9P
MX'[@H+/"RUTVE$]>];)LT-:%?L^POP8"P Q_V<!BCU(_OXCSG3!&1/84RKP@
M,60:U$BAWT7<@X]6"CLC.N@4PJWMHZ<Z<)-QT![Z H9P8:GXKUBI/)*0YK$!
M')[ XZL-\0>^BMG]1:VDNHWL62WZ'<4.S:87)#NW)+[L#&*?J\W2PVU/L]R(
MIA?O]-D+,S]/FN<]\.T7O>'<G,[G5+><&%L/].N38[?8SEP=\&!9&'(]KQMW
M'0TTA [R,?0+IAV:Z8"HHZ_'7)Q^?_WDP/W1L8<S870O4_!IA.NDN<U6JS!'
MCH05<N?1/&9+ GP5'%H!^A74#FW$$AWT\:%*53$C@7\E#2_:''TV"J+?)K6%
M6IZ#J6&X X343I*-G+3+HM\0W9<6E?FN7@O-+[,^Q"&'-1'C?2T89.=^Z _P
M^Z'U*O\G6<7)7R=%S4Y=%\U?-]LQW.K>J$X<:6:3/AFO,>(.%@'3:K]#3U9F
M9IJS5L.B>@P7,A<7S9?V-'S4RCK&R4Z+4H%?4[_N?T(FH&A (K]&'(D!:OH<
M0+B0BQTB+7)+:E>%D7P%NVJ=Q$L2:.X\*HH[1HBNL35W[7*#:E=@T-\]O:0B
MWX5F%]TNBGU#O0L32HO1%]-3GZ^5\C>?Q&+R/#HFJX O2TV\&,2PKXAWX0B$
M!#I?NX^XFVB2E\:^MMV%'9W=Z*1(4FL!!C:5"/;MZ(X#G!X!=(YN:,IG/^I7
M.;-,!*G*8]]([L*.WG9T:MJ;,=WJN5W6F15!:R?66C"K##WX0V>+!^R[OUH_
M_'K!R"#@J?H#)5"TS?,DR:A_DC%N67&Z_(V$&3V.HT?>9#D9U_/BYU0$8&]3
M\AOZ:_=JG5FJ@+KVOO =]$TH!0)%C^F_!8'K=68YU;$)60*(/INC)=H=?LEE
M8M NQ>XA+K8L A.&OQ)@O]QZ.2$&>RRW+#@</FK?>L$U((7#'I;FBB34>[>(
M']]3SR]TF3VN3H+$"^,D8UL_>W$L^N./7[]\_#!Y.]F6X/^8D?7D,9GPR2$_
M,8X\6OO[_D>>=0V+ANCYV_;'_R$NJWU+:I_??KU%9JTU<DF0X/[]"6#!XTIU
M@"G4W/P5V?4/A6RWX^Q8T.\QI1G9TV>^(!'O2!WS_KV(V5IQ%L;+*HHZ@'FC
M==2 5>C<ZTF7&>1I&#85X0M I4.+B^@E\"'7-IL:_GH[MNFCQV#AG$]'CX&?
MD5#=QIME\)'6-.ZFLC6GRTBM>JN!J35+2N)C*V\1N\U7HOBXS7;J__,N%AL5
M=:MM%,$'5M-H&[K6_$$CM=F- H86VRJ'#ZNT*>PVUY;6XS;62TK$6D?=5'<*
MX".J::@[FM9\3F.N=^_X!N6(5_B;?N%;*P:_!=C[3G'OU6_+VEY]+V;4C^-;
M&E)QT:'D_HI(WX?E915%P>CW?[2EQ3$V*8Z"M_CT=B5Y/9\''F7)661H]0 Q
M, _]'U 9,8YM#$'A948I^YG%V2KW;0,8T0J N>C_3,B""X#-8X]&^<6]K6)&
M%K0"8!;Z/U:Q8 %@\^A](;X3=VCS5==2=@T@;SR-0F"T^S\"L6KS4MO&1WCJ
MI7Q_%:Y%')\):&E9,-[]GW'8X:VQ=&38\XT"UTAH81Q:E(7!P/=_,&$!O,'6
ML9<]<<1UN>*-X7%A'EO4I<'8]Y\'"+C8-%F*"'RN2:TS@O"7"H%IZ#]?3P<:
M-'9C#$ ;U>##D%H$GD]D"":@*,=0<U!8*8[=1114 1M?#2]7^1M:P7Q.Q6O2
MU$B3;1U@W@;9-=OSU@VCT9T9NZ9\2_(1N'8/]R8U[B@LZP 3.<BVVY[(;ABA
M$[G)W6U-GTP23-H@^_,^2%/C@4Y5:X5J39FN!C!U@VSJ^Z#.C,_(%$H& .'1
M+OT1!O; PF#B!O$/V!-GB0IZM\L?5.O:XQ3"8,X&\3'TT=FTJ(S=S\A]%A)V
M$20IY*1+4QS,RR NB Y]R60Y_HBGW RKRH(Y&,05T<MXAND K<91"R:,0F!*
M!G%+V%,"1 $]'%_Z3+TTX7.]&#R')(J32*YT"W'<.TX=#O"5W4=>$LS28#=3
MY0QHCN_QAJU\-2%B/4Q82PN"H1[L"JD):HU]&)Y2[2'!;@DPMH/=PC1A*[-H
M_&-'=7C/YH]@*(=\F$D+9<..D5$T!DIU"H\:(,$F[1J<YD"85!S]S!M"J<@)
M33P6Y.YF4YP40 [,R"";6D-X%-CNT<?C*O'0EP^?'K?-R'AZ910#TS'(7K9;
M!P&C,?8 'R71431/$S[9F"/85(7!C QSR-XMGE9O^>@GBNEZ^L1\$ _*PF >
MACEE[\2#P?+1L__*+[2>,B968MI+K5]:EUK%0[)\@[<6N7UY#7%$XRP)UY/I
M$^%,^!-1)8V27,LQ[KA6^ES/6_:T*-IM<C#)47I*\?U*(<V-5WE)_.L4-BS4
M.XK4G+&OPHIW#LI+[B?\_]5W6*0%\<'7-9\:V%+M1[X0>YA7,8$ OU[+_"-<
MRZQW(YI2M@RB'"+1I\S#1EL"]^)6QX$; L+8F[/%(BUM4+O+&F5PKVV!0(R5
MRN,LZDL%^*YOG02):56O+(U[44L!96MAHC1S9-1OT]]FS+MF=PD[3=*@>'WD
MDJ8/L6]@ ":)>U7+R(:-^6,?AFSS'4$&($UQW(M:1@Z,AN(-]U=Q^@^Z&4*I
MJ4O )'%O<AGIL#%_9&;.N+EQ1*N5!5^PJ4\)5&5Q[W49T=>;>$ 'YPU#3C)Z
M%Y\^"P<.Y2M"\=*5EZ]/E .:506XE\9L686 @=NU<@V_!7&8(W@]_\]X28_C
M+$K9^H(\67&FKP7WQIGE.KDK2 YPR3=?O_.=;3 /O%+;._)\1",Z#]+$BD]S
M3;C7UWK@% H6+J]\  E)5"IXOER)E\NXPO=!&*1KPTJE8U6XU^'VHDK)N!V,
M>)L T*I'5Q[W3EQ/Y)D!.: UDL08Z!ZO51[WHMQP[.+N!>N324P3OB&ZH;]G
M =M8:AAG;>1Q;\WUQ* ]8(Z<6>>GS'<!7RTL].?6GYOGUKGDI! =.0USH?0R
MU_A"?R:M*#J*0T5\.CGFL/ V=1FM J&#YBA:5Q[_*$F+>=V/HK%B['/HPSP<
M-;<;\Q'IB/F87X](,2[/%-V1?T#_XFZC&#[<\,8MMZ#7$(#.ST\<D83Z]<"L
M*6,BWUK^2/O1>EMF1M:Y@TL8L;4D\F=\[R56[Z:'>8?Y&G(SD#,K97\8^T=.
M.UW.G)O6;CA-41?'C6RP6@'H[!W[8*O2!W*\JRR,&]E@C;T39[F5-C-&_90M
M(_\L)++G>FJ*-XHB1S58HBZU$ZNU\]YW'"4^ X#>+(L<O=!AG&E;B@3[?\9/
M6WV 8XU*!CF P9(&O>5CWZ:KYIY@286/1ZP>OI%0W16T LBA"T B #9C= KI
M8A_2,TR"R"$->_M#L/N(5#/M,8M> CD881\^#O<L)3?GE\AGX7JQ?1%5':^K
M+HX;DF!%G\Y>C$YT^LR\&0L\7;>IE<$-%+!"NF49!KP_\]U^?L/FC 0L?U9:
M@[.L,.[YO17@:EM'1GZWCZTO?TOS=G#\$"UFGF)T,<G@'L5#>8!9[LCYW7F4
M!!RT.T;R0.*:8TQVB/>U>8A7BD]*^<E.!:.<T#34;Q'3/*U1EQ]E7Y&R\(ZR
M97(]OV,^_[YA(:LK#^P-0W0%,^SU?871YK'S[.5::%>JC2) J <9=JRPEIIV
M0,O1C?YW8M0Q<%.6 2^'G"%GQ[BQ0W.RD'[\</_U(U=EZL>KE&H<?,K"0,P'
M\>]986XP=_P$0E;XZ\H#*1C$MV=%@=EHE/$_UT-[35A6#HCZ((Z\#H.-S$C$
M >>.+:,4.-[4RP)1'\11UWFX:1N+.]J8P-<4!^(_B&-NG[$&G8)JP0M(2J H
M"H1^$*=:AP%'82H*[*?/JX"!4&^6!((^B'^M ^AR0U$P/\D*171H;\N ]U6.
M -VT#@7BFMMZL9@^DB!49XG7"4#!=V57J[7;27?:+ X#C^L[8_$F"*[N3ONS
MR9U653 AD3\1M5"?%T3PK-4M:3&E<[$I!,>)WBX5\>M*&/=< #%G/&]:6G:B
MO(%0C#R@R?6ZBM-2-8-WU$+<'0_>?IQIL!E]"$RR*'G@%MP'\>J!L"5YY\7+
M8ARLY0B^GA]E"2^5M$\4?OSP\5-S"*Q)BHR6&UF48.UKMB!1\*\<F^,X2C@1
M?M%D(G]6P^UZ?L87O9$7D/"VNL>53.^35-R*E;3=LOZ>JL<)9-]+>5BJYCY@
MVB>[\U"9Y'MM5HV(]Z%H<6ET.2))D%S/Z^;(QI;6E<-<3HPJ.Y(X]V\\3Z2\
MJ,T'YN%")X,S!E2C<VW0YLU,0@^@EW>I"[D?FTEL=,[N>+G4_6[H(V4)O4VY
M?K>K,)#$"O#>]Z6=J#H7F^1RDU*P2[--[N=+T19_^/#Y\\>\/=X>G5W^NOU8
M6T%-YQ*R,-%.?4RA;.L[NAXB)'0"6-T #MUN;S#9TVKR?1Q;HW67J?=[%B1!
M,>E>Q8S,\@+GD?=.UF]:,38U>3%WB1HF1163O [4D?\X7MZ7_EX^DDV3A*8U
M?<USFFT].//<)64+WEIK&B5<2\[2*B[_N65,FX*UK+!K?<CS73?2&W/@?EBZ
M- ^>\PJC17 ?TAP"Z2SX0]O%5PE-2BF4%OUS'/M/01ARZ)MF;-4U=U_+:G!Z
MKUHS0%<%"2/WRTYD-KJE!4@N]4%Q-3N=L7A%6;KF]I_R464E]K*RSMCRM^?2
M_VM2R>=N]FT-*(VUTB57K6Z0N3,"1'$ZH%(QJYYH5PMREP33V.B&7:!RJ3^>
M1X^\SIBM9?WO+^W)L"J--#&4G[>9\K1"6!-<2R70S*:30NX_ &I:$Y@9A)>R
MI;R@)*'2]>:/S2Y6%AW$SU+4#?:M-(OC=)8+OH&A])J/LD1X[@JE -W%).>&
M$T9.2:.KP"!X*9VE>+3WCCQ+>\RGUH-Z1?E)(8 TGI<:V\U+&B&L>:FE$FA>
MTDFASTM&:EKSDAD$EU9PER0BQ0V^W"W#J)<6N2 VCTA*.M''9B?:UI)OJJIZ
M]G^-TC@I&?4'SU<6-?5Y-%#_P@T-22J2ER50MX6HPJH&-^8M:];J9PD=$'.I
MQQV359"*8_BZ?K7.U8J1*06*DS2<*4KL2].U>59JED-*NBB >HA#WI*30J.K
M.*56LY)%%<A3E)R:9F)$6T1<ZC#?B;AF+G6X?VH%?6P*#S+;5+6#)Y6V0)]S
M1U4[?*[02K@Q-Z@PKD\! ,-?RG[FE+"([]K$*^AYZE)9+V@%7U1"$RXU*<1P
MYHV&\H 91"F!,Y<T]0','1H1[+G"0$=CUC#:[M(L<4L78CUY0U<Q$VX.63]I
M!5N40I.M%,Z"I:&[N9NH)9"67 U][!9;$&'DKF.BJ+G@@N/A4B>ZH L27I(T
MY>M$60=JQ3?D I-* J7I\>W@,DB+8.F([P3S"$T:B?A,&X>:9358WNPM/TTM
M04YMD#AR5^M$:,OG;0&42SWP-KM/Z.\9K_=4''!)>V$KL&$K-"FE<":!ANZ
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M*1S!)U4D:HD37TL)]/=R5JK(G3N\:ZJ"3<SPIJJ"W13I+FQ+T)C*VU0MCZ0
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M%XNY9,"/*7E4KRU%&'PD+<)<R8SJP!-^_$RL'KY\5EX.X?SKCBD!"WZ#OQ@
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M+=4\H,Z:K5JKWJQ=4'!Q<75S6;O%!=+%5P5/MHB%OP:*#;8ML+T%\YJY:(2
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MNBQIZ8@/?/"ES_Y;Z)>HWOD/H98[2#*R(KX)^?(9,CF$W280'PI= (TII,?
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M,'/A84;@,YV)*3*[&.(@6,U+6E82L"XQ0L4$ >,((U1D:#9^Z;W-YV4%RXI
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MHA"[BO9FC0NST+A<F\ 0%7ER3WK0L#"SEJ5V]=RH5$LLX--8EGSLVWC#Q50
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M68+F'4'S,J.8:<4VAF;C[RQOUB(VL@NQ-GSSIW\;]L?=.ZWU,XWY6U%-5>Y
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M"[@'0KQD\KVH8V^3TQPS+T_0-,VAP D2_F+32U>!"V:G3S4LM/>C6 .\!+J
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M"??(8^< L>L^KLN]$T2VA5[6NC4K=G7PN(:FRNLDS.*6),"6O H[2%P).+$
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MHNQEH5'IV!PGX,7T &MV3&+':(:Z 8;Y*W&^.7*<2"<;(:0#1$\%B,X/[7C
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M7]IM]KH["C [:^EW/YMZ^NQ07?W65ME1@-F%\Z%^?*Q4KA^T\1TMRK-6V5&
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M/]?O[X=/@R\/E]_M]-U@9R82KJ-\(S_1WUJZ'UZ='>EM_?9S[T?ICW\(3I(
MU/:+-M[G (YM>*@O3%%MK>1XN?7H5$BX3M#1N>SLL!3K]@QKX-=<G]D'<.4&
M>Y2J'3(091*?NA:IR8Y+CW['0GE@]4UX)3%K'6$#PD*'O^R!''7*'4CA]HJ1
M[?EC2<*!+RJ8*EU2%QFB(!<09)^ZKF6;;.#X&Q9;)04 =%!>B2XJO?W7]M0!
MJ@[1Q_\LRMET4<9X6K5R).VIO9YMO>A= (TQ2/V9AV]IG+QT<W7TB>QF$$8M
M-&OV\I\D31TX!Z (H[.X!Y*3 L"XXLBN1T&/:@B<2QR(/.D#21$U\:B(C&R=
MO\A)(1,%W3G47V(KA)Y4FF+K=6FTT;3#2;'#R4+L RHP^MXS6Q:?#X@+X8Y2
MNDM*/FP(#ZJQ%L,8I L&8DMZUMN6;7F.,3B03@+WF0KGI596(EG),P&=N9;1
M8&Z?,7Z:GFJC(U:@DW 7-V%Y>+5#\(.]H<[8@%^D0#>, SR.CP*\7+V[:+H6
M=A (:<&D::8#T1E <M5'V$AC$$6-X%4AJCDZ.E_H;O#%!ZES2R*W(8_ VN@U
ML3W8>1]VVL4QP^*RDGPF8J+J0#) R6USO1;TVP8HN>X 7R9\YMR6$FZ<*")U
M51%&3I&I;IJ,'T8X=R@6!.^ \S<-5>]N3G=Z4V';TEC8%G@4%0R[Q]BG8J+Z
M,#(!:-)O[H<GM^6KW.?O^=//[ZKBLS"]XO/D?GAT?%F]^_JE=OBC3=.A!8 D
M#J$/W6$]N[LP4R-RO3 J7'3'\8#@%<'7T1L#=$,F;F+.:&3R>9R#8J!$XD.M
M,(B&L3*0>G5#1?,[16'H%L5!-+"W@<':C@A"V<]ZDSEO:CC;E)P71;D?UG^E
M?W0>G4RZ4]@5FMYU/!W=U[0>&[G1'AMSYI5]=-+83">-W+8[:?CW_6K],G:*
M;':<J!N1%-LGY3Z=+@>47KL^/DMEP'"LG%<^'Y\=GU\+27(E'=6NJC=75[6+
M<ZER?@3_6SF]NZI=21<GTDGMO')>K55.I>K%^5'MVG_F\OCJYO2:'KFH'U]6
M\(NK#ZUAZ8O38[T@--UI>@Z9+4Z',D0;Z(97R;P$+?O!,R/&A.79LV/ 9"6:
MELLS*&P&AEF0"HO_UDU,V]*=5&1M\8##H0>TC[T7]PW+>J3DE?#=PO!&/:7+
M5$R9YL%SOLE,L1+.E :#B"?U5)KDK5#*V2QEO0&K0VM6EGB:;6KT41Z)"MZH
M'">\\=@/8X6OSB6]>N1!GJP6.4N81>(G-:5B24\Q8Q\L.9Z=PTU/--,Q"0@^
M!ZV+<MATS"O'Y"296])-SU!M X?E6HXP6#U7QPPCX?D!>Z ]X/WP5)Z.E4G_
M#0:E+)+X4N*COFX8_F?^8QQAXI\:^B,S!O%/T7IMND[\8XP?-/4>YC6,_0)0
MO1O]PM]*@QDZ>^8^ GP>0"V^Z8%.&K['LLF)H=H\(3\\+G=P3$&RABK2_R@\
M+4+C3=[IP4E19!O4ZRYE^(G()<.+,J1GU=8M#ZY6=QXY(0#]\%:$(A\.;J!)
M=-94/0?3*UR/PEHXHIH[4_16"S1Q/+K-8RO"UX4W"!N!1V%W:.K3K4T^QH%4
MZU(X#0[04KEB_FA:?8J:>0E[H??YZXI]H-#GP1GR^O%L.!\9>;@NQ?//B3FH
MILF/0U@*$#RQ["XPO/UO(TGML9QV?ZAP_D"Z%;EWZ(C!T)_5,'R?",7Z;#0Q
M\&J]'G(@\IO$0) *08!)+XPWDX1#""@CP9JL'TWHDJ661RE]U*'2P?=3*+JO
M8_":O309<&QRY0PX?Q2Q19$FV.L90'V(98;:/Y#N+ \AEE*U9YP_+DL=JP\O
M1O<?#U?B)FCC?%$MR/ &_H;YJG!T2C(S>$R2M\9T$,;B%QR^]'1+-UB8QG-U
M7!5I>[LI?W99.B9Z1RH-RW-3XTFG'RK(LKN[!<+ 9(YX^G73SW%'MN-G&?FY
MU_AO0V^Q?4=]QK^[3 .Y83(B"E6BC'#DO0P]IB2N;;5';T9*5)VH7]PRFR0&
M."-';X9NJX9#O(?*8]R^-1K&"*(7.B90[>F?QA*+@_SWR!=!&KRDAH$0OQ\M
M,1T_.YJ[=(&8A;PQ!GPCA30/B<,I$I+*17HZ3\0*0^-<'NWIL,M9N=)BSX'V
MP;^<M6]_VU*P;9%%QM,"P*:6+JZKL7SWW<3%W::4FIGR,U]D!',D&X-'5'JV
MU4.<QW[>B!,CZ7SP9=M6N]&TSR[53VA((8C$WY0#1>I>GE<09:33\SJ(Y:;:
M _%$<@>_D>#=;0;_2J'XQMP.4*HP\]2.HMGAR=E^_10U8%S5!7K#@$=';^@X
M>HP$/Q!AT,KYJG)Y)54MVS*!F&T/:;C%U>W?!E/6*J.J015*ZB+(W?D04$M[
MUCT[%1;VQ-.A8L5!@._ M)F/VN3S(C4^8-RC4DZ4@0@7N6J >ADR_8"'<\O!
M</WPLTI-"7@S<LLV-))5#F./N)*#=JG0WOWU!8?VS1%WT.,N?\K%96T2BS8:
MID)-#J3C7[MZ*TDXL_&BARDNWM7K(=8$B57+*5X_0Q186,W<!Q.*F8ZO^%U1
M^CGMH]*V&<?3OY"IC>A>:I,L,9Y2&A*?3H:O+'0CGK@N.C,ZO$B?^=3+J3&D
MO,9 ZGF@<:J.GT.!DI4VHEF.HV,Z(AGD(2FAIP6('33(Z-;@IR999WQSP8_)
M5OO"5 /^(]9TT<ZE<04V:Z/TM4"@4X[&,[$,'26H%:;<']!VT)L4><AJ8NTB
MF/2Q=X,UR0LJ_?XQ+4G)2%VXA(ZHGPR@@/S-L0S?KHV>QE ;S#B0DM)@4Z^;
M4?U!@VNBP:H-*!J2(1$;;6+C!,>SO#CI2ZKG=BS;KZ?EZ3M\C@A275R<!J1W
M+9*'\%]^]M (8JL&NK5]NHHF$TNP/5^_!K@:1NC@"2G3\O@NT'\64!UM:83>
M_#*K,;++Y??!G.-Y8HL1W0?-O5^:._+) W!]66&W',UAYQ<1 !K=@1KL@(LJ
M7X=<(^7!\B-$,TH1?!>C5.$FK#&9.M92F,'_WT%>-W?&T/G8TK:V-'_62OXC
M:V6'LE;R'UDK;YU\U^PW^,S],"G1B 7$RJ@@,P82*GN@S:$+1R21-VS*80#L
MXKYV$E #/QPO0J$H!44<@B+O(#<UG>2F2%!P\/=^83UOHY.B-\/[Q+;X"U01
M2 [BA!AGI B 'X1UJ2@V>36WHYJ)NY9)L<5O?&>4\ ^#0MT%N&+&1S^H,'"8
MWU1$I6Y@X@@MY@YD;! &VVP.*+'AR5-Y:GHKL(]%I)UKS,%>#J1;-(+5<'VZ
M!#_2T\>A>BGR8*'F,O)4-)ZANQ)MET*=L<<<K]'5>0[)N&$M,B["1] +CKGP
M&/>1*HT&%A"CKSMUSOK2$;[O*GQXKW)^=/4IZ1U!W3'J44V\!5"B>+B_P]=O
M(J)AU@!&:4.;O!ZH1?#HB65ITB' "<R%O2_UD\-/*8!H[  5@,R$ SM2VPH\
M?0&^!8X )PDGHC\_D&K\ D5K"9$#U(<K\8M.1E;&7C-42A#U4@A+B>N+>V&0
M#5,ZL+P%U5'5%7$!GE)#[2<TWZGZ28XY+##3A*<OIU10?UTQB!&SD@V=FE[L
MG5]4/_$& _S2:B(U@1.2Q!O:2GM'M?-//CZ*&+TILG#@#?0">(0T82 I'Y7_
M#QVE\"[T_?J&7FK4,]O#7!)W]+VA)AX215BN*EU0NZLPR$E&);^BZ%ZH%(1^
M+','$BS38&WQ:,J_7$+UNFKN!_&Y^JAV#F@C8-6KUBN?0'C ]GAPT]^<H=.\
MSM"/#08X/S1ZFIEM8_ &_XU9$IA&I#.>^])B&G5X:(,N;YOD^:87-@!9L'4)
M9>'\+H&<]0?'8S'@T29$BX>#_WH[+O,YAZ T9@^B7M@@7VYF]6^YD_5-LVG$
MK2)?)R?K8TT'0"<+T,>_1^*A"P,TW%MQO7N[#C-5N/\'#(EU;36[WJVBJJ+%
M][8$-JQM3Q50V37,(G!9$KC6MLX%"$JK9]F6HSL;7>C$ A5.?0&:*^96I;GU
M0;EK6)K>T\W- KF*J="@:SF4LKS1I<XM&]?9,3#W]!>UH9KO!<C'A@Z6@;-C
M0 :52>_9ZM R-HO-%;!'>LZ@V4'[9;,K89UX:[!C<':)Q*B'P7M!Z%- '3C6
MC@%ZJ*,'H#MH;AC0B- -WM=6-3:ZTB]^HET3@X?,5;'09M-R\ <>J&UM= WX
M>,>DWZ%NJ)N';<4PF-T>;'2-0X.]N,S<+?!607-GCHJU0!L]_)<!>CPQ?\3:
M,#MRU2:<:6>A+'VI7O]Z5Z"6ZH:W8]I<E1FL:;WHC8U+OGW=;!EJMTL^[\TJ
M-'"FALUV3/A5X1E;'[X'_GS):*X%VS$ @U5BM0SK1=V*(J=OW"RA ^T:C%W5
ML,#ZZVZ8@FF(@V0R^QGSIIR!X[)-+PE*A[ICT#9T4U.W9)AL'I^/5 -)<]=@
M;/5TS6K;;+,FV1:M[+JA/NL[)OV.U)[:-G1@S\,-(_.1KC:8RS;M9;9?]/:.
ML8LC+*O:M"/_,]B8MH6-*]'6W+ ?HVH!Q]@Q->/(,EF/#?4-GWS[$A">QAX-
MNP;MET%ST#0VKC9OS3?W0V_87*;O&*0]4)W9QOU'KZ':#;H-U7!WC5M[+K!2
M^$[;+,!O;.K4L%GJ>;8TU=XQUG'L--^OM8(1.&/77!S'0WBHJS?>390;#P3D
M,P7*ZZB2V9E$O(^-K&\C\U>_%#ZJ7W:H^J7P4?WR*A2R2UN(PCT]!O7TML>&
M;B =>!-9HB>Z.4VAC2^]SB30*3IN$CM9FZ/-MIRFNF/I+">&U[3,[:1GM3RS
MO6%S^4AOP8'4'3.6 <COU%@&G!ZJ.Y;9\EEMJ#TL3]IP(MSVH7W./-O"@^T6
MP+\,-!L=;QW#LJTG;QO.MZZ*Y5$;9B9U0T5]3I]FT;T"N$_1RMPXP[X0/3LW
M&QAAH"WMF*?ME.%3MMID[OOS!'UCO=[. =RS54?7K"VPC>TDB)^JKJ?M&)#/
MF(M5I>\AFOH95=9>!^S1'0.Q;KOJ4-U\W<[VV<8EZS+0/'8,WO!O9GB/8$:^
M^1RY*S#\/4/5=\PZO#!4\WUB]*]!S]ZY#*X0W-+%T?4'R+<"\NXVTO2W&(7"
M$[ELQVSR$,R;S]/?/JQW,%._KIJNM8VZ2Y[A13&4S=N+="K#VC'DKJOV>W7O
MJ2^[YOVHP\>FAE,8WDT&;A7;^CB#70.TK;ZW@F(Z4K,S-47C52#-VFH#5GEW
M#NO3 0[)VS5H>TW*\]IT*MVMU67F_SD2;[:V8?O<L>!N=\Q _^[!0^_2>H2/
MK2>/[1@?">$M_;Q\KR"'H^T6U"_A5^])&ZD8[LY545SB< )LO@=O>X>>D3/U
M!40$!WG\?*\*=LOQWIL.6+69LW--9>!CQ+EW*"E_@;G>VK%4_RO=T)BIMC;,
ML[=12O%#5]N[%L^]5C75>!?0K<+#N]90[9H97?U]>:S/X E8;'<!_:Y\UCZT
M=]!I?6WU=%OM;KHH&3-!FI;Y[!F.:FXV=@PGVKW^HC>V8P&V;=ABZ5@&,W2W
MHZN;;N**Y]DM"/]0;6;JFZ]#ONI:C]BD'%O44R?^#5^IVNWM6JL(4#"[NK -
MWY_RW-7;:P&W_]RVFIC_ D[>-":D]&U[,[&;HVU,OKUM[Z[6!;D_M3O6:U:-
MCNRWA/O]=^K"LT>&V(T,L&,VPUD67=VDD>:,)MOHSTPZ8DU&4T*RBBQETIF\
M+-E,\YK1H:_X>SZ$872V DU]+"J2:Z4*Z?4-NG@'A:,?&UF^E+;X44J[0Z6T
MQ8]2VK=)JFL>R%,S4T@Q)%C$*"D<X\OGF 63>D;D@QR(C4Q&\G\, I__B(\2
MEGIZCZ%"+H4CLY0,#2%&<U#'\5F2H7IFLT-#6CT;_I.BN:^LJ^HT$]5JH> J
MT$ KAXVO1(.TX%,;)T;Y4UP[7A?@(*:4@5V@.I$=-$?L?AF.Q:MN9*D=RZN2
M4\U$!50&4<R3[F7)$X]*S-2L)AQ _%,5#56Y));Y(*]XD]6/^5&KB)M;)C4
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M]=W3H+)H\&2WRVS\IX048 I_-MYQS[-[EH/.P19^!MQ)=:=@7HIPBMX-%Y]
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MYIN2P#=$:$ M@2_3%+"94[:0<ZU&IJ-P:LRX2FW"M$@YO*SKF%&,IP6:A:H
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MV\=)?4(S?38>Q#'<A5 0\-MOE_AA@2)1;HI5D,A88OE6E10X$F&;Y5=AMA.
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M:NV1*A5+>4DSFL-OD?5G0YU8@9^Z;YG?_P]02P$"% ,4    " !3@JU<1'J
M8W\?   E(0  "               @ $     ;&]G;RYJ<&=02P$"% ,4
M" !3@JU<9 _YP/H*   ?=@  $0              @ &E'P  <V)F;2TR,#(V
M,#,S,2YX<V102P$"% ,4    " !3@JU<1,I&_MX.  !,M   %0
M    @ '.*@  <V)F;2TR,#(V,#,S,5]C86PN>&UL4$L! A0#%     @ 4X*M
M7(&W"Q_N'   FL(! !4              ( !WSD  '-B9FTM,C R-C S,S%?
M9&5F+GAM;%!+ 0(4 Q0    ( %."K5P"1QB1RT0  -+@ P 5
M  "  0!7  !S8F9M+3(P,C8P,S,Q7VQA8BYX;6Q02P$"% ,4    " !3@JU<
MYT6IG \U  !T2 , %0              @ '^FP  <V)F;2TR,#(V,#,S,5]P
M<F4N>&UL4$L! A0#%     @ 4X*M7 ;+)PMM!P  Z#0  !,
M ( !0-$  '-U;G-H:6YE7V5X,S$P,2YH=&U02P$"% ,4    " !3@JU<M0!!
M@&$'  #9-   $P              @ '>V   <W5N<VAI;F5?97@S,3 R+FAT
M;5!+ 0(4 Q0    ( %."K5S>1M?\$@0  #<6   3              "  7#@
M  !S=6YS:&EN95]E>#,R,#$N:'1M4$L! A0#%     @ 4X*M7'2$0_WNU
MY_4( !@              ( !L^0  '-U;G-H:6YE7VDQ,'$M,#,S,3(V+FAT
7;5!+!08     "@ * (H"  #7N0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>sunshine_i10q-033126_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:SBFM="http://sunshinebiopharma.com/20260331"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sbfm-20260331.xsd" xlink:type="simple"/>
    <context id="From2026-01-01to2026-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-05-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <instant>2026-05-13</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-162024-04-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <startDate>2024-04-16</startDate>
            <endDate>2024-04-17</endDate>
        </period>
    </context>
    <context id="From2024-08-072024-08-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <startDate>2024-08-07</startDate>
            <endDate>2024-08-08</endDate>
        </period>
    </context>
    <context id="From2022-10-192022-10-20_custom_NoraPharmaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">SBFM:NoraPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-19</startDate>
            <endDate>2022-10-20</endDate>
        </period>
    </context>
    <context id="AsOf2022-10-20_custom_NoraPharmaMember_custom_MalekChamounMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">SBFM:MalekChamounMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">SBFM:NoraPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-20</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_NoraPharmaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">SBFM:NoraPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-04-212024-04-22_custom_NoraPharmaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">SBFM:NoraPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-21</startDate>
            <endDate>2024-04-22</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_NoraPharmaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">SBFM:NoraPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_VehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_VehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_AllDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">SBFM:AllDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_AllDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">SBFM:AllDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_Director1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">SBFM:Director1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_Director2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">SBFM:Director2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_Director3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">SBFM:Director3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_Director4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">SBFM:Director4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_Director5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">SBFM:Director5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_Director1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">SBFM:Director1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_Director2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">SBFM:Director2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_Director3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">SBFM:Director3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_Director4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">SBFM:Director4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_Director5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">SBFM:Director5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_SeriesBPreferredStockMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_SeriesBPreferredStockMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-022025-01-03_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-02</startDate>
            <endDate>2025-01-03</endDate>
        </period>
    </context>
    <context id="From2025-01-022025-01-03_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-02</startDate>
            <endDate>2025-01-03</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-04-02_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-02</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-04-02_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-02</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-04-03_us-gaap_CommonStockMember_custom_RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">SBFM:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-03</endDate>
        </period>
    </context>
    <context id="From2025-10-152025-10-16_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-15</startDate>
            <endDate>2025-10-16</endDate>
        </period>
    </context>
    <context id="From2025-10-152025-10-16_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-15</startDate>
            <endDate>2025-10-16</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_TradeableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:TradeableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_TradeableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:TradeableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_PreFunded2022WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:PreFunded2022WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_PreFunded2022WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:PreFunded2022WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_InvestorWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:InvestorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_InvestorWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:InvestorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_AprilWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:AprilWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_AprilWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:AprilWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_MayPreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:MayPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_MayPreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:MayPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_MayInvestorWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:MayInvestorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_MayInvestorWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:MayInvestorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_PreFunded2024WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:PreFunded2024WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_PreFunded2024WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:PreFunded2024WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_PreFunded2025WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:PreFunded2025WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_PreFunded2025WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:PreFunded2025WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-02-102024-02-11_custom_AprilWarrantsAndMayInvestorWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:AprilWarrantsAndMayInvestorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-10</startDate>
            <endDate>2024-02-11</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_TradeableWarrants1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:TradeableWarrants1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_TradeableWarrants1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:TradeableWarrants1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_InvestorWarrants1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:InvestorWarrants1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_InvestorWarrants1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:InvestorWarrants1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_SeriesBWarrants1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:SeriesBWarrants1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_SeriesBWarrants1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:SeriesBWarrants1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="CAD">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="Segment">
        <measure>SBFM:Segment</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2026-01-01to2026-03-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2026-01-01to2026-03-31" id="Fact000004">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2026-01-01to2026-03-31" id="Fact000005">2026</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2026-01-01to2026-03-31" id="Fact000006">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2026-01-01to2026-03-31" id="Fact000007">0001402328</dei:EntityCentralIndexKey>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0350"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0351"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2026-01-012026-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0381"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-01-012025-03-31_us-gaap_ComprehensiveIncomeMember"
      id="xdx2ixbrl0382"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0388"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2025-01-012025-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0390"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NumberOfOperatingSegments
      contextRef="From2026-01-01to2026-03-31"
      decimals="INF"
      id="xdx2ixbrl0408"
      unitRef="Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="From2026-01-01to2026-03-31"
      decimals="INF"
      id="xdx2ixbrl0410"
      unitRef="Segment">1</us-gaap:NumberOfReportableSegments>
    <dei:DocumentType contextRef="From2026-01-01to2026-03-31" id="Fact000016">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2026-01-01to2026-03-31" id="Fact000017">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2026-01-01to2026-03-31" id="Fact000018">2026-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2026-01-01to2026-03-31" id="Fact000019">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2026-01-01to2026-03-31" id="Fact000020">001-41282</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2026-01-01to2026-03-31" id="Fact000021">SUNSHINE BIOPHARMA INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2026-01-01to2026-03-31" id="Fact000022">CO</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2026-01-01to2026-03-31" id="Fact000023">20-5566275</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2026-01-01to2026-03-31" id="Fact000024">333 Las Olas Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2026-01-01to2026-03-31" id="Fact000025">CU4 Suite 433</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2026-01-01to2026-03-31" id="Fact000026">Fort Lauderdale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2026-01-01to2026-03-31" id="Fact000027">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2026-01-01to2026-03-31" id="Fact000028">33301</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2026-01-01to2026-03-31" id="Fact000029">954</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2026-01-01to2026-03-31" id="Fact000030">330-0684</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      id="Fact000031">Common     Stock</dei:Security12bTitle>
    <dei:Security12bTitle
      contextRef="From2026-01-012026-03-31_us-gaap_WarrantMember"
      id="Fact000032">Common     Stock Purchase Warrants</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      id="Fact000033">SBFM</dei:TradingSymbol>
    <dei:TradingSymbol
      contextRef="From2026-01-012026-03-31_us-gaap_WarrantMember"
      id="Fact000034">SBFMW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      id="Fact000035">NASDAQ</dei:SecurityExchangeName>
    <dei:SecurityExchangeName
      contextRef="From2026-01-012026-03-31_us-gaap_WarrantMember"
      id="Fact000036">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2026-01-01to2026-03-31" id="Fact000038">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2026-01-01to2026-03-31" id="Fact000039">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2026-01-01to2026-03-31" id="Fact000040">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2026-01-01to2026-03-31" id="Fact000041">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2026-01-01to2026-03-31" id="Fact000042">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2026-01-01to2026-03-31" id="Fact000043">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2026-05-13"
      decimals="INF"
      id="Fact000044"
      unitRef="Shares">5005945</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000052"
      unitRef="USD">6913013</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000053"
      unitRef="USD">9123308</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000055"
      unitRef="USD">4011632</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000056"
      unitRef="USD">3459864</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000058"
      unitRef="USD">13168430</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000059"
      unitRef="USD">13472025</us-gaap:InventoryNet>
    <us-gaap:DepositAssets
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000061"
      unitRef="USD">71740</us-gaap:DepositAssets>
    <us-gaap:DepositAssets
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000062"
      unitRef="USD">0</us-gaap:DepositAssets>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000064"
      unitRef="USD">618361</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000065"
      unitRef="USD">798384</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000067"
      unitRef="USD">24783176</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000068"
      unitRef="USD">26853581</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000073"
      unitRef="USD">516349</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000074"
      unitRef="USD">557370</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000076"
      unitRef="USD">1917812</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000077"
      unitRef="USD">1889370</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000079"
      unitRef="USD">713038</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000080"
      unitRef="USD">778846</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000082"
      unitRef="USD">3147199</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000083"
      unitRef="USD">3225586</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000085"
      unitRef="USD">27930375</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000086"
      unitRef="USD">30079167</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000094"
      unitRef="USD">5104868</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000095"
      unitRef="USD">5664212</us-gaap:AccountsPayableCurrent>
    <SBFM:EarnoutPayable
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000097"
      unitRef="USD">295797</SBFM:EarnoutPayable>
    <SBFM:EarnoutPayable
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000098"
      unitRef="USD">295797</SBFM:EarnoutPayable>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000100"
      unitRef="USD">268276</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000101"
      unitRef="USD">268276</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000103"
      unitRef="USD">209226</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000104"
      unitRef="USD">215637</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000106"
      unitRef="USD">5878167</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000107"
      unitRef="USD">6443922</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000112"
      unitRef="USD">535614</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000113"
      unitRef="USD">596785</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000115"
      unitRef="USD">535614</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000116"
      unitRef="USD">596785</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000118"
      unitRef="USD">6413781</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000119"
      unitRef="USD">7040707</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000127"
      unitRef="USDPShares">0.10</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000129"
      unitRef="USDPShares">0.10</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2026-03-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000131"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000133"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2026-03-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000135"
      unitRef="Shares">130000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2026-03-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000137"
      unitRef="Shares">130000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000139"
      unitRef="Shares">130000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000141"
      unitRef="Shares">130000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000124"
      unitRef="USD">13000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000125"
      unitRef="USD">13000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000146"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000148"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000150"
      unitRef="Shares">3000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000152"
      unitRef="Shares">3000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000154"
      unitRef="Shares">4905945</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000156"
      unitRef="Shares">4905945</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000158"
      unitRef="Shares">4905945</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000160"
      unitRef="Shares">4905945</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000143"
      unitRef="USD">4905</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000144"
      unitRef="USD">4905</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000162"
      unitRef="USD">98100990</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000163"
      unitRef="USD">98100990</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000165"
      unitRef="USD">-343306</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000166"
      unitRef="USD">-65309</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000168"
      unitRef="USD">-76258995</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000169"
      unitRef="USD">-75015126</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000171"
      unitRef="USD">21516594</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000172"
      unitRef="USD">23038460</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000174"
      unitRef="USD">27930375</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000175"
      unitRef="USD">30079167</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000177"
      unitRef="USD">8088765</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000178"
      unitRef="USD">8901341</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000180"
      unitRef="USD">5907775</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000181"
      unitRef="USD">6170915</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000183"
      unitRef="USD">2180990</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000184"
      unitRef="USD">2730426</us-gaap:GrossProfit>
    <us-gaap:ProfessionalFees
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000189"
      unitRef="USD">175809</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000190"
      unitRef="USD">293759</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000192"
      unitRef="USD">143148</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000193"
      unitRef="USD">365287</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:NoninterestExpenseDirectorsFees
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000195"
      unitRef="USD">100000</us-gaap:NoninterestExpenseDirectorsFees>
    <us-gaap:NoninterestExpenseDirectorsFees
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000196"
      unitRef="USD">100000</us-gaap:NoninterestExpenseDirectorsFees>
    <us-gaap:LegalFees
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000198"
      unitRef="USD">89076</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000199"
      unitRef="USD">27199</us-gaap:LegalFees>
    <us-gaap:MarketingExpense
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000201"
      unitRef="USD">250223</us-gaap:MarketingExpense>
    <us-gaap:MarketingExpense
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000202"
      unitRef="USD">398361</us-gaap:MarketingExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000204"
      unitRef="USD">871608</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000205"
      unitRef="USD">925878</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000207"
      unitRef="USD">31724</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000208"
      unitRef="USD">215277</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SalariesAndWages
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000210"
      unitRef="USD">1708484</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000211"
      unitRef="USD">1525446</us-gaap:SalariesAndWages>
    <SBFM:Taxes
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000213"
      unitRef="USD">129656</SBFM:Taxes>
    <SBFM:Taxes
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000214"
      unitRef="USD">110176</SBFM:Taxes>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000216"
      unitRef="USD">76859</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000217"
      unitRef="USD">64793</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000219"
      unitRef="USD">3576587</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000220"
      unitRef="USD">4026176</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000222"
      unitRef="USD">-1395597</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000223"
      unitRef="USD">-1295750</us-gaap:OperatingIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000225"
      unitRef="USD">-18</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000226"
      unitRef="USD">451</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:InterestIncomeDebtSecuritiesOperating
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000228"
      unitRef="USD">48426</us-gaap:InterestIncomeDebtSecuritiesOperating>
    <us-gaap:InterestIncomeDebtSecuritiesOperating
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000229"
      unitRef="USD">75367</us-gaap:InterestIncomeDebtSecuritiesOperating>
    <us-gaap:OtherIncome
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000231"
      unitRef="USD">103320</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000232"
      unitRef="USD">0</us-gaap:OtherIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000234"
      unitRef="USD">151728</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000235"
      unitRef="USD">75818</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000237"
      unitRef="USD">-1243869</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000238"
      unitRef="USD">-1219932</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000240"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000241"
      unitRef="USD">-40161</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000243"
      unitRef="USD">-1243869</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000244"
      unitRef="USD">-1179771</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000246"
      unitRef="USD">-277997</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000247"
      unitRef="USD">26189</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000249"
      unitRef="USD">-1521866</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000250"
      unitRef="USD">-1153582</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2026-01-01to2026-03-31"
      decimals="INF"
      id="Fact000252"
      unitRef="USDPShares">-0.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-012025-03-31"
      decimals="INF"
      id="Fact000253"
      unitRef="USDPShares">-0.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-01-01to2026-03-31"
      decimals="INF"
      id="Fact000255"
      unitRef="Shares">4905945</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-012025-03-31"
      decimals="INF"
      id="Fact000256"
      unitRef="Shares">2703293</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000261"
      unitRef="USD">-1243869</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000262"
      unitRef="USD">-1179771</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000267"
      unitRef="USD">76859</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000268"
      unitRef="USD">64793</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000270"
      unitRef="USD">609601</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000271"
      unitRef="USD">-426673</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000273"
      unitRef="USD">-78399</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000274"
      unitRef="USD">568834</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000276"
      unitRef="USD">71740</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000277"
      unitRef="USD">70457</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000279"
      unitRef="USD">-154726</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000280"
      unitRef="USD">-139931</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <SBFM:IncreaseDecreaseInReductionInRightofuseAsset
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000282"
      unitRef="USD">52788</SBFM:IncreaseDecreaseInReductionInRightofuseAsset>
    <SBFM:IncreaseDecreaseInReductionInRightofuseAsset
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000283"
      unitRef="USD">35993</SBFM:IncreaseDecreaseInReductionInRightofuseAsset>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000285"
      unitRef="USD">-455836</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000286"
      unitRef="USD">-486009</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000288"
      unitRef="USD">-54001</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000289"
      unitRef="USD">-17160</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000291"
      unitRef="USD">175</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000292"
      unitRef="USD">-40161</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000294"
      unitRef="USD">-2072100</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000295"
      unitRef="USD">-1695002</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000300"
      unitRef="USD">99389</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000301"
      unitRef="USD">204527</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000303"
      unitRef="USD">5129</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000304"
      unitRef="USD">7490</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000306"
      unitRef="USD">-104518</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000307"
      unitRef="USD">-212017</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000312"
      unitRef="USD">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000313"
      unitRef="USD">355297</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000315"
      unitRef="USD">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000316"
      unitRef="USD">355297</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000318"
      unitRef="USD">9123308</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000319"
      unitRef="USD">9686529</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000321"
      unitRef="USD">-2176618</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000322"
      unitRef="USD">-1551722</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000324"
      unitRef="USD">-33677</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000325"
      unitRef="USD">-10197</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000327"
      unitRef="USD">6913013</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact000328"
      unitRef="USD">8124610</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000333"
      unitRef="USD">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000334"
      unitRef="USD">0</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000336"
      unitRef="USD">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000337"
      unitRef="USD">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000346"
      unitRef="Shares">4905945</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000339"
      unitRef="USD">4905</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000340"
      unitRef="USD">98100990</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000348"
      unitRef="Shares">130000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000341"
      unitRef="USD">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_ComprehensiveIncomeMember"
      decimals="0"
      id="Fact000342"
      unitRef="USD">-65309</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000343"
      unitRef="USD">-75015126</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000344"
      unitRef="USD">23038460</us-gaap:StockholdersEquity>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2026-01-012026-03-31_us-gaap_ComprehensiveIncomeMember"
      decimals="0"
      id="Fact000353"
      unitRef="USD">-277997</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000354"
      unitRef="USD">-1243869</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000355"
      unitRef="USD">-1521866</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000364"
      unitRef="Shares">4905945</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000357"
      unitRef="USD">4905</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000358"
      unitRef="USD">98100990</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-03-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000366"
      unitRef="Shares">130000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000359"
      unitRef="USD">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_ComprehensiveIncomeMember"
      decimals="0"
      id="Fact000360"
      unitRef="USD">-343306</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000361"
      unitRef="USD">-76258995</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000362"
      unitRef="USD">21516594</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000375"
      unitRef="Shares">2580098</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000368"
      unitRef="USD">2580</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000369"
      unitRef="USD">93354907</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000377"
      unitRef="Shares">130000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000370"
      unitRef="USD">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_ComprehensiveIncomeMember"
      decimals="0"
      id="Fact000371"
      unitRef="USD">-829959</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000372"
      unitRef="USD">-69039774</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000373"
      unitRef="USD">23500754</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000386"
      unitRef="Shares">127443</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000379"
      unitRef="USD">127</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000380"
      unitRef="USD">355171</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000384"
      unitRef="USD">355298</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2025-01-012025-03-31_us-gaap_ComprehensiveIncomeMember"
      decimals="0"
      id="Fact000391"
      unitRef="USD">26189</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000392"
      unitRef="USD">-1179771</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000393"
      unitRef="USD">-1153582</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000402"
      unitRef="Shares">2707541</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000395"
      unitRef="USD">2707</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000396"
      unitRef="USD">93710078</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000404"
      unitRef="Shares">130000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000397"
      unitRef="USD">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_ComprehensiveIncomeMember"
      decimals="0"
      id="Fact000398"
      unitRef="USD">-803770</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000399"
      unitRef="USD">-70219545</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact000400"
      unitRef="USD">22702470</us-gaap:StockholdersEquity>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000406">&lt;p id="xdx_802_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z2DeaOnl6Xod" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note
1 &#x2013;&#160;&lt;span id="xdx_823_z8EtEQjhjm5g"&gt;Description of Business&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;The
Company was incorporated under the name Mountain West Business Solutions, Inc. on August 31, 2006, in the State of Colorado. Effective
October 15, 2009, the Company acquired Sunshine Biopharma Inc. in a transaction classified as a reverse acquisition. Upon completion
of the reverse acquisition, the Company changed its name to Sunshine Biopharma Inc. and began operating as a pharmaceutical
company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;Sunshine
Biopharma has two wholly owned subsidiaries: (i) Nora Pharma Inc. (&#x201c;Nora Pharma&#x201d;), a Canadian corporation with a portfolio
of pharmaceutical products consisting of 60 generic prescription drugs on the market in Canada, and (ii) Sunshine Biopharma Canada Inc.
(&#x201c;Sunshine Canada&#x201d;), a Canadian corporation which develops and sells nonprescription, over-the-counter (&#x201c;OTC&#x201d;)
supplements. The Company operates the two subsidiaries as a &lt;span id="xdx_901_eus-gaap--NumberOfOperatingSegments_dxL_uSegment_c20260101__20260331_zNOp7mPIYGI" title="Number of operating segments::XDX::1"&gt;&lt;span id="xdx_90A_eus-gaap--NumberOfReportableSegments_dxL_uSegment_c20260101__20260331_zb7KR8S8GwB8" title="Number of reportable segments::XDX::1"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0408"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0410"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; business segment. Sales of the OTC supplements represent less than
3% of the Company&#x2019;s total annual sales.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;The
Company is not subject to material customer concentration risks as it sells its products directly to pharmacies in several Canadian Provinces.
However, Provincial governments in Canada reimburse patients for their prescription drug expenditures to various degrees under drug reimbursement
programs, making generic drugs prices highly dependent on government policies which may change over time. The most recent negotiations
between the pan-Canadian Pharmaceutical Alliance (&#x201c;pCPA&#x201d;), the entity that negotiates drug prices on behalf of the government,
and the Canadian Generic Pharmaceutical Association (&#x201c;CGPA&#x201d;) resulted in updated generic pricing for certain products which
took effect on October 1, 2023. The updated prices are valid for three years and the agreement contains an option to extend for an additional
two years. On February 10, 2024, the Canadian federal government joined the generic drug reimbursement program as a payor under the Pharmacare
Act. This development further strengthened the Canadian generic drug market, which is the Company&#x2019;s current focus.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;In
addition, the Company is engaged in the development of the following proprietary drugs:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;K1.1 mRNA, a lipid nano-particle
    (LNP) targeted for liver cancer&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;SBFM-PL4, a protease inhibitor
    for treatment of SARS Coronavirus infections&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000412">&lt;p id="xdx_80A_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zzs47lfM0e63" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note
2 &#x2013;&#160;&lt;span id="xdx_82A_zp5BfBoUACYi"&gt;Basis of Presentation&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;The
unaudited financial statements of the Company for the three month periods ended March 31, 2026 and 2025 have been prepared in accordance
with accounting principles generally accepted in the United States of America for interim financial information and pursuant to the requirements
for reporting on Form 10-Q and Regulation S-X. Accordingly, they do not include all the information and footnotes required by accounting
principles generally accepted in the United States of America for complete financial statements. However, such information reflects all
adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation
of the financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results
to be obtained for a full fiscal year. The balance sheet information as of December 31, 2025, was derived from the audited financial
statements included in the Company's financial statements as of and for the year ended December 31, 2025, included in the Company&#x2019;s
Annual Report on Form 10-K filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on April 3, 2026. These financial
statements should be read in conjunction with that report.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;











</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <SBFM:ReverseStockSplitTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000418">&lt;p id="xdx_80C_ecustom--ReverseStockSplitTextBlock_zMBrGX1JIYm7" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note
3 &#x2013;&#160;&lt;span id="xdx_82C_zqhTk9skmFO9"&gt;Reverse Stock Splits&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;Effective
April 17, 2024 and August 8, 2024, the Company completed &lt;span id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20240416__20240417_zZEm5MJxDUae" title="Reverse stock split"&gt;1-for-100&lt;/span&gt; and &lt;span id="xdx_907_eus-gaap--StockholdersEquityReverseStockSplit_c20240807__20240808_zEdhenjeYUZf" title="Reverse stock split"&gt;1-for-20&lt;/span&gt; reverse splits of its common stock, respectively. The
Company had previously completed three (3) reverse stock splits including a 1-for-200 reverse split on February 9, 2022, and two 1-for-20
reverse splits, one in 2019 and the other in 2020. The Company&#x2019;s financial statements included in this report reflect all five
(5) reverse stock splits on a retroactive basis for all periods presented and for all references to common stock, unless specifically
stated otherwise.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; background-color: white"&gt;On
February 18, 2026, Dr. Steve N. Slilaty, the Company&#x2019;s chief executive officer and holder of the majority of the voting power of
the stockholders of the Company, approved by written consent an authorization of the Company&#x2019;s board of directors to effect a reverse
split of the Company&#x2019;s issued and outstanding common stock in a ratio of up to 1-for-10, with the board of directors having the
discretion as to whether or not to effect the reverse split and at what ratio. The shareholder consent became effective March 23, 2026
(20 days after the definitive information statement relating to such consent was mailed to stockholders).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</SBFM:ReverseStockSplitTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2024-04-162024-04-17" id="Fact000420">1-for-100</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2024-08-072024-08-08" id="Fact000422">1-for-20</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000424">&lt;p id="xdx_80E_eus-gaap--MergersAcquisitionsAndDispositionsDisclosuresTextBlock_zkAWd58ZUlv3" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note
4 &#x2013;&#160;&lt;span id="xdx_827_zq1M8UeYyyqf"&gt;Acquisition of Nora Pharma Inc.&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;On
October 20, 2022, the Company acquired all of the issued and outstanding shares of Nora Pharma Inc. (&#x201c;Nora Pharma&#x201d;), a Canadian
privately held pharmaceutical company. The purchase price for the shares was $&lt;span id="xdx_906_eus-gaap--BusinessCombinationConsiderationTransferred1_pp0p0_c20221019__20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zkeRq1qaKeY5" title="Purchase price of shares"&gt;18,860,637&lt;/span&gt; which was paid in cash ($&lt;span id="xdx_90D_eus-gaap--PaymentsToAcquireBusinessesGross_pp0p0_c20221019__20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zBLZdlIByqbl" title="Payments to acquire shares"&gt;14,346,637&lt;/span&gt;) and by
the issuance of &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20221019__20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zhy3BozGrXO4" title="Stock issued for acquisition"&gt;1,850&lt;/span&gt; shares of the Company&#x2019;s common stock valued at $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pp0p0_c20221019__20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zQYFB46JHll9" title="Stock issued for acquisition, value"&gt;4,514,000&lt;/span&gt; or $2,440.00 per share. Nora Pharma sells generic
pharmaceutical products in Canada. Nora Pharma&#x2019;s operations are authorized by a Drug Establishment License issued by Health Canada.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;As
part of the consideration for Nora Pharma, the Company agreed to a $&lt;span id="xdx_905_ecustom--EarnoutPayable_iI_uCAD_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember__srt--CounterpartyNameAxis__custom--MalekChamounMember_zb2Li8AFI7L6" title="Earnout payable"&gt;5,000,000&lt;/span&gt; CAD ($&lt;span id="xdx_90A_ecustom--EarnoutPayable_iI_uUSD_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember__srt--CounterpartyNameAxis__custom--MalekChamounMember_zOnq5VD5kxf6" title="Earnout payable"&gt;3,632,000&lt;/span&gt; USD) earnout amount payable to Mr. Malek
Chamoun, the seller of Nora Pharma. The earnout is payable in the form of twenty (20) payments of $250,000 CAD for every $1,000,000 CAD
increase in gross sales (as defined in the Purchase Agreement) above Nora Pharma&#x2019;s June 30, 2022 gross sales, provided that his
employment with the Company is not terminated pursuant to the Company&#x2019;s employment agreement with him. The total earnout amount
of $3,632,000 has been recorded as a salary payable. During the fiscal year ended December 31, 2023, the Company paid an earnout amount
of $&lt;span id="xdx_905_ecustom--EarnoutLiabilityExpenseFirstInstallment_uCAD_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zY3tWokHGfld" title="Earnout liability expense, first installment"&gt;1,426,914&lt;/span&gt; CAD (approximately $&lt;span id="xdx_903_ecustom--EarnoutLiabilityExpenseFirstInstallment_uUSD_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zs0NxXrA9d3"&gt;1,036,500&lt;/span&gt; USD) for the fiscal year ended December 31, 2022. On April 22, 2024, the Company paid another
earnout amount of $&lt;span id="xdx_90E_ecustom--EarnoutLiabilityExpenseSecondInstallment_uCAD_c20240421__20240422__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zfZrJ5g5oqC1" title="Earnout liability expense, second installment"&gt;3,093,878&lt;/span&gt; CAD (approximately $&lt;span id="xdx_902_ecustom--EarnoutLiabilityExpenseSecondInstallment_uUSD_c20240421__20240422__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zGaPIbLfbqY2"&gt;2,247,400&lt;/span&gt; USD) for the fiscal year ended December 31, 2023. As of December 31, 2025,
the remaining earnout balance was $&lt;span id="xdx_906_ecustom--EarnoutLiabilityBalance_uCAD_c20250101__20251231__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zuOeX3DLC4ni" title="Remaining earnout balance"&gt;479,208&lt;/span&gt; CAD ($&lt;span id="xdx_901_ecustom--EarnoutLiabilityBalance_uUSD_c20250101__20251231__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_z2Y22ItIazQc"&gt;295,797&lt;/span&gt; USD). This remaining earnout amount is currently in dispute following dismissal
of Mr. Chamoun by the Company on April 14, 2025 (See Note 15).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2022-10-192022-10-20_custom_NoraPharmaMember"
      decimals="0"
      id="Fact000426"
      unitRef="USD">18860637</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="From2022-10-192022-10-20_custom_NoraPharmaMember"
      decimals="0"
      id="Fact000428"
      unitRef="USD">14346637</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2022-10-192022-10-20_custom_NoraPharmaMember"
      decimals="INF"
      id="Fact000430"
      unitRef="Shares">1850</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2022-10-192022-10-20_custom_NoraPharmaMember"
      decimals="0"
      id="Fact000432"
      unitRef="USD">4514000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <SBFM:EarnoutPayable
      contextRef="AsOf2022-10-20_custom_NoraPharmaMember_custom_MalekChamounMember"
      decimals="0"
      id="Fact000434"
      unitRef="CAD">5000000</SBFM:EarnoutPayable>
    <SBFM:EarnoutPayable
      contextRef="AsOf2022-10-20_custom_NoraPharmaMember_custom_MalekChamounMember"
      decimals="0"
      id="Fact000436"
      unitRef="USD">3632000</SBFM:EarnoutPayable>
    <SBFM:EarnoutLiabilityExpenseFirstInstallment
      contextRef="From2023-01-012023-12-31_custom_NoraPharmaMember"
      decimals="0"
      id="Fact000438"
      unitRef="CAD">1426914</SBFM:EarnoutLiabilityExpenseFirstInstallment>
    <SBFM:EarnoutLiabilityExpenseFirstInstallment
      contextRef="From2023-01-012023-12-31_custom_NoraPharmaMember"
      decimals="0"
      id="Fact000439"
      unitRef="USD">1036500</SBFM:EarnoutLiabilityExpenseFirstInstallment>
    <SBFM:EarnoutLiabilityExpenseSecondInstallment
      contextRef="From2024-04-212024-04-22_custom_NoraPharmaMember"
      decimals="0"
      id="Fact000441"
      unitRef="CAD">3093878</SBFM:EarnoutLiabilityExpenseSecondInstallment>
    <SBFM:EarnoutLiabilityExpenseSecondInstallment
      contextRef="From2024-04-212024-04-22_custom_NoraPharmaMember"
      decimals="0"
      id="Fact000442"
      unitRef="USD">2247400</SBFM:EarnoutLiabilityExpenseSecondInstallment>
    <SBFM:EarnoutLiabilityBalance
      contextRef="From2025-01-012025-12-31_custom_NoraPharmaMember"
      decimals="0"
      id="Fact000444"
      unitRef="CAD">479208</SBFM:EarnoutLiabilityBalance>
    <SBFM:EarnoutLiabilityBalance
      contextRef="From2025-01-012025-12-31_custom_NoraPharmaMember"
      decimals="0"
      id="Fact000445"
      unitRef="USD">295797</SBFM:EarnoutLiabilityBalance>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000447">&lt;p id="xdx_801_eus-gaap--IntangibleAssetsDisclosureTextBlock_zRMSdqXcZ4Z2" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note
5 &#x2013;&#160;&lt;span id="xdx_823_zwxlD5TNgw8b"&gt;Intangible Assets&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;Intangible assets
consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zrHEKQakZ3Sc" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details - Intangible assets)"&gt;
  &lt;tr style="border-bottom: Black 1pt solid; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BC_zjUH5gaAFaSf" style="display: none"&gt;Schedule of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Period Ended&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31, 2026&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2025&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%; text-align: left"&gt;Intangible assets at beginning of period, net&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_c20260101__20260331_zD5wRK6fN5Z5" style="width: 15%; text-align: right" title="Intangible assets at beginning of period"&gt;1,889,370&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_c20250101__20251231_zdMKpexTbQc5" style="width: 15%; text-align: right" title="Intangible assets at beginning of period"&gt;3,019,717&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;Purchase of additional intangible assets (drug licenses &amp;amp; dossiers)&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_c20260101__20260331_zDAq4Jptygvk" style="border-bottom: Black 1pt solid; text-align: right" title="Purchase of additional intangible assets"&gt;68,147&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_c20250101__20251231_zn7s50IPzU4d" style="border-bottom: Black 1pt solid; text-align: right" title="Purchase of additional intangible assets"&gt;774,355&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_c20260101__20260331_zBoFOLvWnGf7" style="text-align: right" title="Intangible assets at ending of period"&gt;1,957,517&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_c20250101__20251231_zRrJJxlOcb3b" style="text-align: right" title="Intangible assets at ending of period"&gt;3,794,072&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less impairment*&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_d0_c20260101__20260331_zucHPxh3hrYc" style="text-align: right" title="Less impairment"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_d0_c20250101__20251231_z8WFuNRTXsY8" style="text-align: right" title="Less impairment"&gt;(1,748,247&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;Less accumulated amortization&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20260331_zBjftBibnAV4" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated amortization"&gt;(39,705&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20251231_z0qHyqKRU3h7" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated amortization"&gt;(156,455&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;Intangible assets, net&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20260331_zv2kVbMPjWMg" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net"&gt;1,917,812&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20251231_zzC3glplQt55" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net"&gt;1,889,370&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"&gt;*
The impairment was a result of the determination by the Company that certain product licenses could not be commercialized&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p id="xdx_8A5_zLMyeyqstI9l" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;











</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000449">&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zrHEKQakZ3Sc" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details - Intangible assets)"&gt;
  &lt;tr style="border-bottom: Black 1pt solid; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BC_zjUH5gaAFaSf" style="display: none"&gt;Schedule of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Period Ended&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31, 2026&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2025&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%; text-align: left"&gt;Intangible assets at beginning of period, net&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_c20260101__20260331_zD5wRK6fN5Z5" style="width: 15%; text-align: right" title="Intangible assets at beginning of period"&gt;1,889,370&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_c20250101__20251231_zdMKpexTbQc5" style="width: 15%; text-align: right" title="Intangible assets at beginning of period"&gt;3,019,717&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;Purchase of additional intangible assets (drug licenses &amp;amp; dossiers)&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_c20260101__20260331_zDAq4Jptygvk" style="border-bottom: Black 1pt solid; text-align: right" title="Purchase of additional intangible assets"&gt;68,147&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_c20250101__20251231_zn7s50IPzU4d" style="border-bottom: Black 1pt solid; text-align: right" title="Purchase of additional intangible assets"&gt;774,355&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_c20260101__20260331_zBoFOLvWnGf7" style="text-align: right" title="Intangible assets at ending of period"&gt;1,957,517&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_c20250101__20251231_zRrJJxlOcb3b" style="text-align: right" title="Intangible assets at ending of period"&gt;3,794,072&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less impairment*&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_d0_c20260101__20260331_zucHPxh3hrYc" style="text-align: right" title="Less impairment"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_d0_c20250101__20251231_z8WFuNRTXsY8" style="text-align: right" title="Less impairment"&gt;(1,748,247&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;Less accumulated amortization&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20260331_zBjftBibnAV4" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated amortization"&gt;(39,705&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20251231_z0qHyqKRU3h7" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated amortization"&gt;(156,455&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;Intangible assets, net&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20260331_zv2kVbMPjWMg" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net"&gt;1,917,812&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20251231_zzC3glplQt55" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net"&gt;1,889,370&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"&gt;*
The impairment was a result of the determination by the Company that certain product licenses could not be commercialized&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;/p&gt;

</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000451"
      unitRef="USD">1889370</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000453"
      unitRef="USD">3019717</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000455"
      unitRef="USD">68147</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2025-01-012025-12-31"
      decimals="0"
      id="Fact000457"
      unitRef="USD">774355</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000459"
      unitRef="USD">1957517</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000461"
      unitRef="USD">3794072</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000463"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2025-01-012025-12-31"
      decimals="0"
      id="Fact000465"
      unitRef="USD">-1748247</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000467"
      unitRef="USD">39705</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000469"
      unitRef="USD">156455</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000471"
      unitRef="USD">1917812</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000473"
      unitRef="USD">1889370</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000479">&lt;p id="xdx_80E_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zMIx7KkCNkCd" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note
6 &#x2013;&#160;&lt;span id="xdx_823_zbYbj6wcgaPi"&gt;Plant, Property and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;Property,
plant and equipment are stated at cost. Depreciation of property, plant and equipment begins in the month when the asset is placed into
service and is provided using the straight-line method for financial reporting purposes at rates based on the estimated useful lives
of the assets. Estimated useful lives range from three to twenty years. Property, plant and equipment consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--PropertyPlantAndEquipmentTextBlock_z6mp9R2mdPu1" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Plant, Property and Equipment (Details)"&gt;
  &lt;tr style="border-bottom: Black 1pt solid; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B6_z40TVLdXvfu8" style="display: none"&gt;Schedule
    of plant property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20260331_z72JAJAYhzSe" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20251231_zAyr9df3LW6j" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Period Ended&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31, 2026&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2025&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zjMYTRzIS1O3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%"&gt;Equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;352,278&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;335,464&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zJ0IJRA1hAe7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Computer equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;79,029&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69,139&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zq5fmfY3cMEf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;44,702&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45,462&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_d0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z22PQyDrIIFa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;91,157&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;92,706&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zZwQlgZRqdcl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;Vehicles&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;498,995&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;507,478&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzbhx_zBlydmVUX0ye" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,066,161&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,070,249&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzbhx_zeiRvQSraykh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;Less accumulated depreciation&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(549,812&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(512,879&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzbhx_zBsJlbwC3TO3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;Plant, property and equipment, net&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;516,349&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;557,370&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000481">&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--PropertyPlantAndEquipmentTextBlock_z6mp9R2mdPu1" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Plant, Property and Equipment (Details)"&gt;
  &lt;tr style="border-bottom: Black 1pt solid; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B6_z40TVLdXvfu8" style="display: none"&gt;Schedule
    of plant property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20260331_z72JAJAYhzSe" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20251231_zAyr9df3LW6j" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Period Ended&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31, 2026&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2025&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zjMYTRzIS1O3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%"&gt;Equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;352,278&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;335,464&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zJ0IJRA1hAe7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Computer equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;79,029&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69,139&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zq5fmfY3cMEf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;44,702&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45,462&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_d0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z22PQyDrIIFa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;91,157&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;92,706&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zZwQlgZRqdcl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;Vehicles&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;498,995&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;507,478&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzbhx_zBlydmVUX0ye" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,066,161&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,070,249&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzbhx_zeiRvQSraykh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;Less accumulated depreciation&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(549,812&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(512,879&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzbhx_zBsJlbwC3TO3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;Plant, property and equipment, net&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;516,349&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;557,370&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2026-03-31_us-gaap_EquipmentMember"
      decimals="0"
      id="Fact000483"
      unitRef="USD">352278</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-12-31_us-gaap_EquipmentMember"
      decimals="0"
      id="Fact000484"
      unitRef="USD">335464</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2026-03-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      id="Fact000486"
      unitRef="USD">79029</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-12-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      id="Fact000487"
      unitRef="USD">69139</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2026-03-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      id="Fact000489"
      unitRef="USD">44702</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      id="Fact000490"
      unitRef="USD">45462</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2026-03-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="Fact000492"
      unitRef="USD">91157</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="Fact000493"
      unitRef="USD">92706</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2026-03-31_us-gaap_VehiclesMember"
      decimals="0"
      id="Fact000495"
      unitRef="USD">498995</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-12-31_us-gaap_VehiclesMember"
      decimals="0"
      id="Fact000496"
      unitRef="USD">507478</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000498"
      unitRef="USD">1066161</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000499"
      unitRef="USD">1070249</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000501"
      unitRef="USD">549812</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000502"
      unitRef="USD">512879</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000504"
      unitRef="USD">516349</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000505"
      unitRef="USD">557370</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000507">&lt;p id="xdx_80B_eus-gaap--InventoryDisclosureTextBlock_z8d6pnAaH0r9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note
7 &#x2013;&#160;&lt;span id="xdx_82E_zx5ntqyfPwBi"&gt;Inventory&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;Inventory
consists solely of finished goods purchased for resale. Inventory is stated at cost which represents the amount paid to acquire the finished
goods. The Company evaluates inventory for potential obsolescence based on a combination of factors, including (i) aging, (ii) historical
sell-through patterns, and (iii) product-specific considerations. When estimated net realizable value is lower than cost, the Company
records an allowance for obsolescence for the difference. Write-downs are recorded within cost of goods sold and are not subsequently
reversed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;Inventory is comprised
of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zU4MbZn7yvg4" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Inventory (Details)"&gt;
  &lt;tr style="border-bottom: Black 1pt solid; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B5_zETUbe8XGd6i" style="display: none"&gt;Schedule of inventory&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20260331_zHkpY92a1YUi" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20251231_zPXaqC6zP3Lc" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Period Ended&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31, 2026&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2025&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--InventoryFinishedGoods_iI_zn2V82HAaZ93" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%; text-align: left"&gt;Finished goods&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;14,035,748&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;13,947,178&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--AllowanceForObsoleteInventory_iI_d0_msARNCzj7C_zCBCR87CSehl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;Allowance for obsolete inventory&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(867,318&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(475,797&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--InventoryNet_iI_zdZJYi514ez" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;Total Inventory, net of allowance&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;13,168,430&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;13,472,025&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;













</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000509">&lt;table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zU4MbZn7yvg4" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Inventory (Details)"&gt;
  &lt;tr style="border-bottom: Black 1pt solid; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B5_zETUbe8XGd6i" style="display: none"&gt;Schedule of inventory&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20260331_zHkpY92a1YUi" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20251231_zPXaqC6zP3Lc" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Period Ended&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31, 2026&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2025&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--InventoryFinishedGoods_iI_zn2V82HAaZ93" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%; text-align: left"&gt;Finished goods&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;14,035,748&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;13,947,178&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--AllowanceForObsoleteInventory_iI_d0_msARNCzj7C_zCBCR87CSehl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;Allowance for obsolete inventory&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(867,318&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(475,797&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--InventoryNet_iI_zdZJYi514ez" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;Total Inventory, net of allowance&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;13,168,430&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;13,472,025&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoods
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000511"
      unitRef="USD">14035748</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000512"
      unitRef="USD">13947178</us-gaap:InventoryFinishedGoods>
    <SBFM:AllowanceForObsoleteInventory
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000514"
      unitRef="USD">-867318</SBFM:AllowanceForObsoleteInventory>
    <SBFM:AllowanceForObsoleteInventory
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000515"
      unitRef="USD">-475797</SBFM:AllowanceForObsoleteInventory>
    <us-gaap:InventoryNet
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000517"
      unitRef="USD">13168430</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000518"
      unitRef="USD">13472025</us-gaap:InventoryNet>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000525">&lt;p id="xdx_807_eus-gaap--LesseeOperatingLeasesTextBlock_zWCY5Y0Zbhkh" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note
8 &#x2013;&#160;&lt;span id="xdx_821_zuZsUxx7hggb"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;The
Company has obligations as a lessee for warehouse and office space with initial non-cancellable terms in excess of one year. The Company
classified the lease as an operating lease. The lease contains a renewal option for a period of five years. Because the Company is certain
to exercise the renewal option, the optional period is included in determining the lease term, and associated payments under the renewal
option are included in the lease payments. The Company&#x2019;s lease does not include termination options for either party to the lease
or restrictive financial or other covenants. Payments due under the lease contract include fixed payments plus a variable payment. The
Company&#x2019;s office space lease requires it to make variable payments for the Company&#x2019;s proportionate share of building&#x2019;s
property taxes, insurance, and common area maintenance. These variable lease payments are not included in lease payments used to determine
lease liability and are recognized as variable costs when incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;Amounts
reported on the balance sheet as of March 31, 2026 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--LeaseCostTableTextBlock_zYThboU7nwxk" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Lease information)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;span id="xdx_8BE_zIKgWA6AvVpa" style="display: none"&gt;Schedule of lease information&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 83%; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;Operating lease ROU asset&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;span id="xdx_905_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20260331_zafwhQI5qDgk" title="Operating lease ROU asset"&gt;713,038&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;Operating Lease liability - Short-term&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;span id="xdx_902_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20260331_zaa4VAJ76ZH5" title="Operating Lease liability - Short-term"&gt;209,226&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;Operating lease liability - Long-term&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;span id="xdx_90D_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20260331_zAo3Rz0ElP16" title="Operating lease liability - Long-term"&gt;535,614&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;Remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_ecustom--LesseeOperatingLeasesRemainingLeaseTerm_c20260101__20260331_zDtTkwGTbcG4" title="Remaining lease term"&gt;4
                                            Years 6 Months&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20260331_zHglqOXb5u6k" title="Discount rate"&gt;6&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;Amounts
disclosed for ROU assets obtained in exchange for lease obligations and reductions of ROU assets resulting from reductions of lease obligations
include amounts reduced from the carrying amount of ROU assets resulting from deferred rent.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;Maturities
of lease liabilities under non-cancellable operating leases at March 31, 2026 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zWPaPM7ACZnd" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Maturities of lease payments)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;span id="xdx_8B5_zeE9O9ujvNoc" style="display: none"&gt;Schedule of maturities of lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20260331_z7gTOmIqKAi2" style="text-align: center"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_zIzx0IxDJXNf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 83%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;2026&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;158,031&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_z6p3oWnArCyk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;2027&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;201,011&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_zeo1i9pHWJ52" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;2028&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;190,554&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_zlYLJ4n2U9Yb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;2029&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;180,634&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_iI_zIjglAIRDXOe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;14,610&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;














</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000527">&lt;table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--LeaseCostTableTextBlock_zYThboU7nwxk" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Lease information)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;span id="xdx_8BE_zIKgWA6AvVpa" style="display: none"&gt;Schedule of lease information&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 83%; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;Operating lease ROU asset&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;span id="xdx_905_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20260331_zafwhQI5qDgk" title="Operating lease ROU asset"&gt;713,038&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;Operating Lease liability - Short-term&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;span id="xdx_902_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20260331_zaa4VAJ76ZH5" title="Operating Lease liability - Short-term"&gt;209,226&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;Operating lease liability - Long-term&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;span id="xdx_90D_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20260331_zAo3Rz0ElP16" title="Operating lease liability - Long-term"&gt;535,614&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;Remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_ecustom--LesseeOperatingLeasesRemainingLeaseTerm_c20260101__20260331_zDtTkwGTbcG4" title="Remaining lease term"&gt;4
                                            Years 6 Months&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20260331_zHglqOXb5u6k" title="Discount rate"&gt;6&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000529"
      unitRef="USD">713038</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000531"
      unitRef="USD">209226</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000533"
      unitRef="USD">535614</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <SBFM:LesseeOperatingLeasesRemainingLeaseTerm contextRef="From2026-01-01to2026-03-31" id="Fact000535">4
                                            Years 6 Months</SBFM:LesseeOperatingLeasesRemainingLeaseTerm>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000537"
      unitRef="Pure">0.06</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000539">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zWPaPM7ACZnd" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Maturities of lease payments)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;span id="xdx_8B5_zeE9O9ujvNoc" style="display: none"&gt;Schedule of maturities of lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20260331_z7gTOmIqKAi2" style="text-align: center"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_zIzx0IxDJXNf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 83%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;2026&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;158,031&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_z6p3oWnArCyk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;2027&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;201,011&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_zeo1i9pHWJ52" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;2028&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;190,554&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_zlYLJ4n2U9Yb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;2029&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;180,634&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_iI_zIjglAIRDXOe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;14,610&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;














</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000541"
      unitRef="USD">158031</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000543"
      unitRef="USD">201011</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000545"
      unitRef="USD">190554</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000547"
      unitRef="USD">180634</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <SBFM:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000549"
      unitRef="USD">14610</SBFM:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000556">&lt;p id="xdx_806_eus-gaap--IncomeTaxDisclosureTextBlock_zMc8Je7sKiSh" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note
9 &#x2013; &lt;span id="xdx_825_zF0exUUgRsdc"&gt;Income Taxes&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;The
Company&#x2019;s income tax (expense) / benefit of $&lt;span id="xdx_900_eus-gaap--IncomeTaxExpenseBenefit_c20260101__20260331__us-gaap--IncomeTaxAuthorityAxis__country--US_z5Gq1oSxMVc5" title="Income tax (expense) / benefit"&gt;0&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--IncomeTaxExpenseBenefit_c20250101__20250331__us-gaap--IncomeTaxAuthorityAxis__country--US_ztyyHlDXBy2i" title="Income tax (expense) / benefit"&gt;40,161&lt;/span&gt; for the three months ended March 31, 2026 and March 31, 2025, respectively,
is primarily due to operations outside of the United States and changes in valuation allowance related to certain deferred tax assets
generated or utilized in the applicable period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;Deferred
tax assets are regularly reviewed for recoverability by jurisdiction and valuation allowances are established based on historical and
projected future taxable losses and the expected timing of the reversal of existing temporary differences. The Company has recorded valuation
allowances against the majority of its deferred tax assets of March 31, 2026, and the Company expects to maintain these valuation allowances
until there is sufficient evidence that future earnings can be achieved, which is uncertain at this time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;The
Company's consolidated financial statements contain various tax related entries as a result of operations of the two Canadian subsidiaries
and are in compliance with Canadian tax laws.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;The
Company only recognizes tax benefits from an uncertain tax position if it is more likely than not that the tax position will be sustained
on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial
statement from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized
upon ultimate resolution. To date, the Company has not recognized such tax benefits in its financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;On
July 4, 2025, the One Big Beautiful Bill Act ("OBBBA") was enacted in the U.S. The OBBBA makes permanent key elements of the
Tax Cuts and Jobs Act, including 100% bonus depreciation, domestic research cost expensing, and the business interest expense limitation.
&lt;i&gt;ASC Topic 740, Income Taxes&lt;/i&gt;, requires the tax effects of changes in tax rates and laws to be recognized in the period in which
the legislation is enacted. Those effects, both current tax and deferred tax, are reported as part of continuing operations. The Company
is currently assessing the impact of OBBBA on its Consolidated Financial Statements but does not believe that the OBBBA will
have a material impact on the Company's income tax expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;In July 2025, OBBBA amended section 951A for
taxable years beginning after December 31, 2025, replacing the prior Global Intangible Low-Taxed Income (&#x201c;GILTI&#x201d;) regime
with a net Controlled Foreign Corporation (&#x201c;CFC&#x201d;) tested income inclusion framework. The legislation also modified related
provisions, including the deduction under section 250 for amounts included under section 951A. The Company has evaluated the impact of
these changes on its income tax accounting and related disclosures under &lt;i&gt;ASC 740&lt;/i&gt;, including the effect on its estimated annual
effective tax rate and taxes on foreign earnings. The Company does not expect the impact of these changes to be material to its financial
statements.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;















</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2026-01-012026-03-31_country_US"
      decimals="0"
      id="Fact000558"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-012025-03-31_country_US"
      decimals="0"
      id="Fact000560"
      unitRef="USD">40161</us-gaap:IncomeTaxExpenseBenefit>
    <SBFM:CompensationRelatedCostsDisclosureTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000568">&lt;p id="xdx_803_ecustom--CompensationRelatedCostsDisclosureTextBlock_z9wSjC2uBp6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note
10 &#x2013;&#160;&lt;span id="xdx_826_zMBjyqxfVry"&gt;Management and Director Compensation&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;The
Company paid its officers aggregate cash compensation of $&lt;span id="xdx_905_eus-gaap--SalariesWagesAndOfficersCompensation_c20260101__20260331_zGCm2NvkgRMl" title="Officers compensation"&gt;251,160&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--SalariesWagesAndOfficersCompensation_c20250101__20250331_zuoDamZJ3KJj" title="Officers compensation"&gt;269,496&lt;/span&gt; for the three-month periods ended March 31, 2026 and 2025,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;The
Company paid its directors aggregate cash compensation of $&lt;span id="xdx_901_eus-gaap--NoninterestExpenseDirectorsFees_c20260101__20260331__srt--CounterpartyNameAxis__custom--AllDirectorsMember_zlSSZTZ77nnk" title="Directors cash compensation"&gt;&lt;span id="xdx_90E_eus-gaap--NoninterestExpenseDirectorsFees_c20250101__20250331__srt--CounterpartyNameAxis__custom--AllDirectorsMember_zdjOyJoq1LAl"&gt;100,000&lt;/span&gt;&lt;/span&gt; for each of the three-month periods ended March 31, 2026 and 2025
($&lt;span id="xdx_90A_eus-gaap--NoninterestExpenseDirectorsFees_c20260101__20260331__srt--CounterpartyNameAxis__custom--Director1Member_z3Qm1mGxeSNk" title="Directors cash compensation"&gt;&lt;span id="xdx_908_eus-gaap--NoninterestExpenseDirectorsFees_c20260101__20260331__srt--CounterpartyNameAxis__custom--Director2Member_zuqpt13lVj0c"&gt;&lt;span id="xdx_90B_eus-gaap--NoninterestExpenseDirectorsFees_c20260101__20260331__srt--CounterpartyNameAxis__custom--Director3Member_zyo0TTG5Sj88"&gt;&lt;span id="xdx_90F_eus-gaap--NoninterestExpenseDirectorsFees_c20260101__20260331__srt--CounterpartyNameAxis__custom--Director4Member_zP4Nmu8XVkik"&gt;&lt;span id="xdx_901_eus-gaap--NoninterestExpenseDirectorsFees_c20260101__20260331__srt--CounterpartyNameAxis__custom--Director5Member_zpK3tJmPkAG2"&gt;&lt;span id="xdx_905_eus-gaap--NoninterestExpenseDirectorsFees_c20250101__20250331__srt--CounterpartyNameAxis__custom--Director1Member_zj22bX0PRrge"&gt;&lt;span id="xdx_905_eus-gaap--NoninterestExpenseDirectorsFees_c20250101__20250331__srt--CounterpartyNameAxis__custom--Director2Member_z3oiYXci0MBa"&gt;&lt;span id="xdx_901_eus-gaap--NoninterestExpenseDirectorsFees_c20250101__20250331__srt--CounterpartyNameAxis__custom--Director3Member_z6NziEE1ATjd"&gt;&lt;span id="xdx_90A_eus-gaap--NoninterestExpenseDirectorsFees_c20250101__20250331__srt--CounterpartyNameAxis__custom--Director4Member_z8kxXIQCgCra"&gt;&lt;span id="xdx_903_eus-gaap--NoninterestExpenseDirectorsFees_c20250101__20250331__srt--CounterpartyNameAxis__custom--Director5Member_z43cJtQsHaTk"&gt;20,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; per director).&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</SBFM:CompensationRelatedCostsDisclosureTextBlock>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000570"
      unitRef="USD">251160</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000572"
      unitRef="USD">269496</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:NoninterestExpenseDirectorsFees
      contextRef="From2026-01-012026-03-31_custom_AllDirectorsMember"
      decimals="0"
      id="Fact000574"
      unitRef="USD">100000</us-gaap:NoninterestExpenseDirectorsFees>
    <us-gaap:NoninterestExpenseDirectorsFees
      contextRef="From2025-01-012025-03-31_custom_AllDirectorsMember"
      decimals="0"
      id="Fact000575"
      unitRef="USD">100000</us-gaap:NoninterestExpenseDirectorsFees>
    <us-gaap:NoninterestExpenseDirectorsFees
      contextRef="From2026-01-012026-03-31_custom_Director1Member"
      decimals="0"
      id="Fact000577"
      unitRef="USD">20000</us-gaap:NoninterestExpenseDirectorsFees>
    <us-gaap:NoninterestExpenseDirectorsFees
      contextRef="From2026-01-012026-03-31_custom_Director2Member"
      decimals="0"
      id="Fact000578"
      unitRef="USD">20000</us-gaap:NoninterestExpenseDirectorsFees>
    <us-gaap:NoninterestExpenseDirectorsFees
      contextRef="From2026-01-012026-03-31_custom_Director3Member"
      decimals="0"
      id="Fact000579"
      unitRef="USD">20000</us-gaap:NoninterestExpenseDirectorsFees>
    <us-gaap:NoninterestExpenseDirectorsFees
      contextRef="From2026-01-012026-03-31_custom_Director4Member"
      decimals="0"
      id="Fact000580"
      unitRef="USD">20000</us-gaap:NoninterestExpenseDirectorsFees>
    <us-gaap:NoninterestExpenseDirectorsFees
      contextRef="From2026-01-012026-03-31_custom_Director5Member"
      decimals="0"
      id="Fact000581"
      unitRef="USD">20000</us-gaap:NoninterestExpenseDirectorsFees>
    <us-gaap:NoninterestExpenseDirectorsFees
      contextRef="From2025-01-012025-03-31_custom_Director1Member"
      decimals="0"
      id="Fact000582"
      unitRef="USD">20000</us-gaap:NoninterestExpenseDirectorsFees>
    <us-gaap:NoninterestExpenseDirectorsFees
      contextRef="From2025-01-012025-03-31_custom_Director2Member"
      decimals="0"
      id="Fact000583"
      unitRef="USD">20000</us-gaap:NoninterestExpenseDirectorsFees>
    <us-gaap:NoninterestExpenseDirectorsFees
      contextRef="From2025-01-012025-03-31_custom_Director3Member"
      decimals="0"
      id="Fact000584"
      unitRef="USD">20000</us-gaap:NoninterestExpenseDirectorsFees>
    <us-gaap:NoninterestExpenseDirectorsFees
      contextRef="From2025-01-012025-03-31_custom_Director4Member"
      decimals="0"
      id="Fact000585"
      unitRef="USD">20000</us-gaap:NoninterestExpenseDirectorsFees>
    <us-gaap:NoninterestExpenseDirectorsFees
      contextRef="From2025-01-012025-03-31_custom_Director5Member"
      decimals="0"
      id="Fact000586"
      unitRef="USD">20000</us-gaap:NoninterestExpenseDirectorsFees>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000588">&lt;p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z0cSDmzvLXij" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note
11 &#x2013;&#160;&lt;span id="xdx_827_zqlYsOhx7Gna"&gt;Capital Stock&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;The
Company&#x2019;s authorized capital is comprised of &lt;span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_c20260331_zfHywfOGgZH1" title="Common stock, shares authorized"&gt;3,000,000,000&lt;/span&gt; shares of common stock, par value $&lt;span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20260331_zW4mXuAL7lF8" title="Common stock, par value"&gt;0.001&lt;/span&gt;, and &lt;span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_c20260331__srt--TitleOfIndividualAxis__srt--DirectorMember_zBZOto6NZHY9" title="Preferred stock, shares authorized"&gt;30,000,000&lt;/span&gt; shares of preferred
stock, $&lt;span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20260331__srt--TitleOfIndividualAxis__srt--DirectorMember_zTpXD9DWYBAl" title="Preferred stock, par value"&gt;0.10&lt;/span&gt; par value. As of March 31, 2026, the Company had authorized &lt;span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zzIBLwDJDn9k" title="Preferred stock, shares authorized"&gt;&lt;span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zmVXkKzxpwT8" title="Preferred stock, shares authorized"&gt;1,000,000&lt;/span&gt;&lt;/span&gt; shares of Series B Preferred Stock. The Series B Preferred
Stock is non-convertible and non-redeemable. It has a liquidation preference equal to the stated value of $0.10 per share, relative to
the common stock and gives the holder the right to 1,000 votes per share. As of March 31, 2026, &lt;span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zrqXSQEvdD5a" title="Preferred stock, shares outstanding"&gt;&lt;span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zVGPa0S5ZXY9" title="Preferred stock, shares outstanding"&gt;130,000&lt;/span&gt;&lt;/span&gt; shares of Series B Preferred
Stock were outstanding and held by the Company&#x2019;s Chief Executive Officer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;On
January 3, 2025, the Company issued &lt;span id="xdx_907_eus-gaap--ConversionOfStockSharesIssued1_c20250102__20250103__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zP5cXv0nejl" title="Stock converted, shares issued"&gt;127,443&lt;/span&gt; shares of common stock upon the exercise of &lt;span id="xdx_900_eus-gaap--ConversionOfStockSharesConverted1_c20250102__20250103__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zwkYoJyH51B3" title="Stock converted, shares converted"&gt;127,443&lt;/span&gt; Series B Warrants and received $&lt;span id="xdx_90A_eus-gaap--ProceedsFromWarrantExercises_c20250102__20250103__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zsZN3W3qXy4j" title="Proceeds from warrant exercise"&gt;355,298&lt;/span&gt;
in net proceeds.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;On
April 2, 2025, the Company issued &lt;span id="xdx_905_eus-gaap--ConversionOfStockSharesIssued1_c20250401__20250402__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zc3jPVyy4ktd" title="Stock converted, shares issued"&gt;660,000&lt;/span&gt; shares of common stock upon the exercise of &lt;span id="xdx_90F_eus-gaap--ConversionOfStockSharesConverted1_c20250401__20250402__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zfKECF2GVxvh" title="Stock converted, shares converted"&gt;660,000&lt;/span&gt; Series B Warrants and received $&lt;span id="xdx_905_eus-gaap--ProceedsFromWarrantExercises_c20250401__20250402__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zU8k8UuhPru4" title="Proceeds from warrant exercise"&gt;1,840,014&lt;/span&gt;
in net proceeds.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;On
April 3, 2025, the Company issued an aggregate of &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250401__20250403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember_zbpIFmjAnzuc" title="Aggregate shares Issued"&gt;1,188,404&lt;/span&gt; shares of common stock in connection with a registered direct offering and
received $&lt;span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250401__20250403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember_zqNlYkY17PZf" title="Net proceeds"&gt;1,828,596&lt;/span&gt; in net proceeds.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;On
October 16, 2025, the Company issued &lt;span id="xdx_90F_eus-gaap--ConversionOfStockSharesIssued1_c20251015__20251016__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zc3yksZ0fY8" title="Stock converted, shares issued"&gt;350,000&lt;/span&gt; shares of common stock upon the exercise of &lt;span id="xdx_901_eus-gaap--ConversionOfStockSharesConverted1_c20251015__20251016__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zEQoAFSHTUmf" title="Stock converted, shares converted"&gt;350,000&lt;/span&gt; Series B Warrants and received net proceeds
of $&lt;span id="xdx_90F_eus-gaap--ProceedsFromWarrantExercises_c20251015__20251016__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zbOxhfV3BFd3" title="Net proceeds"&gt;724,500&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;As
of March 31, 2026 and December 31, 2025, the Company had &lt;span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_c20260331_zufR67krgkK5"&gt;&lt;span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_c20260331_zF266wFxJ4X4"&gt;&lt;span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_c20251231_z42oS2fULTXd" title="Common stock, shares issued"&gt;&lt;span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_c20251231_zyRqUKWfpyL9" title="Common stock, shares outstanding"&gt;4,905,945&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; shares of common stock issued and outstanding.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;The
Company has declared no dividends since inception.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000590"
      unitRef="Shares">3000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000592"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2026-03-31_srt_DirectorMember"
      decimals="INF"
      id="Fact000594"
      unitRef="Shares">30000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31_srt_DirectorMember"
      decimals="INF"
      id="Fact000596"
      unitRef="USDPShares">0.10</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2026-03-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000598"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000600"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2026-03-31_us-gaap_SeriesBPreferredStockMember_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact000602"
      unitRef="Shares">130000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_SeriesBPreferredStockMember_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact000604"
      unitRef="Shares">130000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2025-01-022025-01-03_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000606"
      unitRef="Shares">127443</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2025-01-022025-01-03_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000608"
      unitRef="Shares">127443</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2025-01-022025-01-03_custom_SeriesBWarrantsMember"
      decimals="0"
      id="Fact000610"
      unitRef="USD">355298</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2025-04-012025-04-02_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000612"
      unitRef="Shares">660000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2025-04-012025-04-02_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000614"
      unitRef="Shares">660000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2025-04-012025-04-02_custom_SeriesBWarrantsMember"
      decimals="0"
      id="Fact000616"
      unitRef="USD">1840014</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-04-012025-04-03_us-gaap_CommonStockMember_custom_RegisteredDirectOfferingMember"
      decimals="INF"
      id="Fact000618"
      unitRef="Shares">1188404</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-04-012025-04-03_us-gaap_CommonStockMember_custom_RegisteredDirectOfferingMember"
      decimals="0"
      id="Fact000620"
      unitRef="USD">1828596</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2025-10-152025-10-16_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000622"
      unitRef="Shares">350000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2025-10-152025-10-16_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000624"
      unitRef="Shares">350000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2025-10-152025-10-16_custom_SeriesBWarrantsMember"
      decimals="0"
      id="Fact000626"
      unitRef="USD">724500</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000627"
      unitRef="Shares">4905945</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000628"
      unitRef="Shares">4905945</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000630"
      unitRef="Shares">4905945</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000632"
      unitRef="Shares">4905945</us-gaap:CommonStockSharesOutstanding>
    <SBFM:WarrantsDisclosureTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000634">&lt;p id="xdx_804_ecustom--WarrantsDisclosureTextBlock_zgefdF98JNlb" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note
12 &#x2013;&#160;&lt;span id="xdx_82D_z41R79xKmNGg"&gt;Warrants&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;The
Company accounts for issued warrants either as a liability or equity in accordance with &lt;i&gt;ASC 480-10&lt;/i&gt; or &lt;i&gt;ASC 815-40&lt;/i&gt;. Under
&lt;i&gt;ASC 480-10&lt;/i&gt;, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other
assets, or a variable number of shares. If warrants do not meet liability classification under &lt;i&gt;ASC 480-10&lt;/i&gt;, the Company considers
the requirements of &lt;i&gt;ASC 815-40&lt;/i&gt; to determine whether the warrants should be classified as a liability or as equity. Under &lt;i&gt;ASC
815-40&lt;/i&gt;, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering
event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change
in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss.
If warrants do not require liability classification under &lt;i&gt;ASC 815-40&lt;/i&gt;, in order to conclude warrants should be classified as equity,
the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under &lt;i&gt;ASC
815-40&lt;/i&gt; or other applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no
changes in fair value recognized after the issuance date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;











&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;In
2022, 2023, 2024, and 2025, the Company completed six (6) financing events, and in connection therewith, it issued warrants as follows:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--ScheduleOfWarrantsIssuedWithFinancingTableTextBlock_z3kLv63CZYD2" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Warrants (Details - Warrants issued with financing)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;span id="xdx_8B7_zQgPJrzqilac" style="display: none"&gt;Schedule of warrants issued with financing&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;Issuance Date/Type&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 9pt"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 9pt"&gt;Exercise
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;Expiry Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 47%; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;Feb 17, 2022 (&#x201c;Tradeable Warrants&#x201d;)*&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_fKg_____zFNlPbkCNnu4" style="width: 13%; text-align: right" title="Warrants outstanding"&gt;&lt;span style="font-size: 9pt"&gt;2,051&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_z3XURb75j5Hd" title="Warrant expiration date"&gt;4,440.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 17%; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90B_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_zwd5RSFiipmf" title="Warrant expiration date"&gt;February 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;Mar 14, 2022 (&#x201c;2022 Pre-Funded Warrants&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--PreFunded2022WarrantsMember_zSDVm8DZs7Z9" style="text-align: right" title="Warrants outstanding"&gt;&lt;span style="font-size: 9pt"&gt;1,846&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--PreFunded2022WarrantsMember_zsWwnKfq3Aek" title="Warrant expiration date"&gt;2.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_909_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--PreFunded2022WarrantsMember_zbHvGRYNtgc2" title="Warrant expiration date"&gt;Unlimited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;Mar 14, 2022 (&#x201c;Investor Warrants&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_zlpEKgtvk7fa"&gt;1,801&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_zXXBuzTZihpa"&gt;4,440.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_909_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_zhehrWq1HAKl"&gt;March 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;Apr 28, 2022 (&#x201c;April Warrants&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_z9UtQ5ylKBDb" style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;4,862&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_z3tX4rpVkpkf"&gt;7,520.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_908_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_zDrzvMaDeGwk"&gt;April 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;May 16, 2023 (&#x201c;May Pre-Funded Warrants&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_zzCltop3CFh3" style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;1,751&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_zPq6QUFjLh2"&gt;2.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90C_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_z6WLCW2CXcei"&gt;Unlimited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;May 16, 2023 (&#x201c;May Investor Warrants&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_zfITJ50GfMAl" style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;5,952&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_zCZUCd9cxTtk"&gt;1,180.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_903_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_znIgoCy4VMBd"&gt;November 2028&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;Feb 15, 2024 (&#x201c;2024 Pre-Funded Warrants&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--PreFunded2024WarrantsMember_zy1UPEFRHGt5" style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;22,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--PreFunded2024WarrantsMember_zajtJ1lI2685"&gt;2.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_905_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--PreFunded2024WarrantsMember_znK4aYMNJJQ3"&gt;Unlimited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;Feb 15, 2024 (&#x201c;Series A Warrants&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsMember_fKio___zn90kykWzd14"&gt;3,986&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsMember_zPt1hEIIFu19"&gt;4,200.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90A_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsMember_zpfrT5HPcF73"&gt;August 2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;Feb 15, 2024 (&#x201c;Series B Warrants&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_fKio___zvirEpFfnwld"&gt;7,973&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_zzQ60PND3ey1"&gt;4,760.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_909_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_zsdf2Nigsi07"&gt;February 2029&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;Apr 3, 2025 (&#x201c;2025 Pre-Funded
    Warrants&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--PreFunded2025WarrantsMember_zT99q5RoPUIb" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;260,000&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--PreFunded2025WarrantsMember_zyrbsgWJ1hO4" title="Exercise price"&gt;0.001&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_906_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--PreFunded2025WarrantsMember_z6t3H9lj4OE9"&gt;Unlimited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 13px; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"&gt;These warrants trade on Nasdaq
    under the symbol SBFMW.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"&gt;**&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"&gt;Subject to adjustment.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AD_z5HcTIeerYsd" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;On
February 11, 2024, the Company redeemed all of the April Warrants and all of the May Investor Warrants for an aggregate purchase price
of $&lt;span id="xdx_906_eus-gaap--PaymentsForRepurchaseOfWarrants_pp0p0_c20240210__20240211__us-gaap--AwardTypeAxis__custom--AprilWarrantsAndMayInvestorWarrantsMember_zivYVWX2iQEh" title="Payments for repurchase of warrants"&gt;3,139,651&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;As
of March 31, 2026, all of the 2022 Pre-Funded Warrants, all of the May Pre-Funded Warrants, all of the 2024 Pre-Funded Warrants, all
of the 2025 Pre-Funded Warrants, a total of &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20260101__20260331__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_zQbLPOgNWyLi" title="Warrants exercised"&gt;1,569&lt;/span&gt; Tradeable Warrants, &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20260101__20260331__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_zX9mPRLxsq5i" title="Warrants exercised"&gt;1,401&lt;/span&gt; Investor Warrants, all of the Series A Warrants, and &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20260101__20260331__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_zjnNEqsQfuy4" title="Warrants exercised"&gt;2,269,303&lt;/span&gt;
Series B Warrants (as adjusted) were exercised resulting in aggregate net proceeds of $&lt;span id="xdx_901_eus-gaap--ProceedsFromWarrantExercises_c20260101__20260331__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_zex3fqzh3ESj" title="Proceeds from warrant exercises"&gt;18,136,992&lt;/span&gt; received by the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;The
Company&#x2019;s outstanding warrants as of March 31, 2026 consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zwjN9QTuTio2" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Warrants (Details - Warrants outstanding)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;span id="xdx_8BA_z3oHWhyX2Sh1" style="display: none"&gt;Schedule of warrants outstanding&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;Type&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 9pt"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 9pt"&gt;Exercise
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;Expiry Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 47%; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;Tradeable Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--TradeableWarrants1Member_zCi5SgCW8vCl" style="width: 13%; text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-size: 9pt"&gt;482&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--TradeableWarrants1Member_zFGms0kom2ek" style="width: 13%; text-align: right" title="Warrant exercise price"&gt;&lt;span style="font-size: 9pt"&gt;220.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 17%; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90D_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--TradeableWarrants1Member_zhugGfv1zUD1" title="Expiry date"&gt;February 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;Investor Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--InvestorWarrants1Member_zTfNuEF7Cyg1"&gt;400&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--InvestorWarrants1Member_zroxUTMCZRul"&gt;4,000.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_901_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--InvestorWarrants1Member_zWW4t5pyMry"&gt;March 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;Series B Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesBWarrants1Member_fKg_____zOtM0PWEXcO6"&gt;15,227,962&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesBWarrants1Member_fKg_____zbY4R4eA4br9"&gt;2.07&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_903_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--SeriesBWarrants1Member_zXvA6KIeZgL7" title="Expiry date"&gt;February 2029&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify; width: 12px"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"&gt;As adjusted following the
    financing event of April 3, 2025 and subject to further adjustment of the number of warrants and exercise price upon certain corporate
    actions such that the aggregate exercise price of the warrants remains unchanged&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A6_zR3R2HostCad" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;













</SBFM:WarrantsDisclosureTextBlock>
    <SBFM:ScheduleOfWarrantsIssuedWithFinancingTableTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000640">&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--ScheduleOfWarrantsIssuedWithFinancingTableTextBlock_z3kLv63CZYD2" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Warrants (Details - Warrants issued with financing)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;span id="xdx_8B7_zQgPJrzqilac" style="display: none"&gt;Schedule of warrants issued with financing&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;Issuance Date/Type&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 9pt"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 9pt"&gt;Exercise
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;Expiry Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 47%; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;Feb 17, 2022 (&#x201c;Tradeable Warrants&#x201d;)*&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_fKg_____zFNlPbkCNnu4" style="width: 13%; text-align: right" title="Warrants outstanding"&gt;&lt;span style="font-size: 9pt"&gt;2,051&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_z3XURb75j5Hd" title="Warrant expiration date"&gt;4,440.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 17%; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90B_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_zwd5RSFiipmf" title="Warrant expiration date"&gt;February 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;Mar 14, 2022 (&#x201c;2022 Pre-Funded Warrants&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--PreFunded2022WarrantsMember_zSDVm8DZs7Z9" style="text-align: right" title="Warrants outstanding"&gt;&lt;span style="font-size: 9pt"&gt;1,846&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--PreFunded2022WarrantsMember_zsWwnKfq3Aek" title="Warrant expiration date"&gt;2.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_909_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--PreFunded2022WarrantsMember_zbHvGRYNtgc2" title="Warrant expiration date"&gt;Unlimited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;Mar 14, 2022 (&#x201c;Investor Warrants&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_zlpEKgtvk7fa"&gt;1,801&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_zXXBuzTZihpa"&gt;4,440.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_909_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_zhehrWq1HAKl"&gt;March 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;Apr 28, 2022 (&#x201c;April Warrants&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_z9UtQ5ylKBDb" style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;4,862&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_z3tX4rpVkpkf"&gt;7,520.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_908_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_zDrzvMaDeGwk"&gt;April 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;May 16, 2023 (&#x201c;May Pre-Funded Warrants&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_zzCltop3CFh3" style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;1,751&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_zPq6QUFjLh2"&gt;2.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90C_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_z6WLCW2CXcei"&gt;Unlimited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;May 16, 2023 (&#x201c;May Investor Warrants&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_zfITJ50GfMAl" style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;5,952&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_zCZUCd9cxTtk"&gt;1,180.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_903_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_znIgoCy4VMBd"&gt;November 2028&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;Feb 15, 2024 (&#x201c;2024 Pre-Funded Warrants&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--PreFunded2024WarrantsMember_zy1UPEFRHGt5" style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;22,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--PreFunded2024WarrantsMember_zajtJ1lI2685"&gt;2.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_905_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--PreFunded2024WarrantsMember_znK4aYMNJJQ3"&gt;Unlimited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;Feb 15, 2024 (&#x201c;Series A Warrants&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsMember_fKio___zn90kykWzd14"&gt;3,986&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsMember_zPt1hEIIFu19"&gt;4,200.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90A_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsMember_zpfrT5HPcF73"&gt;August 2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;Feb 15, 2024 (&#x201c;Series B Warrants&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_fKio___zvirEpFfnwld"&gt;7,973&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_zzQ60PND3ey1"&gt;4,760.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_909_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_zsdf2Nigsi07"&gt;February 2029&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;Apr 3, 2025 (&#x201c;2025 Pre-Funded
    Warrants&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--PreFunded2025WarrantsMember_zT99q5RoPUIb" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;260,000&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--PreFunded2025WarrantsMember_zyrbsgWJ1hO4" title="Exercise price"&gt;0.001&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_906_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--PreFunded2025WarrantsMember_z6t3H9lj4OE9"&gt;Unlimited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 13px; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"&gt;These warrants trade on Nasdaq
    under the symbol SBFMW.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"&gt;**&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"&gt;Subject to adjustment.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</SBFM:ScheduleOfWarrantsIssuedWithFinancingTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2026-03-31_custom_TradeableWarrantsMember"
      decimals="INF"
      id="Fact000642"
      unitRef="Shares">2051</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-31_custom_TradeableWarrantsMember"
      decimals="INF"
      id="Fact000644"
      unitRef="USDPShares">4440.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SBFM:WarrantExpirationDate
      contextRef="From2026-01-012026-03-31_custom_TradeableWarrantsMember"
      id="Fact000646">February 2027</SBFM:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2026-03-31_custom_PreFunded2022WarrantsMember"
      decimals="INF"
      id="Fact000648"
      unitRef="Shares">1846</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-31_custom_PreFunded2022WarrantsMember"
      decimals="INF"
      id="Fact000650"
      unitRef="USDPShares">2.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SBFM:WarrantExpirationDate
      contextRef="From2026-01-012026-03-31_custom_PreFunded2022WarrantsMember"
      id="Fact000652">Unlimited</SBFM:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2026-03-31_custom_InvestorWarrantsMember"
      decimals="INF"
      id="Fact000653"
      unitRef="Shares">1801</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-31_custom_InvestorWarrantsMember"
      decimals="INF"
      id="Fact000654"
      unitRef="USDPShares">4440.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SBFM:WarrantExpirationDate
      contextRef="From2026-01-012026-03-31_custom_InvestorWarrantsMember"
      id="Fact000655">March 2027</SBFM:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2026-03-31_custom_AprilWarrantsMember"
      decimals="INF"
      id="Fact000656"
      unitRef="Shares">4862</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-31_custom_AprilWarrantsMember"
      decimals="INF"
      id="Fact000657"
      unitRef="USDPShares">7520.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SBFM:WarrantExpirationDate
      contextRef="From2026-01-012026-03-31_custom_AprilWarrantsMember"
      id="Fact000658">April 2027</SBFM:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2026-03-31_custom_MayPreFundedWarrantsMember"
      decimals="INF"
      id="Fact000659"
      unitRef="Shares">1751</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-31_custom_MayPreFundedWarrantsMember"
      decimals="INF"
      id="Fact000660"
      unitRef="USDPShares">2.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SBFM:WarrantExpirationDate
      contextRef="From2026-01-012026-03-31_custom_MayPreFundedWarrantsMember"
      id="Fact000661">Unlimited</SBFM:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2026-03-31_custom_MayInvestorWarrantsMember"
      decimals="INF"
      id="Fact000662"
      unitRef="Shares">5952</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-31_custom_MayInvestorWarrantsMember"
      decimals="INF"
      id="Fact000663"
      unitRef="USDPShares">1180.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SBFM:WarrantExpirationDate
      contextRef="From2026-01-012026-03-31_custom_MayInvestorWarrantsMember"
      id="Fact000664">November 2028</SBFM:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2026-03-31_custom_PreFunded2024WarrantsMember"
      decimals="INF"
      id="Fact000665"
      unitRef="Shares">22500</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-31_custom_PreFunded2024WarrantsMember"
      decimals="INF"
      id="Fact000666"
      unitRef="USDPShares">2.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SBFM:WarrantExpirationDate
      contextRef="From2026-01-012026-03-31_custom_PreFunded2024WarrantsMember"
      id="Fact000667">Unlimited</SBFM:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2026-03-31_custom_SeriesAWarrantsMember"
      decimals="INF"
      id="Fact000668"
      unitRef="Shares">3986</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-31_custom_SeriesAWarrantsMember"
      decimals="INF"
      id="Fact000669"
      unitRef="USDPShares">4200.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SBFM:WarrantExpirationDate
      contextRef="From2026-01-012026-03-31_custom_SeriesAWarrantsMember"
      id="Fact000670">August 2026</SBFM:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2026-03-31_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000671"
      unitRef="Shares">7973</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-31_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000672"
      unitRef="USDPShares">4760.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SBFM:WarrantExpirationDate
      contextRef="From2026-01-012026-03-31_custom_SeriesBWarrantsMember"
      id="Fact000673">February 2029</SBFM:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2026-03-31_custom_PreFunded2025WarrantsMember"
      decimals="INF"
      id="Fact000674"
      unitRef="Shares">260000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-31_custom_PreFunded2025WarrantsMember"
      decimals="INF"
      id="Fact000676"
      unitRef="USDPShares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SBFM:WarrantExpirationDate
      contextRef="From2026-01-012026-03-31_custom_PreFunded2025WarrantsMember"
      id="Fact000677">Unlimited</SBFM:WarrantExpirationDate>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="From2024-02-102024-02-11_custom_AprilWarrantsAndMayInvestorWarrantsMember"
      decimals="0"
      id="Fact000679"
      unitRef="USD">3139651</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2026-01-012026-03-31_custom_TradeableWarrantsMember"
      decimals="INF"
      id="Fact000681"
      unitRef="Shares">1569</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2026-01-012026-03-31_custom_InvestorWarrantsMember"
      decimals="INF"
      id="Fact000683"
      unitRef="Shares">1401</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2026-01-012026-03-31_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000685"
      unitRef="Shares">2269303</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2026-01-012026-03-31_custom_SeriesBWarrantsMember"
      decimals="0"
      id="Fact000687"
      unitRef="USD">18136992</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000689">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zwjN9QTuTio2" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Warrants (Details - Warrants outstanding)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;span id="xdx_8BA_z3oHWhyX2Sh1" style="display: none"&gt;Schedule of warrants outstanding&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;Type&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 9pt"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 9pt"&gt;Exercise
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;Expiry Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 47%; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;Tradeable Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--TradeableWarrants1Member_zCi5SgCW8vCl" style="width: 13%; text-align: right" title="Number of warrants outstanding"&gt;&lt;span style="font-size: 9pt"&gt;482&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--TradeableWarrants1Member_zFGms0kom2ek" style="width: 13%; text-align: right" title="Warrant exercise price"&gt;&lt;span style="font-size: 9pt"&gt;220.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 17%; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90D_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--TradeableWarrants1Member_zhugGfv1zUD1" title="Expiry date"&gt;February 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;Investor Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--InvestorWarrants1Member_zTfNuEF7Cyg1"&gt;400&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--InvestorWarrants1Member_zroxUTMCZRul"&gt;4,000.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_901_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--InvestorWarrants1Member_zWW4t5pyMry"&gt;March 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;Series B Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesBWarrants1Member_fKg_____zOtM0PWEXcO6"&gt;15,227,962&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesBWarrants1Member_fKg_____zbY4R4eA4br9"&gt;2.07&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: justify"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_903_ecustom--WarrantExpirationDate_c20260101__20260331__us-gaap--AwardTypeAxis__custom--SeriesBWarrants1Member_zXvA6KIeZgL7" title="Expiry date"&gt;February 2029&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify; width: 12px"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"&gt;As adjusted following the
    financing event of April 3, 2025 and subject to further adjustment of the number of warrants and exercise price upon certain corporate
    actions such that the aggregate exercise price of the warrants remains unchanged&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2026-03-31_custom_TradeableWarrants1Member"
      decimals="INF"
      id="Fact000691"
      unitRef="Shares">482</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-31_custom_TradeableWarrants1Member"
      decimals="INF"
      id="Fact000693"
      unitRef="USDPShares">220.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SBFM:WarrantExpirationDate
      contextRef="From2026-01-012026-03-31_custom_TradeableWarrants1Member"
      id="Fact000695">February 2027</SBFM:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2026-03-31_custom_InvestorWarrants1Member"
      decimals="INF"
      id="Fact000696"
      unitRef="Shares">400</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-31_custom_InvestorWarrants1Member"
      decimals="INF"
      id="Fact000697"
      unitRef="USDPShares">4000.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SBFM:WarrantExpirationDate
      contextRef="From2026-01-012026-03-31_custom_InvestorWarrants1Member"
      id="Fact000698">March 2027</SBFM:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2026-03-31_custom_SeriesBWarrants1Member"
      decimals="INF"
      id="Fact000699"
      unitRef="Shares">15227962</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-31_custom_SeriesBWarrants1Member"
      decimals="INF"
      id="Fact000700"
      unitRef="USDPShares">2.07</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SBFM:WarrantExpirationDate
      contextRef="From2026-01-012026-03-31_custom_SeriesBWarrants1Member"
      id="Fact000702">February 2029</SBFM:WarrantExpirationDate>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000709">&lt;p id="xdx_802_eus-gaap--EarningsPerShareTextBlock_zO7Ldk3ifIx9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note
13 &#x2013;&#160;&lt;span id="xdx_829_zKfKVMw6O033"&gt;Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;The
following table sets forth the computation of basic* net income (loss) per share:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zpQEZ9JHPha3" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Earnings Per Share (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: justify"&gt;&lt;span id="xdx_8B1_zECYMIfCWOZb" style="display: none"&gt;Schedule of computation of basic and diluted net income per share&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20260101__20260331_zlIAU8PI8XT6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20250101__20250331_zQ3KM1lhh95" style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;Quarter Ended March 31,&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zorBPa59UqDf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: justify"&gt;Net gain (loss) attributable to common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;(1,243,869&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;(1,179,771&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Weighted average outstanding shares of common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331_zF5Bz74xNNWl" title="Weighted average outstanding shares of common stock"&gt;4,905,945&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250331_zVHfdv2NhM6c" title="Weighted average outstanding shares of common stock"&gt;2,703,293&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: justify"&gt;Net gain (loss) per share attributable to common stock&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20260101__20260331_zGmiQVdh5BBg" title="Net gain (loss) per share attributable to common stock"&gt;(0.25&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20250101__20250331_zSQMIZwOmeuh" title="Net gain (loss) per share attributable to common stock"&gt;(0.44&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"&gt;*
Diluted net income (loss) per share is not included in this table as the Company incurred net losses for the years ended December
31, 2026 and 2025 and inclusion of dilutive instruments would have an anti-dilutive effect.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8A7_zbApCWCEJAw" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000711">&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zpQEZ9JHPha3" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Earnings Per Share (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: justify"&gt;&lt;span id="xdx_8B1_zECYMIfCWOZb" style="display: none"&gt;Schedule of computation of basic and diluted net income per share&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20260101__20260331_zlIAU8PI8XT6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20250101__20250331_zQ3KM1lhh95" style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;Quarter Ended March 31,&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zorBPa59UqDf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: justify"&gt;Net gain (loss) attributable to common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;(1,243,869&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;(1,179,771&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Weighted average outstanding shares of common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331_zF5Bz74xNNWl" title="Weighted average outstanding shares of common stock"&gt;4,905,945&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250331_zVHfdv2NhM6c" title="Weighted average outstanding shares of common stock"&gt;2,703,293&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: justify"&gt;Net gain (loss) per share attributable to common stock&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20260101__20260331_zGmiQVdh5BBg" title="Net gain (loss) per share attributable to common stock"&gt;(0.25&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20250101__20250331_zSQMIZwOmeuh" title="Net gain (loss) per share attributable to common stock"&gt;(0.44&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"&gt;*
Diluted net income (loss) per share is not included in this table as the Company incurred net losses for the years ended December
31, 2026 and 2025 and inclusion of dilutive instruments would have an anti-dilutive effect.&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2026-01-01to2026-03-31"
      decimals="0"
      id="Fact000713"
      unitRef="USD">-1243869</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000714"
      unitRef="USD">-1179771</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-01-01to2026-03-31"
      decimals="INF"
      id="Fact000716"
      unitRef="Shares">4905945</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-012025-03-31"
      decimals="INF"
      id="Fact000718"
      unitRef="Shares">2703293</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2026-01-01to2026-03-31"
      decimals="INF"
      id="Fact000720"
      unitRef="USDPShares">-0.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-012025-03-31"
      decimals="INF"
      id="Fact000722"
      unitRef="USDPShares">-0.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000724">&lt;p id="xdx_801_eus-gaap--SegmentReportingDisclosureTextBlock_zLl9MK93R4X5" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note 14 &#x2013; &lt;span id="xdx_827_z9UtBIoYlVqj"&gt;Segment Reporting&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company operates as one operating segment,
which is also its one reportable segment, as the Chief Executive Officer, acting as the Chief Operating Decision Maker (&#x201c;CODM&#x201d;),
evaluates financial performance and allocates resources on a consolidated, enterprise-wide basis. The Company&#x2019;s operations are managed
as an integrated pharmaceutical business focused on the research, development, and commercialization of prescription drugs and supplements.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;Although the Company conducts activities through
multiple legal entities &#x2014; including Sunshine Biopharma Inc. (U.S.), Sunshine Biopharma Canada Inc. (Canada), and Nora Pharma Inc.
(Canada) &#x2014; these entities operate under a unified management structure with shared economic characteristics, common product development
objectives, and centralized decision making. As such, they do not meet the criteria for separate operating segments under &lt;i&gt;ASC 280 &#x2013;
Segment Reporting&lt;/i&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with &lt;i&gt;ASU 2023-07&lt;/i&gt;, the Company
provides the following information regarding its single reportable segment:&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Measure of Segment Profit (Loss): The CODM evaluates performance using consolidated operating income (loss), which is consistent with the amounts presented in the accompanying consolidated financial statements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Significant Segment Expenses: Research and development expenses, and supply chain costs, selling and marketing expenses, and general and administrative expenses are all incurred and reviewed on a consolidated basis.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Other Segment Items: Interest income, interest expense, foreign exchange gains and losses, and other non-operating items are also managed and reviewed on a consolidated basis.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Reconciliation: As the Company has only one reportable segment, no additional reconciliation to consolidated totals is required beyond what is presented in the consolidated statements of operations.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s operations are conducted in
Canada and substantially all long-lived assets are located in this jurisdiction. Revenues are generated from customers located in Canada.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:LegalMattersAndContingenciesTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000726">&lt;p id="xdx_80D_eus-gaap--LegalMattersAndContingenciesTextBlock_zqyHjRQr0Yyd" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note
15 &#x2013; &lt;span id="xdx_828_zSMDigiWGpV8"&gt;Legal Matters&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;On April 14, 2025, the Company terminated the
employment of Mr. Malek Chamoun, president of the Company&#x2019;s wholly owned Canadian subsidiary, Nora Pharma. On April 17, 2025, the
Company received a demand letter from the attorneys of Mr. Chamoun requesting that the Company pay to Mr. Chamoun $7,307,025 CAD (approximately
$5,300,000 USD) within five (5) days. In response to the demand letter, the Company sent a letter on May 1, 2025 stating that the demands
contained in the demand letter, including the sum of $7,307,025 CAD (approximately $5,300,000 USD), are completely unfounded and that
it intends to defend itself vigorously. Following a series of communications between the parties&#x2019; legal counsels, there has been
no response to the Company&#x2019;s letter dated October 14, 2025, nor any action taken by Mr. Chamoun&#x2019;s attorneys since that date.
No provision or accrual was made in the financial statements for any litigation liability or legal expense which the Company may incur
in connection with this alleged claim.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2026-01-01to2026-03-31" id="Fact000728">&lt;p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zFW9S4GQ5LG9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note
16 &#x2013;&#160;&lt;span id="xdx_82F_zDERCYJHIBVg"&gt;Subsequent Events&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;On
April 14, 2026, the Company issued 100,000 restricted shares of common stock under the Company&#x2019;s 2023 Equity Incentive Plan to
one of its directors for services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2026-01-01to2026-03-31" id="Fact000729">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2026-01-01to2026-03-31" id="Fact000730">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2026-01-01to2026-03-31" id="Fact000731">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2026-01-01to2026-03-31" id="Fact000732">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
